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This report is the last of a three-part series on the health of children and young people in New Zealand and fits 
into the reporting cycle as follows: 
Year 1 (2014): The determinants of health for children and young people  
Year 2 (2015): The health status of children and young people 
Year 3 (2016): The health of children and young people with chronic conditions and disabilities  
Chronic conditions and disabilities 
This report aims to assist district health boards to plan to meet current and future demands in order to improve 
the quality of life for children with disabilities and chronic conditions by providing: 
1. Information from a range of routinely collected data on children and young people’s disability and 
chronic conditions, including prevalence of conditions arising in the perinatal period 
2. Information about children’s and young people’s use of secondary health services 
3. Evidence for good practice derived from current policies, guidelines and evidence-based interventions 
for each of the indicators presented 
The choice of indicators included in this report was informed by an indicator framework developed by the NZ 
Child and Youth Epidemiology Service and by recent peer-reviewed literature about chronic conditions in 
children and young people.1-3 Chronic conditions and disabilities often affect people for life. Having a good 
quality of life and flourishing to your best ability is dependent, at least in part, on what happened as you were 
growing up. Understanding the dimensions of chronic conditions and disabilities among children and young 
people is essential to planning and developing good quality health services for New Zealand’s children and 
young people.  
About 11% of children aged 0–14 years have a disability according to the 2013 New Zealand Disability 
Survey.4 Of these children, the survey identified that 49% of children with impairments that limited daily 
activity were affected by conditions that existed at birth, while for a third of the children, the reason was one of 
a range of ‘other causes’, not usually diagnosed at birth, which include autism spectrum disorder, attention 
deficit hyperactivity disorder, developmental delay, dyslexia and dyspraxia. Learning difficulty was the most 
common impairment with 6% of children surveyed, and 52% of disabled children having difficulty learning. 
Boys had a disability rate of 13% compared with the girls’ rate of 8%, with boys having higher rates in 
psychiatric/psychological, speaking and learning impairments. Māori children had a disability rate of 15% 
compared with 9% for non-Māori children. Twenty five percent of disabled children had impairments that were 
caused by a disease or illness, and 3% by an injury.4  
The New Zealand Health Survey (NZHS) also indicates chronic conditions and disabilities that affect children 
and young people in New Zealand. The majority of 2–24 year olds have a BMI category of healthy weight, 
however, an estimated 11% prevalence of obesity was found among 2–14 year olds in the 2014/15 NZHS. This 
is of concern because there are implications for future health, given the association with type 2 diabetes and the 
risk of high blood pressure, coronary heart disease and stroke later in life.5 The unadjusted prevalence rate of 
childhood obesity in the 2014/15 NZHS was significantly higher than that in the 2006/07 survey. The rate for 
type 2 diabetes among 15–24 year olds is less than 1% and has been much the same in recent years. 
The prevalence of children being diagnosed with autism spectrum disorder varies with age, with the 2014/15 
NZHS rate being about 0.5% among those aged 2–4 years and 1.5% among the 10–14 year olds. Rates have 
increased over the years, reflecting similar trends overseas not fully understood but possibly influenced by 
increased recognition of the condition. 
The NZHS 2014/15 indicated that prevalence rates for eczema have been increasing, especially among those 
aged 0–4 years. Hospitalisations of 0–24 year olds has risen from below 100 to over 200 per 100,000 population 
for eczema and dermatitis as the primary diagnosis, while the rates rose from about 540 to 790 per 100,000 
population for cases where eczema and dermatitis were reported but were not the primary reason for the 
hospitalisation. These are often for the 0–4 year olds. The presence of such conditions for children and young 





New indicators and new thinking have been taken into consideration in presenting data in this report. While 
obesity has traditionally been viewed as separate from eating disorders, increasingly they are being considered 
as parts of a continuum with common risk factors and scope for integrated prevention. Musculoskeletal 
conditions have been included reflecting an increasing rate of hospitalisations for the suite of conditions that 
includes juvenile arthritis, juvenile osteochondrosis, and scoliosis. 
A major limitation of this report is that it cannot address questions that require outpatient data. These data are 
not available at a national level. While the inclusion of the New Zealand Health Survey data provides a little 
more detail about estimated population prevalence for a few indicators, the full picture of outpatient and primary 
health care data is required for planning nationally and by district health boards.  
A further limitation in this report is the lack of data on the transition of children and young people into adult 
services, particularly in health, a process that those with chronic conditions and disabilities almost inevitably 
face. A transition into adults able to reach their potential by achieving in education, gaining meaningful 
employment, and participating in their community is an aim that many children and young people with chronic 
conditions and disabilities aspire to.  
Review topics 
Two issues were selected by participating DHBs for review and inclusion in this report: Fetal alcohol spectrum 
disorder (FASD) by Judith Adams, and The health needs of children and young people in State care by Mavis 
Duncanson. 
Fetal alcohol spectrum disorder (FASD) contributes to many poor outcomes for New Zealand’s young people 
including early mortality, abuse and neglect, poor educational achievement, engagement with the criminal 
justice system, benefit dependence, and mental health and alcohol and drug problems. This chapter provides 
information on the features of FASD, the life course consequences of FASD and the comorbidities of FASD. It 
discusses international studies on the epidemiology of FASD. Diagnosis of FASD is not straightforward so 
methods of diagnosis are reviewed, along with the findings from a review of the Hawke’s Bay DHB’s FASD 
assessment pathway. Subsequent sections look at the evidence base for interventions to address the difficulties 
faced by people with FASD and their families. The final sections reviews what is known about New Zealand 
women’s drinking habits, the patterns of drinking that are associated with the greatest risk of FASD and the 
evidence regarding the effectiveness of interventions to prevent the harm resulting from prenatal exposure to 
alcohol. 
In New Zealand there have consistently been around 5,000 children and young people in the custody of the 
Chief Executive of Child, Youth and Family (in CYF care) each year. Many children and young people referred 
to Child, Youth and Family have high levels of long-term need and disadvantage. Health and educational 
assessments (Gateway Assessments) of children and young people in CYF care have identified multiple health 
needs for most children. Internationally it is well recognised that children and young people in State care often 
present with complex and serious health problems. This chapter uses published reports to describe the group of 
children in CYF care in New Zealand and to outline key characteristics of the current and proposed new care 
and protection systems, particularly those relevant to health services. The chapter also provides a rapid review 
of New Zealand and international literature regarding the health needs of children and young people in 
State care and guidelines for best practice in providing care to them. 
Appendices  
The content of the appendices may be helpful when interpreting information in this report. Appendix 1 provides 
an overview of the methods used to develop the reviews of evidence for good practice, which appear at the 




Appendix 2 describes the statistical methods used, including a description of rates calculated within the data. 
Appendix 3 contains information on the data sources used to develop each indicator and discusses data 
limitations. Appendix 4 deals with the measurement of ethnicity and also provides an overview of the NZ 
Deprivation Index; NZDep 2013 is used where data relate to the 2013 Census. Appendix 5 displays the tables 
of clinical codes referred to in this report.  
Conclusion 
This report reviews the prevalence of a range of disabilities and chronic conditions experienced by children and 
young people living in New Zealand. These conditions place demands on health and disability support services. 
This report provides information on the secondary health service utilisation patterns of children and young 
people with chronic conditions and disabilities. It is unable to provide data on all health service use as these data 
are not collated nationally. It does, however, aim to provide some insights into two quite different perspectives 
of disability and chronic conditions: the consequences and management of children with fetal alcohol syndrome, 
and a review of the health needs of children in care. 
While the data presented are at times imperfect, and at best only provide a glimpse of the health needs of these 
diverse groups of children and young people, the current paucity of data should not preclude DHBs reviewing 
the health and disability support services available locally (including those with a public health focus), with a 
view to considering whether further improvements are required within the region. 
Increasingly high quality evidence is becoming available to direct future initiatives for a number of the 
conditions included here. The number of systematic reviews has risen exponentially in many of these fields. 
Some of these will inform the development of integrated services to benefit the children and young people with 
chronic conditions and disabilities, and those who care for them. 
Table 1 presents an overview of children and young people hospitalised in New Zealand with chronic 
conditions, babies born with congenital anomalies and babies who died as a result of congenital anomalies, and 
cancer notifications of children and young people. 






Primary diagnosis All cases 
Cystic fibrosis                 336                  2,122                          2,625  
Diabetes              4,137                 6,466                        12,308  
Eating disorders               1,012                  1,509                           2,301  
Autism spectrum disorder              1,853                      485                           3,015  
Cerebral palsy              1,678                 2,458                          5,852  
Epilepsy             4,336                 7,440                          9,876  
Chronic lower respiratory diseases           29,184              37,909                       48,433  
Inflammatory bowel disease              1,447                  5,168                          5,999  
Constipation           14,578                 7,805                        18,723  
Eczema and dermatitis            15,331                 5,022                        18,950  
Musculoskeletal disorders              1,506                  2,431                           3,016  
        
  n NZ rate 95% CI 
Babies with one or more congenital anomalies            21,219                 67.56  66.66–68.48  
Infant mortality with congenital anomalies                 439                      1.41  1.28–1.55  
Cancer notifications 0–14 year olds                 699                  14.67  10.53–19.91  
Cancer notifications 15–24 year olds                  821                 26.34  24.57–28.21  
Unique individuals* were identified as being hospitalised at least once from 2011–2015; Hospitalisations are all relevant 
hospitalisations 2011–2015; Congenital anomaly data are 2009–2013; Congenital anomaly rates are per 1,000 total births; 
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Congenital anomalies, also known as birth defects, congenital disorders or congenital malformations, are 
structural or functional anomalies that exist at or before birth (although they may not be detected until later in 
life).1 They are major causes of fetal, infant and child deaths, and chronic illness and disability.1 Congenital 
anomalies may occur in isolation or they may occur together in a pattern corresponding to a named syndrome, 
such as Down syndrome or achondroplasia (dwarfism).2 
Congenital anomalies vary in severity from the inevitably lethal, such as absent kidneys, to minor abnormalities 
of cosmetic significance only. Major anomalies, those anomalies that have medical and/or social implications 
and often require surgical repair, occur in approximately three to four percent of all live births.3 Common major 
anomalies include heart defects, cleft lip and palate, neural tube defects, and chromosomal abnormalities (the 
most common of which is Down syndrome).3 
In at least half of all occurrences of congenital anomaly, no cause can be identified.1,4 Genetic factors are 
important in many congenital anomalies, particularly syndromic anomalies.1 Genetic factors cause around one 
third of all congenital anomalies and about 85% of those with known causes.5 Environmental factors of various 
kinds, including vitamin deficiencies, can cause congenital anomalies, for example: insufficient maternal intake 
of folic acid increases the risk of neutral tube defects; maternal infection with Zika virus seems to cause 
microcephaly; and poorly controlled pregestational maternal diabetes increases the risk of major anomalies in 
the cardiovascular and central nervous systems and in craniofacial structures.1,6 
The following section uses data from the National Minimum Dataset to describe congenital anomalies in babies 
from 2000–2015 and concludes with a brief overview of some of the evidence relating to early diagnosis of 
these conditions. 
Data sources and methods 
Indicators  
 Prevalence of congenital anomalies Infant mortality associated with congenital anomalies 
Definition  
Anomalies diagnosed in stillbirths and live born babies up to one year of age are included, and cases identified based on 
codes adapted from those used by BINOCAR and by registers in Australia7 
Stillbirths are of at least 400g birthweight or 20 weeks gestation (as defined by the Ministry of Health) 
Numerators: Live born infants hospitalised: National Minimum Dataset 
 Stillbirths: National Mortality Collection 
 Infant deaths associated with congenital anomalies: National Mortality Collection 
Denominators:  Total births 
 
Live births: Birth Registration Dataset 
Stillbirths: National Mortality Collection 
Prevalence per 1,000 live births 
Additional information 
Anomalies are year of birth; births are registration year. 
Codes used for identifying cases are documented in Appendix 5  
Maternal age was only available for 72% of cases. 
Prevalence rates presented for sex-specific anomalies are sex-specific rates. 





National trends and distribution 
The number of babies with at least one congenital anomaly (including minor defects) gradually increased from 
2000 to 2007. There was a noticeable dip between 2008 and 2011, which corresponded with a decrease in 
diagnoses of minor skin anomalies, such as tags and birthmarks. From 2012 onwards, numbers have been 
similar to those in 2007 (Figure 1). The proportion of babies born with one or more congenital anomalies has 
fluctuated slightly from year to year but, on average, has been around seven per cent (Table 2). 
Figure 1. Number of babies born and those with one or more congenital anomalies, by year, New Zealand 
2000-2015 
 
Source: National Minimum Dataset, National Mortality Collection, Birth registration dataset. (Total) births corresponds to live 
births and fetal deaths, * 2014 and 2015 are live births only 
Table 2. Proportion of babies with one or more congenital anomalies, by year, New Zealand 2000–2015 
Year Babies with an anomaly (n) Total births (n) % of total births 
New Zealand 
Congenital anomalies 
2000–2008 39,291 536,368 7.3 
2009 3,744 63,767 5.9 
2010 4,004 65,168 6.1 
2011 3,991 62,624 6.4 
2012 4,650 62,483 7.4 
2013 4,830 60,026 8.0 
2014* 4,971 58,285 8.5 
2015* 4,535 62,122 7.3 
Total 70,016 970,843 7.2 
Source: National Minimum Dataset, National Mortality Collection, Birth registration dataset. Total births corresponds to live 
births and fetal deaths, * 2014 and 2015 are live births only 
Diagnosis  
Table 3 presents the number of cases and prevalence for each congenital anomaly subgroup. The group of 
anomalies with the highest prevalence between 2009 and 2013 was digestive system anomalies, followed by 
congenital heart defects, and then limb anomalies. Refer to Appendix 5 for details on the specific congenital 




















































































Table 3. Babies with one or more congenital anomalies, by anomaly subgroup, New Zealand 2009–2013 
Babies with an anomaly (n) 





All cases* 21,219 67.56 66.66–68.48 
Digestive system 7,075 22.53 22.01–23.06 
Congenital heart defects 3,902 12.42 12.04–12.82 
Limb 3,536 11.26 10.89–11.64 
Genital 2,140 6.81 6.53–7.11 
Urinary 1,322 4.21 3.99–4.44 
Respiratory 1,186 3.78 3.56–4.00 
Nervous system 748 2.38 2.21–2.56 
Chromosomal anomalies 701 2.23 2.07–2.40 
Ear, Face and Neck 689 2.19 2.03–2.36 
Orofacial clefts 524 1.67 1.53–1.82 
Eye 233 0.74 0.65–0.84 
Abdominal wall defects 228 0.73 0.63–0.83 
Neural tube defects 150 0.48 0.40–0.56 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly. *Babies are counted once overall, once for each sub-group 
and for each anomaly documented  
Demographic distribution 
Table 4 presents the demographic distribution of congenital anomalies in New Zealand between 2009 and 2013. 
There were no significant differences by New Zealand Deprivation Index quintile. The prevalence of anomalies 
was significantly higher for male babies. Māori, Pacific, Asian/Indian and MELAA babies all had statistically 
significantly lower congenital anomaly prevalence rates than babies of European/Other ethnicities but only the 
Māori rate was markedly lower than the European/Other rate. Compared to babies born to mothers aged 30–34 
years, babies born to mothers aged 20–29 years had slightly but significantly lower rates while babies born to 
mothers aged over 35 years had significantly higher rates. Over the period 2000–2015, rates for the four largest 
ethnic groups were reasonably steady although there was a dip in rates between 2006 and 2012 (Figure 2). 




Table 4. Babies with one or more congenital anomalies, by demographic factor, New Zealand 2009–2013 
Variable 2009–2013 (n) 
Prevalence per 
1,000 births 
Rate ratio 95% CI 
Congenital anomalies 
NZ Deprivation Index quintile 
Deciles 1–2 3,088 67.77 1.00   
Deciles 3–4 3,430 68.06 1.00 0.96–1.05 
Deciles 5–6 3,731 64.79 0.96 0.91–1.00 
Deciles 7–8 4,737 68.61 1.01 0.97–1.06 
Deciles 9–10 6,168 68.35 1.01 0.97–1.05 
Prioritised ethnicity  
Māori 4,353 47.76 0.61 0.59–0.63 
Pacific 2,445 69.47 0.89 0.85–0.93 
Asian/Indian 2,865 72.82 0.93 0.90–0.97 
MELAA 343 64.29 0.82 0.74–0.91 
European/Other 11,144 77.97 1.00   
Gender 
Female 8,442 55.20 1.00   
Male 12,773 79.28 1.44 1.40–1.47 
Maternal age 
<20 years 996 48.55 1.00 0.93–1.06 
20–24 years 2,526 43.52 0.89 0.85–0.94 
25–29 years 3,554 45.02 0.92 0.88–0.96 
30–34 years 4,291 48.79 1.00   
35+ years 3,860 56.26 1.15 1.11–1.20 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Babies with at least one diagnosed anomaly, Rate ratios are unadjusted, Ethnicity is level 1 prioritised, 
Decile is NZDep2013, Maternal age reported where available 
Figure 2. Babies with one or more congenital anomalies, by ethnicity, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 


































The lowest prevalence rate of congenital anomalies between 2009 and 2013 was for babies born to mothers aged 
20–24 years at delivery. Prevalence was significantly lower for babies born to mothers aged 20–29 years and 
significantly higher for babies born to mothers 35 years and over (compared to mothers aged 30–34 years; 
Table 4, Table 5). The prevalence of chromosomal anomalies increased with increasing maternal age with the 
highest prevalence being for babies born to mothers aged 35 years and over. Prevalence of non-chromosomal 
anomalies was highest for babies born to mothers aged under 20 years and 35 years and over (U-shaped 
distribution across the maternal age groups). Most of the non-chromosomal anomaly subgroups had a U-shaped 
prevalence distribution except for abdominal defects, for which the prevalence was highest for the under 20 year 
maternal age group and decreased as maternal age increased (Table 5). 




Total <20 years 20–24 years 25–29 years 30–34 years 35+ years 
Congenital anomalies 
New Zealand 
Total births (n) 314,068 20,513 58,042 78,941 87,956 68,616 
Babies with an 
anomaly (n) 
21,219 996 2,526 3,554 4,291 3,860 





























































































































































Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. * Babies are counted once overall, some babies will have multiple anomalies and appear in more than one 
row, Maternal age reported where available. ** Non-chromosomal anomalies exclude cases with chromosomal anomalies 
present, NS = Nervous system, CHD = Congenital heart defects, OFC = Oro-facial clefts, Abdominal = Abdominal wall defects 
The overall prevalence of babies with one or more congenital anomalies was significantly higher than the 
national rate between 2009 and 2013 in the four Northern DHBs, and in Hutt Valley and Capital & Coast DHBs. 
The prevalence was significantly lower than the national rate in Waikato, Bay of Plenty, Lakes, Taranaki, 
Hawke’s Bay, MidCentral, Whanganui and Nelson Marlborough DHBs. There was no significant difference 




Table 6. Babies with one or more congenital anomalies, by district health board, New Zealand 2009–2013 
Babies with an anomaly 2009–2013 (n) Rate per 1,000 births Rate ratio 95% CI 
Congenital anomalies 
Northland 847 72.90 1.08 1.01–1.15 
Waitemata 3,321 83.90 1.24 1.20–1.29 
Auckland DHB 2,394 72.59 1.07 1.03–1.12 
Counties Manukau 3,175 73.01 1.08 1.04–1.12 
Waikato 1,563 56.61 0.84 0.80–0.88 
Bay of Plenty 898 61.03 0.90 0.85–0.96 
Lakes DHB 465 58.78 0.87 0.80–0.95 
Tairawhiti 226 60.07 0.89 0.78–1.01 
Taranaki 312 39.49 0.58 0.52–0.65 
Hawke's Bay 534 46.23 0.68 0.63–0.74 
MidCentral 544 47.91 0.71 0.65–0.77 
Whanganui 257 58.21 0.86 0.76–0.97 
Hutt Valley 870 83.47 1.24 1.16–1.32 
Capital & Coast 1,498 77.03 1.14 1.08–1.20 
Wairarapa 183 68.49 1.01 0.88–1.17 
Nelson Marlborough 450 55.07 0.82 0.74–0.89 
South Canterbury 215 68.45 1.01 0.89–1.15 
Canterbury 2,035 64.49 0.95 0.91–1.00 
West Coast 134 63.12 0.93 0.79–1.10 
Southern DHB 1,242 67.41 1.00 0.94–1.05 
New Zealand 21,219 67.56 1.00   
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 
Mortality Collection. Prevalence per 1,000 births. (Total) births corresponds to live births and fetal death. Babies with one or 
more diagnosed anomalies 
Figure 3. Babies with one or more congenital anomalies, by district health board, New Zealand, 2009–2013 
 
Numerator: National Minimum Dataset and National Mortality Collection, Denominator: Birth registration dataset and National 





























































































































































Congenital anomaly-related infant mortality 
The infant mortality rate in New Zealand between 2009 and 2013 was 5.14 per 1,000 live births. Over 27% of 
the infants who died had at least one congenital anomaly (Table 7). The infant mortality rate associated with 
congenital anomalies gradually decreased from 1990–91 to 2006–07 and from then on increased slightly from 
year to year (Figure 4). Congenital heart defects, nervous system defects, and chromosomal anomalies were the 
predominant congenital anomaly subgroups contributing to infant mortality (Table 7).  
Table 7. Infant mortality with one or more congenital anomalies, by anomaly subgroup, New Zealand 2009–2013 
2009–2013 n 
Rate per 1,000 live 
births 
95% CI 
Congenital anomaly infant mortality 
New Zealand 
Infant mortality 1,603 5.14 4.89–5.40 
Infant mortality with a congenital anomaly* 439 1.41 1.28–1.55 
Congenital heart defects 181 0.58 0.50–0.67 
Nervous system 82 0.26 0.21–0.33 
Chromosomal anomalies 79 0.25 0.20–0.32 
Digestive system 64 0.21 0.16–0.26 
Urinary 54 0.17 0.13–0.23 
Respiratory 48 0.15 0.11–0.20 
Neural tube defects 33 0.11 0.07–0.15 
Limb 20 0.06 0.04–0.10 
Abdominal wall defects 11 0.04 0.02–0.06 
Eye <10 s s 
Orofacial clefts <10 s s 
Genital <10 s s 
Ear, Face and Neck 0 .. .. 
Numerator: National Mortality Collection, Denominator: Birth registration data. Congenital anomaly infant mortality per 
1,000 live births. *Infant mortality with one or more anomalies. One infant excluded for presence of single anomaly of minor 
severity; Some Infant mortality will have multiple anomalies and appear in more than one subgroup 
Figure 4. Infant mortality with one or more congenital anomalies, by year, New Zealand 1990–2013 
 
Numerator: National Mortality Collection, Denominator: Birth registration dataset. Babies with one or more diagnosed 
congenital anomalies 
The congenital anomaly infant mortality rate was significantly higher than the national rate between 2009 and 
2013 in Counties Manukau DHB, and was significantly lower in Waitemata and Canterbury DHBs. There was 




























































































Figure 5. Infant mortality with one or more congenital anomalies, by district health board, New Zealand, 
2009– 2013 
 
Numerator: National Mortality Collection, Denominator: Birth registration dataset. Infant mortality with one or more diagnosed 
congenital anomalies; Congenital anomaly infant mortality per 1,000 live births 
Table 8. Infant mortality with one or more congenital anomalies, by district health board, New Zealand 2009–2013 
DHB 
Infant mortality with 
an anomaly (n) 
Rate* Rate ratio 95% CI 
% of infant 
deaths 
Congenital anomaly associated infant mortality 
Northland 16 1.39 0.99 0.60–1.62 19.8 
Waitemata 25 0.64 0.45 0.30–0.68 21.4 
Auckland 55 1.68 1.19 0.90–1.58 38.5 
Counties Manukau 86 1.99 1.42 1.12–1.78 27.4 
Waikato 44 1.60 1.14 0.84–1.55 25.7 
Bay of Plenty 26 1.78 1.26 0.85–1.87 29.2 
Lakes 12 1.53 1.08 0.61–1.92 25.0 
Tairawhiti <5 s s s s 
Taranaki 12 1.53 1.09 0.61–1.93 29.3 
Hawke's Bay 21 1.83 1.30 0.84–2.02 30.4 
MidCentral 19 1.69 1.20 0.76–1.90 33.9 
Whanganui 11 2.51 1.79 0.98–3.24 33.3 
Hutt Valley 13 1.26 0.89 0.51–1.55 24.5 
Capital & Coast 25 1.29 0.92 0.61–1.37 34.2 
Wairarapa <5 s s s s 
Nelson Marlborough 9 1.11 0.79 0.41–1.52 32.1 
South Canterbury 7 2.24 1.59 0.76–3.36 31.8 
Canterbury 28 0.89 0.63 0.43–0.93 19.9 
West Coast <5 s s s s 
Southern 18 0.98 0.70 0.44–1.12 25.4 
New Zealand 439 1.41 1.00   27.4 
Numerator: National Mortality Collection, Denominator: Birth registration dataset. Infant mortality with one or more diagnosed 
















































































































































































Evidence for good practice 
Possibilities for prevention 
The majority of congenital malformation have no known cause. For this reason, the avenues for prevention are 
limited and the effects of interventions modest. Some major structural malformations can be detected during 
pregnancy via ultrasound examination and most chromosomal and some genetic disorders can be detected via 
amniocentesis, chorionic villus sampling or non-invasive prenatal testing. Prenatal diagnosis allows parents to 
choose termination when their fetus has a condition likely to be fatal or severely disabling, or delivery in a 
tertiary centre with appropriate surgical expertise when their baby will require surgery soon after birth. 
Table 9 indicates where prenatal detection is possible (to a variable degree), by ultrasound examination and/or 
genetic testing, where optimal health status before and during pregnancy and good antenatal care may reduce the 
incidence of the condition, and where early postnatal detection improves outcomes. For genetic conditions 
(including cystic fibrosis), pre-natal genetic testing is generally offered only in cases where there is a family 
history of the condition or where a genetic condition is suspected, for example, as a result of findings from 
maternal blood tests and/or prenatal ultrasound examination. The prenatal detection rate varies from condition to 
condition. The overall detection rate for structural anomalies via ultrasound in the first trimester is around 50%,8 
and for lethal anomalies the ultrasound detection rate in the second semester is over 80%.9,10 





Incidence reduced by 
optimal health status before 
and during pregnancy 






Down syndrome and other 
chromosomal disorders 
 x* x 11,12 
Cystic fibrosis    13-15 
Neural tube defects    16 
Cardiovascular anomalies    17-20 
Other structural congenital anomalies    8-10 
Genetic metabolic disorders  x  21,22 
Congenital hearing loss     23-25 
*Incidence is lower in younger women 
Brief notes relevant to the prevention of congenital anomalies  
Some neural tube defects can be prevented by peri-conceptional folic acid supplementation: The Ministry 
of Health recommends that women wishing to become pregnant who are at low risk of having a pregnancy 
affected by a neural tube defect should take 800 µg of folic acid daily for at least four weeks prior to conception 
and for 12 weeks after.26 The 2015 Cochrane review on this topic found high quality evidence that daily folic 
acid supplementation prevents some neural tube defects (risk ratio 0.31, 95% CI 0.17 to 0.58; five studies; 6708 
births).16 Since this review, some evidence has been published for a possible protective effect of folic acid in 
relation to congenital heart defects and cleft lip and palate.27,28 
Maternal smoking is associated with an increased risk of non-chromosomal birth defects: Odds ratios in 
the range 1.25–1.50 for limb reduction defects, clubfoot, oral clefts and defects of the eyes and gastrointestinal 
system (especially gastroschisis and abdominal hernias), and odds ratios in the range 1.09–1.19 for digit 
anomalies, cryptorchidism and defects of the heart and musculoskeletal system.29 
Heavy drinking in pregnancy, especially binge drinking, can have severe effects on the developing fetus by 
disrupting brain development leading to cognitive, motor and behavioural disability with life-long 
consequences.30,31 Fetal alcohol syndrome also produces distinctive facial anomalies if fetal exposure occurs in 
mid-gestation, and growth retardation, and is associated with a greatly increased risk of vision and hearing 
impairments, and a wide variety of congenital malformations.30,32 
Maternal obesity seems to be associated with a small increase in the rates of some congenital anomalies, 
including heart defects and neural tube defects, and the risk may increase with greater degree of obesity.33-35 In 
addition, maternal obesity is associated with at least 20% lower rates of detection of fetal anomalies via 




Diabetic women who become pregnant have a risk of having a baby with a major congenital anomaly around 
that is twice that of other women38 and a risk having a baby with a congenital heart defect that is almost four 
times higher.17 These risks can be reduced by optimising maternal health in the peri-conception period 
especially by maintaining good control of blood glucose levels.20 
Maternal infections known to cause birth defects include toxoplasmosis, rubella, cytomegalovirus, herpes, 
and syphilis (the TORCH infections), as well as varicella, influenza, Zika virus and Lymphocytic 
Choriomeningitis (the last two are not known to occur in New Zealand).39-42 
Common medications causing birth defects include: angiotensin converting enzyme inhibitors (for 
hypertension), anticonvulsants (for epilepsy), anti-neoplastic agents (for cancer), and systemic retinoids (for 
acne and other skin conditions).39,43,44 In general, medicines should be prescribed to pregnant women only when 
absolutely necessary, when the benefits outweigh the risks. Risks associated with some medications can be 
mitigated, for example folic acid supplementation can reduce risks associated with anti-convulsant medication. 
Key points for achieving optimal pre-pregnancy health status to reduce congenital anomaly risk:45 
• Take folic acid supplements (to prevent neural tube defects) 
• Seek medical advice before becoming pregnant if you have a chronic condition such as diabetes, 
hypothyroidism, epilepsy or hypertension where the condition itself, or the medication used to treat it, 
may increase the risk of congenital anomalies in your baby 
• Avoid smoking, alcohol and recreational drugs 
• Lose weight if obese 
• Seek medical advice before becoming pregnant if there is a family history of a genetic disorder 
• Make sure you are immune to rubella, consider varicella vaccination if not already immune 
Key points for achieving optimal health status during pregnancy to reduce congenital anomaly risk45-47 
• Avoid smoking, alcohol and recreational drugs 
• Take folic acid and iodine 
• Do not take therapeutic drugs except on medical advice that the benefits outweigh the risks 
• Register with a Lead Maternity Carer early in pregnancy (before 10 weeks’ gestation) 
• Make a decision about screening tests 
• Take care with personal and food hygiene, wash hands before eating (especially if you have contact 
with young children), and avoid contact with cat faeces 
Although listeria infection does not cause congenital anomalies, pregnant women should avoid eating soft 
cheeses, delicatessen meats, pâtés, hummus-based spreads, refrigerated smoked seafood and salad bar cold 
salads to prevent miscarriage, preterm birth and stillbirth due to listeria infection.48,49 
The following section uses data from the National Minimum Dataset to describe congenital anomalies in babies 
from 2000–2015 and concludes with a brief overview of some of the evidence relating to early diagnosis of 
these conditions. 
Evidence-based health care for children, young people and parents affected by 
congenital anomalies  
There are many thousands of different congenital anomalies so it is not practical to provide information here on 
the specific care each one requires. Instead, this section offers information on some new developments in 
prenatal and postnatal detection of congenital anomalies and highlights some of the findings from a review of 
the maternity care received by women who experienced perinatal deaths due to congenital anomalies in New 
Zealand in 2010.  
In New Zealand, pregnant women are offered screening tests for Down syndrome and a fetal anatomy scan at 
18–20 weeks’ gestation.50 The aim of fetal anomaly screening is to identify potential problems so that parents 
can make an informed choice about whether to continue the pregnancy if an anomaly is identified, and have 
time to prepare for what is to come, whether it is a termination, a baby who will need postnatal treatment or 
palliative care, or a child who will have long term disability.51 Prenatal detection also allows planning for 
delivery in a specialist centre and, for a few conditions, intra-uterine therapy.51 Ultrasound scanning to detect 
fetal malformations reduces perinatal mortality rates if there is a high level of diagnostic expertise and 




In New Zealand in 2010 there were 211 perinatal deaths due to congenital anomalies (30% of the 704 perinatal 
deaths in that year).53 A review project based on the Perinatal and Maternal Mortality Review Committee 
dataset assessed the quality of the maternity care received by the women with one of the 137 perinatal deaths 
that were due to a congenital cardiovascular, central nervous system or chromosomal abnormality in that year.53 
The review found that first contact with a health practitioner (most often a GP) occurred within 10 weeks of 
gestation in 74% of the women and within 14 weeks in 85% but there was often a significant delay in registering 
with a lead maternity carer (LMC). This meant that some women presented to a LMC too late for first trimester 
screening for Down syndrome. Of the 129 women who presented to a health professional at less than 20 weeks’ 
gestation, 97 (71% of the 137) were offered first and/or second trimester screening and 82 (60% of the 137) had 
first and or second trimester screening. Fifteen women (11% of the 137) declined screening. 
The review also found that only 7% of the women were documented as having taken folate supplements (to 
prevent neural tube defects) prior to pregnancy although 54% had taken them during pregnancy. On review of 
the women’s ultrasound images it was found that some anomalies could have been detected earlier. The review 
made a number of recommendations, including those following. All women should receive preconception 
counselling to optimise their health and identify any risks for congenital anomalies resulting from previous 
obstetric history or family history. There should be a media campaign to promote peri-conceptional folate and 
the evidence on fortification of bread with folate should be further investigated. All women should be educated 
about the importance of booking before 10 weeks. GPs should be effective at offering first trimester screening 
since they are often a woman’s first point of contact with maternity care and they should expedite booking with 
a LMC. If screening has not already been arranged then LMCs should offer all women first and second trimester 
screening, as required by the Ministry of Health, as this will enable the early diagnosis of a proportion of 
congenital anomalies. 
It is now possible to test for Down, Edwards and Patau syndromes early in pregnancy using cell-free fetal DNA 
obtained from a sample of the mother’s blood (non-invasive prenatal testing, NIPT).54 A recent systematic 
review commissioned by the UK National Screening Committee, which included 41 studies relevant to Down 
syndrome, found that NPIT has very high sensitivity (99.3%) and specificity (99.9%) for Down syndrome.55 
Nevertheless, in the general obstetric population where the prevalence of Down syndrome is low, it could be 
expected that for every four Down syndrome cases detected there would be one false positive result so it is 
essential that, if a woman is considering a termination following a positive NIPT result, she has the diagnosis 
confirmed with an invasive diagnostic test (amniocentesis or chorionic villus sampling).55 Non-invasive prenatal 
testing is available to New Zealand women on a user pays basis but is not yet part of publicly funded ante-natal 
screening.56 
Congenital heart disease (CHD) causes more early neonatal deaths that any other type of congenital anomaly, 
accounting for around 30% of all early neonatal deaths associated with congenital anomalies in EUROCAT (a 
European network of population-based registries) in 2008–2012.57 In cases of major or critical CHD (defined as 
cases requiring intervention or resulting in death within one year or within four weeks, respectively) delayed 
diagnosis is associated with increased mortality and morbidity.58 
In New Zealand during 2006–2010 antenatal ultrasound picked up only 46% of critical CHD.59 Postnatal 
physical examination cannot detect all babies with CHD as some do not display any physical symptoms until 
after hospital discharge.58 Almost 20% of New Zealand infants with critical CHD are not diagnosed until after 
initial hospital discharge.59 
Newborn pulse oximetry will detect hypoxaemic infants and is a simple and non-invasive method for screening 
for CHD which increases detection rates for CHD when used as an adjunct to physical examination.58 A number 
of developed countries have such screening and a pulse oximetry pilot programme is currently underway in 
Auckland and Wellington.60,61 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of congenital anomalies are provided for further reading. 
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Cystic fibrosis (CF) is a multi-organ disease with an autosomal recessive pattern of inheritance. For a child to 
have CF both parents need to be carriers of a CF gene. It is most common in populations of predominantly 
Northern European descent where around one in 3,000 babies are born with the condition.1 Most developed 
countries where CF is common, including New Zealand, have national newborn screening programmes that 
identify most babies with CF soon after birth.1,2  
Cystic fibrosis is caused by a number of mutations in the gene encoding the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein.3 The CFTR regulates anion transport across cell membranes. When 
CFTR activity is reduced or absent the mucus secreting functions of the epithelial cells lining the airways, 
pancreatic ducts and other tissues are impaired.3 The most significant result of this dysfunction is obstruction of 
the small airways by thick mucus leading to frequent infections, bronchiectasis and progressively worsening 
lung function. Other effects include pancreatic insufficiency leading to malabsorption of nutrients (and diabetes 
in some cases), and cirrhosis of the liver. Most males with CF have congenital absence of the vas deferens 
which makes them infertile.4  
Life expectancy for people with CF is improving due to better treatment and it is now around forty years.1,5 
Recently, new drugs have been developed that correct the basic defect in one genetic mutation in CFTR.6 These 
drugs hold the promise of effective disease-modifying treatment and could potentially prevent lung disease if 
they were started as soon as the disease was identified by newborn screening.1 
The following section reviews cystic fibrosis in children and young people using information from the newborn 
metabolic screening programme, New Zealand Cystic Fibrosis Registry, National Mortality Collection and 
National Minimum Dataset. The section concludes with a brief overview of possibilities for prevention and 
evidence-based health care for children and young people with CF. 
Data sources and methods 
Indicator  
 Rates of cystic fibrosis (CF) among 0–24 year olds 
Definition  
Hospitalisations of 0–24 year olds with cystic fibrosis per 100,000 population 
Data sources 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
Cystic fibrosis was the primary diagnosis or was documented as one of the first 15 diagnoses 
Codes used for identifying cases are documented in Appendix 5. 
National trends and distribution 
There were 14 deaths of 0–24 year olds with cystic fibrosis (CF) as the underlying cause of death in New 
Zealand during 2009 to 2013, as documented within the National Mortality Collection. 
CF is one of the 20 congenital metabolic disorders that babies are screened for within the New Zealand 
Newborn Metabolic Screening Programme (NMSP).2 Screening tests are performed utilising blood samples 
obtained from the babies’ heels during the first 48–72 hours of life. The NMSP screened 58,673 babies in 2014, 
of which 15 had cystic fibrosis detected. The 2014 incidence rate of CF was 27.1 per 100,000 live births, 
including one case diagnosed outside of the NMSP. 
The National Cystic Fibrosis Data Registry includes over 95% of people with CF in New Zealand. Around two-
thirds (n=293) of the 443 individuals registered in 2014 were registered before 24 years. Of those registered, 33 
(7.4%) were aged 0–3 years at registration.7  
Cystic fibrosis 
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The number of 0–24 year olds hospitalised with CF during 2011 to 2015 is presented in Table 10. It also 
presents the number of hospital discharges in which CF was documented as the primary diagnosis or as any 
diagnosis. 
While there has been year-on-year variability in hospitalisations for CF since 2000, the hospitalisation rate has 
remained relatively stable over the last five years (Figure 6). 
Table 10. Individuals aged 0–24 years hospitalised with cystic fibrosis using primary diagnosis compared to all 
cases, New Zealand 2011–2015 
Age group Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary  
Primary diagnosis All cases 
Cystic fibrosis 
Hospitalisation 
0–24 years 336 2,122 2,625 1.24 
0–14 years 226 1,199 1,533 1.28 
15–24 years 147 923 1,092 1.18 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with cystic fibrosis listed in any of the first 15 
diagnoses; The sum of the age groups may total to more than the 0–24 year old total 






























































































s Cystic fibrosis 0–24 years
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 





The majority of hospitalisations of 0–24 year olds involving cystic fibrosis had CF as the primary reason for 
hospitalisation. The diagnoses with the highest hospitalisation rate were CF with pulmonary or other 
manifestations (Table 11). 
Table 11. Hospitalisations involving cystic fibrosis in 0–24 year olds, by primary diagnosis, New Zealand 
2011– 2015 
Primary diagnosis n 
Annual 
average 
Rate 95% CI % 
Cystic fibrosis* in 0–24 year olds 
New Zealand  
Cystic fibrosis with pulmonary manifestations 955 191 12.43 11.67–13.25 36.4 
Cystic fibrosis with intestinal manifestations 76 15 0.99 0.79–1.24 2.9 
Cystic fibrosis with other manifestations 968 194 12.60 11.83–13.42 36.9 
Cystic fibrosis, unspecified 123 25 1.60 1.34–1.91 4.7 
Cystic fibrosis total 2,122 424 27.63 26.48–28.83 80.8 
Other endocrine, nutritional and metabolic diseases 12 2 0.16 0.09–0.27 0.5 
Diseases of the respiratory system 106 21 1.38 1.14–1.67 4.0 
Diseases of the musculoskeletal system and connective tissue 76 15 0.99 0.79–1.24 2.9 
Factors influencing health service contact 75 15 0.98 0.78–1.22 2.9 
Symptoms and/or abnormal clinical findings NEC 69 14 0.90 0.71–1.14 2.6 
Injury and/or poisoning 58 12 0.76 0.58–0.98 2.2 
Infectious and parasitic diseases 38 8 0.49 0.36–0.68 1.4 
Other diagnoses 69 14 0.90 0.71–1.14 2.6 
Total 2,625 525 34.18 32.89–35.51 100.0 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Cystic fibrosis in any of the 
first 15 diagnoses; Rate per 100,000 0–24 year olds; NEC = not elsewhere classified  
Demographic distribution 
Table 12 presents the demographic distribution of individuals with CF in New Zealand between 2011 and 2015. 
CF was significantly lower among individuals residing in areas with high deprivation scores (NZDep2013 
deciles 9–10), and significantly higher among 0–4 year olds compared to 15–24 year olds. The majority of 
individuals with CF were of European/Other ethnicities.  
Although the age specific rate of 0–4 year olds with CF is higher than those for the other age groups, 
hospitalisations have generally been lower for 0–4 year olds (Figure 7). The hospitalisation rate for Māori has 
gradually increased since 2000, although is still consistently lower than the hospitalisation rate for 
European/Other (Figure 8).  
Cystic fibrosis 
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Rate per 100,000 
population 
Rate ratio 95% CI 
Cystic fibrosis* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 97 6.84 1.00   
Deciles 3–4 105 7.85 1.15 0.87–1.51 
Deciles 5–6 100 6.94 1.01 0.77–1.34 
Deciles 7–8 97 5.97 0.87 0.66–1.16 
Deciles 9–10 74 3.98 0.58 0.43–0.79 
Prioritised ethnicity 
Māori 38 2.11 0.30 0.22–0.43 
Pacific 5 0.71 0.10 0.04–0.25 
Asian/Indian 6 0.63 0.09 0.04–0.20 
MELAA 5 4.96 0.71 0.30–1.73 
European/Other 285 6.94 1.00   
Gender 
Female 154 4.10 1.00   
Male 183 4.66 1.14 0.92–1.41 
Age group (years) 
0–4 106 6.80 1.45 1.13–1.86 
5–14 153 5.13 1.09 0.87–1.37 
15–24 147 4.69 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. Cystic fibrosis* in any of the 
first 15 diagnoses; Rate per 100,000 age-specific population; Rate ratios are unadjusted; Ethnicity is Level 1 prioritised; Decile is 
NZDep2013 
Figure 7. Hospitalisations for cystic fibrosis in 0–24 year olds, by age group, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 






































































































































































































Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with cystic fibrosis listed in any of the first 15 diagnoses 
Regional distribution 
Table 13 presents the number of individuals resident in each district health board that had a CF diagnosis during 
2011 to 2015. It also presents the number of hospital discharges in which CF was documented as the primary 
diagnosis or any diagnosis.  
The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and avoid undercounting that would occur if only primary diagnoses are included in 
discharge data. For CF the All:Primary diagnosis ratio was higher than the national ratio in Counties Manukau, 
Waikato, Bay of Plenty, Whanganui, Hutt Valley, and Canterbury DHBs and lower in Northland, Waitemata, 
Auckland, Lakes, Taranaki, Hawke's Bay, MidCentral, Nelson Marlborough, and Southern DHBs. Ratios were 
similar to the national ratio in the remaining district health boards (Table 13). 
Cystic fibrosis 
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Table 13. Hospitalisations for cystic fibrosis in 0–24 year olds, by district health board, New Zealand 2011–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary  
Primary diagnosis All cases 
Cystic fibrosis in 0–24 year olds 
Northland 8 45 48 1.07 
Waitemata 27 138 159 1.15 
Auckland 35 170 203 1.19 
Counties Manukau 26 70 90 1.29 
Waikato 32 209 280 1.34 
Bay of Plenty 28 167 228 1.37 
Lakes 9 81 92 1.14 
Tairawhiti <5 s s s 
Taranaki 11 50 60 1.20 
Hawke's Bay 15 79 87 1.10 
MidCentral 18 167 178 1.07 
Whanganui 8 47 62 1.32 
Hutt Valley 10 65 90 1.38 
Capital & Coast 27 115 143 1.24 
Wairarapa <5 s s s 
Nelson Marlborough 18 142 157 1.11 
South Canterbury <5 s s s 
Canterbury 59 310 397 1.28 
West Coast <5 s s s 
Southern 27 167 200 1.20 
New Zealand 336 2,122 2,625 1.24 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with cystic fibrosis listed in any of the first 15 
diagnoses 
Evidence for good practice 
Possibilities for prevention 
Preconception carrier screening of couples planning a pregnancy and prenatal testing early in pregnancy are 
both possible and recommended by the American College of Medical Genetics,8 the American College of 
Obstetricians and Gynecologists,9 the National Institutes of Health,10 and the Human Genetics Society of 
Australasia.11 The sensitivity of carrier screening varies between ethnic groups and ranges (in the US 
population) from almost 90% in non-Hispanic whites to around 50% in Asian Americans.9 In places where 
carrier screening has been carried out, there has been a decrease in the incidence of cystic fibrosis.12,13 
In New Zealand, carrier screening and prenatal testing is free only for family members and partners of people 
with CF and relatives and partners of known carriers of CF.11,14 In Australia, since 2006, CF carrier screening 
has been available to individuals and couples in Victoria as a fee-for-service programme at a cost of $150 per 
patient.15 There has been some resistance to the uptake of CF screening from both the public (who lack 
awareness of CF) and health professionals. Some health professionals have concerns about the time needed to 
counsel patients about genetic testing, lack knowledge about carrier frequency and the risks of CF and are 
unaware that 95% of cases of CF occur without a family history of the condition.15 
It is difficult to assess the cost-effectiveness of carrier screening and published economic evaluations of CF 
screening have had considerable variation in methods and results.16 Estimating cost-effectiveness involves 
weighing the cost of screening against the cost savings that result from the lifetime healthcare costs averted 
because there are fewer people with CF (because couples who are both carriers can choose to terminate their 
affected foetuses or to use IVF with preimplantation genetic testing). There are new developments in genetic 
testing, including next-generation DNA sequencing, that make it possible to screen for many disorders at once 
and are likely to bring down the cost of genetic testing.17 Therapies for CF are advancing, and it is possible that 
in the future there may be treatments that can be given from birth to correct the defect in CFTR function and 
prevent some or all of the complications of CF.18 The availability of such therapies could have several 
consequences: people with CF would be more likely to live longer with a good quality of life (although new 
drugs will probably be very expensive), and couples might be less likely to terminate a CF pregnancy if they 




Evidence-based health care for children and young people with cystic fibrosis 
Newborn screening leads to better nutritional outcomes for children with CF and has the potential to improve 
pulmonary outcomes.19 When a couple have a baby with CF, there is a 25% risk that any future pregnancies may 
also be affected by CF, so genetic counselling is indicated. The international consensus is that a person newly 
diagnosed with CF should have immediate and on-going access to a CF specialist centre staffed by a 
multidisciplinary team.20 New Zealand does not have the population to support the types of specialist CF centres 
found overseas. Care for New Zealand children with CF should be provided using a shared care model. The 
majority of care should be based in a clinic at a hospital near their home, supplemented with at least annual 
reviews at a regional CF centre.21 
To maintain the best possible lung function, people with CF (PWCF) need meticulous daily management of 
their lung disease. This may involve the use of airway clearance techniques taught by physiotherapists and 
inhaled aerosol medications together with prompt and aggressive treatment of infective exacerbations.20 There is 
no good evidence to indicate which is the best way of educating PWCF to manage their disease.22 People with 
CF need monitoring of their nutritional status as they are at risk of CF-related malnutrition due to pancreatic 
insufficiency and they (and their families) need psychosocial support to deal with the demoralisation that results 
from having multiple health problems.20 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of CF are provided for further reading. 
New Zealand guidelines 
• Standards of Care for Cystic Fibrosis in New Zealand Group, Medical Advisory Committee of Cystic 
Fibrosis Association of New Zealand. 2011. Standards of Care for Cystic Fibrosis in New Zealand Cystic 
Fibrosis Association of New Zealand.  
http://www.cfnz.org.nz/wp-content/uploads/Standard-of-Care-NZ-2011.pdf 
International guidelines 
• Lahiri T, Hempstead SE, Brady C, et al. 2016. Clinical Practice Guidelines from the Cystic Fibrosis 
Foundation for preschoolers with cystic fibrosis. Pediatrics. 
http://pediatrics.aappublications.org/content/137/4/e20151784.long 
• Smyth AR, Bell SC, Bojcin S, et al. 2014. European Cystic Fibrosis Society Standards of Care: Best 
Practice guidelines. Journal of Cystic Fibrosis, 13 Suppl 1, S23–42. 
http://www.sciencedirect.com/science/article/pii/S156919931400085X 
• Conway S, Balfour-Lynn IM, De Rijcke K, et al. 2014. European Cystic Fibrosis Society Standards of 
Care: Framework for the Cystic Fibrosis Centre. Journal of Cystic Fibrosis, 13, S3-S22. 
http://www.sciencedirect.com/science/article/pii/S1569199314000848 
• Stern M, Bertrand DP, Bignamini E, et al. 2014. European Cystic Fibrosis Society Standards of Care: 
Quality management in cystic fibrosis. Journal of Cystic Fibrosis, 13, Supplement 1, S43-S59. 
http://www.sciencedirect.com/science/article/pii/S1569199314000861 
• Cystic Fibrosis Trust. 2011. Standards for the clinical care of children and adults with cystic fibrosis in the 
UK (second edition). London: Cystic Fibrosis Trust. 
https://www.cysticfibrosis.org.uk/~/media/documents/the-work-we-do/care/consensus-
documents/standards-for-the-clinical-care-of-children-and-adults-with-cf-dec-11.ashx?la=en 
Evidence-based medicine reviews 
• The Cochrane Library Reviews relating to Cystic Fibrosis 
http://www.cochranelibrary.com/topic/Lungs%20%26%20airways/Fibrosis%3A%20cystic%20fibrosis/?per
-page=100&stage=review  
• Edmondson C, Davies JC. 2016. Current and future treatment options for cystic fibrosis lung disease: latest 
evidence and clinical implications. Therapeutic Advances in Chronic Disease, 7(3), 170-83. 
http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27347364/ 
• Saiman L, Siegel JD, LiPuma JJ, et al. 2014. Infection prevention and control guideline for cystic fibrosis: 
2013 update. Infection Control & Hospital Epidemiology, 35 Suppl 1, S1-S67.  
(summary at http://www.guideline.gov/content.aspx?id=48772&search=cystic+fibrosis)  
• Mogayzel PJ, Jr., Naureckas ET, Robinson KA, et al. 2013. Cystic fibrosis pulmonary guidelines. Chronic 
medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine, 
187(7), 680-9. (summary at https://www.guideline.gov/content.aspx?id=45307) 
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Other relevant publications 
• Quon BS, Rowe SM. 2016. New and emerging targeted therapies for cystic fibrosis. BMJ, 352, i859. 
http://www.bmj.com/content/352/bmj.i859.long 
• Massie J, Ioannou L, Delatycki M. 2014. Prenatal and preconception population carrier screening for cystic 
fibrosis in Australia: where are we up to? The Australian & New Zealand Journal of Obstetrics & 
Gynaecology, 54(6), 503-9 
• PORT CFNZ National Data Registry. 2014 Registry Report. Cystic Fibrosis New Zealand. 
http://cfnz.org.nz/wp-content/uploads/2015/12/2014-PORT-CFNZ-Registry-Report.pdf 
Websites 
• National Institute for Health and Care Excellence Cystic Fibrosis 
https://www.nice.org.uk/guidance/conditions-and-diseases/genetic-conditions/cystic-fibrosis 
• Cystic Fibrosis Association Of New Zealand Publications http://www.cfnz.org.nz/our-
services/library/downloads/ 
• Cystic Fibrosis Trust (UK) Consensus Documents https://www.cysticfibrosis.org.uk/the-work-we-
do/clinical-care/consensus-documents 
• European Cystic Fibrosis Society Standards of care available in open access 
https://www.ecfs.eu/content/ecfs-standards-care-available-open-access 
• Cystic Fibrosis Foundation (US) CF Clinical care guidelines https://www.cff.org/For-Caregivers/CF-
Clinical-Care-Guidelines 
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Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which there is progressive destruction of the β 
cells in the pancreas.1 The disease is believed to develop as a result of interaction between susceptibility genes 
and as yet unidentified environmental factors.2 The pancreas no longer produces the hormone insulin, which 
promotes the absorption of glucose from the blood into cells and is essential for life, and so people with T1DM 
must take exogenous insulin for the rest of their lives to keep their blood sugar levels under control.1  
Excess blood glucose (hyperglycaemia) leads to diabetic ketoacidosis, the leading cause of morbidity and 
mortality in children with T1DM. In the long-term high blood glucose levels can damage blood vessels and 
nerves resulting in atherosclerosis, loss of vision, kidney disease and nerve damage. Intensive insulin therapy, 
which aims to keep blood glucose as close to normal as possible, prevents nerve damage,3 kidney damage and 
macrovascular complications such as heart disease and stroke but is associated with an increased risk of severe 
hypoglycaemia (low blood glucose).4 Mild hypoglycaemia can produce irritability and inattention while severe 
hypoglycaemia can produce loss of consciousness and seizures and there is some suggestion that episodes of 
severe hypoglycaemia in early childhood can have long lasting (although mild) effects on cognitive function.5 
Type 1 diabetes mellitus is much the most common type of diabetes in children and young people.6 Most people 
with T1DM (around 75%) were diagnosed in childhood or young adulthood.6 The incidence of T1DM has been 
rising over recent decades, both globally6 and in New Zealand.7  
The following section reviews diabetes in children and young people using information from the National 
Minimum Dataset and New Zealand Health Survey. The section concludes with a brief overview of evidence-
based health care for children and young people with diabetes. 
Data sources and methods 
Indicators  
 Prevalence of diabetes 
 Hospitalisations for diabetes 
Definitions  
Prevalence of diabetes 
 Diabetes (diagnosed, excluding diabetes during pregnancy) among adults aged 15+ years 
Hospitalisations for diabetes 
 Hospitalisations of 0–24 year olds with a diagnosis of diabetes per 100,000 population 
Data sources 
Prevalence of diabetes 
New Zealand Health Survey (2006/07–2014/15), see Appendix 3 
Hospitalisations for diabetes 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
Prevalence of diabetes 
Adult respondents (aged 15+ years) are defined as having diabetes if they had ever been told by a doctor that they have 
diabetes. This does not include diabetes during pregnancy (gestational diabetes). 
Note that NZHS definition is likely to underestimate the true number of people with diabetes, as some people may not be 
aware that they have diabetes. 
Hospitalisations for diabetes 
Diabetes was the primary diagnosis or was documented as one of the first 15 diagnoses. 
Codes used for identifying cases are documented in Appendix 5. 
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National trends and distribution 
The percentage of those aged 15–24 years diagnosed with diabetes in the New Zealand Health Surveys was 
similar for the years 2006/07 to 2014/15, with the exception of 2012/13, although this year was not significantly 
different. The percentage of males diagnosed with diabetes was slightly higher than for females, but not 
significantly so (Figure 9). 
There was a total of 19 deaths of 0–24 year olds where diabetes was the underlying cause of death in New 
Zealand between 2000 and 2013, as documented within the National Mortality Collection. The majority of these 
deaths were due to type 1 diabetes. 
The number of 0–24 year olds hospitalised with diabetes during 2011 to 2015 is presented in Table 14. It also 
presents the number of hospital discharges in which diabetes was documented as the primary diagnosis or as any 
diagnosis. The majority of hospitalisations were for type 1 diabetes. 
The rate of hospitalisations for diabetes has increased since 2000, particularly where diabetes was documented 
within the first 15 diagnoses (Figure 10). 
























Source: NZ Health Survey 
Table 14. Individuals aged 0–24 years hospitalised with diabetes using primary diagnosis compared to all cases, 
New Zealand 2011–2015 
  Unique individuals (n) 
Hospitalisations (n) 
Ratio All : Primary 
Primary diagnosis All cases 
Diabetes 
Hospitalisation 
0–24 years 4,137 6,466 12,308 1.90 
0–14 years 1,772 2,771 4,252 1.53 
15–24 years 2,614 3,695 8,056 2.18 
Diabetes in 0–24 year olds 
Diabetes: Type 1 3,242 6,098 9,796 1.61 
Diabetes: Type 2 718 257 1,462 5.69 
Diabetes: other 350 111 1,056 9.51 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with diabetes listed in any of the first 15 
diagnoses; The sum of the age groups or of the diagnoses may total to more than the 0–24 year old total 
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Figure 10. Hospitalisations for diabetes in 0–24 year olds, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with diabetes listed in any of the first 15 diagnoses 
Diagnosis  
The majority of hospitalisations of 0–24 year olds involving type 1 diabetes had diabetes as the primary reason 
for hospitalisation within which type 1 diabetes mellitus with ketoacidosis was the diagnosis with the highest 
hospitalisation rate (Table 15). 
Table 15. Hospitalisations involving type 1 diabetes in 0–24 year olds in 0–24 year olds, by primary diagnosis, New 






Rate 95% CI % 
Type 1 diabetes* in 0–24 year olds 
New Zealand  
Type 1 diabetes mellitus with ketoacidosis† 3,109 622 40.48 39.08–41.92 31.7 
Type 1 diabetes mellitus with poor control 816 163 10.62 9.92–11.38 8.3 
Type 1 diabetes mellitus with hypoglycaemia 598 120 7.79 7.19–8.44 6.1 
Type 1 diabetes mellitus with ophthalmic 
complications‡ 
85 17 1.11 0.90–1.37 0.9 
Type 1 diabetes mellitus with other complications 107 21 1.39 1.15–1.68 1.1 
Type 1 diabetes mellitus without complication 1,383 277 18.01 17.08–18.98 14.1 
Type 1 diabetes mellitus total 6,098 1,220 79.39 77.42–81.41 62.2 
Other endocrine, nutritional and metabolic 
diseases 
60 12 0.78 0.61–1.01 0.6 
Symptoms and/or abnormal clinical findings NEC 580 116 7.55 6.96–8.19 5.9 
Infectious and parasitic diseases 553 111 7.20 6.62–7.83 5.6 
Injury and/or poisoning 458 92 5.96 5.44–6.53 4.7 
Other diagnoses 2,047 409 26.65 25.52–27.83 20.9 
Total 9,796 1,959 127.54 125.04–130.09 100.0 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Type 1 diabetes in any of 
the first 15 diagnoses; Rate per 100,000 0–24 year olds; NEC = not elsewhere classified; † Type 1 diabetes mellitus with 
ketoacidosis includes those hospitalised with/without coma and/or lactic acidosis or where stated as uncontrolled; ‡ Type 1 
diabetes mellitus with ophthalmic complications includes those hospitalised with ophthalmic complications stated as 
uncontrolled, with advanced ophthalmic disease, with other specified ophthalmic complication, with proliferative or other 










































































































Table 16 presents the demographic distribution of individuals with diabetes in New Zealand between 2011 and 
2015. There was a social gradient among these individuals with statistically significant increases in prevalence 
in each deprivation quintile (NZDep deciles 3–4 to 9–10) compared with those living in least deprived areas 
(deciles 1–2). Diabetes was significantly lower among males, and among 0–4 and 5–14 year olds (compared to 
15–24 year olds), and significantly lower for Māori and Asian/Indian than for European/Other ethnic groups.  
Table 16. Individuals aged 0–24 years hospitalised with diabetes, by demographic factor, New Zealand 




Rate per 100,000 
population 
Rate ratio 95% CI 
Diabetes* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 754 53.13 1.00   
Deciles 3–4 792 59.23 1.11 1.01–1.23 
Deciles 5–6 891 61.81 1.16 1.06–1.28 
Deciles 7–8 1,103 67.90 1.28 1.16–1.40 
Deciles 9–10 1,371 73.79 1.39 1.27–1.52 
Prioritised ethnicity 
Māori 857 47.51 0.74 0.69–0.80 
Pacific 455 64.21 1.00 0.91–1.11 
Asian/Indian 185 19.30 0.30 0.26–0.35 
MELAA 50 49.58 0.78 0.59–1.03 
European/Other 2,626 63.91 1.00   
Gender 
Female 2,185 58.20 1.00   
Male 1,953 49.74 0.85 0.80–0.91 
Age group (years) 
0–4 260 16.67 0.20 0.18–0.23 
5–14 1,590 53.28 0.64 0.60–0.68 
15–24 2,614 83.33 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Diabetes in any of the first 
15 diagnoses; Rate per 100,000 age-specific population; Rate ratios are unadjusted; Ethnicity is Level 1 prioritised; Decile is 
NZDep2013 
Since 2000, hospitalisations for diabetes had generally increased for each age group (Figure 11). The increase 
was most notable for the 0–4 year olds, for whom rates were consistently higher despite the age specific diabetes 
rate being lower than those for the other age groups. Over the same period, the primary diagnosis hospitalisation 




Figure 11. Hospitalisations involving diabetes in 0–24 year olds, by age group, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with diabetes listed in any of the first 15 diagnoses; Caution rates for under 5 year olds are based on 
small numbers 
Figure 12. Hospitalisations involving diabetes in 0–24 year olds, by ethnicity, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with diabetes listed in any of the first 15 diagnoses 
Regional distribution 
Figure 13 shows the prevalence of diagnosed diabetes for the district health boards from the 2011/12 to 2013/14 
New Zealand Health Surveys. None of the district health boards were significantly different to the New Zealand 
rate. 
Table 17 presents the number of individuals resident in each district health board that had a diabetes diagnosis 
during 2011 to 2015. It also presents the number of hospital discharges in which diabetes was documented as the 
primary diagnosis or any diagnosis.  
The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and avoid undercounting that would occur if only primary diagnoses are included in 







































































































































































































Waitemata, Auckland, Counties Manukau, Waikato, Tairawhiti, Hutt Valley, and Canterbury DHBs. Ratios 
were lower than the national ratio in the remaining district health boards (Table 17).  





























































































































































Source: NZ Health Survey 





Ratio All : Primary 
Primary diagnosis All cases 
Diabetes in 0–24 year olds 
Northland 147 192 452 2.35 
Waitemata 524 644 1,321 2.05 
Auckland 433 423 975 2.30 
Counties Manukau 540 557 1,275 2.29 
Waikato 409 574 1,126 1.96 
Bay of Plenty 215 346 642 1.86 
Lakes 102 225 402 1.79 
Tairawhiti 34 70 149 2.13 
Taranaki 131 194 348 1.79 
Hawke's Bay 169 354 579 1.64 
MidCentral 175 290 529 1.82 
Whanganui 66 92 162 1.76 
Hutt Valley 142 180 346 1.92 
Capital & Coast 271 345 625 1.81 
Wairarapa 35 179 263 1.47 
Nelson Marlborough 124 234 427 1.82 
South Canterbury 64 167 226 1.35 
Canterbury 457 577 1,121 1.94 
West Coast 35 49 90 1.84 
Southern 338 743 1,187 1.60 
New Zealand 4,137 6,466 12,308 1.90 




Evidence for good practice 
Possibilities for prevention 
There are currently no interventions proven to prevent or delay the onset of clinically apparent type 1 diabetes.1 
Primary prevention trials to date have been dietary interventions for infants at increased genetic risk designed to 
interrupt putative environmental risk factors for T1DM (such as infant formulas free of either cow's milk or 
bovine insulin, delayed introduction of gluten-containing foods, and vitamin D supplementation) and none of 
the dietary factors investigated have been shown to be unequivocal risk factors.1 The European Nicotinamide 
Diabetes Intervention Trial found no effect of nicotinamide on the prevention or delay of T1DM development in 
at-risk relatives.8 
Evidence-based health care for children and young people with diabetes 
Insulin 
From the time of diagnosis children and young people with type 1 diabetes require either multiple daily 
injections of insulin or continuous subcutaneous insulin infusion (via a pump) to control their blood glucose 
levels.9 They (or their parents) also need to plan and monitor their carbohydrate intake so they can adjust their 
insulin dosage accordingly, and to monitor their blood glucose levels at least five times per day.9 Intensive 
glucose control, which requires frequent blood glucose monitoring, has become standard therapy for T1DM 
because there is evidence that it lowers the risk of developing microvascular complications (such as eye and 
kidney disease), particularly in younger patients in the early stages of disease.10 
Care by a multidisciplinary team 
Children and young people with T1DM and their families need ongoing access to a multidisciplinary paediatric 
diabetes team.9 Regular clinic attendance (four times per year) is associated with better blood glucose control.11 
The Ministry of Health’s quality standards for diabetes care12 state that: “young people with diabetes should 
have access to an experienced multidisciplinary team including developmental expertise, youth health, health 
psychology and dietetics”. However, a 2012 survey which enquired about resourcing for services for children 
and young people with diabetes in New Zealand secondary care services found that, by international standards, 
New Zealand services were significantly under-resourced.13 All centres were below the international 
recommendations for medical staff, there was wide variation in nurse educator numbers, and most centres did 
not have dedicated psychologists or dieticians.  
Diabetes education 
Children and young people with T1DM and their families need on-going education covering insulin therapy, 
blood glucose monitoring, the effects of diet, physical activity and intercurrent illness on blood glucose control, 
managing sick days, detecting and managing hypoglycaemia, hyperglycaemia and ketosis, and for adolescents, 
the effects of alcohol on blood glucose and the particular hazards of smoking, recreational drugs and pregnancy 
for people with diabetes.9 The recent (2015) NICE guideline did not identify any RCTs that had evaluated the 
content of education programmes but noted that there are many discussion papers suggesting appropriate 
content for such programmes.9 
Hospital admission 
It is common for children and young people to be admitted to hospital soon after diagnosis of T1DM.14 A 
significant proportion of children with diabetes have ketoacidosis at diagnosis and moderate to severe 
ketoacidosis necessitates hospitalisation for intravenous therapy.14,15 There is some evidence suggesting that it is 
possible to receive initial management as an outpatient which does not lead to any disadvantages in terms of 
metabolic control, acute diabetic complications and hospitalisations, psychosocial variables and behaviour, or 
total costs.14 Outpatient initial management is unlikely to be suitable for young children, children who live a 
long way from a hospital or children from families affected by complex social and/or emotional problems.9  
Management of diabetes is complex. It can be expected that children with T1DM will experience complications 
of inadequate blood glucose control, such as hypoglycaemia and ketoacidosis, and may then require admission 
to hospital.14,16 A recently published Welsh study looking at all-cause hospitalisation rates in a cohort of 1,577 
children with newly-diagnosed T1DM (who were followed up for a total of 12,102 person years) found that 
these children had a rate of hospital admission almost five times higher than control children.16 Ketoacidosis in 
children with established T1DM has been reported to be associated with insulin omission or treatment error in 
around 75% of cases and with inadequate insulin therapy during intercurrent illness in the remainder.17 It has 
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been suggested that hospital admissions for ketoacidosis could be reduced by better supporting families of 
children with T1DM, especially those who find diabetes management challenging due to chaotic and 
dysfunctional family situations18,19 but there is no good quality evidence to indicate which particular types of 
support are most effective.9,20 
Evidence-based health care for children and young people with diabetes 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of diabetes are provided for further reading. 
Ministry of Health Publications and webpages  
• Ministry of Health. 2016. Diabetic Retinal Screening, Grading, Monitoring and Referral Guidance. 
Wellington. http://www.health.govt.nz/system/files/documents/publications/diabetic-retinal-screening-
grading-monitoring-referral-guidance-mar16.pdf  
• Ministry of Health. 2015. Living well with diabetes: A plan for people at high risk off diabetes 2015−2020. 
Wellington: Ministry of Health. http://www.health.govt.nz/system/files/documents/publications/living-well-
with-diabetes-oct15.pdf  
• Ministry of Health. 2014. Quality standards for diabetes care. http://www.health.govt.nz/our-work/diseases-
and-conditions/diabetes/quality-standards-diabetes-care  
• Ministry of Health. 2014. Quality Standards for Diabetes Care Toolkit 2014. Wellington: Ministry of 
Health. http://www.health.govt.nz/publication/quality-standards-diabetes-care-toolkit-2014  
• Ministry of Health. 2014. National Diabetes Work Programme 2014/15. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/national-diabetes-work-programme  
International Guidelines 
• American Diabetes Association. 2016. Standards of medical care in diabetes—2016. 
http://professional.diabetes.org/content/clinical-practice-recommendations/?loc=rp-slabnav  
• National Institute for Health and Care Excellence. 2015. Diabetes (type 1 and type 2) in children and young 
people: diagnosis and management. https://www.nice.org.uk/Guidance/NG18  
• National Institute for Health and Care Excellence. 2015. Diabetes (type 1 and type 2) in children and young 
people: diagnosis and management. Methods evidence and recommendations. 
https://www.nice.org.uk/guidance/ng18/evidence  
• International Society for Pediatric and Adolescent Diabetes. 2014. ISPAD Clinical Practice Consensus 
Guidelines 2014. http://www.ispad.org/?page=ISPADClinicalPract  
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. 2013. Canadian Diabetes 
Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. 
Canadian Journal of Diabetes, 37(suppl 1):S1-S212. http://guidelines.diabetes.ca/fullguidelines  
• Copeland KC, Silverstein J, Moore KR, et al. 2013. Management of Newly Diagnosed Type 2 Diabetes 
Mellitus (T2DM) in Children and Adolescents. Pediatrics 131(2) 364–82. 
http://pediatrics.aappublications.org/content/early/2013/01/23/peds.2012-3494.abstract  
• Working Group of the Clinical Practice Guideline on Diabetes mellitus type 1. 2012. Clinical practice 
guideline for diabetes mellitus type 1. Vitoria-Gasteiz, Spain: Basque Office for Health Technology 
Assessment (Osteba). http://www.guiasalud.es/GPC/GPC_513_Diabetes_1_Osteba_compl_en.pdf  
• Craig ME, et al. for the Australian Type 1 Diabetes Guidelines Expert Advisory Group. 2011. National 
evidence-based clinical care guidelines for type 1 diabetes in children, adolescents and adults. Canberra: 
Australian Government Department of Health and Ageing. 
https://diabetessociety.com.au/documents/Type1guidelines14Nov2011.pdf  
• Klonoff DC, et al. 2011. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. 
Journal of Clinical Endocrinology and Metabolism, 96(10), 2968-79. 
http://jcem.endojournals.org/content/96/10/2968.long  
• Scottish Intercollegiate Guidelines Network. 2010. Management of Diabetes: A national clinical guideline. 




Recent Evidence-Based Medicine Reviews 
• The Cochrane Library reviews relevant to diabetes:  
http://www.cochranelibrary.com/topic/Endocrine%20%26%20metabolic/Diabetes/?per-
page=100&stage=review  
• Edwards D, Noyes J, Lowes L, et al. 2014. An ongoing struggle: a mixed-method systematic review of 
interventions, barriers and facilitators to achieving optimal self-care by children and young people with type 
1 diabetes in educational settings. BMC Pediatrics, 14 228. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263204/?report=classic  
• Hynes L, Byrne M, Dinneen SF, et al. 2014. Barriers and facilitators associated with attendance at hospital 
diabetes clinics among young adults (15-30 years) with type 1 diabetes mellitus: a systematic review. 
Pediatric Diabetes, 17(7) 509–518. http://dx.doi.org/10.1111/pedi.12198  
• Sheehan AM, While AE, Coyne I. 2015. The experiences and impact of transition from child to adult 
healthcare services for young people with Type 1 diabetes: a systematic review. Diabetic Medicine, 32(4), 
440-58. http://onlinelibrary.wiley.com/doi/10.1111/dme.12639/abstract  
Other Relevant Publications 
• Jefferies C, Cutfield SW, Derraik JG, et al. 2015. 15-year incidence of diabetic ketoacidosis at onset of type 
1 diabetes in children from a regional setting (Auckland, New Zealand). Scientific Reports, 5, 10358 
• Jefferies C, Owens N, Wiltshire E. 2015. Care for children and adolescents with diabetes in New Zealand 
District Health Boards: Is the clinical resourcing ready for the challenge? New Zealand Medical Journal, 
128(1424). https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2015/vol-128-no-1424-
30-october-2015/6707  
• Jefferies C, Carter P, Reed PW, et al. 2012. The incidence, clinical features, and treatment of type 2 
diabetes in children <15 yr in a population-based cohort from Auckland, New Zealand, 1995-2007. 
Pediatric Diabetes, 13(4), 294-300. 
• Obaid B, Britt E, Wallace-Bell M, et al. 2012. The demographics and prevalence of youth (15–24 year olds) 
with type 1 diabetes in the Canterbury District Health Board catchment area in 2010: has the prevalence 
changed since 2003? New Zealand Medical Journal, 125(1363), 22-8. 
https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2012/vol-125-no-1363/article-obaid  
• Derraik JG, Reed PW, Jefferies C, et al. 2012. Increasing incidence and age at diagnosis among children 
with type 1 diabetes mellitus over a 20-year period in Auckland (New Zealand). PLoS One, 7(2), e32640. 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0032640  
• de Bock M, Gunn AJ, Holt JA, et al. 2012. Impact of insulin pumps on glycaemic control in a pump-naive 
paediatric regional population. Journal of Paediatric and Child Health, 48(3), 247-52. 
• American Diabetes Association. 2012. Diabetes management at camps for children with diabetes. Diabetes 
Care, 35 Suppl 1, S72-5. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632173/  
Websites 
• Health Quality and Safety Commission New Zealand. Diabetes. http://www.hqsc.govt.nz/our-
programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/diabetes/  
• Diabetes New Zealand http://www.diabetes.org.nz/home  
• Diabetes Youth New Zealand http://www.diabetesyouth.org.nz/  
• Australian Diabetes Society https://diabetessociety.com.au/  
• British Society for Paediatric Endocrinology and Diabetes https://www.bsped.org.uk/  
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WEIGHT AND EATING DISORDERS 
Introduction 
This section covers a broad spectrum of eating- and weight-related problems. Although traditionally viewed as 
separate entities, they are increasingly considered as parts of a continuum with common risk factors and scope 
for integrated prevention.1-4  
Obesity is a condition of excess body fat in relation to lean body mass to the extent that it may have a negative 
effect on health.5 Body mass index (BMI) is the measure commonly used to classify body weight, with sex and 
age-specific BMI cut-off points used to define thinness, overweight and obesity in children.6 In contrast with 
adult health, there is currently a lack of scientific evidence on the relationship between specific BMI thresholds 
and any potential short- and long-term health risks in childhood.5 Factors associated with an increased risk of 
developing childhood obesity include maternal over-nutrition, pre-term birth and infants being small or large for 
gestational age.7,8 Children with developmental disabilities and autism also have higher prevalence of obesity 
than other children.9,10 Obese children are at greater risk than other children of short- and long-term health 
problems including musculoskeletal problems, asthma, and psychological problems, and may develop abnormal 
lipid profiles, impaired glucose tolerance and high blood pressure at a younger age than non-obese peers.6  
Eating disorders comprise a range of syndromes encompassing physical, psychological and social features, 
including anorexia nervosa and bulimia nervosa. Eating disorders can be chronic conditions with substantial 
long-term physical and social sequelae.11 Onset is usually in adolescence, although is increasingly recognised at 
much younger ages.1 Alongside asthma and obesity, eating disorders are among the most prevalent chronic 
conditions for adolescent girls.2 Children and younger adolescents with eating disorders have a higher risk of 
rapid medical deterioration compared with older adolescents and adults. Young people are also at risk of 
potentially irreversible effects of physical and emotional development.12 Major depression is commonly co-
morbid with eating disorders and is associated with poorer prognosis.13 
In the current obesogenic environment, unhealthy weight loss and muscle gaining behaviours have been 
observed in children as young as ten years.3 Risk factors for both obesity and eating disorders include dieting 
(caloric restriction with the goal of weight loss), weight talk, weight teasing and body dissatisfaction.1  
The following section uses data from the New Zealand Health Survey to describe the weight of 0–24 year olds 
and presents data on eating disorders from the New Zealand Health Survey, the National Minimum Dataset and 
the National Mortality Collection. The section concludes with brief overviews of evidence for good practice for 
these conditions and references to relevant literature including obesity-related in-depth topics published in 
NZCYES 2013 reports.14  
Data sources and methods 
Indicators  
 Prevalence of underweight and overweight/obese individuals among 2–24 year olds 
 Rates of eating disorders among 0–24 year olds 
Definition  
Prevalence of underweight and overweight/obese individuals among 2–24 year olds 
BMI was calculated using measured height and weight. The extended international IOTF BMI cut-offs for underweight, healthy 
weight, overweight and obese categories are age and sex-specific. 
Underweight: BMI less than 18.5 
Healthy weight: BMI of 18.5–24.9 
Overweight: BMI of 25.0–29.9 
Obese: BMI of 30 or greater 
Rates of eating disorders among 0–24 year olds 
Hospitalisations of 0–24 year olds with an eating disorder per 100,000 population 
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Data sources 
Prevalence of underweight and overweight/obese individuals among 2–14 year olds 
New Zealand Health Survey (2006/07–2014/15), see Appendix 3 for more detail 
Rates of eating disorders among 0–24 year olds 
Numerator: Hospitalisations: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
Hospitalisation discharge events 
This section presents analyses where the condition was the primary diagnosis or was documented within any of the first 15 
diagnoses (all cases). The rationale for presenting all cases is to highlight the full spectrum of health issues experienced by 
those with this condition, and their consequent requirement for acute health services. 
Different growth reference populations for 2–18 year olds have been used in New Zealand and internationally in clinical 
practice, each with different definitions of overweight and obesity. Well Child providers and the B4School Check currently use 
the WHO growth reference population but apply different definitions for overweight and obese (referred to as NZ-WHO). The 
NZ Health Survey data reported in this section use the International Obesity Taskforce (IOTF) reference population. 
Codes used for identifying cases are documented in Appendix 5 
National trends and distribution 
From 2009 to 2013 there were seven deaths of 0–24 year olds with obesity as an underlying cause, as 
documented within the National Mortality Collection.  
Using the IOTF standard, the majority of 2–17 year olds had a BMI category of healthy weight (Figure 14). 
Among 16–24 year olds the proportion with healthy weight was significantly lower than the proportion with 
healthy weight in younger age groups, and the proportion who was obese was significantly higher than for those 
in the younger age groups (Figure 15). There was no significant difference by gender in either age group 
(Figure 16). Since 2006 there has been year to year variability in prevalence of thinness, overweight and obesity 
within the age groups. The greatest variability has been amongst 2–4 year olds (Figure 17, Figure 18). 
Prevalence of underweight for 2–14 year olds was significantly lower for Māori compared with non-Māori and 
significantly higher for Asian compared with non-Asian (Figure 19; Figure 20). 
The prevalence of overweight or obesity was higher for 2–14 year olds living in areas with the highest 
deprivation scores (NZDep2013 deciles 9–10) compared with those living in areas with the lowest NZDep2013 
scores areas (deciles 1–2). There was no significant difference by gender in this age group. Prevalence of 
obesity was significantly higher among Pacific 2–14 year olds compared with non-Pacific and for Māori 
compared with non-Māori, and significantly lower for Asian compared with non-Asian (Figure 21, Figure 22). 
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Figure 14. Body mass index (BMI) category in 2–24 year olds, by age group and BMI category, NZ Health Survey 
2014/15 
 
Source: NZ Health Survey  
Figure 15. Body mass index (BMI) category in 2–24 year olds, by age group, NZ Health Survey 2014/15 
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Figure 16. Body mass index (BMI) category in 2–24 year olds, by age group and sex, NZ Health Survey 2014/15 
 
Source: NZ Health Survey 
Figure 17. BMI: Underweight among 2–24 year olds, by age group and survey year, NZ Health Surveys 2006/07–
2014/15 
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Figure 18. BMI: Overweight or obese among 2–24 year olds, by age group and survey year, NZ Health Surveys 
2006/07–2014/15 
 
Source: NZ Health Survey 
Figure 19. BMI: Underweight in 2–14 year olds, by ethnicity and sex, NZ Health Survey 2014/15 
 
Source: NZ Health Survey. Ethnicity is total response 
Figure 20. BMI: Underweight among 2–14 year olds, by demographic factor, NZ Health Survey 2014/15 
 
Source: NZ Health Survey. Underweight=children who are thin, with a BMI equivalent to an adult BMI of 18.5 or lower. Ethnicity 
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Figure 21. BMI: Overweight or obese in 2–14 year olds, by ethnicity and sex, NZ Health Survey 2014/15 
 
Source: NZ Health Survey. Ethnicity is total response 
Figure 22. BMI Overweight or obese among 2–14 year olds, by demographic factor, 2014/2015 NZ Health Survey 
  
Source: NZ Health Survey. Children who are overweight or obese have a BMI equivalent to an adult BMI of 25.0 or greater. 
Ethnicity is total response 
From 2009 to 2013 there were fewer than five deaths of 0–24 year olds with an eating disorder as an underlying 
cause, as documented within the National Mortality Collection.  
Hospitalisation rates were higher for 15–24 year olds than 0–14 year olds (Table 18). Since 2000 hospitalisation 
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Table 18. 0–24 year olds hospitalised with eating disorders using primary diagnosis compared to all cases, 
New Zealand 2011–2015  
  Unique individuals (n) 
Hospitalisations (n) 
Ratio All : Primary 
Primary diagnosis All cases 
Eating disorders 
Hospitalisation 
0–24 years 1,012 1,509 2,301 1.52 
0–14 years 266 363 417 1.15 
15–24 years 781 1,146 1,884 1.64 
Eating disorders in 0–24 year olds 
Anorexia nervosa 632 1,174 1,467 1.25 
Bulimia nervosa 145 90 264 2.93 
Other eating disorders† 382 245 598 2.44 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with an eating disorder in any of the first 15 
diagnoses; The sum of the age groups may total to more than the 0–24 year old total 
Figure 23. Hospitalisations for eating disorders in 0–24 year olds, New Zealand 2000–2015 
  
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘‘All cases’ corresponds to 
hospitalisations with an eating disorder in any of the first 15 diagnoses 
Diagnosis 
Most hospitalisations of 0–24 year olds with eating disorders had Anorexia nervosa as the primary diagnosis, 
though other eating disorders and other mental and behavioural disorders also feature highly as primary 
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Table 19. Hospitalisations involving eating disorders in 0–24 year olds, by primary diagnosis, New Zealand 
2011– 2015  
Primary diagnosis 2011–2015 (n) 
Annual 
average 
Rate 95% CI % 
Eating disorders* in 0–24 year olds 
New Zealand  
Anorexia nervosa 1,174 235 15.28 14.44–16.18 51.0 
Bulimia nervosa 90 18 1.17 0.95–1.44 3.9 
Other eating disorders 245 49 3.19 2.81–3.61 10.6 
Eating disorders total 1,509 302 19.65 18.68–20.66 65.6 
Other mental and behavioural disorders 389 78 5.06 4.59–5.59 16.9 
Injury and/or poisoning 126 25 1.64 1.38–1.95 5.5 
Endocrine, nutritional and metabolic diseases 105 21 1.37 1.13–1.65 4.6 
Symptoms and/or abnormal clinical findings NEC 71 14 0.92 0.73–1.17 3.1 
Other diagnoses 101 20 1.31 1.08–1.60 4.4 
Total 2,301 460 29.96 28.76–31.21 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Eating disorder in any of 
the first 15 diagnoses; Rate per 100,000 0–24 year olds; NEC = not elsewhere classified 
Table 20 presents the demographic distribution of individuals with eating disorders in New Zealand between 
2011 and 2015. The prevalence of eating disorders was significantly lower among individuals residing in areas 
with higher deprivation scores (NZDep2013 deciles 3–10) compared to the lowest deprivation scores 
(deciles 1– 2), and significantly higher among 15–24 year olds compared to 0–14 year olds. The majority of 
0– 24 year olds with eating disorders were of European/Other ethnicity. 




Rate per 100,000 
population 
Rate ratio 95% CI 
Eating disorders* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 323 22.76 1.00   
Deciles 3–4 217 16.23 0.71 0.60–0.85 
Deciles 5–6 217 15.05 0.66 0.56–0.79 
Deciles 7–8 222 13.67 0.60 0.51–0.71 
Deciles 9–10 148 7.97 0.35 0.29–0.43 
Prioritised ethnicity 
Māori 76 4.21 0.20 0.16–0.25 
Pacific 6 0.85 0.04 0.02–0.09 
Asian/Indian 53 5.53 0.26 0.20–0.35 
MELAA 10 9.92 0.47 0.25–0.88 
European/Other 866 21.08 1.00   
Gender 
Female 918 24.45 1.00   
Male 94 2.39 0.10 0.08–0.12 
Age group (years) 
0–4 9 0.58 0.02 0.01–0.04 
5–14 257 8.61 0.35 0.30–0.40 
15–24 781 24.90 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Eating disorders in any of 
the first 15 diagnoses; Rate per 100,000 age-specific population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile 
is NZDep2013; Summation of components may equal more than the 0–24 year old unique total 
Regional distribution 
Figure 24 shows the percentage of 2–14 and 15–24 year olds in each DHB who were assessed as overweight, 
and Figure 25 shows the percentage who were assessed as obese, in the 2011/12 to 2013/14 New Zealand 
Health Survey. Prevalence of overweight and of obesity were similar to the national prevalence in all DHBs. 
Prevalence of being assessed as overweight was significantly higher than the national prevalence for 2–14 year 
olds in Northland, Waikato, and Tairawhiti and for 15–24 year olds in Wairarapa. Prevalence of being assessed 
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as obese was significantly higher than the national prevalence for 2–14 year olds in Counties Manukau, 
Tairawhiti, Taranaki and Whanganui and for 15–24 year olds in Hawkes Bay.  
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Source: NZ Health Survey 
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Source: NZ Health Survey 
Table 21 presents the number of individuals resident in each district health board area that had an eating 
disorder diagnosis between 2011 and 2015. It also presents the number of hospital discharges in which an eating 
disorder was documented as the primary diagnosis or any diagnosis.  
The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and result in less undercounting than would occur if only the primary diagnosis is 
included in discharge data. For eating disorders, the All:Primary diagnosis ratio was particularly high in 
Taiarawhiti, and higher than the national ratio in Taranaki, Capital & Coast, Nelson Marlborough, Canterbury 
and Southland DHBs and lower in Northland, Waitemata, Auckland, Counties Manukau, Waikato, Bay of 
Plenty, Lakes, Hawke’s Bay, Mid Central, Whanganui, Wairarapa and South Canterbury DHBs. Ratios were 
similar to the national ratio in the remaining district health boards (Table 21). 
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Table 21. Hospitalisations for eating disorders in 0–24 year olds, by district health board, New Zealand 2011–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Eating disorders in 0–24 year olds 
Northland 30 49 71 1.45 
Waitemata 119 216 311 1.44 
Auckland 114 161 203 1.26 
Counties Manukau 46 56 80 1.43 
Waikato 48 82 119 1.45 
Bay of Plenty 39 81 109 1.35 
Lakes 14 22 26 1.18 
Tairawhiti 8 5 15 3.00 
Taranaki 17 15 27 1.80 
Hawke's Bay 21 29 37 1.28 
MidCentral 40 53 72 1.36 
Whanganui 9 16 20 1.25 
Hutt Valley 39 52 77 1.48 
Capital & Coast 146 198 312 1.58 
Wairarapa 11 19 27 1.42 
Nelson Marlborough 29 49 77 1.57 
South Canterbury 17 25 32 1.28 
Canterbury 188 222 443 2.00 
West Coast 9 14 21 1.50 
Southern 105 144 221 1.53 
New Zealand 1,012 1,509 2,301 1.52 
Numerator: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with eating disorders listed in any of the first 
15 diagnoses; Rate per 100,000 0–24 year olds; Rate ratios are unadjusted; Note that individuals may appear in multiple DHBs 
Evidence for good practice  
Possibilities for prevention 
The increase in obesity worldwide over the past few decades suggests a key role for environmental determinants 
rather than changes in humans’ basic genetic code.8 Obesity prevention and treatment requires a whole-of-
government approach in which policies across all sectors systematically take health into account, avoid harmful 
health impacts, and thus improve population health and health equity.15 It is important that interventions to 
prevent obesity do not result inadvertently in disordered eating or increase weight stigmatisation.1,2 From a 
social justice perspective BMI screening does not address underlying issues that lead to obesity, such as genetic 
predisposition and economic inequality, and nor does it ensure access to healthy food.3 There is moderate 
evidence that health promoting schools (HPS) interventions seeking to reduce BMI and increase physical 
activity or fitness and fruit and vegetable intake have positive effects at an individual level with potential to 
produce public health benefits at the population level.16 Conversely, the provision of sugary drinks in schools 
and in reward packets can be considered direct-to-consumer marketing of unhealthy, empty calories.7 An 
integrated approach to prevention of both eating disorders and obesity will focus on sustainable, healthy, family-
based lifestyle modification rather than on weight, promote a positive body image, encourage more frequent 
family meals, facilitate healthy eating and physical activity especially within the family, and address any history 
of maltreatment or bullying.1 Different BMI thresholds and descriptors may be relevant for population 
surveillance compared with individual level clinical management.5 
Evidence-based health care for children and young people with obesity or 
eating disorders  
For children and young people identified as obese or overweight, family-based lifestyle interventions that 
include dietary, physical activity and behavioural components produce significant and clinically meaningful 
weight reductions in the short and the long term. Parental involvement is important, particularly for pre-
adolescent children. It is not possible to say whether any one lifestyle intervention is better than any other.14 
Pharmacological treatment or bariatric surgery may be indicated, as part of a multidisciplinary treatment 
programme, for post-pubertal adolescents with severe obesity and associated severe co-morbidities.17,18 Family 
members, including siblings, should also be included in the treatment of children and adolescents with eating 
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disorders.11 Outpatient family-based treatment is the treatment of choice for children and adolescents with eating 
disorders, although some will need a period of management as an inpatient. Medical and nutritional stabilisation 
is the first and most important goal of inpatient treatment and this is usually necessary before psychological 
therapy can be effective.12 Mindfulness training is associated with a decrease in disordered eating patterns.19,20 
When assessing outcomes of treatment it is important to use an appropriate rating scale that includes the 
perceptions of the child or young person. Qualitative studies of parents of children with health conditions have 
shown that the process of answering many personal and negative questions found in some instruments can have 
a negative impact.21 
New Zealand publications and guidelines 
• Ministry of Health. 2016. Health targets: Raising healthy kids. http://www.health.govt.nz/new-zealand-
health-system/health-targets/about-health-targets/health-targets-raising-healthy-kids  
• Ministry of Health. 2016. Childhood obesity plan. http://www.health.govt.nz/our-work/diseases-and-
conditions/obesity/childhood-obesity-plan  
• Ministry of Health. 2016. Weight management in 2–5 year olds. 
http://www.health.govt.nz/publication/weight-management-2-5-year-olds  
• Ministry of Health CTRU. 2009. Clinical guidelines for weight management in New Zealand children and 
young people. Wellington: Ministry of Health. http://www.health.govt.nz/publication/clinical-guidelines-
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International guidelines 
• National Institute for Health and Care Excellence. 2016. Obesity overview. 
https://pathways.nice.org.uk/pathways/obesity  
• National Institute for Health and Care Excellence. 2016. Diet overview. 
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AUTISM SPECTRUM DISORDER (ASD) 
Introduction 
Autism spectrum disorder (ASD) comprises a cluster of childhood onset neurodevelopmental conditions 
characterised by delays or difficulties in social communication and social interactions and restricted, repetitive 
patterns of behaviour, interests or activities.1 The diagnostic criteria in the DSM-5 for ASD1 list two dimensions 
which must be present. The first is a persistent impairment in reciprocal social communication and interaction, 
for example, the failure to engage in reciprocal conversations, lack of eye contact, and not understanding social 
context such as nonverbal communication. The second is inflexibility in thinking and behaviour, characterised 
by repetitive or stereotyped movements and ritualised patterns of behaviour.  
Prevalence studies across developed countries have identified individuals with ASD with an average prevalence 
of between 1% and 2% but there is considerable variation between countries and studies.2 There has been much 
less research on the prevalence of autism in adults but it appears to be similar to that in children.3 The ratio of 
males to females is around 3:1 among those with the most severe forms of ASD and around 8:1 among those 
with less severe forms of ASD4 According to the World Health Organization (WHO), the prevalence of ASD is 
increasing.5 Changes in the diagnostic criteria, development in services and greater awareness of the condition 
may explain the increase that is being seen worldwide, although other factors, as yet unknown, may contribute.6  
The manifestations of ASD vary considerably, in severity, and by developmental stage and age.1,7 Among young 
children aged 1–3 years, a lack of development in language and play can become more obvious with increasing 
age and there can be a gradual or rapid deterioration of social behaviours or language.8 Social and educational 
demands can increase difficulties for children aged 5–8 years and feeling socially isolated or having relationship 
difficulties is likely to be experienced by adolescents and adults with ASD.7  
There are a number of genetic conditions associated with autism including Down syndrome, fragile X, muscular 
dystrophy, neurofibromatosis, and tuberous sclerosis.9 Other conditions associated with autism include birth 
defects associated with central nervous system malformation and/or dysfunction, such as cerebral palsy, and 
premature birth.9,10 Research has indicated that around 70% of people with ASD met the criteria for one or more 
other psychiatric disorders, for example ADHD or anxiety, although they may not have received a formal 
diagnosis of such a disorder.9 About half of the children with autism have an intellectual disability with an IQ 
below 70.9 Epilepsy is substantially more common in people with autism than in the general population, 
especially in those who also have intellectual disability.11  
Experiencing discrimination and stigmatisation, including unjust deprivation of health, education and 
opportunities to participate in community, is common for people with ASD.9 People with ASD have the same 
general health problems as the rest of the population and they may also have specific health care needs relating 
to their ASD or other co-occurring conditions.9 Compared to the general population they have higher unmet 
need for health care.9 One reason may be that health care providers lack sufficient knowledge of ASD.9 
Increased diagnosis is putting greater demands on diagnostic services and on services providing care and 
support. Caring for people with ASD can be a very heavy emotional and economic burden for their family, 
particularly for families caring for people with severe ASD where access to services and support are 
inadequate.9  
The following section reviews ASD in children and young people using information from the New Zealand 
Health Survey and National Minimum Dataset. The section concludes with a brief overview of evidence for 
good practice in caring for children and young people with ASD. 
Data sources and methods 
Indicators  
 Prevalence of autism spectrum disorder (ASD) 
 Hospitalisations for ASD 
Definition  
Prevalence of autism spectrum disorder (ASD) 
Diagnosed Autism Spectrum Disorder (including Asperger’s Syndrome) (2–14 years) 12 Child respondents (aged 2–14 years) are 
defined as having autism spectrum disorder if the child’s parents or caregivers had ever been told by a doctor that the child 
has autism spectrum disorder* 
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Hospitalisations for ASD 
Hospitalisations of 0–24 year olds with a diagnosis of autism spectrum disorder per 100,000 population 
Data sources 
Prevalence of ASD 
New Zealand Health Survey (2006/07–2014/15), see Appendix 3 
Hospitalisations for ASD 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
*This definition is likely to underestimate the true number of children with autism spectrum disorder, as some people may not 
be aware that their child has autism spectrum disorder. 
Hospitalisation discharge events for ASD 
The term 'autism spectrum disorder' (ASD) in this part of the report covers autism or other pervasive developmental disorders. 
This section presents analyses where the condition was the primary diagnosis or was documented within any of the first 15 
diagnoses (all cases). The rationale for presenting all cases is to highlight the full spectrum of health issues experienced by 
those with this condition, and their consequent requirement for acute health services. 
Codes used for identifying cases are documented in Appendix 5. 
National trends and distribution 
There were fewer than five deaths of 0–24 year olds with autism as the underlying cause of death in New 
Zealand from 2000 to 2013, as documented within the National Mortality Collection. 
About one in a hundred children aged 2–14 years were reported to have received a diagnoses of ASD in the NZ 
Health Survey 2014/15.13 Figure 26 shows the percentage of children reported as having ever been diagnosed 
with ASD over the year of the NZ Health Surveys from 2006/07 to 2014/15. A greater percentage of children 
aged 5–9 years and 10–14 years were reported than those aged 2–4 years. The percentage for males was 
significantly higher than that for females (Figure 27).  
Children aged 5–9 years and 10–14 years had higher rate of diagnosis than those aged 2–4 years, and 
European/Other children had higher rates than Māori, and both had higher rates than other ethnicities. There was 
little difference between the NZDep 2013 index quintile scores (Figure 28).  
Males were more likely to be diagnosed with ASD than females (Figure 29) and of all the demographic factors 
collected, sex was the only factor that was statistically significantly different (Figure 30).  
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Source: NZ Health Survey; Diagnosed Autism Spectrum Disorder (including Asperger’s Syndrome) (2–14 years); Percent of 
children (among children aged 2–14 years, by sex (unadjusted prevalence, 95% confidence intervals) 
Figure 27. Autism Spectrum Disorder (diagnosed) in 2–14 year olds, by sex and survey year, NZ Health Surveys 
2006/07–2014/15 
 
Source: NZ Health Survey; Diagnosed Autism Spectrum Disorder (including Asperger’s Syndrome) (2–14 years); Percent of 
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Source: NZ Health Survey; Diagnosed Autism Spectrum Disorder (including Asperger’s Syndrome) (2–14 years); Percent of 
children (among children aged 2–14 years, by sex (unadjusted prevalence, 95% confidence intervals) 































Source: NZ Health Survey; Diagnosed Autism Spectrum Disorder (including Asperger’s Syndrome) (2–14 years); Ethnicity is total 
response 
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Source: NZ Health Survey; Diagnosed Autism Spectrum Disorder (including Asperger’s Syndrome) (2–14 years); Comparisons for 
children (among children aged 2–14 years) by sex, ethnic group, neighbourhood deprivation, 2014/15 (adjusted rate ratios, 95% 
confidence intervals) 
The number of 0–24 year olds hospitalised with autism or other pervasive developmental disorders (autism) 
between 2011 and 2015 is presented in Table 22 together with the number of hospital discharges in which 
autism was documented as the primary diagnosis or as any diagnosis.  
Table 22. Individuals hospitalised with autism, 0–24 year olds, New Zealand 2011–2015 
Age group Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Autism  
Hospitalisation 
0–24 years 1,853 485 3,015 6.22 
0–14 years 1,228 250 1,816 7.26 
15–24 years 674 235 1,199 5.10 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with autism or other pervasive developmental 
disorder listed in any of the first 15 diagnoses; Note:  The sum of the age groups may total to more than the 0–24 year old total 
The rate of hospitalisations for autism has increased overall since 2000, particularly for 5–14 and 15–24 year 
olds. In all age groups the hospitalisation rate was consistently much higher where autism was documented 
within the first 15 diagnoses than for autism as the primary diagnosis (Figure 31).  
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Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with autism or other pervasive developmental disorder listed in any of the first 15 diagnoses 
Diagnosis 
The most frequent primary diagnosis for 0–24 year olds hospitalised with any diagnosis of autism was dental 
caries. Only 16.1% of hospitalisations involving autism had autism or other pervasive developmental disorders 
as the primary diagnosis (Table 23). 








24 year olds 
95% CI % 
Autism* in 0–24 year olds 
New Zealand  
Childhood autism 340 68 4.43 3.98–4.92 11.3 
Atypical autism 17 3 0.22 0.14–0.35 0.6 
Rett syndrome 16 3 0.21 0.13–0.34 0.5 
Asperger syndrome 83 17 1.08 0.87–1.34 2.8 
Pervasive developmental disorders, other or unspecified  29 6 0.38 0.26–0.54 1.0 
Total autism or other pervasive developmental disorders  485 97 6.31 5.78–6.90 16.1 
Other mental and behavioural disorders 387 77 5.04 4.56–5.57 12.8 
Dental caries 586 117 7.63 7.04–8.27 19.4 
Other diseases of the digestive system 258 52 3.36 2.97–3.79 8.6 
Other diagnoses 1,299 260 16.91 16.02–17.86 43.1 
Total 3,015 603 39.25 37.88–40.68 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population. * Autism or other pervasive 
developmental disorder in any of the first 15 diagnoses 
Demographic distribution 
Table 24 presents the demographic distribution of individuals with autism hospitalised in New Zealand between 
2011 and 2015. There was a social gradient among these individuals with significantly higher hospitalisation 
rates in areas with higher NZDep2013 scores (NZDep deciles 3–4 to 9–10) compared with those living in areas 
with the lowest scores (deciles 1–2). Hospitalisation rates were significantly higher among males compared with 
females, and significantly lower for Māori, Pacific and Asian/Indian than for European/Other ethnic groups. 
Compared with 15–24 years olds, hospitalisation prevalence rates were significantly higher for 5–14 year olds 
and lower for 0–4 year olds. 
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Table 24. Individuals aged 0–24 years hospitalised with autism, by demographic factor, New Zealand 2011–2015 
Variable 
Unique individuals 2011–2015 
(n) 
Rate per 100,000 
population 
Rate ratio 95% CI 
Autism* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 278 19.59 1.00   
Deciles 3–4 335 25.05 1.28 1.09–1.50 
Deciles 5–6 355 24.63 1.26 1.07–1.47 
Deciles 7–8 448 27.58 1.41 1.21–1.63 
Deciles 9–10 574 30.89 1.58 1.37–1.82 
Prioritised ethnicity 
Māori 391 21.68 0.82 0.73–0.92 
Pacific 131 18.49 0.70 0.58–0.84 
Asian/Indian 220 22.95 0.87 0.75–1.00 
MELAA 35 34.71 1.31 0.94–1.84 
European/Other 1,086 26.43 1.00   
Gender 
Female 465 12.38 1.00   
Male 1,388 35.35 2.85 2.57–3.17 
Age group (years) 
0–4 275 17.63 0.82 0.71–0.94 
5–14 998 33.44 1.56 1.41–1.72 
15–24 674 21.49 1.00   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population. * Autism or other pervasive 
developmental disorder in any of the first 15 diagnoses; Rate ratios are unadjusted; Ethnicity is Level 1 prioritised; Decile is 
NZDep2013; Summation of components may equal more than the 0–24 year old unique total 
Regional distribution 
The 2011/12 to 2013/14 data for the district health boards shows that only Waitemata had a significantly higher 
percentage of ASD diagnosis than the New Zealand rate while Nelson Marlborough had a significantly lower 
percentage. Apart from Taranaki which had the highest percentage of all DHBs, most had very wide confidence 
intervals (Figure 32).  
Figure 32. Autism Spectrum Disorder (diagnosed) in 2–14 year olds, by district health board, NZ Health Survey 



























































































































































Source: NZ Health Survey 
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Table 25 presents the number of individuals resident in each district health board that had any diagnosis of 
autism or other pervasive developmental disorder (autism) between 2011 and 2015. It also presents the number 
of hospital discharges in which autism was documented as the primary diagnosis or as any diagnosis. The 
All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and avoid undercounting that would occur if only primary diagnoses are included in 
discharge data. For autism the All:Primary diagnosis ratio was six nationally, and close to four or higher in all 
DHBs. Counting only hospitalisations with autism as the primary diagnosis will underestimate considerably the 
number and rate of hospitalisations of children and young people with this condition. 






Primary diagnosis All cases 
Autism* spectrum disorder in 0–24 year olds 
Northland 52 19 73 3.84 
Waitemata 267 61 395 6.48 
Auckland 216 72 302 4.19 
Counties Manukau 251 40 352 8.80 
Waikato 140 25 191 7.64 
Bay of Plenty 147 26 270 10.38 
Lakes 40 <5 64 s 
Tairawhiti 27 5 44 8.80 
Taranaki 28 11 37 3.36 
Hawke's Bay 59 9 136 15.11 
MidCentral 105 11 149 13.55 
Whanganui 63 9 103 11.44 
Hutt Valley 52 24 87 3.63 
Capital & Coast 99 39 147 3.77 
Wairarapa 13 <5 17 s 
Nelson Marlborough 71 18 137 7.61 
South Canterbury 14 <5 29 s 
Canterbury 140 69 277 4.01 
West Coast 12 <5 15 s 
Southern 91 34 180 5.29 
New Zealand 1,853 485 3,015 6.22 
Source: National Minimum Dataset. All cases’ corresponds to hospitalisations with autism* listed in any of the first 15 diagnoses; 
* Autism or other pervasive developmental disorder; Note that individuals may appear in multiple DHBs; s = data suppressed 
due to small numbers 
Evidence for good practice 
Possibilities for prevention 
Currently there is no evidence that any intervention can prevent ASD in the general population. It is thought that 
interaction between complex genetic and environmental factors is the cause of ASD as parents have a greater 
likelihood of having a subsequent child with ASD if a previous child has this condition and it is common for 
identical twins to both develop ASD.10 Increasing maternal and paternal age is associated with increased autism 
risk.14,15 
Maternal use of sodium valproate for the treatment of epilepsy and other neuropsychological disorders is 
associated with a significantly increased rate of autism in offspring, even after adjusting for the increased risk 
associated with maternal epilepsy.16 The absolute risk is still small, however, so women need to weigh the 
benefits of treatment to control their epilepsy against the potential risks for their unborn child.16 Folic acid 
supplementation may mitigate the risks associated with this medication.17 
There is also an association between antidepressant use, particularly selective serotonin reuptake inhibitors 
(SSRI) in the second and/or third trimester of pregnancy, and increased risk of ASD in children, even after 
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considering risks associated with maternal depression. More research is needed to assess the risks associated 
with different type of antidepressant.18 
Current research is exploring factors that may potentially increase the risk of ASD in offspring, such as maternal 
infection,19 mitochondrial dysfunction,20 and possible overlap between risk genes for ASD, schizophrenia and 
bipolar disorder.21 
Evidence-based care for children and young people with ASD 
While there is no cure for ASD, interventions can help improve the quality of life for children with ASD in 
relation to some of the features, symptoms, behaviours and problems commonly associated with the condition.22 
Due to the heterogeneous nature of ASD no single intervention can be expected to work for all people with 
ASD.5 Programmes that may be effective include behavioural therapy, educational interventions, speech 
therapy, occupational therapy, social skills therapy, and medication (for problems like attention, hyperactivity 
and sleep).5  
Early diagnosis is important for children with ASD because early intervention may improve prognosis and 
because families can then be linked to information and support services.23 Although the clinical diagnosis of 
ASD is based on behavioural criteria, a thorough diagnostic evaluation may detect comorbidities that have 
implications for the diagnosis, treatment and prognosis not only of the child himself or herself, but also, in the 
event a genetic disorder such as fragile X is identified, for other family members including future siblings.23  
Early intervention for communication, care and support 
The quality of life for children with ASD is improved by early interventions to promote optimal development 
and wellbeing.5 Efficacious interventions that address communication, social behaviour and behaviour 
inflexibility through psycho-educational, developmental, and behavioural methods are very labour intensive and 
therefore costly.24  
Interventions should support both the individual with ASD and their family and carers.5 A recent Cochrane 
review reported sufficient evidence of the effectiveness of parent-mediated interventions in treatment of ASD in 
young children. Child outcomes such as language improved when individual or groups of parents or carers were 
trained by professionals to be more observant and responsive during interactions with their child and improved 
communication skills decreased some of their other ASD related difficulties.25  
It is good practice for local service providers to use approaches that facilitate parent participation in therapies.25 
Combining parent-mediated interventions with other locally available services can reduce the burden on parents. 
Non-specialists in school, family and community settings should task-share to deliver psychosocial 
interventions as this can increase access to care in low-resource settings. Changes that make the physical, social, 
and attitudinal environments more accessible, inclusive and enabling complement interventions for individuals 
with ASD.24 
Music therapy  
Music therapy has been shown to be better than a placebo, or standard care, for social interaction, non-verbal 
and verbal communication skills, initiating behaviour and social emotional reciprocity.26  It is also better for 
social adaptation, joy, and quality of parent-child relationships.26 There were no negative side effects. It is best 
delivered by specialists with academic and clinical training.26  
Early intensive behavioural intervention (EIBI)  
Early intensive behavioural intervention (EIBI) is widely used for increasing functional behaviours and skills in 
young children with ASD. It is based on the principles of applied behaviour analysis and delivered over multiple 
years at an intensity of 20 to 40 hours per week. There have been very few RCTs of EIBI but limited 
low-quality evidence suggests that children who received EIBI performed better than control children after 
1-3 years of treatment on tests of adaptive behaviour, intelligence, social skills, communication and language, 
autism symptoms and quality of life.27  
Assessment of ASD 
A systematic review of tools used for measuring outcomes in anxiety interventions studies for children with 
ASD examined studies in which at least half the participants were aged 8–14 years.28 Most studies were with 
children with high functioning ASD. The studies had small sample sizes but the review authors concluded that 
there is encouraging evidence that cognitive behavioural therapy (CBT) can be efficacious for children with 
ASD and anxiety disorder. Three questionnaires were considered to be robust: Spence Children’s Anxiety Scale 
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(revised), the Revised Children’s Anxiety and Depression Scale and the Screen for Child Anxiety Related 
Emotional Disorders. 
Assessment tools for anxiety are designed for typically developing children and young people, and there has 
been little discussion about whether these are appropriate for young people with ASD.29 Based on available 
research, and a clinical consensus process where data were lacking, a set of recommendations has been 
developed to assist primary care providers with the assessment and treatment of anxiety in children with ASD.30 
This research has resulted in two sets of recommendations, the first for the assessment of anxiety, as a 
systematic approach is needed to evaluate symptoms and factors such as the stage of development of the child. 
The second set of recommendations address the treatment of ASD associated anxiety, including coordination of 
care, education, modified cognitive behavioural therapy, and with care, possibly medication. 
Childhood IQ is a reliable predictor of cognitive functioning in mid to later adulthood.31,32 In people with higher 
IQ childhood scores, there appears to be greater IQ stability over time, however, even with an IQ that is above 
average, social outcomes in later life are generally poor.31 A review of tools to measure outcomes for young 
children with ASD has recently been published.33 It found that it is not yet possible to recommend fully robust 
tools and that there are gaps in outcome measurement tools for assessing the results of intervention studies, 
wellbeing and participation outcomes, and family quality of life outcomes, which are domains particularly 
valued by the review’s informants ( young people with ASD and parents). 
Treatment for anxiety 
It has been estimated that about 50% of children with ASD meet the criteria for at least one anxiety disorder.34 A 
number of systematic reviews of treatments for anxiety in children and young people with ASD have been 
undertaken in recent years29,34,35 yet there is a paucity of evidence for effective short and long term treatments.29 
The lack of large RCTs examining psychopharmacological treatment is of concern particularly given the 
concerns regarding adverse effects associated with certain selective serotonin reuptake inhibitors (a class of anti-
depressant commonly used to treat anxiety). These include agitation, impulsivity, insomnia and disinhibition 
without manic symptoms.29 There is potentially a problem with over prescribing, given the level of adverse 
effects.29 
There is evidence that CBT is efficacious in achieving moderate improvements in a range of outcome measures 
in youth with high functioning ASD and anxiety.34,35 In the absence of manuals specific to anxiety in ASD, the 
standard CBT treatment manuals for typically developing young people may be used if adapted according to the 
recommendations for ASD-specific content modifications that have been developed by the UK’s National 
Institute for Clinical Excellence (NICE).22,35 Cognitive behavioural therapy can be delivered in individual or 
group sessions, with or without parents.34 Most studies of CBT have found it to be to be at least promising.29 
Although around 70% of youth with ASD and anxiety responded to CBT in research studies, the same success 
rate may not be achieved in clinical practice where compliance may be lower and individuals miss sessions 
thereby interrupting skill acquisition.29 It is important that CBT is delivered by trained and experienced 
practitioners. There are limitations to the evidence base, especially related to small sample sizes and 
heterogeneity and there is a need for further research on a range of issues relating to the use of CBT in people 
with ASD.36  
Interventions to reduce problem behaviours such as irritability and aggression 
Mental health and behavioural problems are more prevalent in children with ASD than typically developing 
children.37 Tantrums and rages may become chronic and disabling and limit opportunities for education and 
recreation.37 They may also result in inpatient psychiatric care or residential placement.37 Early intervention to 
reduce disruptive, aggressive and self-injurious behaviour is likely improve cognitive functioning as an adult.32 
CBT does not appear to be an effective intervention for outwardly-directed aggression in children with 
intellectual disabilities.38 
A multidisciplinary team sponsored by the Autism Intervention Research Network on Physical Health and 
Autism Speaks Autism Treatment Network have developed a practice irritability and aggression pathway for 
primary care practitioners caring for children with ASD.37 It has not yet been tested in primary health care 
settings. 
The atypical antipsychotics, particularly risperidone and aripiprazole, are effective in reducing irritability, 
stereotypical behaviours and hyperactivity.39,40 They are the only two medications approved by the US FDA for 
treating aggression, self-injury and tantrums in children with ASD.40 They are commonly associated with 
metabolic adverse events, including weight gain and dyslipidaemia.40 Methylphenidate is effective in reducing 
attention-deficit hyperactivity disorder (ADHD) symptoms in children with ASD and ADHD.40 Atomoxetine 
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and alpha-2 agonists appear effective in reducing ADHD symptoms.40 Selective serotonin reuptake inhibitors do 
not reduce repetitive behaviours in children with ASD, and often cause adverse events.40 The efficacy of 
antiepileptic drugs is inconclusive.40 The efficacy and tolerability of pharmacotherapy in children with ASD are 
generally less favourable than in typically developing children with similar symptoms. Newer agents, including 
glutamatergic agents and oxytocin, appear promising but results from trials have been mixed. 40 
Behavioural interventions combined with anti-psychotic medication may be more effective in treating 
aggression in people with ASD than either intervention alone.41,42 
ASD and sleep 
The prevalence of sleep difficulties among children with ASD has been estimated to be from 50% to 80%. 
Medications for sleep problems that are commonly used in children with ASD include melatonin, α-agonists, 
anticonvulsants, antidepressants, atypical antipsychotics, and benzodiazepines.43 Although medication may 
improve sleep in the short term this can be at the cost of worsening daytime behaviour.43 Further research is 
needed to develop evidence-based interventions for promoting night time sleep in children with ASD.43 
Evidence-based health care for children and young people with autism 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of autism are provided for further reading. 
New Zealand guidelines 
• Ministries of Health and Education 2016 New Zealand Autism Spectrum Disorder Guideline (2nd edn) 
Wellington: Ministry of Health. http://www.health.govt.nz/publication/new-zealand-autism-spectrum-
disorder-guideline  
International guidelines 
The National Institute for Health and Care Excellence (NICE)  
• NICE Pathway – Autism spectrum disorder: https://pathways.nice.org.uk/pathways/autism-spectrum-
disorder 
• NICE: Recognition, referral and diagnosis of autism in children and young people from birth to 19 
years (clinical guideline 128): https://www.nice.org.uk/guidance/cg128 
• NICE: Autism spectrum disorder in under 19s: support and management (clinical guideline 170). 
https://www.nice.org.uk/guidance/cg170 
• Volkmar F, Siegel M, Woodbury-Smith M, et al. 2014. Practice parameter for the assessment and 
treatment of children and adolescents with autism spectrum disorder. Journal of the American 
Academy of Child and Adolescent Psychiatry, 53(2) 237-57. 
http://dx.doi.org/10.1016/j.jaac.2013.10.013  
• Scottish Intercollegiate Guidelines Network. 2007. Assessment, diagnosis and clinical interventions for 
children and young people with autism spectrum disorders. Edinburgh: Scottish Intercollegiate 
Guidelines Network. http://www.sign.ac.uk/guidelines/fulltext/98/  
Evidence-based medicine reviews 
Cochrane reviews 
• Geretsegger M, Elefant C, Mössler KA, et al. 2014. Music therapy for people with autism spectrum 
disorder. Cochrane Database of Systematic Reviews,(6) 
http://dx.doi.org/10.1002/14651858.CD004381.pub3  
• Oono IP, Honey EJ, McConachie H. 2013. Parent-mediated early intervention for young children with 
autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews,(4 ) 
http://dx.doi.org10.1002/14651858.CD009774.pub2  
• Xiong T, Chen H, Luo R, et al. 2016. Hyperbaric oxygen therapy for people with autism spectrum 
disorder (ASD). Cochrane Database of Systematic Reviews, (10) 
http://dx.doi.org/10.1002/14651858.CD010922.pub2 
• Williams K, Wray JA, Wheeler DM. 2012. Intravenous secretin for autism spectrum disorders (ASD). 
Cochrane Database of Systematic Reviews,(4) http://dx.doi.org/10.1002/14651858.CD003495.pub3  
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• Hurwitz R, Blackmore R, Hazell P, et al. 2012. Tricyclic antidepressants for autism spectrum disorders 
(ASD) in children and adolescents. Cochrane Database of Systematic Reviews,(3). 
http://dx.doi.org/10.1002/14651858.CD008372.pub2 
• James S, Stevenson SW, Silove N, et al. 2015. Chelation for autism spectrum disorder (ASD). 
Cochrane Database of Systematic Reviews,(5). http://dx.doi.org/10.1002/14651858.CD010766.pub2  
• Fletcher-Watson S, McConnell F, Manola E, et al. 2014. Interventions based on the Theory of Mind 
cognitive model for autism spectrum disorder (ASD). Cochrane Database of Systematic Reviews,(3). 
http://dx.doi.org/10.1002/14651858.CD008785.pub2 
• Sinha Y, Silove N, Hayen A, et al. 2011. Auditory integration training and other sound therapies for 
autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews,(12). 
http://dx.doi.org/10.1002/14651858.CD003681.pub3  
• Millward C, Ferriter M, Calver S, et al. 2008. Gluten- and casein-free diets for autistic spectrum 
disorder. Cochrane Database of Systematic Reviews,(2). 
http://dx.doi.org/10.1002/14651858.CD003498.pub3 
• Posar A, Visconti P. 2016. Omega-3 supplementation in autism spectrum disorders: A still open 
question? Journal of Pediatric Neurosciences, 11(3) 225-27. http://dx.doi.org/10.4103/1817-
1745.193363 
• Cheuk DK, Wong V, Chen WX. 2011. Acupuncture for autism spectrum disorders (ASD). Cochrane 
Database of Systematic Reviews,(9). http://dx.doi.org/10.1002/14651858.CD007849.pub2 
• Reichow B, Barton EE, Boyd BA, et al. 2012. Early intensive behavioral intervention (EIBI) for young 
children with autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews,(10). 
http://dx.doi.org/10.1002/14651858.CD009260.pub2 
• Hirsch LE, Pringsheim T. 2016. Aripiprazole for autism spectrum disorders (ASD). Cochrane 
Database of Systematic Reviews,(6).  http://dx.doi.org/10.1002/14651858.CD009043.pub3 
Other reviews 
• Anagnostou E, Zwaigenbaum L, Szatmari P, et al. 2014. Autism spectrum disorder: advances in 
evidence-based practice. CMAJ: Canadian Medical Association Journal, 186(7) 509-19. 
http://dx.doi.org/10.1503/cmaj.121756  
• The February 2016 issue of Pediatrics (the journal of the American Pediatric Association) is a 
supplement devoted to autism spectrum disorder.Pediatrics Feb 2016, 137 (Supplement 2) 137S2; 
http://dx.doi.org/10.1542/peds.2016-137S2  
Websites 
• New Zealand Guidelines Group. 2010. What does ASD look like? A resource to help identify autism 
spectrum disorder. Wellington: New Zealand Guidelines Group 
https://www.health.govt.nz/system/files/documents/publications/how-asd-diagnosed.pdf 
• Kidshealth (New Zealand site) http://kidshealth.org/en/teens/autism.html# 
• Ministry of Health. How is ASD diagnosed? http://www.health.govt.nz/publication/how-asd-diagnosed 
• Ministry of Education: ASD information supporting children and young people with ASD and 
resources for working with students who have ASD http://www.education.govt.nz/school/student-
support/special-education/supporting-children-and-young-people-with-autism-spectrum-disorder-asd/ 
• Altogether Autism (A free, nationwide ASD information and advisory service in New Zealand) 
http://www.altogetherautism.org.nz/  
• Mental Health Foundation of New Zealand https://www.mentalhealth.org.nz/get-help/a-
z/resource/8/autism-spectrum-disorders 
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EMOTIONAL OR BEHAVIOURAL PROBLEMS 
Introduction 
Good mental health, as indicated by social and emotional well-being, is fundamental for healthy child 
development and success in school and in later life.1 Mental health problems, which in children are usually 
manifested as emotional and behavioural problems, are estimated to affect 10–20% of children.2-6 Common 
mental health conditions in children include anxiety, depression, attention deficit hyperactivity disorder 
(ADHD), behaviour disorders such as conduct disorder and oppositional defiant disorder, and substance use 
disorders.3,4 
Mental health problems that arise in childhood can have consequences throughout the rest of life that are 
burdens not only for the individuals affected but also for families, communities, and the health, justice and 
welfare systems.7 Without treatment, only half of preschool children grow out of behaviour problems.8 Half of 
all lifetime mental disorders are apparent by age 14 and three-quarters by age 24.9 It is both more effective and 
less costly to address mental health problems early in life, than to attempt to fix long standing problems later in 
life that have resulted from complex interactions between mental health difficulties, family breakdown, 
employment problems and drug and alcohol abuse.10 
The following section provides data from the New Zealand Health Survey for children with emotional or 
behaviour problems and children with ADD/ADHD (Attention Deficit Disorder/Attention Deficit and 
Hyperactivity Disorder) using data from the New Zealand Health Surveys.  
Data sources and methods 
Indicators  
 Prevalence of emotional or behavioural problems  
 Prevalence of ADD/ADHD 
Definition  
Diagnosed emotional or behavioural problems (depression, anxiety disorder, ADD and/or ADHD) (2–14 years)  
Child respondents (aged 2–14 years) are defined as having emotional or behavioural problems if the child’s parents or 
caregivers had ever been told by a doctor that the child has depression, anxiety disorder (this includes panic attack, phobia, 
post-traumatic stress disorder, and obsessive-compulsive disorder), attention deficit disorder (ADD) or attention deficit 
hyperactivity disorder (ADHD). 
Data sources 
New Zealand Health Survey (2006/07–2014/15) 
Additional information 
This definition is likely to underestimate the true number of children with emotional or behavioural problems, as some people 
may not be aware that their child has a mood or anxiety disorder, and also to underestimate the true number of children with 
ADD or ADHD, as some people may not be aware that their child has ADD or ADHD. 
Not all of the respondents who have ever had depression, anxiety disorder, ADD or ADHD would meet the criteria for 
depression, anxiety disorder, ADD or ADHD at the time they were surveyed. 
National trends and distribution 
Over the five years of the NZHS 2006/07 to 2014/15, the percentage of children aged 2–14 years who were ever 
diagnosed with an emotional or behaviour problem is lower for 2–4 year olds than for those older, with 
percentages for 5–9 year olds slightly lower than those of 10–14 year olds (Figure 33). Over the five years of 
the NZHS 2006/07 to 2014/15, the percentage of children aged 2–14 years who were ever diagnosed with 
ADD/ADHD (Attention Deficit Disorder/Attention Deficit and Hyperactivity Disorder) is lower for 2–4 year 
olds, with percentages for 5–9 year olds slightly lower than those of 10–14 year olds (Figure 34). 
Data from NZHS for one year, 2014/15 shown in Figure 35, indicates that the percentages of children aged 5–9 
and 10–14 years with emotional or behavioural problems were significantly higher than for 0–4 year olds. The 
percentages for Māori and European are higher than for Pacific and Asian.  
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Figure 33. Emotional or behavioural problems (diagnosed) in 2–14 year olds, by age group and survey year, NZ 





























Source: NZ Health Survey 
Figure 34. ADD or ADHD (ever diagnosed) in 2–14 year olds, by age group and survey year, NZ Health Survey 
2006/07–2014/15 
 
Source: NZ Health Survey 
Data from NZHS for one year, 2014/15 shown in Figure 36, indicates that the percentages for 5–9 year olds and 
10–14 year olds with ADD/ADHD (Attention Deficit Disorder/Attention Deficit and Hyperactivity Disorder) 
are significantly higher than for 0–4 year olds. The percentages for Māori and European are higher than for 
Pacific and Asian, but not significantly so. The percentages are higher for children in areas with higher 
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Emotional or behavioural problems (diagnosed)
 
Source: NZ Health Survey 
Figure 36. ADD or ADHD (ever diagnosed), by demographic factor, NZ Health Survey 2014/15 
 
Source: NZ Health Survey 
The percentage of emotional or behavioural problems was significantly higher for males and significantly lower 
for Asian children (Figure 37). The percentage of ADD/ADHD (Attention Deficit Disorder/Attention Deficit 
and Hyperactivity Disorder) was significantly higher for males (Figure 38). 
The percentages of emotional or behavioural problems for males were higher for Māori and for European/Other 
(Figure 39). The percentage of ADD/ADHD (Attention Deficit Disorder/Attention Deficit and Hyperactivity 
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Figure 37. Comparisons for 2–14 year olds diagnosed with emotional or behavioural problems (diagnosed), by 
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Source: NZ Health Survey. Ethnicity is total response 
Figure 38. Comparisons for 2–14 year olds diagnosed with ADD/ADHD, by sex, ethnic group, deprivation, 
NZ  Health Survey 2014/15 
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Figure 39. Emotional or behavioural problems (diagnosed) in 2–14 year olds, by ethnicity and sex, 




























Source: NZ Health Survey. Ethnicity is total response 
Figure 40. ADD or ADHD (ever diagnosed) in 2–14 year olds, by ethnicity, and sex NZ Health Survey 2014/15 
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Regional distribution 
Figure 41 shows the distribution across the district health boards was varied. Rates in Taranaki, MidCentral and 
Whanganui DHBs were significantly higher than the New Zealand rate.  
Figure 41. Emotional or behavioural problems (diagnosed) in 2–14 year olds, by district health board, 



























































































































































Source: NZ Health Survey 
Evidence for good practice 
Possibilities for prevention 
Children’s emotional and behavioural problems have both genetic and environmental causes. Since little can be 
done about the genetic factors that may predispose a person to mental health problems, preventive interventions 
primarily focus on optimising children’s environments to prevent or manage emotional and behavioural 
problems.10 The early years are especially important for a child’s healthy mental, social and emotional 
development.11 
Parenting style has been found to be the single most important environmental influence on children’s behaviour 
and therefore most preventive interventions aim to improve parenting skills.10 Parenting programmes are 
designed to improve parents’ capabilities to identify, define, observe and respond to child behaviours in new 
ways. They help parents to identify problem behaviours and to use non-punitive discipline techniques, such as 
ignoring and time out, to discourage undesirable behaviour. They teach parents to use positive reinforcement to 
encourage desirable behaviour, to understand the ways children think and their motives for their behaviour, and 
to adopt strategies that strengthen parent-child relationships such as active listening, and responding warmly and 
sensitively when their child is distressed or seeking interaction.10 
Preventive strategies can be either universal (aimed at the whole population) or targeted (aimed at children who 
have identified risk factors such as young, low-income parents).10 A 2009 systematic review that aimed to 
identify evidence-based preventive interventions for emotional and behavioural problems in children aged 0–8 
years found that over fifty such interventions, most targeting behavioural rather than emotional problems had 
been evaluated through randomised controlled trials.10 The review authors identified a number of interventions 
that were both effective and showed promise in the Australian context. Three US programmes well supported by 
evidence were the individual Nurse Home Visitation Programme (for infants), the individual Family Check-up 
(for pre-schoolers), and the class programme the Good Behaviour Game (for children of school age).10 Three 
parenting programmes in England and Australia were also considered especially worthwhile: the Incredible 
Years (group format), Triple P (individual format), and Parent Education Programme (group format).10 
A 2007 Canadian systematic review identified and reviewed 15 RCTs on programmes intended to prevent 
conduct disorder, anxiety and depression in children aged 0–18 years.1 Four especially noteworthy programmes 
for preventing conduct disorder targeted at-risk children in the early years using parent training or child social 
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skills training (or a combination of both), typically delivered over one to two years in homes, preschools or 
schools by clinicians or teachers.1 All of these four: Fast Track, Johns Hopkins, Nurse Visitation and Perry Pre-
school, significantly reduced two or more symptom measures. One universal group cognitive-behavioural 
training (CBT) programme (the Australian Friends programme) was effective in reducing anxiety in 10–13 year 
olds, with a greater magnitude of effect in at-risk children. Two of the four RCTs of programmes to prevent 
depression, both assessing the targeted US CBT group programme Coping With Stress, showed significant 
reductions in both diagnostic and symptomatic measures of depression.1 Few studies had evaluated costs but the 
review authors pointed out that the lifetime costs of a single case of conduct disorder may be over a million 
dollars therefore the costs of not implementing preventive programmes is high. 
A 2013 review sponsored by the US Agency for Healthcare Research and Quality assessed the effectiveness of 
interventions for preschoolers at risk for attention-deficit/hyperactivity disorder (ADHD).12 The interventions 
evaluated were parent behavior training (PBT), combined home and school/day care interventions, and 
methylphenidate use. Data from eight good-quality studies provided high quality evidence that PBT improved 
child behaviour. Only one relatively small good quality study evaluated use of methylphenidate as a preventive 
strategy and evidence for its effectiveness in asymptomatic children was low. Some adverse effects were 
reported for methylphenidate but not for PBT. Studies of combined home and school/daycare interventions 
showed inconsistent results.  
A recent Cochrane review (2016) assessed cognitive behavioural therapy and other psychological interventions 
for preventing depression in children and adolescents.13 It included 83 trials, most of which (67) were carried 
out in school settings. It found that, overall, there was low to moderate quality evidence of small positive effects 
in depression prevention in the short- to medium-term (up to 12 months). In universal populations, prevention 
programmes showed a lack of effects in comparison with an attention placebo control. Interventions delivered to 
targeted populations, especially where these were selected because of having depression symptoms, had larger 
effects but few of these trials had used an attention placebo control. (An attention placebo control is a control 
intervention that attempts to control for non-specific factors associated with receiving a therapeutic intervention, 
such as being part of a trial and receiving attention from researchers.) The review authors concluded that there is 
still not sufficient evidence to support the implementation of depression prevention programmes. 
Mindfulness-based interventions to improve children’s social and emotional wellbeing have become popular in 
recent years.14,15 Mindfulness is a practice derived from the Buddhist contemplative tradition. Mindfulness 
exercises teach practitioners to continually bring their attention back to present moment experience, noticing 
current thoughts, emotions or bodily sensations.14 There have been a number of studies of mindfulness 
interventions for young people age less than 18 years, including more than ten RCTs.14 The research evidence to 
date suggests that mindfulness is not harmful and that is has small mental health benefits for young people in 
general and moderate benefits for young people with symptoms of psychopathology.14,15 New Zealand’s Mental 
Health Foundation has developed the Pause, Breathe, Smile mindfulness programme for schools.14,16 
Evidence-based healthcare for children with mental health problems 
It is important that children’s mental health difficulties are recognised and treated early since early intervention 
can prevent problems worsening. It is important that all those working with young children and their parents, 
whether they work in in education, health, child welfare or other services, are aware of the importance of 
children having nurturing and responsive relationships with their caregivers. They need to able to recognise and 
respond to emotional and behavioural problems in children and maternal mental health issues that may make it 
difficult for a mother to provide the best care for her child. When a parent seeks help, there should be no wrong 
door: all professionals need to be able to link parents with appropriate services. 
Interventions for emotional and behavioural problems in young children always need to involve parents. There 
is low quality evidence that group-based parenting programmes reduce parent-reported emotional and 
behavioural problems in children under four years old.17 
Parent-infant psychotherapy (PIP) aims to improve parent-infant relationships. 18 It involve a parent-child 
psychotherapist working with a parent and infant at home or in a clinic to identify unconscious patterns of 
relating and behaving, and influences from the parent’s past, that are negatively affecting the parent-child 
relationship.18 A recent Cochrane review concluded that, although PIP seems to be a promising way of 
improving the security of infant attachment, there is no evidence that it improves other outcomes, and no 
evidence to indicate whether it is any more effective than other types of treatment for parents and infants.18 
In children with conduct disorder (up to 11 years old), parent-focused interventions are effective for reducing 
anti-social behaviour.19 Limited evidence suggests that group interventions for parents, interventions based on 
cognitive behavioural principles, and interventions using the Triple P or Incredible Years programmes are 
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especially effective.19 Child-focused interventions for children and young people with conduct disorder also 
seem to reduce anti-social behaviour and limited evidence suggests that they may be more effective if delivered 
in a school rather than a clinic setting.19 It is uncertain whether interventions delivered separately to both the 
parent and the child are any more or less effective than those delivered to parents alone.19 Multi-modal 
interventions may reduce anti-social and offending behaviour in young people with conduct disorder.19 
In children with disruptive behaviour associated with conditions such as conduct disorder, oppositional defiant 
disorder or ADHD, the atypical antipsychotic drug risperidone reduces aggression and conduct problems to 
some degree after six weeks of treatment but is associated with significant weight gain.20 
Young children and school-aged children (6–12 years) with ADHD are likely to benefit from psychological 
interventions, particularly those that train parents in behaviour management techniques.21 Behavioural 
classroom management and behavioural peer interventions are also well-established treatments.21 There is little 
evidence that parent-based interventions are effective in adolescents with ADHD.21 
Pharmacological treatment of ADHD is highly effective in most children with diagnosed ADHD and the 
psychostimulant methylphenidate is the most commonly prescribed drug.22 In patients who cannot tolerate 
psychostimulant therapy or have comorbid conditions, atomoxetine or apha2-adrenergic agonists (such as 
clonidine and guanfacine) may be effective.22 
In children and young people with depression of any severity, psychological therapy, such as cognitive 
behavioural therapy should be offered initially.23 There is little clear evidence to favour one psychological 
therapy over another.23 In young people (12–18 years) with severe depression, antidepressants and 
psychological therapy may be started concurrently as an alternative to trying psychological therapy first and 
starting antidepressants only if this trial is unsuccessful.23 The evidence regarding the relative effectiveness of 
psychological interventions, antidepressant medication and a combination of these interventions in children and 
adolescents with depression is very limited.24 
There is evidence that cognitive behavioural therapy is an effective treatment for anxiety disorders in children 
and adolescents but the evidence suggesting that CBT is more effective than active controls or treatment as 
usual or medication at follow-up, is limited and inconclusive.25 
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Introduction 
There is substantial evidence from both observational studies of humans, and experimental studies in animals, 
that fetal alcohol exposure can cause physical malformations, growth retardation and brain damage.1-5 Alcohol 
exposure in pregnancy is commonly cited as the leading preventable cause of intellectual disability.6,7 
Fetal Alcohol Spectrum Disorder (FASD) is the umbrella term used for the range of physical, cognitive, and 
developmental disabilities caused by exposure to alcohol in utero.8  
The Ministry of Health has recently published an Action Plan Taking Action on Fetal Alcohol Spectrum 
Disorder 2016 to 20197 which is New Zealand’s first attempt at taking a coordinated and strategic national 
approach to FASD. The plan recognises that FASD contributes to many poor outcomes for New Zealand’s 
young people including early mortality, abuse and neglect, poor educational achievement, engagement with the 
criminal justice system, benefit dependence, and mental health and alcohol and drug problems. 
Features of FASD 
The effects of prenatal alcohol exposure include malformations, growth retardation and central nervous system 
dysfunction of varying severity.9 For a child’s long term future the most devastating effects of prenatal alcohol 
exposure are the cognitive and behavioural problems caused by alcohol-induced brain damage.9 
Facial features 
Facial anomalies are characteristic of fetal alcohol syndrome (FAS) and a diagnosis of FAS requires (in addition 
to other criteria) that the following three facial features are present: short palpebral fissures (the distance from 
the inner corner to the outer corner of the eye), a smooth philtrum (absent or shallow vertical groove between 
the upper lip and the nose), and a thin upper lip.6 Assessment of these facial features requires specialised 
training and these features can become less noticeable as children grow up.10,11 Only a small proportion of 
children with FASD have the three facial features, but their presence is highly specific to FAS.12 
Studies of the effects of alcohol on mouse and chick embryos have indicated that the period of vulnerability for 
these anomalies corresponds to the human gestational stage between three and six weeks after fertilisation and 
that there is a general trend for the facial anomalies to become more pronounced as alcohol exposure 
increases.13 
It is often stated that FAS is the most severe form of FASD but cognitive and behavioural impairments can be of 
similar severity in people with FAS and people with FASD who lack the facial features of FAS and it is the 
cognitive and behavioural deficits rather than the facial abnormalities that have the greatest impacts on life 
outcomes.14,15 
Neurodevelopmental problems 
Children exposed to alcohol in utero at any stage of gestation can have impairments of variable severity in many 
areas of central nervous system function.16 Their cognitive and behavioural problems can seem similar to those 
of other neurodevelopmental conditions such as ADHD but specialised assessment can distinguish FASD from 
other conditions.17 Cognitive problems that children with FASD may have include:16,17 
• Lower than normal intellectual ability. The average IQ of children with FASD is in the cognitively 
impaired to low normal range but there is a wide variation18 
• Difficulty with sustaining attention 
• Difficulty with executive function in both cognition-based and emotion-based tasks (problems with 
coordinated planning and execution of tasks) 
• Difficulty with language 
• Difficulty with mathematics 
• Difficulty with memory 
• Deficits in visual-spatial perception and construction 
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• Slower than normal information processing 
Overall, these problems can be summarised as a generalised deficit in processing complex information.17 
Mathematics is a particular area of weakness in children with FASD, and deficits have been found even in 
studies that control for IQ and other potentially confounding variables. It is the cognitive weakness that is most 
highly correlated with the amount of prenatal alcohol exposure.19 
The effects that these problems have on everyday life can be profound. Memory problems and difficulties with 
information processing make it hard to follow instructions and to learn new skills. Teachers may report that 
children with FASD are disorganised, tactless, distractible, lack persistence, and have poor processing and 
reasoning abilities.17,20 
People with FASD commonly have problems with adaptive and social behaviour and their deficits in these areas 
are more severe than those of people with similar verbal IQs who were not exposed to alcohol.21-24 Social 
problems include impairments in social competence and relationships, being inappropriately friendly as 
children, and difficulties in perceiving and responding to social cues, exhibiting consideration for others, 
following social norms, and forming reciprocal friendships.25 These problems often result in social rejection, 
which contributes to poor self-esteem, aggression, anxiety, depression, trouble at school, mental health problems 
and anti-social behaviour.25  
Standardised tests of adaptive functioning, such as the Vineland Adaptive Behavior Scales, may not fully 
capture the extent of the difficulties experienced by a person with FASD since they include only a few questions 
relating to poor decision making and dangerously impulsive behaviours that pose risks both for the person 
themselves and those around them.26 Functioning as an independent adult requires not only being capable of 
shopping, cooking, cleaning and laundry but also being able to deal with problem associates who may enter your 
home, steal your belongings or cause property damage that results in you being evicted.26 The Vineland scales 
have questions covering the former but not the latter skills.26 
Social impairments in people with FASD are life-long and tend to become more pronounced with age. Some 
adults with FASD have been reported to have the social functioning of a six-year-old child.27 
Growth retardation 
Prenatal alcohol exposure is associated with intrauterine growth retardation with smaller weight, length and 
head circumference at birth.28 A number of cohort studies have found growth deficits to persist through 
childhood into adulthood.29-32 Most of the international diagnostic guidelines include growth retardation in the 
diagnostic criteria for FAS and other FASDs,10,33-36 although the latest Canadian37 and Australian38  guidelines 
have adopted the term FASD as a diagnostic term and deleted growth impairment as a diagnostic criterion due 
to the fact that many children with prenatal alcohol exposure and central nervous system dysfunction do not 
have growth impairment. A population-based cohort study done in Western Australia found that, although 
infants of mothers with moderate to heavy alcohol consumption in pregnancy had increased odds of being born 
small for gestational age, this effect was eliminated after adjustment for smoking status.39 
Comorbidities of FASD 
A recent systematic review aimed to estimate the pooled prevalence of co-morbid conditions in people with 
FASD (using data from 33 studies with 1728 participants) and to highlight conditions that were much more 
common in people with FASD than in the general US population.40 There were 18 disorders that were found to 
be present in more than half of those with FASD, including conduct disorder, visual problems and refractive 
errors, speech and language deficits, premature birth, hearing loss, alcohol or drug dependence, and ADHD.40 
The prevalence of hearing impairments was estimated to be 100 times higher in individuals with FASD than in 
the general population, the prevalence of visual impairments at least thirty times higher, and the prevalence of 
mental and behavioural disorders due to multiple drug use around twenty times higher. 
Life course consequences of FASD 
Over the lifespan, the primary impairments of FASD interact with environmental risks to produce secondary 
problems. Infants exposed to alcohol in utero tend to be more irritable than other infants and often have 
disturbed sleep patterns and feeding problems.21 These problems can disrupt mother-infant attachment, which is 
believed to be fundamental to later social interactions, especially interactions between two people.21 
As pre-schoolers, children with FASD may be hyperactive, excessively friendly and fearless, and have poor 
motor coordination and delayed speech, language and other developmental milestones.41 They may be prone to 
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temper tantrums and non-compliant.42 When they go to school, children with FASD struggle with cognitive, 
academic and social, emotional, and behavioural challenges that have negative effects on their ability to learn 
and function in the school environment.43 
The University of Washington’s Secondary Disabilities Study conducted life history interviews with all 
available caretakers or informants of 415 individuals with FAS or fetal alcohol effects, whose ages ranged from 
six to 51 years.44 The most important findings from this study were: 
• 90% of all study participants had experienced mental health problems, most commonly attention deficit 
and behaviour problems in young children, and depression in adults 
• 60% of those aged 12 or more years had been suspended or expelled from school, or dropped out of 
school 
• 60% of those aged 12 and over had been in trouble with the law 
• 50% of those aged 12 and over had experienced loss of liberty (23% because of psychiatric disorders, 
15% via compulsory admission for drug or alcohol dependency, and 35% because of imprisonment by 
the criminal justice system) 
• 50% of those aged 12 and over were reported to have a history of inappropriate sexual behaviour 
• 30% of those aged 12 and over had drug and alcohol problems 
• 80% of the 90 individuals aged 21 years or more were not living independently 
• 80% of those aged over 21 had problems with employment 
The University of Washington study noted that many of the people with FASD had come from dysfunctional, 
transient and abusive living situations which may have contributed to their secondary disabilities.44 It found that 
72% of those aged 12 years and older had experienced violence (physical or sexual abuse, or domestic violence) 
and that having experienced violence was by far the strongest risk factor for inappropriate sexual behaviour. It 
also found that half of those aged 12 years or more had not stayed in each living situation for an average of more 
than two years, and half had spent at least 30% of their lives living with a person who had an alcohol or drug 
problem. 
There have been few longitudinal studies of people with FASD.45-49 
A study done in Finland followed up children born to eighty-two pregnant women who had attended a special 
clinic aimed at reducing heavy drinking in pregnancy.47 Of the 69 surviving children who could be followed up 
at 12 years, 41 had FASD (FAS, fetal alcohol effects or alcohol related neurodevelopmental disorder), 10 had 
growth retardation but no other signs of FASD, and 18 had normal development. Of the 41 children with FASD, 
21 were receiving mainstream education, seven were in a mainstream class with either a personal assistant or 
adjusted requirements in some subjects, and 13 were in a special education class. 
In this study there was a high rate of children being taken into care because of parental alcohol abuse and 
inability to provide adequate daily care for their child, often in combination with psychosocial problems.47 Only 
11 of the 42 children with FASD and 18 of the 28 children without FASD had lived only with a biological 
parent by the age of 12 years. Behavioural problems were common: families of 24 of the 41 children with 
FASD, and nine of the 28 children without FASD had sought help for behavioural problems. According to the 
examining psychologist/child psychiatrist behavioural problems were associated with one or more of the 
following factors: poor quality of early attachment and daily care; repeated experience of neglect; physical 
and/or sexual abuse; having observed a frightening experience (abuse of mother or sibling); not being liked by 
peers – loneliness and poor understanding of social rules; and difficulties in learning capacity, attention and 
impulse inhibition. Eleven biological parents of study children (eight mothers and three fathers) had died. Their 
deaths were due to alcohol abuse and/or psychological problems. Eight biological parents (four mothers and 
four fathers) had been in prison. 
Another prospective longitudinal study50 which assessed 24 children of alcoholic mothers in Sweden at the age 
of 12–14 years had similar findings. A later Swedish study,51 which included some of the same participants as 
the previously mentioned study, used national registers to follow-up a group a 79 Swedish adults with FAS at a 
mean age of 32 years and compare their educational, social adjustment and mental health outcomes with those 
of a comparison group of 3,160 individuals matched on age, gender and place of birth. Compared to the 
comparison group, the FAS group were much more likely to have received special education (25% vs 2%), be 
unemployed (51% vs 15%), and receive a disability pension (31% vs 3%), but they had similar levels of 
criminal offending. They had higher rates of hospital admission for alcohol abuse (9% vs. 2%) and psychiatric 
disorders (33% vs. 5%) and were more likely to have been prescribed psychotropic drugs (57% vs. 27%). 
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The Swedish register-based study51 noted that 81% of the adults with FAS had been placed in state care in their 
youth (compared to 4% of the general population) so the authors attempted to account for the effects of this 
difference. When the outcomes for the 79 adults with FAS were compared to those for a matched group of 122 
adults who had been placed in state care before the age of 18 years it was found that although the FAS group 
were more likely to have attended special education (25% vs. 3%), there were no significant differences 
between the two groups in terms of completed education, income, self-support, or hospital care. Compared to 
the state care group, the FAS group were less likely to have received a criminal conviction (28% vs. 55%) and 
much less likely to have been convicted of a severe crime (6% vs. 30%). The study authors noted that the study 
subjects had full-blown FAS and had received their diagnosis early in life and had therefore received financial 
support and had close contact with social workers during childhood. They suggested that these factors might 
have contributed to the relatively high rates of completed secondary education and employment of the 
individuals with FAS. 
A German study which was a 20-year follow-up study of 37 adults with FASD (out of a cohort of 52 eligible 
subjects originally diagnosed as having FAS or FAE in infancy and childhood) found that, although the facial 
features of FAS were less marked in adulthood, only a very small proportion of the study population were living 
a normal adult life.11 Eighteen (49%) had received special education only. Only five (13%) had ever held an 
“ordinary” job, despite 25 (69%) having received at least some preparatory job training and 21 (58%) having 
either started or progressed to formal occupational training. Assessment of living situations revealed that 27% 
lived in institutions, 35% were in a dependent-living situation, 14% lived independently alone, 8% lived with a 
partner, 8% had their own family and 8% lived with their father plus a mother surrogate. Study subjects had 
higher than normal rates of emotional and behavioural problems, especially attention difficulties and aggressive, 
intrusive and delinquent behaviour. Their mental and behavioural problems were independent of intellectual 
impairment and whether they had been diagnosed with FAS or with fetal alcohol effects. 
Epidemiology of FASD 
There is no New Zealand data on the prevalence of FASD but it has been conservatively estimated to be at least 
one percent in the general population and around 50% in children and youth in Child, Youth and Family (CYF) 
care.7 Ospina and Dennett’s 2013 systematic review of 54 FASD prevalence studies, mostly conducted in North 
America and Europe, found that FASD rates have been examined in a variety of settings including the 
community, schools, foster care settings, prisons and correctional settings.52 The review found considerable 
variation in prevalence estimates. Some of this was due to factors such as differences in methods of case 
ascertainment, diagnostic criteria and study participants’ ages, but variation in prevalence estimates is also likely 
to reflect genuine variation between different geographic and other population groups. 
Ospina and Dennett’s review found the reported prevalence of FASD in the community ranged from 0.2 to 5 per 
1,000 population across five studies.52 The prevalence of FAS in non-South African school settings ranged from 
0.2% to 0.8% giving a pooled estimate of 0.4% (4 per 1,000). The prevalence of partial FAS in schools, based 
on a pooled estimate from the four studies that assessed prevalence in either random samples or the whole 
population, was 2.9%. The prevalence of FASD in special education settings ranged from 2% to 9%. 
The prevalence of FASD was found to be much higher in certain population groups. In foster care settings the 
prevalence of FASD ranged from 30 to 50%.52 Studies in the US and Canada estimated the prevalence in prisons 
and correctional facilities as being between 10% and 23%. Prevalence estimates for FASD in aboriginal 
populations in Canada, the US and Australia were highly variable, but a pooled estimate of FAS prevalence in 
Aboriginal peoples was calculated from six studies as 0.2%, not substantially higher than that found in 
community samples from the general population. 
Diagnosis of FASD 
It is important that children with FASD are recognised early in life because they can then receive the 
understanding and support that will increase their chances of having the best possible outcomes in later life and 
help them avoid some of the secondary problems that can result from their primary neuropsychological 
impairments, such as exclusion from school, criminal offending and mental health problems.23,53-55  
Making a diagnosis of FASD can also enable a child’s mother to get help to address her alcohol problem and 
associated difficulties, and avoid having more children with FASD.53,55 It may lead to the identification of 
siblings with FASD.56 Early diagnosis is helpful for parents because it gives them an explanation for their 
child’s behavioural problems and their parenting skills can increase with greater understanding of their child’s 
disabilities and impairments.57 Professionals often fear that mothers will feel judged and shamed when their 
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child is diagnosed with FASD58 but the New Zealand birth mothers interviewed by Jenny Salmon reported that 
they were relieved when they finally received what they perceived to be the correct diagnosis for their child 
because, as well as knowing what was actually wrong with the child, they could make sense of the confusing 
behaviours that they had observed and had thought were due to their poor mothering skills.59 
Without the capacity to diagnose FASD it is impossible to determine how many people in a community have 
FASD and whether prevention or mitigation efforts are having any effect.60 
Diagnostic criteria 
There a number of international guidelines on the diagnosis of FAS and FASD and there are well-established 
diagnostic criteria for FAS.8,10,33,35-38 There is less international consensus on how to diagnose FASD but there is 
a consensus that a comprehensive physical and neurodevelopmental assessment is needed to understand the full 
impact of fetal alcohol on a child’s development.38,55 Such an assessment requires input from educators, social 
workers and a multidisciplinary team of health professionals.37,55 
According to the Australian diagnostic guidelines38 for a child to receive diagnosis of FASD he or she must 
have:  
• severe impairment in at least three of the following ten neurodevelopmental domains: brain structure; 
motor skills; cognition; language; academic achievement; memory; attention; executive function, 
including impulse control and hyperactivity; affect regulation; and adaptive behaviour, social skills or 
social communication  
AND either 
• All three of the sentinel facial features OR 
• 0,1 or 2 facial features plus confirmed prenatal alcohol exposure 
Confirmed prenatal alcohol exposure is not required if all three facial features are present (small palpebral 
fissures, smooth philtrum and thin upper lip) because it is then unlikely that some other condition is the cause of 
the child’s examination findings. 
Because there is no pattern or type of CNS dysfunction that is specific to FASD, it is never possible to say for 
certain that a child without the facial features of FAS has an alcohol-related neurodevelopmental disorder, only 
to say that, on the balance of probabilities, given known prenatal alcohol exposure and observed CNS 
dysfunction consistent with the diagnostic criteria for FASD, it is likely that he or she does. 
The diagnosis Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE), has been 
proposed for inclusion in DSM-5, The Diagnostic and Statistical Manual, 5th edition, from the American 
Psychiatric Association, to encompass the range of neurodevelopmental disabilities that can be associated with 
prenatal alcohol exposure.61 According to the proposed definition of ND-PAE, diagnosis requires confirmed 
prenatal alcohol exposure plus impairment in all three of the following domains:61  
• neurocognitive (as indicated by impairment in one or more of: intellectual function/global 
development; executive functioning; learning; memory; visual spatial reasoning) 
• self-regulation (as indicated by one or more of: impairment in mood or behavioural regulation; 
attention deficit; impairment in impulse control) 
• adaptive functioning (as indicated by two or more of the following, with at least one of the first two 
symptoms: communication deficits; impairment in social communication and interaction; impairment 
in daily living; motor impairment) 
Practical difficulties in diagnostic assessment 
While guidelines recommend that children suspected of having FASD be assessed by multidisciplinary teams 
who have specific training in assessing children prenatally exposed to alcohol, there are few specialised FASD 
diagnostic services. An international survey conducted in 2006 identified 34 FASD diagnostic clinics: 29 in 
North America, two in Africa, two in Europe and one in South America.62 The UK currently has only one 
specialist FASD clinic.63 A 2011 Canadian survey of clinical capacity for diagnosing FASD found that, based 
on an estimated FASD prevalence of one percent, diagnostic capacity would need to increase seventeen-fold to 
be able to diagnose all cases of FASD.64 A US expert estimated that the US would need another 200 
multidisciplinary teams and the UK would need 39 fulltime teams to identify all new cases of FASD65 and he 
cited the view that the current diagnostic criteria for FASD are so complex that even expert clinicians have 
difficulty applying them.66 
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Another Canadian study estimated that a multidisciplinary diagnostic FASD assessment used between 23 and 33 
hours of staff time (costing between $2,650 to $3,750) and that the total cost for one individual to be screened, 
referred, admitted, and diagnosed ranged from $3,110 to $4,570 (32 to 47 hours per person).57 
Many clinicians lack the training and experience to confidently diagnose FASD.67-69 The Ministry of Health’s 
2015 survey of a wide range of New Zealand clinicians found that those who felt extremely confident about this 
diagnosis were definitely in the minority.7 A 2004 survey of paediatricians in Western Australia found that, 
while 81% knew that abnormal facial appearance was a feature of FAS, only 19% knew all of the essential 
diagnostic features of FAS, and only 23% routinely asked about alcohol use in pregnancy when taking a 
pregnancy history.58 Most admitted having suspected but not diagnosed FAS and almost 70% thought that 
diagnosis could stigmatise a child or family.58 The provision of educational resources did little to change these 
paediatricians' knowledge of the essential diagnostic features of FAS or their confidence in making the 
diagnosis.70 
Most children with FASD do not have the characteristic facial features of FAS. Of 1,270 patients seen at clinics 
belonging to the Washington State Fetal Alcohol Syndrome Diagnostic & Prevention Network during 1993–
2005 who had confirmed prenatal alcohol exposure (or all of the features of FAS) and CNS dysfunction, and 
would therefore meet the criteria for FASD, only 59 (4.6%) could be diagnosed with FAS.71 
Making a diagnosis of FASD in the absence of the facial features characteristic of FAS requires confirmation of 
maternal alcohol intake during pregnancy.53 This can be difficult to obtain. Midwives and other clinicians may 
be reluctant to ask a pregnant woman about the details of her alcohol intake for fear of alienating or stigmatizing 
her, because they lack knowledge about the amounts of alcohol and the patterns of alcohol consumption that are 
especially harmful in pregnancy, or because there is a lack of services to refer a woman to if an alcohol problem 
is identified.72 Women may be reluctant to disclose their alcohol intake because of embarrassment, guilt or fear 
that they may lose custody of their children.73 A woman may not be able to recall the details of her drinking in 
pregnancy if she is asked only years later when her child is being evaluated for developmental and/or 
behavioural problems suggestive of FASD, and she is likely to be especially vulnerable to feeling judged if she 
did drink during pregnancy and knows that there is a possibility that her drinking has contributed to her child’s 
problems.73 For children in foster care or international adoptees it may be impossible to obtain information on 
their mothers’ alcohol consumption.74 
Children exposed to alcohol in utero often have other adversities in their backgrounds so it can be hard to 
determine the whether a child’s emotional and behavioural problems are primarily due to prenatal alcohol or to 
other environmental or possibly genetic factors.74 Children of alcohol abusing parents have been found to be 
more likely than other children to experience emotional, physical and sexual abuse; emotional and physical 
neglect; exposure to domestic violence; substance abuse or mental illness within their household; parental 
separation or divorce; and incarceration of a household member.75,76 Parental substance use disorders have been 
reported to be a contributing factor for between one-third and two-thirds of children involved with child 
protection services in the US.77 
Given their often difficult family environments it is not surprising that children with prenatal alcohol exposure 
often meet the diagnostic criteria for one or more mental health conditions including reactive attachment 
disorder, posttraumatic stress disorder, learning disabilities, depression and anxiety, conduct disorder, and 
attention deficit hyperactivity disorder (ADHD).74,78,79 It can be hard to decide whether these disorders are 
independent of, secondary to, or comorbid with any effects of prenatal alcohol exposure on 
neurodevelopment.74,80 This may be why some clinicians are reluctant to make a formal diagnosis of FASD.74 
New research may develop more specialised assessment tools that will help with discriminating the impairments 
of FASD from those due to other conditions.74,81  
It is important that mental health professionals consider the possibility of FASD in someone with a mental 
health problem because it may be the reason they are not responding to medications and psychosocial therapies, 
and an indication that they need on-going psychosocial support.78 
New Zealand experience with FASD diagnosis: The FASD assessment pathway in 
the Hawke’s Bay DHB 
The Hawke’s Bay District Health Board (DHB) has a Developmental Assessment Programme (DAP) that 
provides multi-disciplinary diagnostic assessments of children with complex developmental and behavioural 
concerns.54 It also provides training in developmental and behavioural conditions for people working in health, 
education and social service settings. One component of the DAP is a FASD Assessment Pathway for children 
whose developmental and behavioural issues are possibly related to pre-natal alcohol exposure. The Health 
Promotion Agency (HPA) commissioned an independent process evaluation of this FASD Assessment Pathway 
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to learn more about this service model and explore considerations related to replication of this programme in 
other regions. A brief summary of the findings from this evaluation, which took place during April to June 2015, 
is presented below.54 
The FASD Assessment Pathway is provided by a multidisciplinary team. Paediatric, speech language, 
psychological and social work assessments are combined in a diagnostic assessment based on Canadian 
guidelines. Key aspects of the pathway are: assessment at home, school and clinic; collaboration with families, 
caregivers, teachers, referring paediatricians and others; presentation of synthesised assessment findings and 
recommendations in a single report, and provision of feedback sessions to the family and to school personnel 
involved with the child. 
The evaluation found that the FASD Assessment Pathway is successfully identifying children with FASD, 
engaging families living in low decile areas, and engaging many Māori whānau. It is reaching into homes and 
schools. Factors identified as being linked to the success of the pathway were categorised as relating either to 
the service model or to the workforce, infrastructure and service context. 
Essential aspects of the service model were: 
• Shared vision and values 
• A best practice multi-disciplinary approach 
• A synthesised report and feedback sessions 
• A team approach 
• Close working relationships with paediatricians 
• Strong and effective relationships with other services 
• Building capacity through training 
Regarding the workforce, infrastructure and service context, the evaluation found that the DAP FASD 
Assessment Pathway is provided by a highly skilled and experienced professional team supported by strong 
leadership. The Pathway is part of a broader assessment programme that is located within a child development 
service. This was viewed as contributing to the programme being sustainable and of high quality. The evaluation 
noted that locating the specialised FASD assessment pathway within a child development service is widely 
viewed as a way of providing an effective continuum of service for children, enabling a flexible and efficient 
use of resources, and helping to ensure programme sustainability. It also noted that the people delivering such a 
programme need specialist training in FASD assessment. (Three of the Hawke’s Bay team members travelled to 
Canada for this.) 
The evaluation highlighted a number of important factors relevant to the replication of the FASD Assessment 
Pathway. The most significant was a general consensus that the effectiveness of the pathway is limited by the 
lack of post-assessment support for children identified as having FASD, and their families. Effectiveness would 
be improved if support could be provided, similar to that provided for children diagnosed with Autism Spectrum 
Disorder (who are also diagnosed within the DAP). Extra funding would be needed for this. Additional on-going 
challenges were: 
• Waiting times 
• A need to keep refining assessment reports so they are both as comprehensive and as user-friendly as 
possible 
• Ensuring cultural responsiveness. Stakeholders suggested that Māori and Pasifika input should be 
obtained in the programme set-up phase to ensure that cultural responsiveness is maximised from the 
outset 
• A mismatch between the perspectives of the health and education sectors: health focuses on diagnosis 
but education is more concerned with functional impact in the learning environment 
• The need to develop and maintain a team culture characterised by strong professionalism, 
collaboration, collegial respect and openness. This requires ensuring that team members have 
opportunities for on-going professional development 
The DAP team aims to provide 40 assessments per year (one a week during school terms), and data indicates 
that approximately one third of these are FASD assessments. The average number of professional hours used per 
FASD assessment (excluding paediatrician, administration and management hours) was 34.5. The FASD 
Assessment Pathway does not accept children until they reach the age of eight years so any child younger than 
eight must wait under the care of a paediatrician until they are old enough to be assessed. Most children assessed 
for FASD receive general health oversight from a paediatrician both before and after assessment. During 
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2010-2015, 74 children accessed the FASD Assessment Pathway. Seventy-four percent were boys and 26% 
girls. Most were Māori (73%). The ages of children (at referral) ranged from three to fifteen years and around 
61% were aged eight or older. Most children lived in high deprivation areas and only 26% lived with two 
parents (birth parents, adoptive parents or whangai parents). 
Of the 42 children with data on FASD assessment outcomes, all but one child met the criteria for at least one 
disorder and 38 (90%) met the criteria for FASD. Most children had more than one disorder: 29% had two 
disorders and 64% had three or more disorders. The other disorders included attention deficit hyperactivity 
disorder, intellectual disability, language disorder, attachment disorder, adaptive behaviour limitations and 
cerebral palsy. 
Interventions for children and families living with FASD 
There is little point in investing in improving capacity to diagnose FASD without also being able to provide 
services that will make a meaningful difference to the lives of children with FASD and their families, both in the 
short term and the long term. 
There is a small but growing evidence base for interventions for children with FASD, children at risk of FASD 
because of known prenatal alcohol exposure, and parents who are themselves affected by FASD.82-84 
Intervention studies in humans have mostly aimed to improve specific cognitive or adaptive skills such as 
language, literacy, mathematics, self-regulation, working memory and social skills. Kodituwakku’s 2011 review 
identified only 12 papers reporting on scientific evaluations (RCTS or quasi-RCTS) of interventions for children 
pre-natally exposed to alcohol.83 While some of these studies found positive effects, only two interventions had 
been evaluated more than once, and none were considered to be well established. Because each person with 
FASD (or prenatal alcohol exposure) is not affected in the same way or to the same degree, a thorough 
assessment of a person’s deficits and strengths is necessary to determine what kind of specific intervention 
might be beneficial for that person.84 Cognitive and behavioural interventions often require time and effort from 
families and therefore they may be ineffective for children in chaotic families.83 Such interventions are more 
likely to be successful when they include both direct child intervention and parent support.82,83 
The 2015 review by Reid et al.85 had broader inclusion criteria and included studies if they reported quantitative 
measures of functioning so that comparisons could be made about potential gains, regardless of the study design 
or type of outcomes. It identified 32 studies, most of which targeted aspects of neurocognitive functioning in 
early to middle childhood although there were two studies which aimed to improve developmental outcomes in 
infants born to substance-abusing mothers, four studies of education and advocacy for parents and caregivers 
(two studies), and teachers or child welfare workers (one each), and two studies of support for parents who were 
themselves affected by FASD. The studies were generally small, at some risk of selection bias, and of variable 
methodological quality. Nineteen were considered to have a “strong” study design (randomised controlled trial 
or controlled clinical trial). 
The only studies with long term follow up (six months or more) were two studies of home visiting programmes 
for substance abusing mothers, neither of which found clear benefits for children’s development at two to three 
years of age.85 The review authors suggested that standard developmental measures may not be the best tools for 
measuring intervention effects in infants and toddlers with prenatal alcohol exposure. Other findings from the 
review were: a number of small studies have found positive effects from interventions to improve self-regulation 
or attentional control; interventions aiming to improve some specific areas of cognitive difficulty in children are 
promising; there is strong evidence for the utility of structured programmes that include both parents and 
children in improving social skills; there is promising evidence that parents and caregivers benefit from support 
in managing their children’s behaviour and that improvements in children’s behaviour are associated with 
improvements in parents’ wellbeing; and support, education and advocacy services for parents, caregivers, and 
child welfare caseworkers can be beneficial both for these adults (increasing confidence, decreasing stress) and 
for the children they support (decreasing school problems, reducing number of changes in foster care 
placement).85 The two small cohort studies of support for parents with FASD (all mothers except one), found 
benefits including decreased drug and alcohol use, and improvements in mental health, finances, housing 
stability, parenting, use of contraception, and use of medical and mental health services.85 
A modification of the Alert Program®86, which was used in three of the studies in the Reid et al. review, and 
found to have positive effects, is being trialled with Aboriginal children attending schools in remote 
communities in Western Australia.87,88 The estimated prevalence of alcohol-related neurodevelopmental 
disorders among these children is almost 20%.89 The Alert Program®, which was designed by occupational 
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therapists, teaches children about self-regulation (the ability to change the arousal state of your nervous system 
so it is appropriate to the task or situation).90  
There has been very little published research on interventions for adolescents or young adults with FASD but a 
recent review identified two recently completed trials in the US.82 One of these, Project Step-Up, found that a 
six-week intervention aimed at reducing or preventing alcohol and substance abuse that was delivered to 
adolescents with FASD and their parents (separately and concurrently) led to reductions in drinking, risky 
drinking, and negative consequences from drinking in the adolescents.91 The other trial, of a multi-component 
intervention for 13–25 year olds with FASD and their families called Partners for Success, did not find any 
positive effects on youth outcomes, but did find changes in parent positive coping and self-controlling 
behaviours.92 This trial’s capability for finding positive effects may have been compromised by problems with 
recruitment and implementation.82 
Animal studies have found a number of substances that, when given to alcohol-exposed pregnant mothers, 
mitigate the effects of alcohol on their offspring. These substances include 5-HT1A agonists, neuroprotective 
peptides, anti-oxidants, and choline and other nutrients.83,93 Some studies of rats with prenatal alcohol exposure 
have found benefits from post-natal nutritional supplementation94,95 and social and environmental enrichment96 
suggesting that these approaches might be of benefit to children with, or at risk of, FASD. Investigating the 
efficacy of these approaches in humans could be difficult because women who drink heavily in pregnancy are 
probably unlikely to reveal their drinking habits to health professionals.83 
Maternal undernutrition may exacerbate the effects of prenatal alcohol exposure on the developing fetus.93 A 
case-control study done in South Africa found that the mothers of children with FAS were significantly smaller 
than control mothers as indicated by height, weight, head circumference, and BMI.97 There has been very little 
research on nutritional supplements for pregnant women to reduce the impact of prenatal alcohol exposure on 
their children but one study of micronutrient supplementation in pregnant Ukrainian women suggested that 
choline supplementation, administered together with routinely recommended multivitamins and minerals, may 
improve basic learning mechanisms involved in encoding and memory of environmental events for infants from 
both alcohol-exposed pregnancies and non or low alcohol-exposed pregnancies.98 
Children with FASD often have ADHD.80 There have been only two very small randomised controlled trials of 
pharmacological treatment of ADHD symptoms in children with FASD.80,99 It appears that, while there is 
considerable individual variability in response to medication, psychostimulant medication, such as 
methylphenidate or dextroamphetamine, improves hyperactivity but not inattentiveness.80,83 A recently 
published consensus guideline from the UK on the identification and treatment of individuals with ADHD and 
associated FASD99, the first such guideline, warns that side effects from medication may be more marked 
(though similar) in individuals with ADHD and FASD than in those with ADHD alone and that the use of short-
acting stimulants in adolescents with FASD and ADHD may potentially contribute to the development of 
addictive disorders during the teenage years. 
The long term outcome for a child with FASD depends on the interaction of the child’s individual characteristics 
with the broader ecological context, including the family, social systems and culture to which the child 
belongs.82 Being raised in a stable and nurturing family who are aware of the child’s diagnosis and can adapt to 
the child’s limitations and advocate for his or her needs reduces the risk of adverse life outcomes.23 Many 
children with FASD, however, experience difficult caregiving environments with adversities such as maternal 
alcohol and drug abuse and depression (resulting in less responsive and less stimulating parenting), abuse and 
neglect, poverty, family violence and multiple foster care placements.100 
There is very little systematic research on the impact of raising a child with FASD on the family, on how parent 
and family variables influence outcomes for people with FASD, or on interventions for families affected by 
FASD.100 For this reason, Olson et al. drew on the findings from both systematic research, and the informal 
literature based on parents’ accounts on raising a child with FASD, to highlight important childrearing and 
family issues.100  
The issues identified from the informal literature included guilt and shame (for birth mothers), financial stress, 
the lack of knowledgeable professionals, the time needed to advocate for the child in the education and justice 
systems, the need for respite care, difficulties in determining the causes of a child’s misbehaviour, the value of 
parent support and self-hep materials from parent support organisations, and the need for formal intervention 
services.100 
Issues identified from research studies included the impact of maternal substance abuse and/or depression on 
infant attachment and maternal responsiveness, child externalising behaviour as the most significant cause of 
parental stress, the need for foster parents who can provide structure and a high level of organisation and are 
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well supported by a care team knowledgeable about FASD, parents’ need for respite care and support in dealing 
with negative emotions regarding their child, the risk of caregiver burnout and depression, and the difficulties of 
dealing with multiple service providers, such as mental health, education, medical and social services, who may 
not agree on the best way of helping the child.100 
Given the lack of research on interventions specifically for families affected by FASD, Olson et al. suggest that 
useful insights can be gained from the more general developmental disabilities literature, and the literature on 
traumatic brain injury, as families of children with these conditions face many problems that are similar to those 
facing families of children with FASD.100  
Petrenko82 suggests that the lived experiences of people with FASD, their parents and caregivers, and service 
providers are a valuable source of information for those developing interventions for people with FASD. A 
qualitative study done in up-state New York asked 25 parents of children with FASD (only one of whom was a 
biological parent) and 18 service providers for their views on desirable characteristics for intervention 
programmes aimed at preventing secondary conditions, such as mental health problems or trouble with the 
law.101 Study participants reported that their children did not qualify for special education or disability support 
services because their IQ scores were too high although some were able to obtain such services after multiple 
appeals and advocacy. The study identified five key characteristics for FASD intervention programmes: 
availability across the lifespan; having a prevention focus; being individualised; being comprehensive; and 
being co-ordinated across systems and developmental stages. The study authors stated that the five key 
characteristics are consistent with the positive behaviour support framework which focuses primarily on 
adapting the environment to improve an individual’s quality of life with reduction of problem behaviours as a 
secondary goal.102 
Drinking in pregnancy as a public health issue in New Zealand 
Alcohol is pervasive in New Zealand society. The 2012/2013 New Zealand Health Survey (NZHS) found that 
76% of New Zealand women aged over 15 years had drunk alcohol in the past 12 months and that one quarter of 
women drinkers drank alcohol regularly, at least three to four times per week.103 Almost half of all women 
drinkers had drunk to intoxication at least once in the past year and around five percent reported drinking to 
intoxication at least weekly.103 
The NZHS included 565 women aged 15–54 years who had been pregnant within the past 12 months and 19% 
of them reported having drunk alcohol at some time during their most recent pregnancy.103 Younger women 
were more likely to have drunk alcohol during pregnancy: 28% of 15–24 year olds compared to 17% of 25–34 
year olds and 13% of 35–54 year olds.103 
Of the women who had been pregnant in the last year, 31% reported that they had stopped drinking before 
becoming pregnant, 55% that they stopped drinking as soon as they learned they were pregnant, and 15% that 
they continued to drink while pregnant.103 Of those who continued to drink, the majority reported reducing their 
drinking while pregnant.103 
Binge drinking or heavy episodic drinking is the pattern of drinking recognised as the most harmful to the 
developing fetus.5 For this reason, the NZHS enquired about past year risky drinking, defined as drinking four 
or more standard drinks on one drinking occasion, in women who had been pregnant in the last year and who 
reported drinking alcohol in their most recent pregnancy. It needs to be understood that rates for past-year risky 
drinking among women who drank during pregnancy are not necessarily the same as the rates of risky drinking 
during pregnancy. Of the women who reported drinking during pregnancy, 78% also reported risky drinking 
during the past year, including 11% who reported risky drinking at least weekly and 16% who reported risky 
drinking at least monthly.103 
Another New Zealand survey, which was a retrospective survey of 723 post-partum women across New 
Zealand, found that overall, 34% of women reported drinking in pregnancy and that 12% of pregnancies were at 
high risk of heavy alcohol exposure in early gestation.104 The percentage of pregnancies with heavy alcohol 
exposure in early gestation was almost five times higher in Māori women and 3.4 times higher in Pacific 
women, than in New Zealand European women.104 
This survey found that 44% of pregnancies were unplanned and that pregnancy confirmation occurred later for 
women with unplanned pregnancies (7.3 vs. 5.3 weeks gestation).104 Three quarters of pregnancies in Māori and 
Pacific women were unplanned.104 The authors of this study suggested that this indicates that alcohol policies 
that facilitate the reduction of heavy episodic drinking throughout Māori and Pacific communities—not just 
among women planning a pregnancy and pregnant women—need to be adopted.104 
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Keriata Stuart conducted in-depth interviews with ten Māori women with the aim of understanding how Māori 
women negotiate decisions about alcohol in pregnancy.105 She used a grounded theory methodology to analyse 
the information gathered and she proposed that Māori women make decisions about drinking during pregnancy 
using a process of Trading off. This process was considered to be individually based but to exist within a 
complex social context; a fluid process that continued throughout pregnancy. Māori women learned social rules 
about alcohol consumption within their whānau and social circles; their beliefs about alcohol consumption in 
pregnancy were acquired in much the same way. Māori women regarded health professionals as a less 
trustworthy source of information. Reasons why women continued drinking while pregnant included fitting in 
(it is hard to be the only non-drinker in a social group), releasing pressure (drinking to relax) and carrying on as 
normal. Supportive partners, friends and whānau surrounding a pregnant woman could make a major 
contribution to a Māori woman’s resource bank making it easier for her to refuse offered drinks and change her 
drinking habits, and also helping her to deal with stresses in her life, maintain a positive self-image, take control, 
and act with self-determination. 
The Growing Up in New Zealand study interviewed 6,822 expectant mothers in either their last trimester of 
pregnancy or soon after the birth of their child and asked them to recall their alcohol consumption in three 
periods: before becoming pregnant or before being aware they were pregnant; in the first three months of 
pregnancy; and after the first three months of pregnancy.106  
Data from this study suggested that 71% of women drank alcohol before becoming aware of their pregnancy, 
23% drank during their first trimester after becoming aware of their pregnancy, and 13% drank after their first 
trimester.106 The proportions of women drinking four or more drinks per week were 29% before becoming 
aware of pregnancy, 7% in the first trimester and less than one percent after the first trimester.106 The women 
who reported drinking in pregnancy were very heterogeneous in regard to their socio-demographic 
characteristics but the heavy drinkers were more likely to be younger women, Māori women, women with no 
secondary qualifications, smokers and women whose pregnancy was unplanned whereas the women who 
reported light drinking (three or fewer drinks per week) were more likely to be older women, European women 
and women from socio-economically advantaged backgrounds.106 
A 2005 survey of a random sample of 1,109 non-pregnant New Zealand women aged 16–40 years aimed to 
assess New Zealand women’s opinions on the safety of alcohol consumption in pregnancy and the 
sociodemographic and lifestyle factors associated with these opinions.107 It found that 44% of women in the 
study were of the opinion that no alcohol is safe in pregnancy and 45% that one standard drink or less on any 
one day is safe. Only 10% thought that more than one standard drink was safe.107 The moderate and heavy 
drinkers, who made up 55% of the study sample, were more likely than abstainers or light drinkers to be of the 
opinion that more than one standard drink on a typical drinking day during pregnancy is safe.107 
In summary: 
• Most New Zealand women drink alcohol (as do most New Zealand men) 
• A sizeable minority engage in risky (binge) drinking 
• Most women stop or reduce their drinking once they are aware they are pregnant 
• Nearly half of all pregnancies are unplanned 
• There is heavy alcohol exposure in early gestation in at least 10% of pregnancies 
• Binge drinking and unplanned pregnancies are more common in younger women and Māori women 
• Women have mostly got the public health message to stop drinking when they are pregnant 
• Women have not got the message not to drink if they are planning to get pregnant or could get pregnant 
Patterns of drinking associated with FASD 
The earliest studies of the effects of pre-natal alcohol exposure, done in the late 1970s and early 1980s, involved 
identifying children with the facial features of FAS whose mothers who were chronic alcoholics.2,108-112 The 
amounts of alcohol consumed by the mothers in these studies were considerable: for example, a study done in 
the west of Scotland reported alcohol intakes during pregnancy in the range from six measures of vodka daily to 
one bottle of vodka daily.112 An early US study of 23 children of alcoholic mothers found that four infants died 
in the perinatal period (a mortality rate of 17%) and that 44% of the surviving children had borderline-to-
moderate mental deficiency and 32% had enough features on physical examination to suggest fetal alcohol 
syndrome.113 
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A prospective study which began in Boston in 1974 questioned 633 women on their alcohol consumption at 
their first prenatal visit and classified women into three groups: abstinent and rare drinkers (326 women), 
moderate drinkers (249 women) and heavy drinkers (58 women, 9%).114 The heavy drinkers were women who 
consumed five or more drinks on occasion and they also had a consistent daily intake of more than 45ml of 
absolute alcohol daily: the average daily intake in this group was 174 ml. A standard drink is defined in New 
Zealand as 12.7 ml (10g) of alcohol and is equivalent to one 330 ml can of beer or one 100ml glass of wine115 so 
these women were drinking an average of around 14 standard drinks per day. Moderate drinkers were women 
who drank more than once per month but did not meet the criteria for heavy drinking. The babies were given 
detailed paediatric, neurological and developmental examinations two or three days after delivery by a physician 
with no prior knowledge of the mothers’ or infants’ histories. The infants of the heavy drinkers had significantly 
higher rates of congenital anomalies than the infants of mothers in the other two groups. Thirty-two percent of 
infants of heavy drinkers had congenital anomalies of any kind and 17% had major anomalies (compared to 3% 
and 2% in the other groups). Ten of the fifteen (67%) heavy drinkers who significantly reduced their alcohol 
intake during pregnancy had apparently normal babies but only two of the 27 (7%) women who drank heavily 
throughout pregnancy did. 
While it soon became clear that daily heavy drinking by a pregnant woman was very hazardous to the fetus, 
attempting to determine exactly what level of alcohol consumption was dangerous was more difficult. Studies 
done in humans usually rely on mothers honestly and accurately recalling their alcohol consumption during a 
specific period and they often do not ask sufficiently detailed questions to establish the amounts and timing of 
drinking in relation to gestation or drinking patterns.5 
In animal studies researchers can control the size, number, pattern and timing of alcohol doses given to the 
mother and so examine the effects of variations in alcohol exposure on the developing fetal brain. Animal 
studies have established that peak blood alcohol concentration is highly correlated with the degree of brain 
damage (as indicated by reduced brain weight). High blood alcohol concentrations are achieved by ingesting a 
large quantity of alcohol over a short period of time, a pattern of drinking known as binge drinking.5 
Populations that have the highest rates of binge drinking tend to have the highest rates of FASD, and the highest 
ratio of FAS rates to partial FAS rates.116 May and Gossage116 compared rates of FAS and partial FAS reported 
from seven community studies and found the highest the highest ratio of FAS to partial FAS rates was in in 
South Africa, where mothers of children with FAS and partial FAS drank heavily (an average of 6.6 standard 
drinks per night) almost every Friday and Saturday evening. 
The timing of maternal drinking determines which anatomical features of the fetus are affected. The facial 
features characteristic of FAS are the result of heavy drinking between the sixth and ninth weeks of gestation.117 
The central nervous system is developing for the whole nine months of pregnancy therefore brain damage can 
result from drinking at any time during pregnancy. It is possible that the specific pattern of behavioural and 
cognitive deficits seen in a child with FASD is related to the timing of the mother’s drinking episodes and future 
research may determine which regions of the brain are linked to particular deficits and behaviours.4,117 
Factors that modify the risk of FASD 
Even if two pregnant women, or one woman during two different pregnancies, have a similar quantity, 
frequency and timing of drinking, the resulting children may not be affected to the same degree.117 The 
incidence of FASD among the children of women who drank heavily in pregnancy is far from 100%. A 1995 
review of 29 prospective studies estimated the incidence of FAS among heavy drinking women (defined as 
those who had average of 2 or more drinks per day, or 5 to 6 drinks per occasion, or a positive score on the 
Michigan Alcoholism Screening Test, or clinical diagnosis for alcohol abuse) as 4.3%.118 
Maternal factors that have been found to increase the risk and severity of FASD are higher maternal age, higher 
number of previous pregnancies, higher number of previous births, smaller body size, undernutrition, low socio-
economic status, smoking, other drug abuse and depression.117 
Genetic factors are probably involved in susceptibility to FASD and there is continuing research in this area.119 
There has been found to be greater concordance of FASD diagnosis and IQ in identical than non-identical twins 
of alcoholic mothers.120 
Women who have children with FASD frequently come from heavy drinking families, have heavy drinking 
partners, move in social circles where heavy drinking is common, and are socially isolated from the mainstream 
economy and society.117 
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Is light or moderate drinking in pregnancy hazardous? 
Government agencies in developed countries, including New Zealand’s Ministry of Health,121 commonly advise 
that even low levels of alcohol intake may be harmful to unborn babies and that pregnant women should abstain 
from alcohol.122-124 There is conflicting evidence about whether occasional or light drinking in pregnancy is a 
risk factor for later mental health or learning problems in exposed children but most studies have not found any 
significant detrimental effects.125-132 
A 2007 systematic review of 46 studies looking at the effects of low to moderate alcohol intake on miscarriage, 
stillbirth, intrauterine growth restriction, prematurity, birthweight, small for gestational age at birth and birth 
defects including fetal alcohol syndrome found no convincing evidence for any of these outcomes. This 
review’s authors stated that many of the studies had methodological weaknesses therefore the evidence 
precludes concluding that low to moderate drinking in pregnancy is safe.133 
All studies of prenatal alcohol in humans rely on maternal self-report and most have not taken into account the 
amount, timing and pattern of maternal drinking.134 If studies classify women’s drinking according to average 
alcohol intake per week then many women who are heavy or binge drinkers on the occasions when they do 
drink may be classified as light drinkers because their average intake is less than one standard drink per day.134 
This may have contributed to some studies failing to find differences between different groups of drinkers. An 
Australian study examining the association between prenatal alcohol exposure and fetal effects compared the 
results of using three different published methods of quantifying maternal alcohol consumption with a 
composite method of categorisation that combined total quantity, dose per occasion and frequency.134 It found 
that effects of moderate and binge drinking were only evident when the composite method was used but effects 
from heavy drinking were evident and similar with all methods. 
A 2012 review of animal studies of moderate alcohol intake found that it was associated with long lasting neuro-
behavioural deficits including alterations in learning, memory, motor coordination, social behaviour, and stress 
responses.135 It was also associated with CNS changes that could account for these behavioural effects including 
alterations in neuronal migration, adult neurogenesis, neurotransmitter receptor function, synaptic plasticity, and 
intracellular signalling pathway. The review defined moderate alcohol intake as that producing a blood alcohol 
level of ≤ 0.17 g/dl, which has been assumed to model human moderate alcohol intake. (New Zealand’s drink 
drive legal alcohol limit is 0.05 g/dl.136) 
Prevention of FASD 
Prenatal brain damage caused by alcohol is irreversible but totally preventable. Heavy drinking and drinking to 
get drunk are a significant part of New Zealand’s drinking culture.137 Compared to previous generations young 
women are drinking from an earlier age and drinking greater quantities when they drink.138 Fetal damage is only 
one of the many individual and community harms produced by alcohol abuse.137 There is not space here to 
discuss in detail strategies to reduce alcohol-related harm in the whole population. The Law Commission’s 2010 
report Alcohol in our lives: Curbing the harm139 states that the international literature indicates that there are 
seven major policy levers for regulating alcohol-related harm: 
• Regulating the physical availability of alcohol through restrictions on time, place and density of outlets 
• Regulating conduct in commercial drinking establishments 
• Taxing alcohol and imposing controls on price 
• Regulating advertising, promotions and marketing 
• Imposing penalties for alcohol-related anti-social behaviour such as drink driving 
• Education and persuasion with the provision of information 
• Increased availability of treatment programmes with screening and brief interventions in health care. 
Only the last two of these are within the ambit of the health system and will be considered here. 
Communication and education strategies 
A 2014 literature review for the Health Promotion Agency, entitled Drinking alcohol in pregnancy,140 
considered, among other things, research on primary prevention communication strategies. These strategies aim 
to influence knowledge, beliefs and attitudes about alcohol use in pregnancy and they can support clinical 
strategies, such as brief interventions, that may be used in maternity or other healthcare settings.140 
Communication strategies include media campaigns, social marketing approaches, educational materials, 
messages for healthcare providers and health warning labels on alcohol containers.140 
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Although there have been many communication campaigns addressing alcohol use in pregnancy, these have 
rarely been based on theory or on formative research that could help identify the target audience, the target 
behaviours, and the factors that influence the behaviours of the target audience.141 Campaign evaluations have 
tended to be of only fair to poor quality and have often not drawn any meaningful conclusions.141 There is 
therefore a lack of evidence to inform the design of campaign strategies and messages.141 Despite this, some best 
practice approaches have been identified from reviews of Canadian campaigns,142-144 as follows: 
• Campaigns should be carefully planned with objectives that are specific, realistic, attainable, 
measurable and time-specific 
• Campaigns should be one component of a broader strategy and should involve a wide range of partners 
• Campaigns should be carefully designed for a specific group or groups. Campaigns are most likely to 
be effective in larger, well-defined lower-risk groups 
• Campaigns should assess the current levels of awareness in the target audience and focus messages on 
areas where awareness is low 
• Campaigns should have good exposure and reach to make messages more likely to be heard and 
remembered. 
There is limited evidence on the specific elements that make a campaign message effective.140 It has been 
suggested that messages need to take a positive and supportive approach and avoid the use of blame, shame and 
fear-based strategies.143 They can link people to further information, services and support.143 The Ministry of 
Health’s Action Plan notes that women are currently receiving mixed messages about the risks of drinking 
during pregnancy and it emphasises the need to disseminate a clear, consistent and unambiguous message that 
women should stop drinking alcohol if they could be pregnant, are pregnant or are trying to get pregnant as there 
is no known safe level of alcohol consumption during pregnancy.7 
The Health Promotion Agency’s review describes a number of international communication campaigns aimed at 
reducing or preventing alcohol use among pregnant women that have been evaluated through assessing 
campaign recall, changes in awareness and knowledge, and intended changes in behaviour in the target 
audience. It also provides brief details on some recent non-evaluated campaigns including the Babies and Booze 
social media campaign developed in Auckland.145 
There is a lack of evidence for the efficacy of public health campaigns in changing behaviour (as opposed to 
knowledge or intentions) regarding consumption of alcohol in pregnancy.146-149 There is also little evidence that 
mass media campaigns have been effective in modifying alcohol use in the general population, except in relation 
to drink driving.150-152 
Identifying at-risk women 
Interventions to prevent FASD need to be directed both at the general population of women of childbearing age 
(universal prevention) and at the women at highest risk of having a child with FASD such as women with 
alcohol addiction, women who themselves have FASD, and women who already have a child with FASD 
(targeted and indicated prevention). It is necessary to identify women with risky drinking patterns and women 
who are alcohol-addicted so that they may be helped to reduce or stop their drinking, to deal with the factors that 
underlie their drinking, and to use effective contraception. Research studies have consistently identified high 
levels of pre-pregnancy drinking as being predictive of drinking during pregnancy.153 
Women may not disclose their alcohol abuse to health practitioners for various reasons including embarrassment 
and denial. The Ministry of Health recommends that primary care health professionals ask women who are 
planning a pregnancy or are pregnant about whether they drink alcohol; provide brief advice about not drinking 
alcohol when planning a pregnancy or when pregnant and explain why; and assist women who are having 
difficulty stopping, or whose drinking is problematic, by directing them to addiction treatment services.154 A 
Pregnancy and Alcohol Cessation Toolkit155 has been developed to support health professionals in this. 
There are a number of standardised screening questionnaires that can be used to identify problem drinking.156,157 
A 2010 systematic review157 looked at cohort or cross-sectional studies that had compared that compared one or 
more brief alcohol screening questionnaire(s) with reference criteria obtained via structured interviews to detect 
‘at-risk’ drinking, alcohol abuse or dependency in pregnant women receiving prenatal care. The review authors 
identified five studies that evaluated the sensitivity, specificity and positive predictive value of seven brief 
screening questionnaires. They concluded that three questionnaires showed promise for screening for risky 
drinking in pregnant women: T-ACE (Take[number of drinks], Annoyed, Cut down, Eye-opener), TWEAK 
(Tolerance, Worried, Eye-opener, Amnesia, Kut down), and AUDIT-C (Alcohol Use Disorder Identification 
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Test – Consumption). They stated that AUDIT-C might also be useful for identifying alcohol dependency or 
abuse. 
Once a woman has been identified as having an alcohol problem, depending on the severity of the problem, she 
can be offered advice, a brief intervention, or referral to an alcohol treatment service.157 
Interventions to reduce alcohol-exposed pregnancies 
Brief interventions for pregnant women typically involve from one to four short counselling sessions with a 
professional trained in motivational interviewing, such as a midwife, GP or social worker, followed by 
personalised feedback.157 There have been a number of randomised controlled trials of brief interventions for 
alcohol use in pregnant women158-162 and the results of these suggest that brief interventions may be useful in 
reducing pregnant women’s alcohol consumption. The Cochrane review that assessed these trials found that the 
evidence is insufficient to determine the type of brief intervention that is likely to be most effective.163 
O’Connor and Whaley examined the effectiveness of a brief intervention in helping low-income minority 
women in Southern California achieve abstinence from alcohol during pregnancy. The intervention consisted of 
10–15 minute counselling sessions guided by a scripted manual. It was delivered in accessible community-based 
settings by nutritionists from the Public Health Foundation Enterprises Management Solutions Special 
Supplemental Nutrition Program for Women, Infants, and Children (PHFE-WIC). Twelve 12 PHFE-WIC 
centres were randomised into assessment only or assessment plus brief intervention and this yielded 255 
pregnant drinkers as study participants. Women who received the brief intervention were five times more likely 
to report abstinence at third trimester follow-up than the women who received assessment only and their infants 
had higher birthweights and birth lengths, and a lower mortality rate (0.9% vs. 2.9%). 
Since almost half of all pregnancies are unplanned,104 there is a need for preconception interventions that help 
drinking women to use effective contraception and/or help women who might become pregnant to reduce or 
stop their drinking. In the US, randomised controlled trials have indicated that several motivational 
interviewing-based interventions targeting risky drinking and ineffective contraception are effective in reducing 
alcohol-exposed pregnancies (AEPs).164  
CHOICES165,166 is a motivational interviewing plus feedback counselling intervention designed to reduce AEPs 
among community women.164 It involves four 30–75 minute counselling sessions and a medical contraception 
counselling appointment. A multi-site RCT that compared CHOICES to provision of an informational brochure 
found a significant 18% reduction in AEP risk (due to reductions in risky drinking, increases in contraception 
effectiveness, or both) in participants who received CHOICES.165 
BALANCE was a modification of CHOICES that contained the same components as the original intervention 
condensed into a single session pre-conception motivational interview plus assessment feedback counselling 
intervention. It was tested in a RCT among college women aged 18–25 at risk of AEP.167 The intervention 
recipients were encouraged to have a contraception counselling visit with a medical provider through student 
health services but this was not a formal part of the intervention as it had been in CHOICES.167 At four-month 
follow-up 80% of BALANCE recipients, vs. 65% of participants who received the information brochure, 
reported no AEP risk, a 15% absolute risk difference.167,168 
EARLY was an adaptation of CHOICES and BALANCE for community women. It was recognised that the 
college women involved in the BALANCE trial were typically younger and less likely to have already given 
birth than community women, and also less likely to have other psychosocial risks associated with increased 
AEP risk including a history of tobacco smoking, recent drug use, a history of inpatient treatment for addiction 
or mental illness, multiple sexual partners or recent physical abuse.169 While CHOICES had been shown to be 
efficacious in community women it was resource-intensive which made it challenging to implement on a large 
scale.164 EARLY aimed to address both these issues. EARLY was a 60-minute, face-to-face, individual, one-
session, motivational interview plus assessment feedback counselling intervention.164 
During the intervention counsellors built rapport, discussed reactions to the baseline assessment, elicited views 
on drinking and use of contraception, provided personalised feedback, showed that participant a video about 
AEP and FASD an elicited the participant’s response, discussed drug use and other mental health issues 
pertinent to prevention of AEP if indicated, selected and performed at least one intervention activity, encouraged 
a contraception visit with a reproductive healthcare practitioner, and summarised the intervention.164 The 
intervention activity addressed the issue (contraception or drinking) that appeared to be most relevant or of 
greater interest to the participant through addressing ambivalence, readiness, tempting situations or goal 
setting.164 
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A three-arm RCT involving 217 participants compared EARLY, an informational video, and an informational 
brochure.164 All three interventions were associated with significant decreases in ineffective contraception rates 
at six months and small decreases in drinks per drinking day. Compared to the other two interventions in this 
trial, EARLY led to greater reductions in ineffective contraception and AEP rates (although the differences were 
not significant) but not in drinks per drinking day. Compared to previous RCTs of CHOICES and BALANCE, 
EARLY produced smaller risk reductions, and, unlike CHOICES and BALANCE, it did not perform better than 
the comparison interventions in its RCT. The study authors suggested that raising women’s awareness of their 
drinking habits through assessment seems to reduce women’s drinking even if no further intervention is 
provided. Other studies have also found this to be the case.159,170-172 This phenomenon may lead to RCTs that 
rely on assessment underestimating the effects of interventions.171 
A program of screening and alcohol brief interventions (ABIs) has recently been implemented in antenatal care 
settings in Scotland.173 A qualitative study was undertaken to explore midwives attitudes and practices regarding 
alcohol screening and ABI.173 The study involved semi-structured interviews with 15 midwives and a focus 
group of six midwifery team leaders. Interview transcripts were analysed in a thematic analysis. Midwives were 
positive about being involved in the screening and ABI programme but they were not completely convinced of 
the programme’s value in antenatal care. They felt that, at the first antenatal appointment, they had not 
established sufficient rapport with a pregnant woman to be able to discuss alcohol issues with ease although they 
recognised that early in pregnancy was the best time to do this. They pointed out that many women were already 
not drinking or drinking very little prior to the first antenatal appointment. Midwives were concerned that the 
women who had not reduced their drinking were the group most likely to be alienated by discussion of alcohol 
issues. They thought that pre-pregnancy preventive measures would have a greater impact on reducing alcohol-
exposed pregnancies. 
Conclusion 
Fetal alcohol spectrum disorder is a significant threat to the health and well-being of New Zealand’s children. 
Prenatal exposure to alcohol can have devastating life-long consequences both for the individual child and for 
those he or she comes into contact with. Fetal alcohol spectrum disorder is exceedingly costly for the health, 
education, child welfare, justice, mental health and social welfare systems. 
Although early identification and support is helpful for children with FASD and their families the evidence base 
for interventions to ameliorate the cognitive and social deficits resulting from alcohol-induced brain damage is 
limited. Even with the best care during childhood and adolescence, many of those with FASD will still need 
continuing support to manage their daily lives in adulthood. It is vital that we change New Zealand’s drinking 
culture from one that encourages and tolerates alcohol abuse to one that supports moderation as normal drinking 
behaviour. 
Health services need to ensure that women of reproductive age do not face barriers to seeking help with alcohol 
and drug problems or associated mental health issues, and that women who have difficulty moderating their 
alcohol consumption have access to effective contraception. 
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Introduction 
This chapter reviews health needs of children and young people in State care and outlines what is required of 
health services to meet these needs. The aim of this chapter is to inform health service providers of some of the 
key issues to be addressed in developing and expanding services for children and young people in State care. 
The voices of children and young people who have experienced State care are included where possible, 
highlighting the importance of their participation in service development and provision. The chapter is not an 
itemised catalogue of evidence for best practice in relation to specific health conditions; this information is 
provided elsewhere through clinical networks and guidelines referred in NZCYES reports. This chapter presents 
some key aspects that will be important to deliver high quality child-centred services to some of the most 
vulnerable children in New Zealand. 
Children and young people in State care have experienced a lack of nurturing care, and this lack can have a 
serious impact on their health. In 2016 it was reported that 4,394 (83%) of the 5,312 children and young people 
in State care lived in out-of-home care either with members of their whānau or extended family, or in foster care 
with people to whom they are unrelated.1 Children in out-of-home care live very complex lives. They 
experience divided loyalties to the people they live with, who provide the day-to-day care and protection they 
need, and also to their birth families for whom they may have strong but ambivalent feelings.2 These children 
need intensive support so that they have the chance to develop a sense of stability and to enjoy the same 
opportunities and outcomes as other New Zealand children.3  
The complex experience of children and young people in State care has important implications for health 
services. For health service systems to enable continuity of care, they need to take account of changes in 
caregivers and in domicile which can occur multiple times for some of those children in State care.4 Strong co-
ordination between District Health Boards (DHBs) is important so that when children or young people move 
they do not have to start again from the beginning of a health assessment process. Within DHBs it is important 
for child health services and child and adolescent mental health services (CAMHS) to work together to meet the 
needs of vulnerable children and their whānau. Effective services for children and young people in State care 
involve multiple government agencies, including health, education and justice, as well as non-government 
organisations. Information sharing between agencies and organisations is an essential part of ensuring that the 
needs of children and young people in State care are prioritised and met.3  
More than half of the children and young people in State care have Māori recorded as their primary ethnicity.5 
Processes to embed a high degree of cultural competence and confidence are required to meet the needs of all 
children and young people in State care.3 In this chapter, the principles of the Meihana model have been used as 
a framework to present findings from the international scholarly literature about the health needs of children and 
young people in State care. The Meihana model acknowledges physical, spiritual, psychological and family 
dimension of health and wellbeing, as well as the role of the services and systems and the physical environment 
in contributing to the health outcomes.6 International experience has been drawn upon to identify possible ways 
forward from the perspective of the health sector.  
The chapter concludes with a description of the child protection process in New Zealand and why and how 
children and young people are taken into State care. In any one year, about 5000 children and young people in 
New Zealand are in the custody of the Chief Executive of Child, Youth and Family. They have been through a 
formal assessment and investigative process and found to need statutory care and protection.1 Further detail 
from recent reviews is also included with an overview of the proposed changes to the child protection system.  
Experiences of children and young people in State care 
Children and young people who enter State care have been exposed to a lack of appropriate and consistent 
parenting and in particular, a lack of nurturing care, which impacts significantly on their wellbeing. The report 
of the Modernising Child, Youth and Family Expert Panel described a marked difference between the intentions 
of New Zealand’s child protection system and the nature of the actual experience described by young people. 
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Although the experiences of the young people differed greatly, themes of chaos, disruption, a sense of loss and 
abandonment came through very strongly during the interviews with them. Their subjective experience was 
dominated by negative emotions such as anxiety, powerlessness and grief. To them, the system lacks humanity 
and struggles to keep children and young people safe, let alone helps them recover from the impact of abuse and 
neglect.7  
Transition into State care often meant that there were abrupt changes in young people’s lives, for example, 
separation from their siblings, living in a different geographical location and having to change school. Few 
young people reported any support to help them manage the trauma and emotional impact of being removed 
from their family or being moved from placement to placement.7 Finding a sense of family in an environment 
where they feel accepted and loved is critical for young people. Caregiving arrangements need to be well 
matched to the young person’s age, gender and stage of development. A key mark of effective caregivers is that 
they identified a strength area or a source of happiness and supported the young person to excel at something.7 
The expert panel heard from 19 young people about their experiences in the New Zealand care and protection 
system. The key messages from these young people are shown in Box 1.7  
Box 1. Main things told by young people to the Modernising Child, Youth and Family Expert Panel 
We need more nurturing and love 
The young people told us the system often did not provide them with the nurturing and love they required. They felt their 
caregivers should provide more than food, shelter and supervision – they should also provide an environment where children 
and young people could learn, grow and heal.  
We want a say in what happens to us  
The young people felt they did not have a voice in important decisions being made about their futures. They felt people 
involved in the process were not being honest and transparent about the decisions that were being made. This left them 
confused, anxious and disempowered. 
We have experienced trauma and need help to make sense of what has happened to us  
Young people described being expected to transition into new environments frequently with little support. Young people 
commented that they need to be empowered to make sense of what they have been through and the reasons why things have 
happened to them. 
We crave belonging and being part of a family who bring out the best in us  
Finding a sense of family is critical for young people. Young people were concerned that if others knew they were in care then 
they would also know that they did not belong to anyone. Many reported the life-changing impacts of finding ‘the one’ adult 
who understood and supported them. 
We want to strengthen our cultural identity and connection  
Young people talked of the value of cultural connections, especially in relation to building their sense of identity and wellbeing. 
They felt this was not well recognised or supported, and adults did not understand the importance of connection and under-
valued it.  
We do not stop needing help, support and nurturing just because we turn 17  
Some young people felt very unprepared, stressed and vulnerable when they age out of the care system at the age of 17. For 
some young people leaving care, the only option is going back to the unsafe environments they were initially removed from. 
Source: Modernising Child, Youth and Family Expert Panel. 2015. Interim report.7 (pp. 8–9) 
The messages from young people who met with the Expert Panel were consistent with what the Children’s 
Commissioner heard from children and young people in the custody of the Chief Executive of Child, Youth and 
Family (in CYF care) through surveys and focus groups. Those in CYF residences were generally positive about 
their experience but experiences were more variable for those in-kin and non-kin out-of-home care. Some 
described overwhelmingly negative experiences including abuse in foster homes, separation from siblings, 
constant change, “Bible bashing”, depression, alcohol and drug use.5 The messages by children and young 
people in the 2016 State of Care report can be summarised as follows:8 (p. 7) 
• We need to feel like we belong. Children and young people wanted help to manage relationships with 
family, opportunities to learn about and connect with their culture, and to be able to enjoy their childhoods 
with a range of activities, a positive school life, and no stigma attached to being a “CYF kid.”  
• Involve us, listen to us, and communicate with us. Children and young people wanted to be given a voice 
in decisions that affect them, involved in care plans and transition planning, and communicated with clearly 
and respectfully.  
• Social workers have a big impact on our lives. Children and young people spoke in detail about their 
interactions with social workers. Their comments highlighted that, as the chief interface between the child 
or young person and CYF, the social worker plays a critical role in determining whether the child has a 
positive or negative experience in the care and protection and youth justice systems. A child in non-kin 
foster care stated “[My social worker is] kind of like family now; like a friend now.”  
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Health needs of children and young people in State care 
There has been limited research on factors associated with wellbeing of children in care in New Zealand, with a 
tendency to rely on international research to inform policy and practice.9 Recent reviews have found that current 
systems in CYF and in the Ministry of Social Development (MSD) are not set up to measure and record the 
most important information about children in care. Reviews have also found that there is poor integration 
between MSD and other government agencies, including health.5 Nevertheless it is recognised that families of 
children who are referred to CYF have often experienced high levels of long-term need and disadvantage, often 
including combined effects of long-term unemployment, low income, unaddressed physical and mental health 
needs, addiction disorders and family violence.7  
Gateway assessments have been provided since 2011 for children and young people who may be at risk of 
coming into CYF care, entering care or already in care.10 Gateway assessments are managed by DHB 
co-ordinators, after referral of children by CYF, and include assessment by health professionals. The Expert 
Panel observed that health needs were identified frequently among the children and young people who had 
completed a gateway assessment. For every ten children or young people who completed a gateway 
assessment:7  
• Three had a mental health need  
• Five had emotional needs  
• Three had developmental needs  
• Six had learning needs  
• Three had dental needs  
• Four had needs as a result of parent or caregiver alcohol or drug addiction. 
Research in other countries has shown that children and young people in State care are a very vulnerable group 
with relatively high levels of unrecognised or unmet health needs.11 Children in State care have been classified 
as a population of children with special health care needs in the USA and in the UK.12 Understanding and 
recognition of the health needs of children and young people in State care is important so that plans are in place 
for them to receive health care wherever they are placed, and to appropriately review the services in place for 
them.11 In addition to their important health care needs, children and young people in State care experience 
barriers in accessing appropriate and continuous care that can worsen their prognoses.13 In this chapter the 
concept of te waka hourua, or the double-hulled waka, is used as a framework to present findings from research 
about the health needs of children and young people in State care.6 
To date there has been inadequate research about the long-term outcomes of foster care. By long-term outcomes 
researchers are referring to what happens among young adults who were in State care as children. This group is 
referred to as having ‘aged out’ of care. Prevalence studies on specific populations of young people who have 
aged out of foster care show high rates of clinically significant mental health problems (54%), chronic medical 
illness (30%), unemployment (19%–37%), poverty (33% live at or below the US poverty level), lack of health 
insurance (33%–50%), and homelessness within one year of leaving care (22%–36%). High school completion 
rates vary and completion may occur years after leaving care. One study of young adults who lived in foster care 
during adolescence found a prevalence of post-traumatic stress disorder (PTSD) twice that of combat veterans. 
Although these prevalence studies of high-risk adult populations are not representative and therefore cannot be 
used to indicate ‘cause and effect’, they do provide a measure of the ongoing health problems affecting young 
people who leave State care as they transition to adulthood.12 
It is difficult to compare information about children and young people in State care in different countries, 
mainly due to different approaches, organisational structures and definitions of formal out-of-home care.7,13. In 
many countries the categories are broader than that used in New Zealand for children and young people in CYF 
care, for example many jurisdictions include children and young people in voluntary placements with family or 
friends and not only those formally in statutory care. Also, in many jurisdictions monitoring and surveillance 
systems continue to follow young people after they have left State care. Despite these limitations, the literature 
suggests that all children who have contact with child welfare services share similar risk factors associated with 
a higher likelihood of poor long-term outcomes whether in out-of-home care, kin care or remaining with 
parent(s).12 The following terms can be considered as synonyms in this part of the report, bearing in mind that 
they may describe slightly different population groups dependent on national definitions: looked-after children 
and young people; looked-after and accommodated children; children in care; and children and adolescents 
involved in the child welfare system (CWS). Children in foster care refers to out-of-home care in a family with 
kin or non-kin carers, and children in kinship care refers to out-of-home care within a child or young person’s 
extended family. 
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Te waka hourua 
The concept of te waka hourua is a key component of the Meihana model, which has been developed to enable 
health practitioners to develop a broader understanding of Māori patients and their needs.6 The principles of the 
model are not unique to Māori, and in this section are applied more widely to all children and young people in 
State care. Importantly, statistics show that over 50% of children and young people in CYF care identified with 
Māori as their primary ethnicity and this model is therefore directly relevant to them.5 
Te waka hourua was the traditional mode of transport used in the migration of Māori from Hawaiki to Aotearoa 
(New Zealand). The two hiwi (hulls) represent the child or young person and their family or whānau on a 
journey to health and wellbeing. The hiwi are joined by five crossbeams:6 (p. 108) 
• Tinana: Physical health and functioning 
• Hinengaro: Psychological and emotional wellbeing 
• Wairua: Beliefs regarding connectedness and spirituality 
• Taiao: Physical environment including home environment and neighbourhood  
• Iwi katoa: Services and systems that provide support within the health environment 
The journey toward health and wellbeing of the child or young person and their whānau or family is also 
impacted by nga hau e wha, the four winds, that represent wider societal and historical influences. The forces of 
colonisation, racism, internal migration from traditional iwi land, and marginalisation have significant influence 
on the journey and are important components of clinical assessment.6  
The concept of nga roma moana, or ocean currents, reflects the way in which each specific child or young 
person, and their whānau, relate to te ao Māori (the Māori worldview), including use of te reo Māori, tikanga 
Māori including karakia and prayer, whānau roles and responsibilities, and specific geographical and 
genealogical connections, or whenua.6 When health practitioners identify aspects of Te Ao Māori that are 
important to a child or young person and their whānau it can help all involved to share more freely in the clinical 
setting and thus facilitate better care.6 Health practitioners can also provide more culturally appropriate services 
when they become familiar with specific cultural principles and integrate these within clinical practice.6 
Whānau  
Whānau may refer to biological family and/or other key support people.6 Occurrence of child abuse strengthens 
rather than diminishes the importance of the whānau: “Parental rights often tend to be seen as secondary to the 
interests of whānau … to ensure that future generations are protected.”14 (p. 73) Many young people with 
experience of the New Zealand care and protection system indicated to the Expert Panel that they “wanted to 
remain in the very environment they were removed from. They could not understand why the offending adult(s) 
remained at the home while the child was the one taken away.”7 (p. 41)  
I just thought it took only one call for me and my sister to be uplifted without a question, without even 
coming in to meet my dad or anything. I mean I understand now he drank a lot and my mum and dad 
used to fight but we were never hit, we were never mistreated, we got our food, we went to school 
sometimes, and I can understand why they took us away now, but being a young kid and being taken 
away, you think oh my gosh my parents are like awesome, they’re like the best. Female, 19, about 
experience in CYF care7 (p. 41) 
It is of critical importance that children and young people in out-of-home care find a sense of family in an 
environment where they feel accepted and loved. A key mark of effective caregivers is that they identified a 
strength area or a source of happiness and supported the young person to excel at something (such as 
cheerleading, music, sport, dance, bike repairs). 
… But if you put them in something they enjoy and something they’re good at, they will be able to see 
the potential in themselves. I loved it because I got involved in sport. I was so involved in sport that I 
didn’t have time to rebel and then with that family I started to see the importance of school and 
education because the oldest daughter she was actually my best friend and because she was in my class 
I was always hanging out with her. I would always do my work, and she was just like a really good role 
model even though she was my age. I graduated high school because of them. Female, 17, about 
experience in CYF care7 (p. 43) 
A competent, caring, nurturing, stable foster or kinship placement can be very important in supporting and 
advocating for the health and wellbeing of a child or young person. For children who have suffered severe 
neglect and abuse, placement in non-kin foster care or kinship care can be an important opportunity for 
intervention and healing.12  
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Tinana 
Childhood trauma and adversity contribute to development of a number of health issues, and the ongoing loss 
and uncertainty in out-of-home care may exacerbate rather than ameliorate problems.12  
Children and young people in State care have at least the same health needs as other children. The New Zealand 
Health Survey estimates that 17% of all 0–14 year olds and 24% of Māori 0–14 year olds have medicated 
asthma.15 It is reasonable to expect similar prevalence amongst children and young people in State care. It is 
important to identify allergies, especially for those children who have anaphylaxis, as the carers need to be 
aware of substances/foods to avoid and to receive advice on management.11  
There are, however, other health conditions more prevalent among children and young people in State care than 
among other children, including incomplete immunisation status and developmental disorders, as well as 
substance use, early sexual initiation and teen pregnancy among young people.11,12 In the US, studies suggest 
that 30–80% of children who enter foster care have at least one physical health problem and at least one-third 
have a chronic health condition. These health problems are commonly undiagnosed and untreated before the 
child enters State care.12 The authors also noted particular health issues for adolescents in foster care, who were 
at high risk of having untreated mental health conditions as well as educational, physical and reproductive health 
and psychosocial needs. Around 50% of young people in foster care had chronic medical problems unrelated to 
behavioural concerns.12 Young people in care are a diverse group who may have come into care as a result of 
behavioural issues such as school truancy or petty criminal activity, or may have grown up in State care. This 
research identified that whatever the circumstances, most young people in State care have experienced neglect 
or abuse at some point in their lives. Those entering foster care as adolescents report high rates of exposure to 
violence, substance abuse and school failure with low literacy levels. Those who have positive peer relationships 
and adult mentors seem to fare better than those without. By age 18 years, 93% of youth in foster care reported 
being sexually active and almost half of these youth reported sexual initiation before the age of 16 years. 
Compared with peers not in foster care, foster care youth were approximately 2.5 times more likely to 
experience a pregnancy by age 19 years. Youth in foster care are more likely than youth not in foster care to 
report unintended pregnancy and less likely to use regular contraception. Repeat pregnancies among youth in 
foster care occur in almost half of all young women, compared with less than one-third of their peers not in 
foster care. Young adults in foster care are almost twice as likely as their peers to have experienced “forced 
sex”.12 (p. e1148) Youth in foster care not only experienced substantial health issues, but also experienced 
difficulties transitioning from adolescence to adulthood with higher rates of unemployment, poverty, and 
homelessness than youth not in foster care.12  
A comprehensive audit of a representative sample of 237 looked-after children in the London Borough of 
Hillingdon (LBH) in the 2014–2015 year found that 79.5% of the children and young people had at least one 
physical, mental or behavioural health need, 17% had a physical or mental impairment which had a substantial 
and long-term effect on the ability to undertake normal daily activities (recognised disability), and 3% had 
extremely complex needs. Prevalence of allergy and of overweight/obesity were comparable to prevalence in the 
general population. While it is encouraging that looked-after children were not more overweight than the local 
population the authors note that healthy diet and exercise continues to be important. Health needs of looked-
after children and young people in LBH differed by age group, with higher prevalence of physical health needs, 
including developmental needs, at younger age groups and higher prevalence of mental health needs in older age 
groups (See Box 2 for further details).11  
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Box 2. Physical health needs by age group of children and young people in State care, representative sample of 
looked-after children, London Borough of Hillingdon (United Kingdom) 2014–2015 
< 1 year: 87% of looked-after children in this age group had one or more health needs. 56% had experienced 
antenatal substance misuse/neonatal abstinence syndrome; 32% had neurodevelopmental problems; 19% had 
congenital abnormalities. 
1–4 years: 78% of looked-after children in this age group had one or more health needs, with 10% having 
complex needs. 14% had suffered antenatal substance misuse/neonatal abstinence syndrome; 53% had 
neurodevelopmental problems, 21% had some toileting difficulties; 21% had both physical and emotional 
problems. 
5–9 years: 61% of looked-after children in this age group had one or more health needs. 42% had 
neurodevelopmental problems or speech and language difficulties. 
10–15 years: 62% of looked-after children in this age group had one or more physical health needs. 1.5% had 
congenital abnormalities; 7% had dental problems, such as caries/orthodontics/enamel loss; 11% had 
gastrointestinal problems; 12% had skin problems, mostly acne; 4% presented with various injuries. 
16–17 years: 66% of looked-after children in this age group had health needs, with half of these having only 
one health need. Symptoms included: skin conditions (17%); musculoskeletal (16%); gastrointestinal, including 
liver disease (13%); ear nose throat (12%); respiratory (10%); dental issues (4%); neurodevelopmental difficulties 
(9%); gynaecology, including pregnancy and female genital mutilation (7%). 
Source: Health needs audit for looked after children and young people in the care of the London Borough of Hillingdon11 
Hinengaro 
To provide appropriate treatment for children, the importance of the role of childhood trauma in the emergence 
of child mental health problems needs to be understood. Children who have experienced trauma, especially 
those who have lacked appropriate caregiving and treatment, may develop depression over time or may have 
comorbid mental health problems.12 Bronsard et al.’s systematic review and meta-analysis of eight 
epidemiological studies across different countries demonstrates the complexity of mental health screening and 
care in children and young people in the child welfare system (CWS). For these children and young people 
externalised and internalised mental health and emotional disorders are associated and complexly entangled.13 
The authors found that almost half (49% pooled prevalence) of children and adolescents in child welfare 
systems met criteria for a current mental disorder, a prevalence almost four times higher than in the general 
child and adolescent population.13 They also cite the clear association between attachment insecurities and 
vulnerability to mental disorders and posit that the central role of child-to-parent attachment in a child’s 
development may explain the high prevalence of mental disorder observed in their work. Adverse experiences 
of children and adolescents in the CWS, including maltreatment and serious neglect, reduce the likelihood of 
creating secure attachments that are crucial for developmental health. Multiple placements and temporary or 
disrupted relationships with caregivers can also potentially prevent the formation of secure attachments by these 
children and adolescents.13 Multiple placements and maltreatment during the time of placement may contribute 
to worsening of pre-existent externalised mental disorders or promote emergence of such disorders. Externalised 
disorders were the most prevalent mental disorders in the meta-analysis: 27% of children and adolescents met 
the diagnostic criteria for a disruptive disorder including 20% with conduct disorder (10 times higher than child 
and adolescent population prevalence) and 12% with oppositional defiant disorder (three times higher than child 
and adolescent population prevalence). The estimated 11% prevalence of attention deficit hyperactivity disorder 
(ADHD) among children and adolescents in the CWS was three times higher than that of their peers. The 
prevalence of internalised disorders such as anxiety disorder (18%) and depressive disorder (11%) was also 
three to four times higher than the prevalence of these disorders in the general child and adolescent population. 
Limitations to this systematic review included heterogeneity of results, possibly influenced by factors such as 
differences between countries in interpretation of symptoms, and patterns of child welfare provision, and the 
small number of epidemiological studies describing children and young people in State care.  
Szilagyi et al.’s data suggest that children in foster care are prescribed psychotropic medications at a rate three 
times that of other Medicaid-enrolled children in the US and they have higher rates of polypharmacy. Once 
psychotropic medications are prescribed, children in foster care are likely to be kept on them longer than 
children who are not in foster care. Treatment with psychotropic medications may not address the underlying 
trauma and attachment issues at the root of challenging behaviours. Factors that may contribute to the apparent 
overtreatment with psychotropic medications include caregiver demand for medication to manage disruptive 
behaviours, lack of understanding of childhood trauma, lack of paediatric mental health resources, and 
misdiagnosis of trauma symptoms as other mental health conditions, such as attention deficit hyperactivity 
disorder.12 Szilagyi et al. note that psychotropic medications should be prescribed for children and young people 
in State care only after a mental health evaluation and trauma assessment by a child mental health expert and 
only for a specific mental health diagnosis. The medication should be appropriate to the diagnosis, initiated at 
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the lowest appropriate dose, and increased slowly while monitoring for efficacy and adverse effects. 
Polypharmacy should be avoided whenever possible.12 
Child health professionals may need assistance from mental health professionals trained in trauma-informed 
care to correctly assess and diagnose mental health problems in children and young people in State care. The 
American Academy of Pediatrics recommends a mental health evaluation within 30 days of out-of-home 
placement, ideally by a child mental health professional trained in trauma-informed care. Periodic reassessment 
of mental health should occur whether or not a child is receiving mental health services because of the many 
uncertainties and transitions that can occur in their lives. Trauma-informed, evidence-based therapies include 
parent-child interaction therapy, child-parent psychotherapy, and trauma-focused cognitive behavioural therapy. 
A shortage of appropriately trained and experienced mental health professionals is a barrier to all children who 
might benefit from these interventions being able to access them.12 Within New Zealand this highlights the 
importance of child health services and child and adolescent mental health services (CAMHS) working closely 
together and facilitating cross-referrals when indicated. Adequate CAMHS service provision is a prerequisite to 
such collaborative working. 
Wairua 
Atwool noted the following with respect to carers: 
Recognition of their vital role in supporting children in short-term and long-term placements 
and ensuring they are in a position to answer questions and contribute to a child’s search for 
meaning is an essential prerequisite for improved practice. All caregivers (including those 
offering short-term care) need to be equipped to support children in keeping an ongoing 
record of their time in care through the use of memory boxes, life story books and digital 
records. Provision of back-up storage in case records are lost or destroyed is also 
needed.16 (p.  10) 
Children and young people in State care expressed a clear need for help to manage relationships with family as 
well as opportunities to learn about and connect with their culture.8 Young people reported a wide range in the 
help they needed to build or maintain cultural connections. One young woman (age 17) reported that her 
caregiver “didn’t understand and she wouldn’t let me go to kapa haka practices and she couldn’t see why it was 
important to me.”7 (p. 44) Such connection is essential for their wellbeing, is an integral part of clinical assessment 
and of providing child-centred care. Life story work is an inclusive term that emphasises the process of 
providing children with access to a coherent story of their life.16 Life story work, adapted to suit a child’s 
interests and needs, can contribute to bolstering self-esteem and a sense of identity. Children and young people 
find that a coherent life story helps them to learn about themselves, their families and their past, and to manage 
emotions, particularly emotions associated with negative experiences. There is currently a rather haphazard 
approach to such work in Aotearoa New Zealand which may contribute to poor outcomes.16 Understanding their 
own 'health history' is an essential part of growing up securely. Inconsistent record keeping can lead to wrong 
decisions by professionals and adversely affect the child or young person.4 Ensuring that a comprehensive 
health record is available to the child, young person and their caregivers, as part of the life story record is a 
positive contribution that health services can make to children and young people in State care. Health 
practitioners can ask to see records of the child’s lived experience to date, and also ensure that important 
medical information is included and available to the child or young person as well as to any future caregivers.  
Taiao 
The underlying model on which New Zealand approaches care and protection is reflected in the direct questions 
asked of the child or young person and their caregivers about their home environment, neighbourhood and 
safety.6 In the UK, Bilson (2016) suggests an alternative approach to the forensic child protection model that is 
common in the UK, USA and New Zealand. Such an alternative approach would aim to improve the conditions 
of families and communities, enabling them to enhance the wellbeing of children, rather than relying on agents 
of child protection to seek out harm. A community orientation would embrace approaches that focus on 
increasing neighbourhood cohesion to promote the wellbeing of children and families, evidence-based delivery 
of early childhood education that increases social capital, and also advocate for increased incomes for poor 
families that, in itself, has been shown to increase the wellbeing of children.17 In New Zealand, many of the 
families of children who are referred to CYF live in areas with high deprivation scores.7 Reducing social 
inequalities overall, and breaking the link between deprivation and extreme interventions by promoting good 
child development, could become a central goal of child protection policy and practice.18,19  
Although it is rare, children may experience further abuse or neglect in foster homes.12 Biehal et al.’s review 
found that it was difficult to come to clear conclusions about the extent of maltreatment in foster care.20 Some 
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studies reported the total number of substantiated or unsubstantiated allegations of maltreatment per foster carer 
or foster family, whereas others reported the number of children experiencing maltreatment or incidents of 
maltreatment, with no indication of the proportion of children or foster carers involved in multiple incidents. 
There were also differences in the data sources used and reporting bias may result from children being unwilling 
or unable to report abuse. These factors need to be borne in mind when considering the following results on the 
extent of maltreatment in foster care. Five US studies of incidence found that between 0.27% and 2% of fostered 
children per year were known to have experienced maltreatment. Some of the variability in reported incidence 
may be due to local variations in thresholds for investigation or in recording policies. Separate studies from 
Baltimore, England and Scotland found that allegations of maltreatment were made in relation to 3–4% of foster 
homes per year, and substantiated in less than 1% of all foster homes. Biehal (2014) further notes that it is 
important to distinguish maltreatment in foster care from maltreatment by foster carers. Although foster carers 
are responsible in the majority of cases of maltreatment, perpetrators also include other children (including other 
fostered children, siblings of the child experiencing maltreatment, foster carers’ own children or other unrelated 
children) and partners of foster ‘mothers’ (mothers may be unaware of the abuse). Fostered children may also be 
reabused during contact with their parents.  
Iwi katoa: Health service implications 
An integral part of the assessment process is to identify whether children, young people and whānau have had 
appropriate access to health services and systems.6 The Expert Panel heard that health services  
“… do not prioritise work with vulnerable children ahead of their general accountability for 
universal services, despite the fact that vulnerable children are harder to reach and have more 
complex needs. If we are to have the same high level of aspiration for vulnerable children as 
we do for all other New Zealand children then we need to establish specific targets for 
children in the care and protection and youth justice system and hold social sector agencies to 
account for the achievement of these targets.”7 (p. 11) 
Health services are key actors in the planned legislative and operational changes to the New Zealand care and 
protection system as children and young people in State care will need access to appropriate services to address 
health concerns. Health services will need to ensure that health needs of children and young people in State care 
are actively prioritised, and respond appropriately to the full range of children’s and young people’s needs.5,8 In 
addition to evidence-based best practice, children in State care have health service needs related to the context in 
which they live and grow.  
Foundational principles and values 
The National Institute for Health Care and Excellence (NICE) in the UK has articulated a group of principles 
that apply to all services for children in State care, including health services:4,21 
• Put the voices of children, young people and their families at the heart of service design and delivery 
• Deliver services that are tailored to the individual and diverse needs of children and young people by 
ensuring effective joint commissioning and integrated professional working 
• Develop services that address health and wellbeing and promote high-quality care 
• Encourage warm and caring relationships between child and carer that nurture attachment and create a 
sense of belonging so that the child or young person feels safe, valued and protected 
• Help children and young people to develop a strong sense of personal identity and maintain the cultural and 
religious beliefs they choose 
• Ensure young people are prepared for and supported in their transition to adulthood 
• Support the child or young person to participate in the wider network of peer, school and community 
activities to help build resilience and a sense of belonging 
• Ensure children and young people have a stable experience of education that encourages high aspiration and 
supports them in achieving their potential 
Participation in health care decision-making by children and young people  
The Children, Young Persons, and Their Families (Oranga Tamariki) Legislation Bill has a renewed emphasis 
on the participation rights of children and young people.22 The participation rights of individuals in their health 
care is well established, including the importance of securing the participation of children in decisions that affect 
them.23,24 Being child-centred is a way of elevating the interests, wellbeing and views of children. The 
overarching reason to be child-centred is to make sure decisions by health services and health professionals do 
not harm children and, in fact, support them to thrive. Services seeking to become more child-centred can seek 
the views of children and young people and ensure that their opinions and views are taken into account when 
Health needs of children and young people in State care 
117 
decisions are made.25 The Children’s Commissioner’s guidance for agencies to become child centred describes 
the following core principles of child-centred thinking necessary in both top-down leadership and bottom-up 
practice: 25 (p. 3)  
• The best interests of the child should be an important consideration in all decisions 
• Children should have the opportunity to have a say in decisions that affect them 
• Decisions should ensure that children are not discriminated against 
• Decisions should support, and not prevent, children to live, grow and achieve their full development 
• Instituting child-centred thinking requires adoption at all levels of the organisation, including leadership 
commitment, training of staff and embedding in operations 
• Any assessment of how children may be affected needs to be made at the beginning of a decision making 
process so issues can be addressed in the ultimate decision 
Identifying children in need of care and protection 
In practice, it is very difficult for CYF to restrict its role to a narrow statutory scope when health, education and 
welfare services are either insufficient or poorly aligned to the needs of vulnerable children and their families.7 
Within current legislation as well as the proposed amendments, health services have a major role in identifying 
child abuse and neglect and lodging appropriate reports of concern. The New Zealand Clinical Network for 
Child Protection (the Network) provides a source of expertise on issues of child abuse and neglect across the 
country and acts to assist in the co-ordination of services to abused and neglected children and young people.26 
New Zealand DHBs have a memorandum of understanding (MoU) with Child, Youth and Family that 
recognises the expertise of DHB staff in the recognition and management of child abuse and neglect to guide 
effective practice. This MoU can be accessed from the Network webpage.26  
The National Institute for Health and Care Excellence (NICE) in the UK has developed a pathway that provides 
an integrated view of guidance, standards and indicators relevant to looked-after babies, children and young 
people.4 There is also a specific pathway with information and resources about attachment difficulties in 
children and young people; although attachment difficulties are not specific to children in State care they do 
affect almost all children and young people in State care. It is essential that all professionals working with 
children in State care understand the complex issues affecting the lives of these children and young people, 
including discrimination and its impact, and recognise the importance of culture, identity and education in 
achieving a state of wellbeing.4 
Information sharing and collaboration 
It is generally accepted that effective child protection requires responses from health, education, justice, police 
and non-government organisations. For example, in New South Wales, the ‘Keep them Safe’ initiative involved 
expanding responsibility for responding to children at risk to increase the involvement of health, education, 
Police and other government agencies, as well as the non-government sector.7 New Zealand is one of the few 
jurisdictions that does not have information-sharing settings in relation to vulnerable children in its care, 
protection and youth justice legislation.3 The Expert Panel noted that New South Wales and Scotland have 
recently introduced major changes to information-sharing settings with some common features:  
• Changing the threshold for information exchange towards promoting safety, welfare and wellbeing of 
children and young people and away from averting threats of serious harm  
• Enabling greater information exchange between a much broader range of people involved in the lives of 
children and young people and their families than just those directly employed by the care and 
protection  service  
• Accompanying information-sharing duties with duties to collaborate with other professionals  
The Children, Young Persons and Their Families (Oranga Tamariki) Legislation Bill includes provision for an 
information sharing framework that will include health services. This may be in response to the Expert Panel’s 
observation that health services and other agencies are not prioritising services for vulnerable children ahead of 
a general accountability for delivery of universal services. Although there is clear government policy for every 
child in State care to receive a comprehensive health and education assessment, CYF data indicate that only five 
to six out of every 10 children in State care have a completed assessment, and there is little record of how many 
of these children have accessed required services to meet assessed needs.7  
Healthcare staff knowledge skill and competence  
In England, providers of health services are expected to identify a named doctor and nurse for looked-after 
children. These named professionals coordinate the provision of services for individual children and also 
provide advice and expertise for fellow professionals.27 To fulfil their role and responsibilities in respect of 
looked-after children, all health staff need access to appropriate training, learning opportunities, and support to 
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facilitate their understanding of the clinical aspects of child welfare and information sharing.4 Those in specific 
child health service roles also need the skills and competences to undertake health assessments, contribute to 
healthcare planning, ensure clinical governance arrangements to assure the quality of services for looked-after 
children, and coordinate care for each young person. The high prevalence of mental health conditions among 
children in State care, and the shortage of mental health professionals, calls for strong collaboration between 
paediatricians and mental health partners, including psychiatrists, psychologists, and developmental and 
behavioural paediatricians, among others. One promising model for the care of children in foster care is 
integrated paediatric and mental health care services in the paediatric medical home setting.12  
The concept of a medical home was first mooted in the US in the 1960s among paediatricians who cared for 
children with chronic health conditions. At that time a medical home was a primary care practice for children 
that offered central coordination of specialists involved and a way to keep all information and data about the 
child in one place.28 A medical home may contribute to mitigating the impact of adverse events on the wellbeing 
of children, and provide support which enhances family and child resilience.29 
Primary prevention of child abuse and neglect 
Bilson’s17 suggested alternative approach to the forensic child protection model common in the UK, USA and 
New Zealand aims to improve the conditions of families and communities, enabling them to enhance the 
wellbeing of children, rather than relying on agents of child protection to seek out harm. A community 
orientation would encompass approaches that focus on increasing neighbourhood cohesion to promote the 
wellbeing of children and families, evidence-based approaches to early years education that increase social 
capital, and advocacy to increase incomes of poor families that on its own has been shown to increase the 
wellbeing of children.17 Reducing social inequalities overall and breaking the link between deprivation and 
extreme interventions by promoting good child development are policy goals that foster good practice for health 
as well as for education and other services.18,19 Neighbourhood-based strategies for child maltreatment 
prevention can be effective in low- and high-resource communities leading to a reduction in child maltreatment 
for children aged under six years.30 Although the authors observed that mechanisms related to successful 
interventions differed in different communities, they noted that the final outcomes always included improved 
child safety.  
Parenting interventions and support of caregivers 
Akin et al.31 reviewed the implementation of evidence-based parenting interventions with substance-affected 
families involved with the child welfare system in five United States (US) counties using the following 
framework: 
• Process factors including staff selection, training, coaching, and performance assessment  
• Provider factors such as health service providers’ attitudes toward evidence-based practice, which may in 
turn be affected by individuals’ education level and professional status 
• Innovation factors including logistical issues such as transport availability and the congruence between the 
planned intervention and the culture, values, and methods of the organisation implementing it  
• Client factors which include the complexity of clients’ presenting concerns as well as environmental 
barriers they may encounter  
• Organisational factors ranging from the culture, climate, attitudes, and values of an agency to its policies 
and procedures 
• Structural factors in the broader operating environment of organisations, including workforce issues, court 
systems, and interagency collaboration 
Successful uptake of an evidence-based parenting intervention was associated with interactive and supportive 
staff training, well-balanced staff composition, programme flexibility that allowed for adaptation to local 
conditions and client circumstances, a focus on family skill development rather than clinical therapy and peer 
support among participants. Strong leadership at executive and management levels, particularly where there was 
a person dedicated to the coordination and implementation of the programme, was critically important for 
successful uptake. Community partners’ donations of space, volunteers, food, and prizes helped successful 
programmes but varied between sites. Lack of adequate funding was a key barrier to effective implementation, 
and was associated with reliance on volunteer input and minimal capacity to make allowance for staff absences 
or staff turnover. Another barrier was difficulty in finding a time that worked well for families. Barriers 
experienced in rural communities included lack of transport, maintaining a minimum number of participants, 
and securing community partners.31  
Many children in foster care have emotional and behavioural difficulties and some carers may respond poorly to 
these challenging behaviours.20 Training in childhood trauma for caseworkers and foster parents has improved 
in recent years, and ongoing support for foster parents by well-educated professionals is important so that they 
have the opportunity to develop specific skills in parenting the traumatised child.12  
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High quality data  
Accurate and up-to-date personal health information has significant implications for the immediate and future 
wellbeing of children and young people during their time in care and afterwards.4 Deficiencies in available data 
have been noted in New Zealand (see Monitoring State care in New Zealand on page 121).5 There is an 
urgent need to improve the range and quality of information on the needs of children, family/whānau and 
caregivers. Reliable information on the range of indicators is required to measure whether we are making a 
difference in the lives of children. Better and more accessible information is required on child and family risk 
factors, and evidence-based practice needs to be implemented by front-line health workforce and other agencies. 
This is likely to require some investment in the data infrastructure, information technology and workforce skills 
and training.7 
Child protection processes in New Zealand 
Since first introduced in 1925, child welfare legislation in New Zealand has demonstrated a strong preference 
for non-institutional foster care over institutional care.9 The current legislative framework is the Children, 
Young Persons, and Their Families Act 1989.32 Family preservation is a key principle underlying this Act, and 
the Act sets forth the family group conference (FGC) as a mechanism to provide for the participation of family, 
whānau, hapu, iwi, and family group in decision-making about the care of a child or young person.9 Under this 
Act, the welfare and interests of the relevant child or young person shall be the first and paramount 
consideration32[Section 6; Section 13]. The guiding principle for determining the welfare and interests of a child or 
young person is that children and young people must be protected from harm and have their rights 
upheld.32[Section 13] Under the current Act, a child is a boy or girl under the age of 14 years. A young person is 
defined as a boy or girl of or over the age of 14 years but under 17 years, but does not include any person who is 
or has been married or in a civil union.32[Section 2] From 1 April 2017 the upper age limit of the statutory definition 
of young person will be increased to 18 years.33 In the 2015/2016 year, ahead of this amendment to the 
Children, Young Persons, and Their Families Act, 1989, the Ministry of Social Development began providing 
increased advice and assistance to support young people aged 15–20 years who have been in statutory care.33,34  
Child, Youth and Family (CYF) is a service arm of the Ministry of Social Development with legal powers to 
intervene to protect and help children who are in need of care and protection.5 The full definition of a child or 
young person in need of care and protection, as contained in the Children, Young Persons, and Their Families 
Act, 1989, is provided in Box 3.  
Box 3. Definition of a child or young person in need of care and protection, Children, Young Persons, and Their 
Families Act, 1989 Section 14. 
(a) the child or young person is being, or is likely to be, harmed (whether physically or emotionally or sexually), ill-treated, 
abused, or seriously deprived; or 
(b) the child’s or young person’s development or physical or mental or emotional wellbeing is being, or is likely to be, impaired 
or neglected, and that impairment or neglect is, or is likely to be, serious and avoidable; or 
(ba) the child is a subsequent child of a parent to whom section 18A applies, and the parent has not demonstrated to the 
satisfaction of a social worker (under section 18A) or the court (under section 18C) that he or she meets the requirements of 
section 18A(3); or 
(c) serious differences exist between the child or young person and the parents or guardians or other persons having the care of 
the child or young person to such an extent that the physical or mental or emotional wellbeing of the child or young person is 
being seriously impaired; or 
(d) the child or young person has behaved, or is behaving, in a manner that— 
  (i) is, or is likely to be, harmful to the physical or mental or emotional wellbeing of the child or young person or to others; and 
  (ii) the child’s or young person’s parents or guardians, or the persons having the care of the child or young person, are unable 
or unwilling to control; or 
(e) in the case of a child of or over the age of 10 years and under 14 years, the child has committed an offence or offences the 
number, nature, or magnitude of which is such as to give serious concern for the wellbeing of the child; or 
(f) the parents or guardians or other persons having the care of the child or young person are unwilling or unable to care for the 
child or young person; or 
(g) the parents or guardians or other persons having the care of the child or young person have abandoned the child or young 
person; or 
(h) serious differences exist between a parent, guardian, or other person having the care of the child or young person and any 
other parent, guardian, or other person having the care of the child or young person to such an extent that the physical or 
mental or emotional wellbeing of the child or young person is being seriously impaired; or 
(i) the ability of the child or young person to form a significant psychological attachment to the person or persons having the 
care of the child or young person is being, or is likely to be, seriously impaired because of the number of occasions on which 
the child or young person has been in the care or charge of a person … for the purposes of maintaining the child or young 
person apart from the child’s or young person’s parents or guardians. 
Families become known to CYF when someone who is worried about the safety and wellbeing of a child and 
their family makes a report of concern to CYF. Reports of concern come from a variety of sources including the 
Police, health, education and social service providers, family members and friends, and concerned members of 
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the public.5 Notifications about a child are first received by a National Contact Centre social worker who 
decides whether the concerns meet the threshold for CYF action. If so, the notification is recorded as a report of 
concern. If not, the notification remains a contact record only.7 The following process for managing reports of 
concern is described by the Office of the Children’s Commissioner5 (p. 8) 
When CYF receives a report of concern, they undertake an initial safety and risk screen about 
the child and family’s situation, and decide whether any further action is required to make 
sure the child is safe. In many cases, no statutory intervention is required; the family may 
simply need some advice, or to be connected with the right support services. 
In more serious cases, CYF care and protection teams work with the family to identify issues 
and find a solution, which could include a formal investigation with Police. When it is 
established that a child is in need of care and protection, a family group conference may be 
held where the child’s family/whānau and other key people agree on a plan to keep the child 
safe and identify the support they need. 
A child or young person comes into statutory CYF care through a formal declaration by the Family Court that 
the child or young person is in need of care and protection, which can occur only after a family group 
conference (FGC) has been held. An interim Custody Order can be put in place without delay if a child or young 
person is in immediate danger.35 The child or young person is then in the custody of the Chief Executive of 
CYF, and a CYF social worker files a report and plan for their care and protection with the Family Court.35 The 
law allows that the child or young person may be placed with:32 
• a parent or guardian of the child or young person; or 
• any other person who previously had the care of the child or young person; or 
• any member of the child’s or young person’s family, whānau, or family group; or 
• any person approved by a social worker. 
If it is not practicable or appropriate to place the child or young person with any of these specified persons the 
child or young person may be placed in a residence.32 
Children and young people in Child, Youth and Family care  
Child, Youth and Family (CYF) data show that as at 30 June 2016 there were 5,312 children and young people 
in New Zealand who were in in CYF care. Of these 5,312 children and young people, 578 (11%) were aged 
under two years; 869 (18%) were 2–4 year olds; 1,538 (29%) were 5–9 year olds; 1,193 (22%) were 10–13 year 
olds and 1,067 (20%) were aged 14 or older.36 The approach to ethnicity classification within CYF is that 
children and young people (or their families) are asked to self-identify their ethnicity. For the purposes of 
reporting, only the client’s self-identified primary ethnic group is extracted. If a client does not nominate a 
primary ethnic group, their ethnicity is reported as “Other / Multiple Ethnicities”.36 As at 30 June 2016 3,208 
(60%) of children and young people in CYF care had Māori recorded as their primary ethnic group; New 
Zealand Pākeha was recorded as the primary ethnic group for 1,478 (28%), Pacific Peoples for 407 (8%), Asian 
for 79 (1%), Other European for 55 (1%) and other or multiple ethnicities for 85 (2%).1 Most (83%) of the 
children and young people in CYF care were in out-of-home placements, with the remainder remaining in their 
own homes, returned to their homes after a period of out-of-home care or in independent living situations.36 
Table 26 presents the numbers of New Zealand children and young people in out-of-home State care by 
placement type, as well as the total numbers in CYF care, in each of the past five years. Numbers of children in 
care have been fairly stable at around 5000 as of 30 June each year and their distribution between placement 
types has also been similar from year to year.  
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Table 26. Individual children and young people in out-of-home State care, by placement type, and total number 












Non Family / Whānau Placement 1,427 1,298 1,269 1,182 1,281 
Family / Whānau Placement 1,639 1,698 1,999 2,193 2,303 
Child and Family Support Services* 518 521 536 502 507 
CYF Family Home Placement 114 103 114 133 154 
Residential Placement 47 47 34 29 35 
Other Supported Accommodation 139 177 177 124 114 
Total children and young people in out-of-home placements 3,884 3,844 4,129 4,163 4,394 
Total children and young people in CYF care 4,979 4,960 5,188 5,026 5,312 
Source: Child, Youth and Family.36 The number of children and young people in out of home placements is as at 30 June each 
year. Out of home placements exclude placement types: 'Independent Living', 'Remain Home' and 'Return Home'; *The 
placement type 'Child and Family Support Services' is approved under s396 CYPF Act, and provided by non-government 
organisations (NGOs); In CYF care = children and young people in the custody of the Chief Executive of Child, Youth and Family 
as at 30 June each year; Each child or young person in CYF care at the point in time shown is counted once in this table 
Children and young people in CYF care represent only around 10% of all children and young people who come 
to the attention of CYF.7 A review of data for every child and young person who was a CYF client showed that 
for every ten 0–17 year olds who came to CYF attention in 2013:7 
• Two were assessed at intake as not requiring a statutory intervention; the case was closed or, in a minority 
of cases, children were referred to a non-government organisation for a partnered response 
• Five were subject to a formal assessment or investigation but no further statutory action was taken; the case 
was closed or, in a minority of cases, children were referred to a non-government organisation for a 
partnered response  
• An additional two were subject to a formal assessment or investigation and as a result received support 
from CYF in the form of family group conferences (FGC) or family whānau agreements (FWA)  
• One was brought into CYF care as a result of care and protection concerns, after a formal assessment or 
investigation, most often when those concerns were not resolved through a FGC process. 
The Interim Report notes that about half of the notified children and young people who were assessed as not 
requiring a statutory intervention were re-referred to CYF within a year because of community or professional 
concern for their safety and care. A change in patterns of repeat referrals has been noticed over time. In 2004 
most notifications to CYF concerned children who were not previously known to the agency. In contrast, 6 out 
of every 10 children referred to CYF in 2014 were already known to the agency and, on average, CYF had 
engaged with these children three times previously.7  
Atwool (2013) notes that children in all children and young people in foster or kin care are members of two or 
more families. They must manage divided loyalties: to the people with whom they live who are their current 
source of care and protection, and also to their birth families toward whom they may have strong but ambivalent 
feelings. Research has generally shown that children want to continue contact with birth families, and some 
never give up hope that they can return to live with them. Contact with birth families puts the child or young 
person into a situation where the two worlds of birth and foster family overlap. The impact of such contact will 
vary depending on the pattern of belonging to each family as experienced by the child or young person.2 
Monitoring State care in New Zealand  
The statutory functions of the New Zealand Children’s Commissioner include monitoring and assessing the 
policies and practices of CYF.5,8,37 In 2015 the Children’s Commissioner found that CYF had strong intake and 
assessment practices with well-developed processes for investigating and making decisions about cases of 
potential abuse and neglect. Once such decisions had been made, however, oversight and case management of 
children in all types of CYF placement was poor. There was little available data about the outcomes for children 
and young people in CYF care, and not enough information to draw any conclusion about whether or not 
children and young people are better off as a result of state intervention.5 The aggregated and summarised 
recommendations from the 2015 State of Care report were:5 
• Set clear expectations about CYF’s core purpose and the outcomes it needs to achieve 
• Ensure CYF is fully child-centred in all its activities 
• Invest more in on-going support for children in all types of care placements 
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• Address capacity and capability issues across the CYF workforce 
• Improve cultural capability across the organisation 
• Collect and analyse relevant data to drive improved outcomes for children 
• Set clear expectations for other state agencies responsible for improving the outcomes of children in care 
The 2016 State of Care report focussed on the quality of CYF case management and found some examples of 
positive practice.8 Children and young people were considered to be safe in all of the six CYF residences visited 
by the Office of the Children’s Commissioner; most were receiving care and services that met daily needs. 
However, the review also found that CYF was not sufficiently child centred and was of variable quality. Barriers 
to achieving high quality case management included inadequate resources, high caseloads, and a lack of cultural 
capacity and other skills to work in child-centred ways. While welcoming the planned changes resulting from 
the Modernising Child Youth & Family Expert Panel reports, the Children’s Commissioner also expressed 
concern at potential risks associated with transition between operating models. There is increased risk of a dip in 
performance at times of operational change. The overarching recommendations from the 2016 State of Care 
report were:8  
• Plan to reduce the risk to children and young people of a dip in performance during the transition period 
• Clarify what child-centred practice means in the New Zealand care and protection and youth justice systems 
• Empower and support staff now to strengthen their child-centred practice 
Child Youth and Family to Oranga Tamariki  
The Children, Young Persons and Their Families (Oranga Tamariki) Legislation Act received Royal assent in 
July 2017.38 The Act changed the name of the principal Act (previously Children, Young Persons and Their 
Families Act 1989) to Oranga Tamariki Act 1989 or Children’s and Young People’s Well-being Act 1989. The 
Act established a statutory framework required to create a more child-centred operating model for the Ministry 
for Children, Oranga Tamariki to meet the needs of children and young people in Aotearoa New Zealand. The 
changes included: 
• Updating the definition of young person to include young persons who are (or have been) married or in civil 
unions  
• Updating the general principles of the principal Act to take a more child-centred approach placing all 
children and young persons (including children with disabilities) at the centre of decision-making, 
considering them within the context of their families, whānau, hapū, iwi, and broader networks and 
communities, with specific recognition and respect for a child’s or young person’s mana tamaiti (tamariki) 
and the whakapapa and whanaungatanga responsibilities of whānau, hapū, and iwi 
• Introducing a new and separate principle of child and young person participation that clearly recognises the 
importance of the voice of the child, elevates its status, and more firmly embeds this aspect of child-
centred  practice  
• Development of National Care Standards and provision of financial support for caregivers that is more 
responsive to the changing needs of children in care. These will set out the rights of children and young 
persons in care, the standard of care that they can expect, and standards for caregiver training, monitoring, 
and support  
• Amendments to extend the youth justice jurisdiction to include 17-year-olds  
• A new entitlement for young persons transitioning out of care to remain or return to living with a caregiver 
up to age 21 and for CYF, where required, to provide transition advice and assistance to young persons 
leaving care or a youth justice facility up to age 25 
• A bespoke information sharing framework within the Act 
• Accountability arrangements to ensure the co-ordination of prevention activity across government and to 
address the needs of children and young persons in need of care or protection. 
The Investing in New Zealand’s children and their families report notes that the scale of change required will 
take many years to rollout and embed. The essential issue is that the change occurs in a way that ensures better 
outcomes for vulnerable children.3 The Expert Panel observed a growing appetite for meaningful and lasting 
change to achieve better outcomes for the children and young people at the heart of the care and protection 
system. The aim of the proposed changes is to achieve better outcomes for vulnerable children. The aspirational 
goals for vulnerable children are that they will enjoy positive childhoods and have the opportunity to fully 
realise their potential.3  
When children are unable to live with their birth parents at home, they require intensive 
support to develop a sense of stability and to build new relationships with a family who will 
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be there for them now and in the future. The State has a role in supporting families to build 
loving and stable relationships with children in their care and to help them ensure that those 
children enjoy the same opportunities and outcomes as other New Zealand children.3  
The operating model envisages a wider range of professional domains (such as health, education, and 
psychology) working with children and families, both within the department and across agencies. This change 
will require transformational leadership at all levels that engages people, communities and all of New Zealand to 
build the momentum to deliver the scale of change required. Services, including health services, would work 
with young people who have been in care to proactively identify and meet their needs up to the age of 25.3  
A key component of the operating model proposed in the Investing in New Zealand’s children and their families 
report is that the future department (Oranga Tamariki) will commission and directly purchase services for 
vulnerable children, including therapeutic interventions and health related services that support healing and 
recovery for children, young people and families. All practitioners will need a robust understanding of child 
development and trauma-informed approaches.3 The Expert Panel recommended legislative mechanisms to 
support more effective interagency and multidisciplinary working at an individual client level, including 
provisions around information exchange, and support governance and collaboration at a system level. This 
might include introducing a duty on agencies such as District Health Boards to collaborate and coordinate 
services to children and families, extending the current obligation under the Vulnerable Children Act. Strong 
leadership will be required to establish, manage and govern a change programme of this size.3 
Conclusion 
Children and young people in State care are a New Zealand population group with high needs across all health 
domains, including secure whānau and family attachment as well as timely assessment and effective 
management of physical, spiritual, and mental health needs. Health services have a major role in identifying 
children and young people in need of care and protection, and in working collaboratively with other agencies to 
address the health needs of children and young people in State care. The proposed direct purchasing of services 
for vulnerable children will mean that DHBs and other health services need to be well prepared to deliver 
services that support healing and recovery for children, young people and families. Key infrastructure elements 
to achieve positive outcomes will include gathering and use of good data, development of staff knowledge, 
skills and understanding, and effective community programmes to improve child safety. 
Within health services it is important to identify children and young people in State care, so that particular 
attention can be paid to ensuring that vulnerable children, young people and their caregivers have a sound 
understanding of existing health concerns and the management of them. This may include specific support for 
caregivers particularly where the children and young people in care have challenging behaviour. Keeping 
accurate health records are important not only at this individual level but also at a service and aggregate national 
level, to add to the sparse evidence base about effective interventions that enable children and young people in 
State care to enjoy the same health outcomes as their peers. 
Health professionals involved with children and young people in State care, and with their whānau, wider 
families and caregivers, need appropriate skills and competencies to assure high quality services. Guidelines for 
staff skill development are available from other jurisdictions and could be adapted for New Zealand context.19,23 
There is a high level of co-occurrence of physical and mental health conditions as well as emotional and sleep 
disorders for many children and young people in State care. Such complex health histories mean that there needs 
to be excellent co-ordination between paediatric and youth health services and mental health services within and 
between DHBs.  
Making our communities and households safe environments for children and young people to develop and grow 
will require strong collaborative efforts from many sectors of society. Health promotion and community 
development initiatives to strengthen parenting skills, provide early additional support when required, reduce 
social inequalities overall and promote good child development have a valid place within health services’ 
mandate. Health professionals are also in a privileged position meeting with children and young people in State 
care and can include assessment of placement safety in clinical encounters.  
Proposed changes in New Zealand signal a commitment to and effective child-centred approach that will enable 
all children, including the most vulnerable, to enjoy positive childhoods and have the opportunity to fully realise 
their potential.  
Suggested citation: Duncanson, Mavis. Health needs of children and young people in State Care. In: Simpson 
J, Duncanson M, Oben G, Adams J, Wicken A, Morris S, and Gallagher S. 2018. The Health of Children and 
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Young People with Chronic Conditions and Disabilities in New Zealand 2016. Dunedin: New Zealand Child 
and Youth Epidemiology Service, University of Otago. 
References 
1. Child, Youth and Family. undated. Key statistics and information for media.  
http://www.cyf.govt.nz/about-us/key-statistics/ accessed November, 2016. 
2. Atwool N. 2013. Birth family contact for children in care: How much? How often? Who with? Child 
Care in Practice, 19(2) 181-98. http://dx.doi.org/10.1080/13575279.2012.758086  
3. Modernising Child, Youth and Family Expert Panel. 2016. Investing in New Zealand's children and 
their families: Final report.  http://www.msd.govt.nz/documents/about-msd-and-our-work/work-
programmes/investing-in-children/investing-in-children-report.pdf accessed November, 2016  
4. National Institute for Health and Care Excellence. 2015. Looked-after babies, children and young 
people overview.  https://pathways.nice.org.uk/pathways/looked-after-babies-children-and-young-
people accessed November, 2016 2016. 
5. Office of the Children's Commissioner. 2015. State of care 2015: What we learnt from monitoring 
Child, Youth and Family.  http://www.occ.org.nz/assets/Publications/OCC-State-of-Care-2016.pdf 
accessed November, 2016  
6. Pitama S, Huria T, Lacey C. 2014. Improving Māori health through clinical assessment: Waikare o te 
waka o meihana. The New Zealand Medical Journal, 127(1393) 107-19. 
http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2014/vol-126-no-
1393/viewpoint-pitama 
7. Modernising Child, Youth and Family Expert Panel. 2015. Interim report.  
https://www.msd.govt.nz/documents/about-msd-and-our-work/work-programmes/cyf-
modernisation/interim-report-expert-panel.pdf accessed November, 2016  
8. Office of the Children's Commissioner. 2016. State of care 2016: What we learnt from monitoring 
Child, Youth and Family.  http://www.occ.org.nz/assets/Publications/OCC-State-of-Care-
2016FINAL.pdf accessed November, 2016. 
9. Fernandez E, Atwool N. 2013. Child protection and out of home care: Policy, practice, and research 
connections Australia and New Zealand. Psychosocial Intervention, 22(3) 175-84. 
http://dx.doi.org/10.5093/in2013a21  
10. Child, Youth and Family, Ministry of Education, Ministry of Health. undated. Interagency guide to 
Gateway Assessments.  http://www.cyf.govt.nz/documents/keeping-kids-safe/gateway-assessments-
interagency-guide.pdf accessed November, 2016  
11. 2016. Health needs audit for looked after children and young people in the care of the London Borough 
of Hillingdon. Adoption & Fostering, 40(2) 188-97. http://dx.doi.org/10.1177/0308575916652599  
12. Szilagyi MA, Rosen DS, Rubin D, et al. 2015. Health care issues for children and adolescents in foster 
care and kinship care. Pediatrics, 136(4) e1142-e66. http://dx.doi.org/10.1542/peds.2015-2656  
13. Bronsard G, Alessandrini M, Fond G, et al. 2016. The prevalence of mental disorders among children 
and adolescents in the child welfare system: A systematic review and meta-analysis. Medicine, 95(7) 
e2622. http://dx.doi.org/10.1097/MD.0000000000002622  
14. Durie M. 1994. Whaiora: Maori health development  Oxford: Oxford University Press. 
15. Collins S. 2016. Our kids at risk: How 77 kids have died in NZ state care. New Zealand Herald. 
http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=11746527  
16. Atwool N. 2016. Life story work: Optional extra or fundamental entitlement? Child Care in Practice, 
1-13. http://dx.doi.org/10.1080/13575279.2015.1126228  
17. Bilson A, Martin KEC. 2016. Referrals and child protection in England: One in five children referred 
to children’s services and one in nineteen investigated before the age of five. British Journal of Social 
Work, 47(3) 793–811. http://dx.doi.org/10.1093/bjsw/bcw054  
18. Bywaters P, Brady G, Sparks T, et al. 2016. Child welfare inequalities: New evidence, further 
questions. Child & Family Social Work, 21(3) 369-80. http://dx.doi.org/10.1111/cfs.12154  
19. Bywaters P, Brady G, Sparks T, et al. 2016. Inequalities in child welfare intervention rates: The 
intersection of deprivation and identity. Child & Family Social Work, 21(4) 452-63. 
http://dx.doi.org/10.1111/cfs.12161  
20. Biehal N. 2014. Maltreatment in foster care: A review of the evidence. Child Abuse Review, 23(1) 48-
60. http://dx.doi.org/10.1002/car.2249  
21. National Institute for Health and Care Excellence. 2015. Looked-after babies, children and young 
people: Public health guideline.  https://www.nice.org.uk/guidance/ph28 accessed November, 2016 
2016. 
22. 2016. Children, Young Persons, and Their Families (Oranga Tamariki) Legislation Bill. 
http://www.legislation.govt.nz/bill/government/2016/0224/latest/DLM7064591.html 
Health needs of children and young people in State care 
125 
23. Winter K. 2006. The participation rights of looked after children in their health care: A critical review 
of the research. International Journal of Children's Rights, 14(1) 77-95. 
http://dx.doi.org/10.1163/157181806776614354  
24. United Nations General Assembly. 1989. Convention on the Rights of the Child. Geneva: United 
Nations. http://www.ohchr.org/en/professionalinterest/pages/crc.aspx 
25. Office of the Children's Commissioner. 2016. Being child-centred: Elevating children's interests in the 
work of your organisation. Wellington: Office of the Children's Commissioner. 
http://www.occ.org.nz/assets/Publications/Being-Child-Centred.pdf 
26. New Zealand Child and Youth Clinical Networks. 2016. Clinical network for child protection.  
https://www.starship.org.nz/for-health-professionals/new-zealand-child-and-youth-clinical-
networks/clinical-network-for-child-protection/ accessed November, 2016 2016. 
27. Royal College of General Practitioners, Royal College of Nursing, Royal College of Paediatrics and 
Child Health. 2015. Looked after children: Knowledge, skills and competences of health care staff. 
Intercollegiate role framework.  
http://www.rcpch.ac.uk/system/files/protected/page/Looked%20After%20Children%202015_0.pdf 
accessed November, 2016  
28. Carrier E, Gourevitch MN, Shah NR. 2009. Medical homes: Challenges in translating theory into 
practice. Medical care, 47(7) 714-22. http://dx.doi.org/10.1097/MLR.0b013e3181a469b0  
29. Balistreri KS. 2015. Adverse childhood experiences, the medical home, and child well-being. Maternal 
and Child Health Journal, 19(11) 2492-500. http://dx.doi.org/10.1007/s10995-015-1770-6  
30. McLeigh JD, McDonell JR, Melton GB. 2015. Community differences in the implementation of Strong 
Communities for Children. Child Abuse & Neglect, 41 97-112. 
http://dx.doi.org/10.1016/j.chiabu.2014.07.010  
31. Akin BA, Brook J, Lloyd MH, et al. 2016. A study in contrasts: Supports and barriers to successful 
implementation of two evidence-based parenting interventions in child welfare. Child Abuse and 
Neglect, 57 30-40. http://dx.doi.org/10.1016/j.chiabu.2016.06.002  
32. 1989. Children, Young Persons, and Their Families Act 
http://www.legislation.govt.nz/act/public/1989/0024/latest/DLM147088.html 
33. 2016. Children, Young Persons, and Their Families (Advocacy, Workforce, and Age Settings) 
Amendment Act. http://www.legislation.govt.nz/act/public/2016/0098/latest/whole.html#DLM6856711 
34. Ministry of Social Development. 2016. Annual Report 2015/2016.  
https://www.msd.govt.nz/documents/about-msd-and-our-work/publications-
resources/corporate/annual-report/2015-2016/annual-report-2015-2016.pdf accessed November, 2016  
35. Ministry of Justice. 2016. Care & protection of children.  https://www.justice.govt.nz/family/care-of-
children/care-and-protection/ accessed November, 2016 2016. 
36. Child, Youth and Family. undated. Kids in care.  http://www.cyf.govt.nz/about-us/key-statistics/kids-
in-care.html accessed November, 2016 2016. 
37. 2003. Children's Commissioner Act. New Zealand. 
http://www.legislation.govt.nz/act/public/2003/0121/latest/whole.html 







Cerebral Palsy (CP) is the name given to a group of disorders characterised by impairments in the development 
of movement and posture due to non-progressive damage or malformation of the fetal or infant brain.1 Although 
the brain damage is non-progressive, its manifestations may change over time as the brain develops.1 Cerebral 
palsy is the most common physical disability in children, affecting around two in every 1,000.2-4 
In addition to motor disorders, children with CP often have other comorbidities including intellectual disability 
(30–65% of cases), epilepsy (30–50%), speech and language deficits (40%), visual impairments (40%), hearing 
problems (5–15%), psychosocial and behavioural problems (20%) and autism spectrum disorder (9%).5 Medical 
complications of CP can involve multiple bodily systems including the genitourinary (incontinence, urinary 
infections, and voiding dysfunction), gastrointestinal (dysphagia, gastroesophageal reflux disease, constipation), 
respiratory (recurrent pneumonia, atelectasis, bronchiectasis, restrictive lung disease), and endocrine (reduced 
growth and osteopenia).5 
In clinical practice, diagnosis of CP is based on observation and parental reports of delayed attainment of motor 
milestones (such as achieving head control, sitting and standing), and evaluation of posture, deep tendon 
reflexes, and muscle tone.6 There is wide variation in the degree of impairment associated with CP. The least 
severely affected children have only minor limitations in speed, balance and coordination, while the most 
severely affected are unable to maintain anti-gravity head and trunk postures, or control leg and arm 
movements, and need wheelchairs and assistance with all aspects of daily life.7,8 
Data sources and methods 
Indicators  
 Rates of cerebral palsy among 0–24 year olds  
Definition  
Hospitalisations of 0–24 year olds with cerebral palsy per 100,000 population 
Data sources 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
This section presents analyses where the condition was the primary diagnosis or was documented within any of the first 15 
diagnoses (all cases). The rationale for presenting all cases is to highlight the full spectrum of health issues experienced by 
those with this condition, and their consequent requirement for acute health services. Analyses are per hospital discharge 
event therefore events are only included if the condition is documented within either the primary diagnosis or within any of 
the first 15 diagnoses. 
Codes used for identifying cases are documented in Appendix 5. 
National trends and distribution 
There were 58 deaths of 0–24 year olds with cerebral palsy as the underlying cause of death in New Zealand 
during 2009 to 2013, as documented within the National Mortality Collection. 
The number of 0–24 year olds hospitalised between 2011 and 2015 with any diagnosis of cerebral palsy is 
presented in Table 27, together with the total number of hospitalisations with cerebral palsy as a primary or any 
diagnosis.  
Since 2000, hospitalisation rates for cerebral palsy as the primary diagnosis have risen steadily for 0–14 year 
olds, peaking in 2012 for 0–4 year olds and 2014 for 5–14 year olds. Hospitalisation rates were lowest for 15–24 
year olds. Overall, there is a steady increase in hospitalisations of children hospitalised with cerebral palsy as the 
primary diagnosis (Figure 42). Similar patterns over time were seen in all ethnic groups (Figure 43). 
The majority of hospitalisations of 0–24 year olds with a primary diagnosis of cerebral palsy had spastic 
cerebral palsy as the primary diagnosis. Other associated primary diagnoses included in respiratory, digestive or 
musculoskeletal conditions (Table 28).  
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Table 27. Individuals hospitalised with cerebral palsy, 0–24 year olds, New Zealand 2011–2015 
Age group Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Cerebral palsy 
Hospitalisation 
0–24 years 1,678 2,458 5,852 2.38 
0–14 years 1,198 2,221 4,469 2.01 
15–24 years 581 237 1,383 5.84 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with cerebral palsy in any of the first 15 
diagnoses; The sum of the age groups may total to more than the 0–24 year old total 

































































































Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population  
Figure 43. Hospitalisations involving cerebral palsy in 0–24 year olds, by ethnicity, New Zealand 2000–2015 
 






































































































Table 28. Hospitalisations involving cerebral palsy in 0–24 year olds, by primary diagnosis, New Zealand 
2011– 2015 
Primary diagnosis 2011–2015 (n) 
Annual 
average 
Rate per 100,000 
0–24 year olds 
95% CI % 
Cerebral palsy* in 0–24 year olds 
New Zealand  
Spastic cerebral palsy 1,958 392 25.49 24.39–26.65 33.5 
Dyskinetic cerebral palsy 85 17 1.11 0.90–1.37 1.5 
Ataxic cerebral palsy 5 1 0.07 0.03–0.15 0.1 
Cerebral palsy, other or unspecified 410 82 5.34 4.85–5.88 7.0 
Cerebral palsy total 2,458 492 32.00 30.76–33.29 42.0 
Other diseases of the nervous system 375 75 4.88 4.41–5.40 6.4 
Diseases of the respiratory system 662 132 8.62 7.99–9.30 11.3 
Diseases of the digestive system 547 109 7.12 6.55–7.74 9.3 
Diseases of the musculoskeletal 
system and connective tissue 
482 96 6.28 5.74–6.86 8.2 
Symptoms and/or abnormal clinical 
findings NEC 
347 69 4.52 4.07–5.02 5.9 
Other diagnoses 981 196 12.77 12.00–13.60 16.8 
Total 5,852 1,170 76.19 74.26–78.17 100.0 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Cerebral palsy in any of the 
first 15 diagnoses; NEC = not elsewhere classified 
Demographic distribution  
Table 29 presents the demographic distribution of individuals with cerebral palsy in New Zealand between 2011 
and 2015. Cerebral palsy rates were significantly higher in higher deprivation areas (NZDep2013 deciles7–10) 
compared to low deprivation areas (NZDep2013 deciles 1–2), and significantly higher among 0–4 year olds and 
5–14 year olds compared to 15–24 year olds. Hospitalisation rates were significantly lower for Asian/Indian 0–
24 year olds than other ethnic groups. The majority of 0–24 year olds with cerebral palsy were of 
European/Other ethnicity. 




Rate per 100,000 
population 
Rate ratio 95% CI 
Cerebral palsy* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 305 21.49 1.00   
Deciles 3–4 328 24.53 1.14 0.98–1.33 
Deciles 5–6 317 21.99 1.02 0.87–1.20 
Deciles 7–8 458 28.19 1.31 1.13–1.52 
Deciles 9–10 574 30.89 1.44 1.25–1.65 
Prioritised ethnicity 
Māori 405 22.45 0.99 0.88–1.11 
Pacific 191 26.95 1.18 1.01–1.38 
Asian/Indian 126 13.14 0.58 0.48–0.69 
MELAA 38 37.68 1.65 1.20–2.29 
European/Other 936 22.78 1.00   
Gender 
Female 723 19.26 1.00   
Male 955 24.32 1.26 1.15–1.39 
Age group (years) 
0–4 439 28.15 1.52 1.34–1.72 
5–14 943 31.60 1.71 1.54–1.89 
15–24 581 18.52 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Cerebral palsy in any of the 




Table 30 presents the number of individuals resident in each district health board area that had a diagnosis of 
cerebral palsy between 2011 and 2015. It also presents the number of hospital discharges in which cerebral 
palsy was documented as the primary diagnosis or any diagnosis.  
The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and result in less undercounting than would occur if only the primary diagnosis is 
included in discharge data. For cerebral palsy the All:Primary diagnosis ratio was higher than the national ratio 
in Northland, Waikato, Bay of Plenty, Lakes, Tairawhiti, Whanganui, Hawkes Bay and Southern DHBs and 
lower in Waitemata, Auckland, Counties Manukau, Taranaki and Wairarapa DHBs. Ratios were similar to the 
national ratio in the remaining district health boards (Table 30). 
Table 30. Hospitalisations for cerebral palsy in 0–24 year olds, by district health board, New Zealand 2011–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Cerebral palsy* in 0–24 year olds 
Northland 55 28 132 4.71 
Waitemata 226 611 985 1.61 
Auckland 165 431 668 1.55 
Counties Manukau 267 402 760 1.89 
Waikato 168 158 577 3.65 
Bay of Plenty 99 86 349 4.06 
Lakes 56 35 167 4.77 
Tairawhiti 16 16 76 4.75 
Taranaki 32 47 96 2.04 
Hawke's Bay 61 34 194 5.71 
MidCentral 51 52 140 2.69 
Whanganui 23 14 78 5.57 
Hutt Valley 52 46 113 2.46 
Capital & Coast 86 100 222 2.22 
Wairarapa 11 14 25 1.79 
Nelson Marlborough 51 44 162 3.68 
South Canterbury 11 10 29 2.90 
Canterbury 214 253 705 2.79 
West Coast 12 13 32 2.46 
Southern 103 62 340 5.48 
New Zealand 1,678 2,458 5,852 2.38 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Cerebral palsy is listed in 
any of the first 15 diagnoses; Rate ratios are unadjusted; Note that individuals may appear in multiple DHBs 
Evidence for good practice 
Possibilities for prevention 
The causes of the brain damage that produces cerebral palsy are not well understood therefore the possibilities 
for prevention are limited.9,10 While it was formerly believed that lack of oxygen during birth was the cause of 
CP, it is now thought that, in the majority of cases (at least 80%), the brain injury or malformation occurs before 
birth and that no more than 10% of cases are the result of perinatal factors.4 A small proportion of cases (5–
10%) are due to postnatal brain injury in the early months and years of life, for example from cerebrovascular 
accident (stroke); head trauma due to motor vehicle crashes, falls or child abuse; near drowning and other forms 
of asphyxia; and infection such as meningitis.4,11 
Few studies investigate more than one risk factor yet it seems probable that, in many cases, CP results from the 




There is a genetic component to cerebral palsy risk as the recurrence rate in families of people with CP is greater 
the closer the degree of genetic relationship.13 Nevertheless, the absolute risks for family members are low 
because CP is not a very common condition. Current guidelines do not recommend routine genetic testing.14 
In developed countries, increasing maternal age and the use of assisted reproduction therapies have both 
increased the rate of multiple births, which have a higher risk of CP than singleton births.15 
Among the few preventable prenatal causes of CP are severe maternal iodine deficiency,16 rhesus 
isoimmunisation,17 consanguineous marriages,9 and maternal methyl mercury poisoning.18 These factors cause 
almost no cases of CP in developed countries.19 
Babies who are born small for their gestational age or well above the normal weight for their gestational age are 
at increased risk of CP but it is uncertain whether the abnormal growth patterns are a cause or a consequence of 
CP.20 
Perinatal 
High quality maternity care can prevent or mitigate complications of labour and delivery that increase the risks 
of adverse health outcomes for babies, including brain damage leading to CP.21 
Preterm birth is an important risk factor for CP and the risk increases markedly with decreasing gestational age, 
nevertheless more than half of all children with CP were born at term.4 Prevention of preterm birth is 
challenging as its causes are multifactorial and poorly understood.22 
In women threatening to or likely to give birth preterm, there is evidence that antenatal magnesium sulphate 
therapy substantially reduces the risk of their child having CP,23 although mothers can experience unpleasant 
side effects such as tachycardia, flushing and nausea/vomiting.24 
A recent review of risk factors for CP in children born at term in developed countries identified 10 statistically 
significant risk factors, three of which were considered possibly preventable.25 These three were: birth asphyxia, 
low birthweight and meconium aspiration.25  
In infants born at 35+ weeks gestation with evidence of peripartum asphyxia (such as needing mechanical 
ventilation or resuscitation at 10 minutes after birth) and encephalopathy (such as seizures), induced 
hypothermia (cooling) reduces mortality and neurodevelopmental disability in survivors.26 
Fetal heart rate monitoring using continuous cardiotocography (CTG) has not been shown in RCTS to reduce 
cerebral palsy rates but it does increase rates of caesarean sections and instrumental vaginal births.27 
The passage of fetal bowel movement (meconium) in the amniotic fluid is common, and it can (rarely) result in 
meconium aspiration syndrome if the baby inhales meconium during the birth process.28 According to a 2012 
Cochrane review, curtailment of post-term pregnancies by induction of labour reduces the occurrence of 
meconium stained amniotic fluid and meconium aspiration syndrome.29 There is little research evidence 
regarding the benefits or otherwise of obstetric interventions such as expedited delivery when there is 
meconium-stained amniotic fluid without other evidence of fetal distress.28 
Postnatal 
Because infants born preterm have a greatly increased risk of developing CP, early intervention programmes 
have been used in the hope of preventing cerebral palsy and promoting normal brain development in preterm 
infants. The evidence indicates that general development programmes for preterm infants have no effect on CP 
rates in survivors of preterm birth.30 There is some evidence that such programmes improve cognitive outcomes 
in the preschool years although not at school age. There is little evidence for positive effects on motor outcomes 
beyond infancy.30,31 It has been argued that early intervention research to date does not provide sufficient 
evidence to exclude the possibility that early intervention could have long lasting benefits for infants at high risk 
of developing CP or with early signs of CP.32 
Interventions to prevent head injuries in infants and toddlers, such as promoting car seat use and preventing 
shaken baby syndrome,33,34 may help prevent post-natally acquired CP. 
Evidence-based health care for children and young people with cerebral palsy 
Children with CP often have multiple medical issues and they typically need services from multiple healthcare 
professionals including paediatricians, orthopaedic surgeons, neurologists, ophthalmologists, optometrists, 
audiologists, physiotherapists, dieticians, occupational therapists, speech language therapists and dentists.35 
They also may need special education services, in-home care and respite care.35 
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The evidence base for CP therapies is limited largely to systematic reviews, meta-analyses, and large 
multicentre prospective cohort studies because of the lack of well conducted prospective randomised controlled 
trials on this topic.11,36 The interventions that are best supported by evidence are: anticonvulsants, bimanual 
training, botulinum toxin, bisphosphonates to prevent osteoporosis, casting, constraint-induced movement 
therapy, context-focused therapy, diazepam, fitness training, goal-directed training, hip surveillance, home 
programmes, occupational therapy after botulinum toxin, pressure care, and selective dorsal rhizotomy.36 
Coordination of care 
In English-speaking developed countries, and increasingly in other developed countries, family-centred service 
provision for children with special needs is considered to be best practice.37,38 This model of service provision 
recognises that each family is unique, that the family is the constant in the child’s life, and that they are the 
experts on the child’s abilities and needs. It involves the family working together with service providers to make 
informed decisions about the services and supports the child will receive and it considers the strengths and needs 
of all family members.39,40 
There has been very little research on family-centred care specifically for families affected by CP but a review 
of 24 studies (including seven RCTs) of family-centred care for US children with conditions associated with 
having special health care needs found positive associations between family-centred care and improvements in 
efficient use of services, health status, satisfaction, access to care, communication, systems of care, family 
functioning, and family financial impact and cost.41 It did not identify any negative outcomes. 
While multidisciplinary teams are an integral part of child health services, they are often lacking in adult 
healthcare services and young adults with CP (or their families) can be left to coordinate their own healthcare at 
a time when they are dealing with many transitions in other areas of life including education and employment, 
finances and benefits, housing, transportation, leisure activities and relationships.42-44 
Caring for a child with cerebral palsy is often challenging for families and primary caregivers of children with 
CP have been found to have lower incomes than other parents despite similar levels of education, to be less 
likely to be working for pay and to have a greater likelihood of physical and psychological health problems.45,46 
In contrast to parents of normal children, parents of children with CP can find that the demands of caregiving 
become greater as their child ages.47 Research has not consistently found that the severity of a child’s motor 
impairment determines the impact of CP on families’ wellbeing but it has consistently found that CP that is 
accompanied by intellectual disability and behaviour problems is associated with a more severe impact.48 
There is research indicating that respite care is an appropriate and effective intervention for decreasing parental 
stress and giving parents the chance to spend time with other family members.49 Respite care can also be 
considered a child abuse prevention intervention, particularly for children with challenging behaviours.49 There 
seems to have been little research on effective models for respite care for children with developmental disability 
and severe behaviour problems.49 
Physiotherapy 
Physiotherapy is an established component of the management of CP. There is an increasing evidence base to 
support a number of physiotherapy interventions including constraint-induced movement therapy (where a 
child’s less-affected hand is restrained in a mitt or cast and the more-affected hand is given intensive 
training)50,51, strengthening interventions for individual muscle groups52 and functional training (training 
focussed on motor activities similar to those involved in daily living such as stair climbing, walking and moving 
from sitting to standing) but research studies have generally been small (< 30 participants).52-54 
Exercise interventions may improve postural control in children with CP.55 There is a moderate level of 
evidence to support gross motor task training, therapeutic horseback riding, treadmill training with no body 
weight support, trunk-targeted training, and reactive balance training.55 
Orthoses, especially ankle-foot orthoses  which aim to facilitate standing upright and walking, are commonly 
prescribed for children with CP although the evidence for their efficacy is limited to low level evidence that they 
improve gait in the short term.56 
To achieve their functional potential children with CP need to be motivated to persist with their rehabilitation 
therapy. There has been very little research on the effects of motivational interventions for children with CP.57 
Treatments for spasticity 
Spasticity (tight muscles as a result of damage to the parts of the brain that control movement) can be a 
significant source of functional disability in many children with CP. Spasticity inhibits movement and causes 
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pain both directly through producing cramp and indirectly through producing extreme joint positions. 
Interventions to manage spasticity include physiotherapy, casting and splinting, orthopaedic and neurosurgery, 
botulinum toxin injections and oral medications.  
Oral medications to treat spasticity include benzodiazepines, dantrolen, baclofen and tizanidine. The evidence 
base for the use of oral medications for spasticity in CP is limited because most studies were conducted many 
years ago and, by modern standards, had methodological limitations.58 The choice of medication is therefore 
largely based on personal experience or trial and error. 
There is a growing body of evidence for the effectiveness of botulinum toxin A (Botox) in reducing spasticity 
and improving motor function in children with CP when it is used in combination with other treatment 
measures.59-61 
There is a small amount of evidence that intrathecal baclofen (baclofen infused by a pump connected to a 
catheter directly into the subarachnoid space around the spinal cord) is an effective treatment for treatment of 
spasticity in children with CP in the short term.62 
Selective dorsal rhizotomy (SDR) is an irreversible neurosurgical procedure involving cutting selected sensory 
nerve roots in the lumbar spine under intraoperative neurophysiological guidance. Intensive post-operative 
physiotherapy is necessary. Selective dorsal rhizotomy is effective for reducing spasticity in certain carefully 
selected young patients with bilateral spastic CP and can reduce the need for further surgical interventions and 
improve quality of life and independence with activities of daily living.63 Further research is needed regarding 
the long term outcomes of SDR, especially with regard to functional activity and participation.36,64 
Orthopaedic surgery 
Musculoskeletal pathology develops in the limbs of most children with CP and orthopaedic surgery procedures 
such as tendon lengthenings, tendon transfers, rotational osteotomies, and joint stabilisation procedures have 
been developed to address the various components of this pathology.65 
Children with severe CP commonly develop hip problems involving displacement of the femoral head resulting 
in pain, caregiving problems, seating problems, pressure sores, fractures and contractures. Regular hip 
surveillance programmes for children with CP allow earlier identification of subluxation and reduces the need 
for surgery on dislocated hips.66 There is on-going debate about the best surgical intervention and the best 
timing of surgical intervention to deal with this problem.67  
Equinus foot deformity is the most common musculoskeletal deformity in CP. There is low quality evidence 
supporting surgical intervention to correct this problem but no evidence to indicate which particular surgical 
technique is best.68 
Surgical correction of thumb-in-palm deformity in children with spastic CP seems to improve hand function, to 
facilitate hygiene, and to improve the appearance and quality of life but the evidence is limited to prospective 
studies comparing pre- and post-operative outcomes.69 
To avoid having to subject a child with CP to multiple hospital stays and rehabilitation periods it has become 
common to do single-event multilevel surgery (SEMLS) in which multiple levels of musculoskeletal pathology 
in both lower limbs are addressed by multiple surgical teams during a single surgical operation.65 The evidence 
base for this approach is limited due to a lack of RCTs.65 Most studies to date have been retrospective studies or 
prospective cohort studies and most have had fewer than 30 participants.65 
Feeding interventions 
Children with severe CP often have problems with sucking, chewing and swallowing their food. This puts them 
at risk of under nutrition and of recurrent aspiration pneumonia (due to inhaling food into their lungs).70 Both 
behavioural and surgical techniques may be used to deal with feeding difficulties. The available research 
literature provides little evidence on the effectiveness of behavioural therapies (such as positioning, altering 
food consistency, or use of feeding devices) due to a lack of RCTs and generally small sample sizes.70,71 There 
is no RCT evidence regarding feeding tubes.72 Evidence from six case series indicates that surgically placed 
feeding tubes (gastrostomy or jejeunostomy tubes) improve weight gain73 but there is insufficient evidence 
regarding their effects on respiratory outcomes, parent and child quality of life, or long term morbidity and 





Evidence-based health care for children and young people with cerebral palsy 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of CP are suggestions for further reading. 
New Zealand guidelines 
• Child Development Centre Therapy Team, Waikato District Health Board. 2014. Cerebral Palsy Clinical 
Practice Guideline. Hamilton: Waikato District Health Board. http://www.waikatodhb.health.nz/assets/for-
health-professionals/Primary-care-management-guidelines/Cerebral-Palsy-Clinical-Practice-Guideline.pdf  
International guidelines 
• National Institute for Health and Care Excellence. 2017. Cerebral palsy in under 25s: assessment and 
management https://www.nice.org.uk/guidance/ng62  
• National Institute for Health and Care Excellence. 2015. Preterm labour and birth. 
https://www.nice.org.uk/guidance/ng25  
• Wynter M, Gibson N, Kentish M, et al. 2014. Australian Hip Surveillance for Children with Cerebral Palsy 
2014. https://ausacpdm.org.au/wp-content/uploads/sites/10/2015/06/140070-THOMASON-HipS-booklet-
A5_web.pdf  
• National Institute for Health and Care Excellence. 2012. Spasticity in under 19s: management. 
https://www.nice.org.uk/guidance/cg145  
• National Collaborating Centre for Women's and Children's Health. 2012. Spasticity in children and young 
people with non-progressive brain disorders: management of spasticity and co-existing motor disorders and 
their early musculoskeletal complications. London: National Collaborating Centre for Women's and 
Children's Health. https://www.nice.org.uk/guidance/cg145/evidence/full-guideline-186774301  
• Magee L, Sawchuck D, Synnes A, et al. 2011. SOGC Clinical Practice Guideline. Magnesium sulphate for 
fetal neuroprotection. Journal of Obstetrics and Gynaecology Canada, 33(5), 516-29. Summary at: 
https://www.guideline.gov/summaries/summary/33561/magnesium-sulphate-for-fetal-neuroprotection  
• National Institute for Health and Care Excellence. 2010. Selective dorsal rhizotomy for spasticity in 
cerebral palsy. https://www.nice.org.uk/guidance/ipg373  
• Delgado MR, Hirtz D, Aisen M, et al. 2010. Practice parameter: pharmacologic treatment of spasticity in 
children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards 
Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology 
Society. Neurology, 74(4), 336-43. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122302/  
• Ashwal S, Russman BS, Blasco PA, et al. 2004. Practice parameter: diagnostic assessment of the child with 
cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and 
the Practice Committee of the Child Neurology Society. Neurology, 62(6), 851-63. 
http://www.neurology.org/content/62/6/851.full  
Evidence-based medicine reviews 
The following review provides an excellent overview of the evidence for interventions for children with cerebral 
palsy: 
• Novak I, McIntyre S, Morgan C, et al. 2013. A systematic review of interventions for children with cerebral 
palsy: state of the evidence. Developmental Medicine & Child Neurology, 55(10) 885-910. 
http://dx.doi.org/10.1111/dmcn.12246  
• The Cochrane Library reviews related to cerebral palsy. 
http://www.cochranelibrary.com/topic/Neurology/Neurodevelopmental%20disorders/Cerebral%20palsy/?st
age=review  
• Ozel S, Switzer L, Macintosh A, et al. 2016. Informing evidence-based clinical practice guidelines for 
children with cerebral palsy at risk of osteoporosis: an update. Developmental Medicine & Child Neurology, 
58(9) 918-923 http://dx.doi.org/10.1111/dmcn.13196  
• Lindsay S. 2016. Child and youth experiences and perspectives of cerebral palsy: a qualitative systematic 
review. Child: Care, Health & Development, 42(2) 153-75. http://dx.doi.org/10.1111/cch.12309  
• Kruijsen-Terpstra AJ, Ketelaar M, Boeije H, et al. 2014. Parents' experiences with physical and 
occupational therapy for their young child with cerebral palsy: a mixed studies review. Child: Care, Health 
& Development, 40(6) 787-96. http://dx.doi.org/10.1111/cch.12097  
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• Park EY, Kim WH. 2014. Meta-analysis of the effect of strengthening interventions in individuals with 
cerebral palsy. Research in Developmental Disabilities, 35(2) 239-49. 
http://dx.doi.org/10.1016/j.ridd.2013.10.021  
• Ferluga ED, Sathe NA, Krishnaswami S, et al. 2014. Surgical intervention for feeding and nutrition 
difficulties in cerebral palsy: a systematic review. Developmental Medicine & Child Neurology, 56(1) 31-
43. http://dx.doi.org/10.1111/dmcn.12170  
• Sakzewski L, Ziviani J, Boyd RN. 2014. Efficacy of upper limb therapies for unilateral cerebral palsy: a 
meta-analysis. Pediatrics, 133(1) e175-204. http://dx.doi.org/10.1542/peds.2013-0675  
• Maltais DB, Wiart L, Fowler E, et al. 2014. Health-related physical fitness for children with cerebral palsy. 
Journal of Child Neurology, 29(8) 1091-100. http://dx.doi.org/10.1177/0883073814533152  
• Ferluga ED, Archer KR, Sathe NA, et al. 2013. Interventions for Feeding and Nutrition in Cerebral Palsy 
(Comparative Effectiveness Reviews, No. 94). Agency for Healthcare Research and Quality. 
http://www.ncbi.nlm.nih.gov/books/NBK132442/  
• Fehlings D, Switzer L, Findlay B, et al. 2013. Interactive computer play as "motor therapy" for individuals 
with cerebral palsy. Seminars in Pediatric Neurology, 20(2) 127-38. 
http://dx.doi.org/10.1016/j.spen.2013.06.003  
• Meyer-Heim A, van Hedel HJ. 2013. Robot-assisted and computer-enhanced therapies for children with 
cerebral palsy: current state and clinical implementation. Seminars in Pediatric Neurology, 20(2) 139-45. 
http://dx.doi.org/10.1016/j.spen.2013.06.006  
• Andersen JC, Majnemer A, O'Grady K, et al. 2013. Intensive upper extremity training for children with 
hemiplegia: from science to practice. Seminars Pediatric Neurology, 20(2) 100-5. 
http://dx.doi.org/10.1016/j.spen.2013.06.001  
• Morgan C, Novak I, Badawi N. 2013. Enriched environments and motor outcomes in cerebral palsy: 
systematic review and meta-analysis. Pediatrics, 132(3) e735-46. http://dx.doi.org/10.1542/peds.2012-3985  
• Tatla SK, Sauve K, Virji-Babul N, et al. 2013. Evidence for outcomes of motivational rehabilitation 
interventions for children and adolescents with cerebral palsy: an American Academy for Cerebral Palsy 
and Developmental Medicine systematic review. Developmental Medicine & Child Neurology, 55(7) 593-
601. http://dx.doi.org/10.1111/dmcn.12147  
• Pin TW, Elmasry J, Lewis J. 2013. Efficacy of botulinum toxin A in children with cerebral palsy in Gross 
Motor Function Classification System levels IV and V: a systematic review. Developmental Medicine & 
Child Neurology, 55(4) 304-13. http://dx.doi.org/10.1111/j.1469-8749.2012.04438.x  
• Tseng SH, Chen HC, Tam KW. 2013. Systematic review and meta-analysis of the effect of equine assisted 
activities and therapies on gross motor outcome in children with cerebral palsy. Disability & Rehabilitation, 
35(2) 89-99. http://dx.doi.org/10.3109/09638288.2012.687033  
• Piskur B, Beurskens AJ, Jongmans MJ, et al. 2012. Parents' actions, challenges, and needs while enabling 
participation of children with a physical disability: a scoping review. BMC Pediatrics, 12(177). 
http://dx.doi.org/10.1186/1471–2431-12-177  
• Franki I, Desloovere K, De Cat J, et al. 2012. The evidence-base for basic physical therapy techniques 
targeting lower limb function in children with cerebral palsy: a systematic review using the International 
Classification of Functioning, Disability and Health as a conceptual framework. Journal of Rehabilitation 
Medicine, 44(5) 385-95. http://dx.doi.org/10.2340/16501977-0983  
• Franki I, Desloovere K, De Cat J, et al. 2012. The evidence-base for conceptual approaches and additional 
therapies targeting lower limb function in children with cerebral palsy: a systematic review using the ICF as 
a framework. Journal of Rehabilitation Medicine, 44(5) 396-405. http://dx.doi.org/10.2340/16501977-0984  
Other relevant publications 
• Goldsmith S, McIntyre S, Smithers-Sheedy H, et al. 2016. An international survey of cerebral palsy 
registers and surveillance systems. Developmental Medicine & Child Neurology, 58 Suppl 2, 11-7. 
http://onlinelibrary.wiley.com/doi/10.1111/dmcn.12999/abstract  
• Lee RW, Poretti A, Cohen JS, et al. 2014. A diagnostic approach for cerebral palsy in the genomic era. 
Neuromolecular Medicine, 16(4), 821-44. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229412/  
• Leach EL, Shevell M, Bowden K, et al. 2014. Treatable inborn errors of metabolism presenting as cerebral 




• Novak I, Autti-Rämo I, Forrsberg H, et al. 2014. International Clinical Practice Guidelines for Cerebral 
Palsy: 2014 Report of the EACD workshop & presidential inter-academy meetings of the EACD, 
AACPDM & AusACPDM. https://www.eacd.org/file-download.php?id=98  
Websites 
• Cerebral Palsy Alliance. About cerebral palsy. https://www.cerebralpalsy.org.au/about-cerebral-palsy/  
• Australasian Academy of Cerebral Palsy and Developmental Medicine. https://ausacpdm.org.au/  
• CanChild. Cerebral palsy related resources. https://www.canchild.ca/en/diagnoses/cerebral-
palsy/related_resources  
• Cerebral Palsy Society. http://www.cerebralpalsy.org.nz/  
• Surveillance of Cerebral Palsy in Europe. Publications. http://www.scpenetwork.eu/en/publications/  
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An epileptic seizure is the manifestation of abnormal or excessive discharge of neurons in the brain.1 Epilepsy is 
defined as recurrent seizures, specifically two or more seizures separated by at least 24 hours but within 18 
months of one another.1 There are many different types of epileptic seizure. Seizures may involve abnormal 
movements such as jerking, twitching, repetitive movements or sudden loss of muscle tone, loss of 
consciousness, abnormal sensory perceptions such as strange tastes or smells or a feeling of déjà vu, or intense 
emotions such as joy or fear.2 Prolonged or recurrent seizures (without a return to normal function between 
seizures) lasting 30 minutes or more constitute status epilepticus.3 
Epilepsy is relatively common in children, affecting around four in every 1,000.4,5 Epilepsy in children often 
occurs in association with mental health disorders or disabilities including developmental delay, attention deficit 
hyperactivity disorder, autism, anxiety and depression.6,7 Epilepsy can result from genetic conditions (such as 
Angelman and Rett syndromes) and metabolic or structural conditions (such as head trauma and central nervous 
system malformations, infections or tumours) but in the majority of cases of epilepsy in children no cause can be 
identified.2,5 
Children with epilepsy and their families need on-going specialist medical care.8 While there are effective drugs 
for treating epilepsy, they are not effective for all children, and some children have difficulty adapting to drug 
treatment.2,8 Living with epilepsy affects many aspects of quality of life. Studies have generally found that the 
emotional impacts are more significant than the physical ones.9 Negative impacts of epilepsy include fatigue, 
medication side effects, anxiety and depression, social isolation due to being unwilling to disclose epilepsy to 
peers, restriction of leisure activities because of fear of having a seizure, and, for young people, being unable to 
get a driver licence, stay up late or drink alcohol.9,10  
The majority of people with childhood-onset epilepsy do not need to take anti-epileptic drugs for life.2 Patients 
followed long term have remission rates of around 65%.11 
Data sources and methods 
Indicators  
 Rates of epilepsy or status epilepticus among 0–24 year olds 
Definition  
Hospitalisations of 0–24 year olds with epilepsy or status epilepticus per 100,000 population 
Data sources 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
This section presents analyses where the condition was the primary diagnosis or was documented within any of the first 15 
diagnoses (all cases). The rationale for presenting all cases is to highlight the full spectrum of health issues experienced by 
those with this condition, and their consequent requirement for acute health services. 
Analyses are per hospital discharge event therefore events are only included if the condition is documented within either the 
primary diagnosis or within any of the first 15 diagnoses 
Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to review 
this appendix before interpreting any trends.  
Codes used for identifying cases are documented in Appendix 5. 
National trends and distribution 
There were 58 deaths of 0–24 year olds with epilepsy or status epilepticus as the underlying cause of death in 
New Zealand during 2009 to 2013, as documented within the National Mortality Collection. 
The number of 0–24 year olds hospitalised between 2011 and 2015 with any diagnosis of epilepsy or status 
epilepticus is presented together with the total number of hospitalisations with epilepsy or status epilepticus as a 
primary or any diagnosis. Most hospitalisations of 0–24 year olds with epilepsy or status epilepticus had this 
condition as the primary diagnosis (Table 31).There has been a small increase in hospitalisation rates for 
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epilepsy or status epilepticus since 2000 with a drop in 2015 (Figure 44). Hospitalisation rates were highest for 
0–4 year olds (Figure 45). Similar patterns over time were seen in Māori and Pacific ethnic groups while rates 
for European/Other are trending down, and Asian ethnicities are trending up (Figure 46).  
Table 31. Individuals aged 0–24 years hospitalised with epilepsy or status epilepticus using primary diagnosis 
compared to all cases, New Zealand 2011–2015 
Age group Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Epilepsy or status epilepticus 
Hospitalisation 
0–24 years 4,336 7,440 9,876 1.33 
0–14 years 2,542 4,809 6,237 1.30 
15–24 years 1,884 2,631 3,639 1.38 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations where epilepsy or status epilepticus was in any of 
the first 15 diagnoses; The sum of the age groups may total to more than the 0– 24 year old total 

































































































s Epilepsy or status epilepticus 0–24 years
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with epilepsy or status epilepticus in any of the first 15 diagnoses 
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Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with epilepsy or status epilepticus in any of the first 15 diagnoses 









































































































Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. Rate per 100,000 age-
specific population; ‘All cases’ corresponds to hospitalisations with epilepsy or status epilepticus listed in any of the first 15 
diagnoses 
Demographic distribution 
Table 32 presents the demographic distribution of individuals hospitalised with epilepsy or status epilepticus in 
New Zealand between 2011 and 2015. The prevalence of epilepsy or status epilepticus was significantly higher 
among individuals residing in areas with high deprivation scores (NZDep2013 deciles 9–10). Compared to 15–
24 year olds, the prevalence was significantly higher among 0–4 year olds and significantly lower among 5–14 
year olds. The prevalence in Māori and Pacific 0–24 year olds was significantly higher than in European/Other 




Table 32. Individuals aged 0–24 years hospitalised with epilepsy or status epilepticus, by demographic factor, 




Rate per 100,000 
population 
Rate ratio 95% CI 
Epilepsy or status epilepticus* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 578 40.73 1.00   
Deciles 3–4 711 53.17 1.31 1.17–1.46 
Deciles 5–6 757 52.51 1.29 1.16–1.44 
Deciles 7–8 1,062 65.37 1.61 1.45–1.78 
Deciles 9–10 1,621 87.24 2.14 1.95–2.36 
Prioritised ethnicity 
Māori 1,230 68.19 1.23 1.14–1.31 
Pacific 491 69.29 1.25 1.13–1.37 
Asian/Indian 289 30.15 0.54 0.48–0.61 
MELAA 70 69.41 1.25 0.98–1.58 
European/Other 2,286 55.64 1.00   
Gender 
Female 2,060 54.87 1.00   
Male 2,276 57.97 1.06 1.00–1.12 
Age group (years) 
0–4 1,195 76.62 1.28 1.19–1.37 
5–14 1,466 49.13 0.82 0.76–0.88 
15–24 1,884 60.06 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Epilepsy or status 
epilepticus in any of the first 15 diagnoses; Rate per 100,000 age-specific population; Rate ratios are unadjusted; Ethnicity is 
level 1 prioritised; Decile is NZDep2013 
Regional distribution 
Table 33 presents the number of individuals resident in each district health board area that had an epilepsy or 
status epilepticus diagnosis between 2011 and 2015. It also presents the number of hospital discharges in which 
epilepsy or status epilepticus was documented as the primary diagnosis or any diagnosis.  
The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and result in less undercounting than would occur if only the primary diagnosis is 
included in discharge data. For epilepsy or status epilepticus the All:Primary diagnosis ratio was higher than the 
national ratio in Northland, Bay of Plenty, Waikato, Taiarawhiti, MidCentral, Nelson Marlborough and 
Canterbury DHBs and lower in Auckland, Counties Manukau, Lakes, Taranaki, Whanganui, Hutt Valley, 
Capital & Coast, Wairarapa, and Southland DHBs. Ratios were similar to the national ratio in the remaining 
district health boards. The pattern of hospitalisations in the Waitemata, Hawke’s Bay, South Canterbury, 




Table 33. Hospitalisations for epilepsy or status epilepticus in 0–24 year olds, by district health board, 
New Zealand 2011–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Epilepsy or status epilepticus in 0–24 year olds 
Northland 192 351 486 1.38 
Waitemata 527 932 1,221 1.31 
Auckland 388 621 789 1.27 
Counties Manukau 616 1,057 1,341 1.27 
Waikato 469 635 877 1.38 
Bay of Plenty 248 359 515 1.43 
Lakes 126 225 286 1.27 
Tairawhiti 48 81 112 1.38 
Taranaki 108 167 212 1.27 
Hawke's Bay 192 394 518 1.31 
MidCentral 184 269 381 1.42 
Whanganui 100 157 198 1.26 
Hutt Valley 106 214 274 1.28 
Capital & Coast 250 465 576 1.24 
Wairarapa 46 80 102 1.28 
Nelson Marlborough 94 147 212 1.44 
South Canterbury 43 51 69 1.35 
Canterbury 427 645 935 1.45 
West Coast 29 37 49 1.32 
Southern 275 505 662 1.31 
New Zealand 4,336 7,440 9,876 1.33 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with epilepsy or status epilepticus listed in any of the first 15 diagnoses; Note that individuals may appear in 
multiple DHBs 
Evidence for good practice 
Possibilities for prevention 
Epilepsy in children is generally not preventable. Interventions to prevent traumatic brain injuries could reduce 
the number of children with epilepsy due to brain injury but this would have only a very small impact on the 
total number of children with epilepsy. 
Evidence-based health care for children and young people with epilepsy 
All children suspected of having epilepsy should be seen by a specialist paediatrician with expertise in epilepsy 
and children diagnosed with epilepsy need on-going regular specialist care.12 Drug therapy is generally 
recommended after a person has had a second epileptic seizure and around two thirds of people with epilepsy 
achieve satisfactory control of their epilepsy with anti-epileptic drugs.12 The use of sodium valproate is 
contraindicated in young women of childbearing age because it poses risks to unborn children (fetuses).13 These 
include increased risks of congenital anomalies, developmental delay and autism.13 
When seizures are not controlled by anti-epileptic drugs other treatments that may be effective include the 
ketogenic diet, vagus nerve stimulation and brain surgery to remove the area of the brain causing the seizures.12 
Most childhood seizures last for less than five minutes. Prolonged or recurrent seizures (without a return to 
normal function between seizures) lasting 30 minutes or more constitute status epilepticus, a potentially fatal 
medical emergency requiring prompt treatment (usually in hospital) to prevent brain damage.3 
Children and families affected by epilepsy need to be given, and have access to, high quality information about 
epilepsy and its management and they should be able to contact a named member of the healthcare team when 




These national and international guidelines, systematic reviews, other publications and websites relevant to the 
management of epilepsy are provided for further reading. 
International guidelines 
• Sauro KM, Wiebe S, Dunkley C, et al. 2016. The current state of epilepsy guidelines: A systematic review. 
Epilepsia, 57(1), 13-23. http://dx.doi.org/10.1111/epi.13273  
• The International League Against Epilepsy. 2015. Guidelines and reports 
http://www.ilae.org/visitors/centre/guidelines.cfm accessed, July 2016 
• Scottish Intercollegiate Guidelines Network (SIGN). 2015. Diagnosis and management of epilepsy in 
adults. Edinburgh: SIGN. http://www.sign.ac.uk/pdf/SIGN143.pdf  
• Huff JS, Melnick ER, Tomaszewski CA, et al. 2014. Clinical Policy: Critical issues in the evaluation and 
management of adult patients presenting to the emergency department with seizures. Annals of Emergency 
Medicine, 63(4), 437-47.e15. http://www.annemergmed.com/article/S0196-0644(14)00080-8/pdf  
• National Institute for Health and Clinical Excellence. 2012. The epilepsies: the diagnosis and management 
of the epilepsies in adults and children in primary and secondary care (Clinical guideline no. 137). London: 
National Institute for Health and Clinical Excellence. https://www.nice.org.uk/guidance/cg137  
• National Clinical Guideline Centre. 2012. The epilepsies: The diagnosis and management of the epilepsies 
in adults and children in primary and secondary care. London: National Clinical Guideline Centre. 
https://www.nice.org.uk/guidance/cg137/evidence/full-guideline-6664855034  (This is the full guideline 
with details of the evidence.) The appendices to the guideline, including a 2014 evidence update, can be 
found here: https://www.nice.org.uk/guidance/cg137/evidence accessed, July 2016 
• American Epilepsy Society. Guidelines https://www.aesnet.org/clinical_resources/guidelines accessed, July 
2016 
• American Academy of Neurology. Practice guidelines Epilepsy. 
https://www.aan.com/Guidelines/home/ByTopic?topicId=23 accessed, July 2016 
Evidence-Based Medicine Reviews 
• The Cochrane Library  has many reviews relating to epilepsy management, mostly concerned with drug 
treatment: http://www.cochranelibrary.com/topic/Neurology/Epilepsy/?per-page=100&stage=review  
• Lewis SA, Noyes J, Hastings RP. 2015. Systematic review of epilepsy self-management interventions 
integrated with a synthesis of children and young people's views and experiences. Journal of Advanced 
Nursing, 71(3), 478-97. http://dx.doi.org/10.1111/jan.12511  
• Fleeman N, Bradley Peter M, Lindsay B. 2015. Care delivery and self management strategies for children 
with epilepsy. Cochrane Database of Systematic Reviews, 
http://dx.doi.org/10.1002/14651858.CD006245.pub3  
• Geerlings RPJ, Aldenkamp AP, de With PHN, et al. 2015. Transition to adult medical care for adolescents 
with epilepsy. Epilepsy & Behavior, 44, 127-35. 
Other relevant publications 
• Keenan N, Sadlier LG. 2015. Paediatric EEG provision in New Zealand: a survey of practice. New Zealand 
Medical Journal, 128(1411), 43-50. http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-
2019/2015/vol-128-no-1411–27-mar-2015/6479  
• Special Issue: Transition of Epilepsy Care from Children to Adults. Epilepsia, 55 (s3), 54–55, August 2014. 
http://onlinelibrary.wiley.com/doi/10.1111/epi.2014.55.issue-s3/issuetoc  
• Ridsdale L, McCrone P, Morgan M, et al. 2013. Can an epilepsy nurse specialist-led self-management 
intervention reduce attendance at emergency departments and promote well-being for people with severe 
epilepsy? A non-randomised trial with a nested qualitative phase. Health Services and Delivery Research, 
1(9). http://www.journalslibrary.nihr.ac.uk/__data/assets/pdf_file/0011/87086/FullReport-hsdr01090.pdf  
Websites 
• Epilepsy NZ. http://epilepsy.org.nz/ 
• Epilepsy Australia. http://www.epilepsyAustralia.net/  
• Epilepsy Society. https://www.epilepsysociety.org.uk/  
• American Epilepsy Society. https://www.aesnet.org/  
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• Epilepsy Foundation. http://www.epilepsy.com/  
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CHRONIC LOWER RESPIRATORY DISEASES 
Introduction 
Chronic lower respiratory diseases, including asthma, chronic suppurative lung disease and bronchiectasis, 
affect the airways and other structures of the lung causing symptoms including: difficulty breathing, chronic 
cough, tiredness and sputum production.1,2 There is a high degree of inequality across the socioeconomic 
spectrum and between ethnic groups in rates of respiratory disease.3 
Chronic lower respiratory diseases are a component of the health status of individuals and also reflect the 
environments within which children live, work, and play. Common risk factors include poverty, poorly heated 
homes and household crowding, poor nutrition, frequent or severe lower respiratory infections during childhood, 
exposure to tobacco smoke and environmental air pollution.1,2 Bronchiectasis is a chronic lung disease that 
causes a decline in lung function and is associated with repeated acute lower respiratory infections especially 
during the first year of life.4,5 Household crowding is associated with an increased risk of hospitalisation with 
severe infections with respiratory syncytial virus (RSV) which is the most common cause of lower respiratory 
tract infections in children worldwide.6,7 The effects of air pollution may begin before birth increasing the 
susceptibility of the unborn child to respiratory and other diseases. Children who develop chronic respiratory 
disease are also more likely than other children to experience adverse effects of air pollution.8  
The following section reviews the community prevalence of asthma using information from the New Zealand 
Health Survey. Chronic lower respiratory diseases are reviewed using information from the National Minimum 
Dataset and the National Mortality Collection. Detailed information about hospitalisations for individual 
conditions is available in the 2015 NZCYES reports at www.otago.ac.nz/nzcyes. The section concludes with a 
brief overview of evidence for good practice for these conditions.  
Data sources and methods 
Indicators  
 
Prevalence of asthma (medicated) 
Rates of chronic lower respiratory diseases among 0–24 year olds 
Definition  
Prevalence of asthma 
Asthma diagnosed by doctor and using inhalers, medicine, tablets, pills or other medication. Child respondents (aged 2–14 
years) are defined as having asthma if the child’s parents or caregivers had ever been told by a doctor that the child has 
asthma and if they now take treatments for asthma (inhalers, medicine, tablets or pills).a Adult respondents (aged 15+ years) 
are defined as having asthma if they had ever been told by a doctor that they have asthma and if they were taking treatments 
for asthma (inhalers, medicine, tablets or pills, or any other treatments). Medication can be taken daily to prevent symptoms, 
or only when needed to relieve symptoms.a 
Rates 
Hospitalisations of 0–24 year olds with a chronic lower respiratory disease per 1,000 population 
Data sources 
Prevalence of asthma (medicated) 
New Zealand Health Survey (2006/07–2014/15, See Appendix 3 
Rates of chronic lower respiratory diseases among 0–24 year olds 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
Prevalence of asthma (medicated): A total of 13,497 adults (15 years and over) and 4,754 children (0–14 year olds) participated 
in the NZ Health Survey 2014/15 during the period 1 July 2014 to 30 June 2015. The coverage rates were 59 percent for adults 
and 69 percent for children.b The NZ Health Survey utilised adjusted rate ratios to account for the potential influence of other 
demographic factors when undertaking demographic comparisons. Gender comparisons are adjusted for age, ethnic 
comparisons are adjusted for age and gender, and deprivation comparisons are adjusted for age, sex and ethnicity.b 
Rates of chronic lower respiratory diseases: A chronic lower respiratory disease was the primary diagnosis or was documented 
as one of the first 15 diagnoses. Chronic lower respiratory diseases comprises asthma (and wheeze), bronchitis, bronchiectasis, 
emphysema and other lower respiratory. Codes used for identifying cases are documented in Appendix 5. 
References 
a. Ministry of Health. 2015. Indicator Interpretation Guide 2014/15: New Zealand Health Survey. Wellington: Ministry of Health. 
b. Ministry of Health. 2015. Methodology Report 2014/15: New Zealand Health Survey. Wellington: Ministry of Health. 
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National trends and distribution 
There was a total of 32 deaths of 0–24 year olds where a chronic lower respiratory disease was the underlying 
cause of death in New Zealand between 2009 and 2013, as documented within the National Mortality 
Collection. The majority of these deaths (26) were due to asthma (including status asthmaticus and wheeze). 
Over the five years of the NZHS 2006/07 to 2014/15, from 14% to 15% of 2–14 year olds and 9% to 12% of 
15–24 year olds were reported to be using medication for asthma diagnosed by a doctor. Prevalence has been 
stable over time with some variation from survey year to survey year (Figure 47).  
In the 2014/15 NZHS year the prevalence of asthma (medicated) was highest among 5–9 year olds and the 
prevalence rate for 15–24 year olds was significantly lower than that for 5–9 and 10–14 year olds (Figure 48). 
Among 2–14 year olds, prevalence was significantly higher for Māori compared with other ethnic groups. There 
was no significant difference in prevalence by NZDep2013 score of home address, nor by gender (Figure 48; 
Table 34).  
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prevalence (%)  
Adjusted rate ratio 95% CI 
Asthma (medicated) in 2–14 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 13.09 1.00   
Deciles 3–4 11.84 …   
Deciles 5–6 17.54 …   
Deciles 7–8 16.66 …   
Deciles 9–10 16.42 1.39 0.96–2.02 
Ethnicity (total response) 
Māori (vs non-Māori) 18.63 1.35 1.14–1.60 
Pacific (vs non-Pacific) 15.38 1.03 0.77–1.36 
Asian (vs non-Asian) 14.09 0.91 0.66–1.26 
European/Other 14.63 …   
Gender 
Female 13.58 1.00   
Male 16.52 1.22 0.99–1.50 
Source: New Zealand Health Survey 
The number of 0–24 year olds hospitalised with chronic lower respiratory diseases during 2011 to 2015 is 
presented in Table 35. It also presents the number of hospital discharges in which chronic lower respiratory 
diseases were documented as the primary diagnosis or as any diagnosis.  
The rate of hospitalisations where a chronic lower respiratory disease was the primary diagnosis has increased 
since 2000 (Figure 49). 
Table 35. Individuals aged 0–24 years hospitalised with chronic lower respiratory diseases using primary diagnosis 
compared to all cases, New Zealand 2011–2015 
  Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Chronic lower respiratory diseases 
Hospitalisation 
0–24 years 29,184 37,909 48,433 1.28 
0–14 years 25,094 33,314 41,913 1.26 
15–24 years 4,236 4,595 6,520 1.42 
Chronic lower respiratory diseases in 0–24 years year olds 
Asthma and wheeze 28,195 35,982 45,274 1.26 
Bronchiectasis 729 1,362 2,516 1.85 
Bronchitis 341 197 384 1.95 
Emphysema 124 24 137 5.71 
Other  219 344 525 1.53 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with chronic lower respiratory diseases listed in 
any of the first 15 diagnoses; The sum of the age groups may total to more than the 0–24 year old total 
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s Chronic lower respiratory diseases 0–24 years
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with chronic lower respiratory diseases listed in any of the first 15 diagnoses 
Demographic distribution 
Table 36 presents the demographic distribution of individuals with chronic lower respiratory diseases in 
New Zealand between 2011 and 2015. Chronic lower respiratory diseases were significantly higher among 
males, and among 0–4 and 5–14 year olds (compared to 15–24 year olds). There was a strong social gradient 
among these individuals, with statistically significant increases in prevalence in each deprivation quintile 
(NZDep deciles 3–4 to 9–10) compared with those living in least deprived areas (deciles 1–2). The rate of 
chronic lower respiratory diseases was significantly lower for European/Other ethnicities than for the other 
ethnic groups.  
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Table 36. Individuals aged 0–24 years hospitalised with chronic lower respiratory diseases, by demographic factor, 




Rate per 1,000 
population 
Rate ratio 95% CI 
Chronic lower respiratory diseases* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 3,458 2.44 1.00   
Deciles 3–4 4,005 3.00 1.23 1.17–1.29 
Deciles 5–6 4,895 3.40 1.39 1.33–1.46 
Deciles 7–8 7,173 4.42 1.81 1.74–1.89 
Deciles 9–10 11,351 6.11 2.51 2.41–2.60 
Prioritised ethnicity 
Māori 9,815 5.44 2.06 2.00–2.12 
Pacific 5,300 7.48 2.83 2.74–2.92 
Asian/Indian 2,825 2.95 1.11 1.07–1.16 
MELAA 490 4.86 1.84 1.68–2.01 
European/Other 10,860 2.64 1.00   
Gender 
Female 12,516 3.33 1.00   
Male 16,670 4.25 1.27 1.24–1.30 
Age group (years) 
0–4 18,079 11.59 8.58 8.30–8.88 
5–14 8,040 2.69 2.00 1.92–2.07 
15–24 4,236 1.35 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Chronic lower respiratory 
diseases in any of the first 15 diagnoses; Rate per 100,000 age-specific population; Rate ratios are unadjusted; Ethnicity is Level 
1 prioritised; Decile is NZDep2013 
Since 2000, both primary diagnosis and all cases hospitalisations for chronic lower respiratory diseases have 
increased considerably for 0–4 year olds (Figure 50). Over the same period, the primary diagnosis 
hospitalisation rate gradually increased for Pacific, Māori, and Asian/Indian ethnic groups, and remained 
relatively constant for European/Other (Figure 51). 
































































































Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with chronic lower respiratory diseases listed in any of the first 15 diagnoses 
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Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with chronic lower respiratory diseases listed in any of the first 15 diagnoses 
Regional distribution 
Figure 52 shows the prevalence of asthma in each DHB, as reported in the NZ Health Survey. Prevalence of 
asthma in 2–14 year olds was slightly but significantly higher than the national prevalence in Northland, 
Tairawhiti and Whanganui DHBs, and signicantly lower than the national prevalence in Auckland DHB.  
Figure 52. Asthma (medicated) in 2–14 year olds, by district health board, NZ Health Survey 2011–2014 
 
Source: NZ Health Survey 
Table 37 presents the number of individuals resident in each district health board that had a chronic lower 
respiratory disease diagnosis during 2011 to 2015. It also presents the number of hospital discharges in which a 
chronic lower respiratory disease was documented as the primary diagnosis or any diagnosis.  
The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and avoids the undercounting that would occur if only primary diagnoses are included 
in discharge data. For chronic lower respiratory diseases the All:Primary diagnosis ratio was higher than the 
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Whanganui, Hutt Valley, Nelson Marlborough, South Canterbury, and West Coast DHBs. Ratios were lower 
than the national ratio in the remaining district health boards (Table 37).  
Table 37. Hospitalisations for chronic lower respiratory diseases in 0–24 year olds, by district health board, New 
Zealand 2011–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Chronic lower respiratory diseases in 0–24 year olds 
Northland 1,218 1,564 2,068 1.32 
Waitemata 3,561 4,492 5,640 1.26 
Auckland 3,815 5,465 6,272 1.15 
Counties Manukau 4,477 5,282 7,061 1.34 
Waikato 2,592 3,190 4,065 1.27 
Bay of Plenty 1,777 2,012 2,860 1.42 
Lakes 775 1,066 1,323 1.24 
Tairawhiti 426 497 741 1.49 
Taranaki 675 878 1,078 1.23 
Hawke's Bay 887 1,002 1,443 1.44 
MidCentral 960 1,085 1,497 1.38 
Whanganui 471 543 780 1.44 
Hutt Valley 1,168 1,409 1,938 1.38 
Capital & Coast 1,764 2,347 2,738 1.17 
Wairarapa 230 298 369 1.24 
Nelson Marlborough 539 546 889 1.63 
South Canterbury 157 154 214 1.39 
Canterbury 2,698 3,721 4,519 1.21 
West Coast 139 144 206 1.43 
Southern 1,488 2,038 2,503 1.23 
New Zealand 29,184 37,909 48,433 1.28 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with chronic lower respiratory diseases listed in 
any of the first 15 diagnoses; Sum of DHBs may equal more than NZ total due to some individuals changing DHB of domicile 
during the period 
Evidence for good practice  
Possibilities for prevention 
Childhood respiratory disease can be prevented or ameliorated by several basic measures including: improving 
childhood nutrition, promoting breastfeeding, complete and timely immunisation, improving living conditions to 
prevent crowding, avoiding tobacco smoke exposure and reducing indoor air pollution. Avoiding smoking 
during pregnancy and avoidance of passive smoke exposure after birth can reduce asthma severity in children.8,9 
The emphasis needs to be on smoking cessation, as exposure to environmental tobacco smoke remains high 
even when smoking parents maintain smoke-free homes and cars.10 Legislation and political action on clean air 
makes a difference and can significantly reduce hospitalisations for respiratory disease.8 
Interventions to effectively reduce disparities in respiratory health are essential and will require change from 
individuals, health care providers and health policy leaders to create the broad societal change needed to address 
the wider determinants of health.11 Addressing social determinants of health and improving health service 
delivery are both important.5 Health service providers need appropriate clinical skills to understand patients’ 
beliefs, attitudes, experiences, and behaviours and demonstrate cross-cultural communication and competence in 
interactions with patients.11 Measures to prevent premature birth and to reduce acute lower respiratory infections 
are important equity issues to reduce bronchiectasis in indigenous children.4,5 
An effective approach to addressing respiratory disease includes ready access to highly skilled health care, early 
(rather than late) intervention, close links between the various components of the health sector and high levels of 
health literacy.2 Asthma severity and hospitalisation rates can be reduced through better treatment, improved 
access to primary care and educational interventions for parents, children and healthcare providers.12 Observed 
disparities in the dispensing of preventive asthma treatment to Māori and Pacific children need to be 
addressed.13,14 Technology such as mobile phones, combined with a culturally sensitive approach, can be used to 
facilitate adherence to treatment.15 It may be appropriate to trial interventions such as patient education 
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delivered by health-care professionals and long-term follow-up after acute care visits provided that an 
appropriate plan is in place to monitor effectiveness.11  
Vaccination against non-typeable Haemophilus influenza can help to prevent infections for children who have 
chronic suppurative lung diseases.5 Long term treatment with weekly azithromycin can decrease pulmonary 
exacerbations in indigenous children with chronic suppurative lung disease but is also associated with carriage 
of azithromycin-resistant bacteria.16 Vaccination with palivizumab is safe and effective for preventing RSV 
hospitalisation in infants at high risk of severe infection, but it is expensive and requires monthly intravenous 
injection.7 Randomised controlled trials are being undertaken in Auckland and Christchurch to study the 
efficacy and safety of maternal RSV vaccination in the third-trimester of pregnancy and particularly whether 
this can prevent RSV infection in their infants.17  
Evidence-based health care for children and young people with chronic lower 
respiratory diseases  
Timely diagnosis and effective treatment are important components of secondary and tertiary prevention of 
chronic lower respiratory disease, including reducing the number and severity of exacerbations for children with 
the conditions and in particular reducing the need for hospitalisation.5,8,18 These national and international 
guidelines, systematic reviews, other publications and websites relevant to the management of chronic lower 
respiratory diseases are suggestions for further reading. 
New Zealand guidelines 
• Asthma and Respiratory Foundation of New Zealand. 2015. Te Hā Ora (The Breath of Life): National 
Respiratory Strategy. Wellington: The Asthma Foundation. https://www.asthmafoundation.org.nz/about-
us/advocacy/national-respiratory-strategy  
• Chang AB, et al. 2015. Chronic suppurative lung disease and bronchiectasis in children and adults in 
Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. 
http://dx.doi.org/10.5694/mja14.00287  
• Edwards E. 2008. Starship Children's Health clinical guideline: Cough - Investigation of chronic cough 
&/or confirmed bronchiectasis. http://www.adhb.govt.nz/starshipclinicalguidelines/_Documents/Cough-
Investigation of Chronic.pdf  
International guidelines 
• Global Initiative for Asthma. 2016. Global Strategy for Asthma Management and Prevention. 
http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/  
• British Thoracic Society, Scottish Intercollegiate Guidelines Network. 2014. British guideline on the 
management of asthma: A national clinical guideline. London, Edinburgh: British Thoracic Society, 
Scottish Intercollegiate Guidelines Network https://www.brit-thoracic.org.uk/document-library/clinical-
information/asthma/btssign-asthma-guideline-2014/  
• Chung KF, Wenzel SE, Brozek JL, et al. 2014. International ERS/ATS guidelines on definition, evaluation 
and treatment of severe asthma. European Respiratory Journal, 43(2), 343-73. 
http://dx.doi.org/10.1183/09031936.00202013  
• Lougheed MD, Lemiere C, Ducharme FM, et al. 2012. Canadian Thoracic Society 2012 guideline update: 
diagnosis and management of asthma in preschoolers, children and adults. Canadian Respiratory Journal, 
19(2), 127-64. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373283/  
• Sveum R, Bergstrom J, Brottman G, et al. 2012. Diagnosis and Management of Asthma. Bloomington, MN: 
Institute for Clinical Systems Improvement. https://www.icsi.org/_asset/rsjvnd/Asthma.pdf  
• M C Pasteur, et al. 2010. British Thoracic Society guideline for non-CF bronchiectasis. Thorax, 
65(Supplement 1), i1-i58 http://dx.doi.org/10.1136/thx.2010.136119  
• Hill AT, et al. 2011. Primary care summary of the British Thoracic Society Guideline on the management 
of non-cystic fibrosis bronchiectasis. Primary Care Respiratory Journal, 20, 135. 
http://dx.doi.org/10.4104/pcrj.2011.00007  
Evidence-based medicine reviews 
• Anderson LM, et al. 2015. Community coalition-driven interventions to reduce health disparities among 
racial and ethnic minority populations. Cochrane Database of Systematic Reviews, (6). 
http://dx.doi.org/10.1002/14651858.CD009905.pub2  
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• Okelo SO, Butz AM, Sharma R, et al. 2013. Interventions to modify health care provider adherence to 
asthma guidelines. Comparative effectiveness review No. 95. (Prepared by Johns Hopkins University 
Evidence-based Practice Center under Contract No. 290-2007-10061-I.) AHRQ Publication No. 13-
EHC022-EF. Rockville, MD: Agency for Healthcare Research and Quality. 
http://www.ncbi.nlm.nih.gov/books/NBK144097/  
• Chang AB, et al. 2016. Children with chronic wet or productive cough—Treatment and investigations: A 
systematic review. Chest, 149(1), 120–42. http://dx.doi.org/10.1378/chest.15-2065  
• Lee AL, et al. 2015. Airway clearance techniques for bronchiectasis. Cochrane Database of Systematic 
Reviews, (11). http://dx.doi.org/10.1002/14651858.CD008351.pub3  
• Welsh Emma J, et al. 2015. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. 
Cochrane Database of Systematic Reviews, http://dx.doi.org/10.1002/14651858.CD010337.pub2 
• Frazer K, et al. 2016. Legislative smoking bans for reducing harms from secondhand smoke exposure, 
smoking prevalence and tobacco consumption. Cochrane Database of Systematic Reviews, (2). 
http://dx.doi.org/10.1002/14651858.CD005992.pub3  
Other relevant publications 
• Jones B, Ingham TR, Reid S, et al. 2015. He māramatanga huangō: Asthma health literacy for Māori 
children in New Zealand. Wellington: University of Otago. 
https://www.asthmafoundation.org.nz/research/he-maramatanga-huango-asthma-health-literacy-for-Māori-
children-in-new-zealand  
• Mogasale V, Vos T. 2013. Cost-effectiveness of asthma clinic approach in the management of chronic 
asthma in Australia. Australia and New Zealand Journal of Public Health, 37(3), 205-10 
http://dx.doi.org/10.1111/1753-6405.12060  
Websites 
• The Asthma Foundation http://asthmafoundation.org.nz/  
• PHARMAC. 2010. Space to breathe. http://www.spacetobreathe.co.nz/  
• Menzies School of Health Research Centre for Research Excellence in respiratory health 
http://www.menzies.edu.au/page/Research/Centres_for_Research_Excellence/Centre_for_Research_Excell
ence_CRE_in_Respiratory_Health/  
• Ministry of Health. 2015. Bronchiectasis. http://www.health.govt.nz/your-health/conditions-and-
treatments/diseases-and-illnesses/bronchiectasis  
• Kidshealth. 2014. Bronchiectasis. http://www.kidshealth.org.nz/bronchiectasis-bx  
• Health Navigator New Zealand. 2015. Bronchiectasis. http://www.healthnavigator.org.nz/health-
topics/bronchiectasis/  
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INFLAMMATORY BOWEL DISEASE (IBD) 
Introduction 
The two main forms of inflammatory bowel disease are ulcerative colitis (UC) and Crohn’s Disease (CD), 
which both involve inflammation of the intestines with symptoms including diarrhoea (which may be bloody 
particularly in UC), abdominal pain, tiredness and weight loss.1,2 IBD can develop at any age, with peak 
incidence between the ages of 15 and 25 years.2 Over recent decades there has been an increase in IBD around 
the world, and the disorders are occurring more commonly in younger children.3,4 These conditions affect 
multiple body systems including liver, joints, bone, skin and eyes.4 Some children present with joint pain or 
rashes before bowel disease is evident.3 Important comorbidities include impaired growth and pubertal 
development, anaemia, osteoporosis and increased risk of developing colorectal cancer.2 Almost all children 
with CD and at least half of children with UC have poor weight gain or weight loss prior to diagnosis.3 
Treatments for IBD can suppress the immune system making children and young people more susceptible to 
vaccine-preventable diseases and increasing risk of some cancers.4 IBD can disrupt normal activities including 
education, reduce quality of life and affect social and psychological wellbeing.2  
The following section reviews IBD in children and young people using information from the National Minimum 
Dataset. The sections conclude with an overview of evidence for good practice for these conditions. 
Data sources and methods 
Indicators  
 Rates of inflammatory bowel disease (IBD) among 0–24 year olds 
Definition  
Hospitalisations of 0–24 year olds with inflammatory bowel disease (IBD) per 100,000 population 
Data sources 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
This section presents analyses where the condition was the primary diagnosis or was documented within any of the first 15 
diagnoses (all cases). The rationale for presenting all cases is to highlight the full spectrum of health issues experienced by 
those with this condition, and their consequent requirement for acute health services. Analyses are per hospital discharge 
event therefore events are only included if the condition is documented within either the primary diagnosis or within any of 
the first 15 diagnoses. 
Codes used for identifying cases are documented in Appendix 5. 
National trends and distribution 
From 2000 to 2013 there were fewer than five deaths of 0–24 year olds with inflammatory bowel disease (IBD) 
as an underlying cause, as documented within the National Mortality Collection.  
The number of 0–24 year olds hospitalised between 2011 and 2015 with any diagnosis of IBD is presented 
together with the total number of hospitalisations with Crohn disease or ulcerative colitis as the primary 
diagnosis or within any of the first 15 diagnoses (Table 38).  
Since 2000 hospitalisation rates for IBD have risen, particularly for 15–24 year olds. Hospitalisation rates were 
consistently higher for 15–24 year olds compared with 0–14 year olds (Figure 53). Hospitalisation rates were 
consistently highest for European/Other 0–24 year olds and lowest for Pacific and Māori 0–24 year olds. The 
rise in rates over time was particularly marked for European/Other and Asian/Indian 0–24 year olds (Figure 54).  
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Table 38. 0–24 year olds hospitalised with inflammatory bowel disease, New Zealand 2011–2015 
  Unique individuals (n) 
Hospitalisations (n) 
Ratio All : Primary 
Primary diagnosis All cases 
Inflammatory bowel disease 
Hospitalisation 
0–24 years 1,447 5,168 5,999 1.16 
0–14 years 312 1,092 1,277 1.17 
15–24 years 1,205 4,076 4,722 1.16 
Inflammatory bowel disease in 0–24 year olds 
Crohn disease 1,050 4,145 4,842 1.17 
Ulcerative colitis 471 1,023 1,176 1.15 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations where inflammatory bowel disease was listed in 
any of the first 15 diagnoses; The sum of the age groups and of the diagnoses may total to more than the 0–24 year old total 





































































































Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations where inflammatory bowel disease was listed in any of the first 15 diagnoses 
Demographic distribution 
Table 39 presents the demographic distribution of individuals with inflammatory bowel disease in New Zealand 
between 2011 and 2015. Inflammatory bowel disease prevalence was significantly lower among individuals 
residing in areas with higher deprivation scores (NZDep2013 deciles 5–10) compared with areas with low 
deprivation scores (NZDep2013 deciles 1–2). Most individuals with IBD were in the 15–24 age group with very 
few aged under five years. By far the majority of 0–24 year olds with IBD were of European/Other ethnicity.  
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Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with inflammatory bowel disease listed in any of the first 15 diagnoses; Rates for Pacific are suppressed (prior to 
2014) due to small numbers 





Rate per 100,000 
population 
Rate ratio 95% CI 
Inflammatory bowel disease* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 374 26.35 1.00   
Deciles 3–4 381 28.49 1.08 0.94–1.25 
Deciles 5–6 302 20.95 0.79 0.68–0.93 
Deciles 7–8 358 22.04 0.84 0.72–0.97 
Deciles 9–10 263 14.15 0.54 0.46–0.63 
Prioritised ethnicity 
Māori 71 3.94 0.14 0.11–0.17 
Pacific 21 2.96 0.10 0.07–0.16 
Asian/Indian 124 12.94 0.45 0.37–0.54 
MELAA 34 33.71 1.16 0.83–1.63 
European/Other 1,193 29.04 1.00   
Gender 
Female 674 17.95 1.00   
Male 773 19.69 1.10 0.99–1.22 
Age group (years) 
0–4 35 2.24 0.06 0.04–0.08 
5–14 281 9.42 0.25 0.22–0.28 
15–24 1,205 38.41 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Inflammatory bowel 
disease is listed in any of the first 15 diagnoses; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
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Regional distribution 
Table 40 presents the number of individuals resident in each district health board area that had an IBD diagnosis 
between 2011 and 2015. It also presents the number of hospital discharges in which inflammatory bowel disease 
was documented as the primary diagnosis or any diagnosis. The All:Primary diagnosis ratio for inflammatory 
bowel disease was close to one nationally and in all DHBs, indicating that IBD was the primary diagnosis for 
most hospitalisations with these conditions. 
Table 40. Hospitalisations for inflammatory bowel disease in 0–24 year olds, by district health board, New Zealand 
2010–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Inflammatory bowel disease in 0–24 year olds 
Northland 36 158 171 1.08 
Waitemata 250 1,059 1,179 1.11 
Auckland 154 510 561 1.10 
Counties Manukau 124 248 320 1.29 
Waikato 127 567 629 1.11 
Bay of Plenty 60 176 192 1.09 
Lakes 23 43 52 1.21 
Tairawhiti 10 27 28 1.04 
Taranaki 29 43 61 1.42 
Hawke's Bay 47 89 115 1.29 
MidCentral 53 296 315 1.06 
Whanganui 12 41 43 1.05 
Hutt Valley 53 168 209 1.24 
Capital & Coast 105 373 436 1.17 
Wairarapa 16 100 116 1.16 
Nelson Marlborough 49 172 206 1.20 
South Canterbury 21 50 59 1.18 
Canterbury 204 583 725 1.24 
West Coast 11 26 30 1.15 
Southern 136 422 534 1.27 
New Zealand 1,447 5,168 5,999 1.16 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ means 
inflammatory bowel disease is listed in any of the first 15 diagnoses; Rate ratios are unadjusted; Note that individuals may 
appear in multiple DHBs 
Evidence for good practice 
Possibilities for prevention 
The precise cause of inflammatory bowel disease (IBD) is not clear although genes, bacteria and immune 
system responses in the digestive tract are all important contributing factors.3 Although there is no strategy for 
primary prevention, one of the aims of IBD treatment is to prevent flare‐ups happening once acute inflammation 
has healed.2 
Evidence-based health care for children and young people with inflammatory 
bowel disease  
Treatment of IBD aims to induce remission by healing inflammation and reducing symptoms during a flare‐up, 
or to maintain remission by preventing flare‑ ups occurring. Various drugs can help with both of these aims and 
surgery may be an option for some young people.2 IBD is a systemic condition that affects many body systems, 
and there are risks associated with the various immunosuppressive treatments used. It is important to be 
attentive to all aspects of physical and psychological health of children and young people with IBD, including 
monitoring growth, bone health and vitamin and mineral deficiencies, ensuring vaccinations are up-to-date, 
screening for depression, monitoring eye and skin health, providing dietary recommendations and making 
special considerations for international travel.4 For young people who plan or become pregnant management of 
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IBD poses particular challenges as there is an increased risk of adverse birth outcomes.5,6 These complex 
management requirements mean that children and young people with IBD benefit from engagement with a 
multidisciplinary team with appropriate specialist experience and expertise. Within New Zealand’s dispersed 
geography this can be achieved by a shared care arrangement involving a tertiary level gastroenterologist in 
Auckland or Christchurch, regional paediatrician, tertiary and regional paediatric dieticians, nurses and other 
allied health professionals, and local primary care services. Regional Health Schools can provide continuity of 
education for children with significant or prolonged disruption to their usual schooling.3  
Details of treatment options for people with inflammatory bowel disease, including risks associated with 
treatment, can be found in the guidelines and other evidence-based information sources provided below for 
further reading. 
New Zealand guidelines 
• Day A & Paediatric Gastroenterology Clinical Network. 2014. Management of inflammatory bowel disease 
in children and adolescents in New Zealand: A clinical guideline. Paediatric Society New Zealand & 
National Child and Youth Clinical Networks. 
https://www.starship.org.nz/media/256562/nz_ibd_clinical_guideline_aug_2015.pdf  
International guidelines 
• National Institute for Health and Care Excellence. 2016. Ulcerative colitis pathway. 
https://pathways.nice.org.uk/pathways/ulcerative-colitis  
• National Institute for Health and Care Excellence. 2016. Crohn's disease pathway. 
http://pathways.nice.org.uk/pathways/crohns-disease  
• Nguyen GC, et al. 2016. The Toronto consensus statements for the management of inflammatory bowel 
disease in pregnancy. Gastroenterology, 150(3), 734-57.e1. http://dx.doi.org/10.1053/j.gastro.2015.12.003  
Evidence-based medicine reviews 
• Ariyaratnam J & Subramanian V. 2014. Association between thiopurine use and nonmelanoma skin cancers 
in patients with inflammatory bowel disease: a meta-analysis. American Journal of Gastroenterology, 109, 
163-69 http://dx.doi.org/10.1038/ajg.2013.451  
• Bonovas S, et al. 2016. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel 
disease: A systematic review and meta-analysis of randomized controlled trials. Medicine, 95(2), e2308. 
http://dx.doi.org/10.1097/md.0000000000002308  
• Huang V, et al. 2014. Distance management of inflammatory bowel disease: Systematic review and meta-
analysis. World Journal of Gastroenterology, 20, 829-42 http://dx.doi.org/10.3748/wjg.v20.i3.829  
• Melek J & Sakuraba A. 2014. Efficacy and safety of medical therapy for low bone mineral density in 
patients with inflammatory bowel disease: a meta-analysis and systematic review. Clinical 
Gastroenterology and Hepatology, 12, 32-44.e5 http://dx.doi.org/10.1016/j.cgh.2013.08.024  
• Mozaffari S, et al. 2015. Pregnancy outcomes in women with inflammatory bowel disease following 
exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis. 
Human and Experimental Toxicology, 34(5), 445-59. http://dx.doi.org/10.1177/0960327114550882 
• Toussi S, et al. 2013. Infections in children and adolescents with juvenile idiopathic arthritis and 
inflammatory bowel disease treated with tumor necrosis factor-alpha inhibitors: Systematic review of the 
literature. Clinical Infectious Diseases, 1318-30 http://dx.doi.org/10.1093/cid/cit489  
• Wang Y, et al. 2016. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane 
Database of Systematic Reviews, 4, CD000543. http://dx.doi.org/10.1002/14651858.CD000543.pub4  
• Wang Y, et al. 2016. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. 
Cochrane Database of Systematic Reviews, 5, CD000544. 
http://dx.doi.org/10.1002/14651858.CD000544.pub4  
• Wedlake L, et al. 2014. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic 
review of randomized controlled trials. Inflammatory Bowel Diseases, 20(3), 576-86 
http://dx.doi.org/10.1097/01.MIB.0000437984.92565.31  
• Williams C, et al. 2014. Systematic review with meta-analysis: malignancies with anti-tumour necrosis 
factor-alpha therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 39, 447-
58 http://dx.doi.org/10.1111/apt.12624  
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Websites 
• Ministry of Health. 2015. Inflammatory bowel disease http://www.health.govt.nz/your-health/conditions-
and-treatments/diseases-and-illnesses/inflammatory-bowel-disease  
• Health Navigator New Zealand. 2015. Inflammatory bowel disease video and information about Crohn’s 
disease http://www.healthnavigator.org.nz/videos/i/inflammatory-bowel-disease/ 
http://www.healthnavigator.org.nz/health-a-z/c/crohns-disease/  
• Crohn’s & Colitis New Zealand http://crohnsandcolitis.org.nz/ includes a teenager’s guide to living with 
IBD. 
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Constipation is common in young children, a frequent cause of referral secondary care, and can become chronic 
in more than one-third of those affected. The most common form is idiopathic constipation, where there is no 
anatomical or physiological explanation for the symptoms.1 Children and young people with Down syndrome, 
autism or cerebral palsy are particularly prone to idiopathic constipation and there is also a higher prevalence in 
children and young people in local authority care.1 Severe constipation can be associated with faecal soiling 
which can have a significant emotional impact on children and young people and be stressful for parents and 
carers; prolonged support may be required to address social, psychological and educational consequences.1,2  
The following section reviews severe constipation in children and young people using information from the 
National Minimum Dataset. The sections conclude with an overview of evidence for good practice for 
these  conditions. 
Data sources and methods 
Indicators  
 Rates of constipation among 0–24 year olds 
Definition  
Hospitalisations of 0–24 year olds with constipation per 100,000 population 
Data sources 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
This section presents analyses where the condition was the primary diagnosis or was documented within any of the first 15 
diagnoses (all cases). The rationale for presenting all cases is to highlight the full spectrum of health issues experienced by 
those with this condition, and their consequent requirement for acute health services. Analyses are per hospital discharge 
event therefore events are only included if the condition is documented within either the primary diagnosis or within any of 
the first 15 diagnoses. 
Codes used for identifying cases are documented in Appendix 5. 
National trends and distribution 
The number of 0–24 year olds hospitalised between 2011 and 2015 with any diagnosis of constipation is 
presented together with the total number of hospitalisations with constipation as a primary or any diagnosis. 
Constipation was the primary diagnosis in half of all such hospitalisations for 0–14 year olds and in one-quarter 
for 15–24 year olds (Table 41). 
Hospitalisation rates for constipation rose in all age groups from 2000 to 2014, with a fall in rates for 0–4 year 
olds from 2014 to 2015. The rise in hospitalisation rates was most marked when all cases were included, 
particularly for 15–24 year olds. Hospitalisation rates were consistently highest for 0–4 year olds until 2014 
(Figure 55). Similar patterns over time were seen in all ethnic groups, with rates for European/Other tending to 
have the highest rates and Asian/Indian tending to have the lowest (Figure 56).  
Table 41. 0–24 year olds hospitalised with constipation New Zealand 2011–2015 
Age group Unique individuals (n) 
Hospitalisations (n) 
Ratio All : Primary 
Primary diagnosis All cases 
Constipation 
Hospitalisation 
0–24 years 14,578 7,805 18,723 2.40 
0–14 years 8,541 5,948 11,247 1.89 
15–24 years 6,108 1,857 7,476 4.03 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations where constipation was listed in any of the first 15 
diagnoses; The sum of the age groups may total to more than the 0–24 year old total 
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Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with constipation listed in any of the first 15 diagnoses; Rate per 100,000 age-specific population 
Figure 56. Hospitalisations involving constipation in 0–24 year olds, by ethnicity, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. All cases corresponds to 







































































































Fewer than half of the hospitalisations of 0–24 year olds with constipation had this condition as the primary 
diagnosis (Table 41). Constipation was included within the first 15 diagnoses in hospitalisations for a variety of 
conditions including intestinal and digestive disorders, pregnancy, childbirth and the puerperium, diseases of the 
genitourinary and respiratory systems and injury and poisoning (Table 42). 









95% CI % 
Constipation* in 0–24 year olds 
New Zealand  
Constipation 7,805 1,561 101.62 99.39–103.89 41.7 
Other functional intestinal disorders 22 4 0.29 0.19–0.43 0.1 
Paralytic ileus and intestinal obstruction without 
hernia 
75 15 0.98 0.78–1.22 0.4 
Fissure and fistula of anal and rectal regions 46 9 0.60 0.45–0.80 0.2 
Irritable bowel syndrome 24 5 0.31 0.21–0.46 0.1 
Other intestinal diseases 55 11 0.72 0.55–0.93 0.3 
Total intestinal diseases 8,027 1,605 104.51 102.25–106.82 42.9 
Inflammatory bowel disease 52 10 0.68 0.52–0.89 0.3 
Other diseases of the digestive system 573 115 7.46 6.87–8.10 3.1 
Symptoms and/or abnormal clinical findings NEC 1,916 383 24.94 23.85–26.09 10.2 
Pregnancy, childbirth and the puerperium 1,162 232 15.13 14.28–16.02 6.2 
Diseases of the genitourinary system 971 194 12.64 11.87–13.46 5.2 
Diseases of the respiratory system 909 182 11.83 11.09–12.63 4.9 
Injury and/or poisoning 897 179 11.68 10.94–12.47 4.8 
Other diagnoses 4,216 843 54.89 53.26–56.57 22.5 
Total 18,723 3,745 243.76 240.30–247.27 100.0 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Constipation in any of the 
first 15 diagnoses; NEC = not elsewhere classified 
Demographic distribution 
Table 43 presents the demographic distribution of individuals with constipation in New Zealand between 2011 
and 2015. There was a slight but statistically significant social gradient with increasing prevalence of 
constipation requiring hospitalisation for individuals living at each increasing NZDep2013 quintile, compared 
with individuals living in areas with lower deprivation scores (NZDep2013 deciles 1–2). Prevalence of 
constipation requiring hospitalisation was significantly higher for 0–4 year olds and lower for 5–14 year olds, 
compared to 15–24 year olds. Compared to rates for European/Other 0–24 year olds, Māori and Pacific rates 








Rate per 100,000 
population 
Rate ratio 95% CI 
Constipation* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 2,174 153.19 1.00   
Deciles 3–4 2,220 166.03 1.08 1.02–1.15 
Deciles 5–6 2,588 179.54 1.17 1.11–1.24 
Deciles 7–8 3,420 210.52 1.37 1.30–1.45 
Deciles 9–10 4,537 244.18 1.59 1.51–1.68 
Prioritised ethnicity 
Māori 3,455 191.55 0.96 0.92–1.00 
Pacific 1,447 204.19 1.02 0.96–1.08 
Asian/Indian 1,136 118.51 0.59 0.56–0.63 
MELAA 318 315.32 1.58 1.41–1.76 
European/Other 8,223 200.14 1.00   
Gender 
Female 8,745 232.92 1.00   
Male 5,833 148.56 0.64 0.62–0.66 
Age group (years) 
0–4 3,746 240.17 1.23 1.18–1.28 
5–14 4,926 165.07 0.85 0.82–0.88 
15–24 6,108 194.71 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Constipation in any of the 
first 15 diagnoses; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
Regional distribution 
Table 44 presents the number of individuals resident in each district health board area that had a constipation 
diagnosis between 2011 and 2015. It also presents the number of hospital discharges in which constipation was 
documented as the primary diagnosis or any diagnosis. The All:Primary diagnosis ratio reflects the extent to 
which hospitalisations of 0–24 year olds with chronic conditions occur when this condition is not the primary 
diagnosis. A high ratio may be associated with more thorough documentation and result in less undercounting 
than would occur if only the primary diagnosis is included in discharge data. For constipation the national 
All:Primary diagnosis ratio was greater than two, with similar ratios in all DHBs. The undercount of 
constipation hospitalisations would be two–three fold if only primary diagnoses were included (Table 44). 
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Table 44. Hospitalisations for constipation in 0–24 year olds, by district health board, New Zealand 2010–2014 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All : Primary 
Primary diagnosis All cases 
Constipation in 0–24 year olds 
Northland 627 283 813 2.87 
Waitemata 1,649 886 2,073 2.34 
Auckland 1,544 745 1,859 2.50 
Counties Manukau 1,961 824 2,338 2.84 
Waikato 1,424 934 1,940 2.08 
Bay of Plenty 644 357 796 2.23 
Lakes 461 161 558 3.47 
Tairawhiti 209 168 295 1.76 
Taranaki 275 174 353 2.03 
Hawke's Bay 438 328 598 1.82 
MidCentral 489 259 590 2.28 
Whanganui 191 139 249 1.79 
Hutt Valley 511 288 661 2.30 
Capital & Coast 926 381 1,146 3.01 
Wairarapa 119 59 162 2.75 
Nelson Marlborough 303 208 415 2.00 
South Canterbury 142 71 187 2.63 
Canterbury 1,574 701 2,010 2.87 
West Coast 80 39 98 2.51 
Southern 1,109 778 1,504 1.93 
New Zealand 14,578 7,805 18,723 2.40 
Numerator: National Minimum Dataset, ‘All cases’ corresponds to hospitalisations with constipation listed in any of the first 15 
diagnoses; Note that individuals may appear in multiple DHBs 
Evidence for good practice 
Possibilities for prevention 
The exact cause of idiopathic constipation is not fully understood; contributing factors may include pain, fever, 
dehydration, dietary and fluid intake, psychological issues, toilet training, medicines and family history of 
constipation.1 If simple measures such as increasing fluid intake, increasing fruit and vegetables in the child’s 
diet, encouraging a regular toileting habit and encouraging more exercise are not effective then early assessment 
by a health professional is important.3 
Evidence-based health care for children and young people with constipation 
Conflicting advice and inconsistent practice make treatment of constipation potentially less effective and 
frustrating for children and their families. Consistent messages from the variety of healthcare professionals from 
whom children and young people with idiopathic constipation seek help is important. This will help to reduce 
rates of ED presentation and unplanned hospitalisation for constipation, reduce rates of recurrent constipation 
and/or impaction in children and young people, increase parent or carer satisfaction with information and 
advice, and enable children and young people to satisfactorily manage constipation.1  
The following national and international guidelines, systematic reviews, other publications and websites 
relevant to the prevention and management of constipation are provided for further reading. 
New Zealand guidelines 
• Starship Children's Health. 2012. Starship clinical guidelines: Constipation. 
https://www.starship.org.nz/for-health-professionals/starship-clinical-guidelines/c/constipation/  
Evidence-based medicine reviews 
• Gordon M, et al. 2016. Osmotic and stimulant laxatives for the management of childhood constipation. 
Cochrane Database of Systematic Reviews. http://dx.doi.org/10.1002/14651858.CD009118.pub3  
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• Lu ML, et al. 2015. Electrical stimulation therapy for slow transit constipation in children: A systematic 
review. International Journal of Colorectal Disease, 30(5), 697-702. http://dx.doi.org/10.1007/s00384-015-
2180-3  
• Siminas S & Losty PD. 2015. Current surgical management of pediatric idiopathic constipation: A 
systematic review of published studies. Annals of Surgery, 262(6), 925-33. 
http://dx.doi.org/10.1097/sla.0000000000001191  
Other relevant publications 
• Sbahi H & Cash BD. 2015. Chronic constipation: A review of current literature. Current Gastroenterology 
Reports, 17(12), 1-13. http://dx.doi.org/10.1007/s11894-015-0471-z  
• Vandenplas Y, et al. 2015. Prevalence and health outcomes of functional gastrointestinal symptoms in 
infants from birth to 12 months of age. Journal of Pediatric Gastroenterology and Nutrition, 61(5), 531-37. 
http://dx.doi.org/10.1097/MPG.0000000000000949  
• Wald A. 2016. Constipation: Advances in diagnosis and treatment. JAMA, 315(2), 185-91. 
http://dx.doi.org/10.1001/jama.2015.16994  
Websites 
• Kidshealth. Constipation. http://www.kidshealth.org.nz/constipation  
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ECZEMA AND DERMATITIS 
Introduction 
Eczema is a chronic inflammatory skin condition, usually beginning in infancy or early childhood, that affects 
over 20 percent of children in New Zealand. It is characterised by itch, scratching and inflamed, dry, scaling and 
crusted areas of skin. Eczema is also known as atopic eczema or atopic dermatitis.1 Eczema is typically an 
episodic condition with flares and remissions, although in some children it is continuous.1-3 Eczema and its 
treatment can negatively affect quality of life for children and their families to an extent similar to that of other 
chronic conditions such as asthma or diabetes. Children with eczema can experience disturbed sleep and fatigue, 
restriction of activities, school absenteeism, bullying, poor self-esteem and poor peer relationships. Children 
with eczema have high rates of psychological problems compared with their peers. Direct medical, hospital and 
treatment costs and indirect costs such as time off work for caregivers can be substantial.4  
There is a strong genetic component to eczema, and affected children often go on to develop co-morbidities of 
asthma and allergic rhinitis. The dry cracked skin that occurs in eczema can provide a portal of entry for 
bacterial and viral skin infections.3 Children and adolescents with eczema have an increased risk for attention 
deficit hyperactivity disorder, possibly affected by sleeping problems, and higher prevalence rates of depression, 
anxiety, conduct disorder, and autism compared with their peers.5 There is emerging evidence that eczema may 
be associated with an increased risk of rheumatoid arthritis and inflammatory bowel disease, and decreased risk 
of type 1 diabetes.6 
The following section reviews eczema and other conditions of the skin and subcutaneous tissue in children and 
young people using information from the New Zealand Health Survey and National Minimum Dataset. The 
section concludes with a brief overview of evidence for good practice for these conditions. 
Data sources and methods 
Indicators  
 Prevalence of eczema 
 Rates of eczema and dermatitis among 0–24 year olds 
Definition  
Prevalence of eczema 
Eczema diagnosed by doctor and using medicines, tablets, pills, cream or ointment (0–14 years); Child respondents (aged 0–14 
years) are defined as having eczema if the child’s parents or caregivers had ever been told by a doctor that the child has 
eczema and if they now have treatments for eczema (cream, ointment, medicine, tablets or pills) 
Rates of eczema and dermatitis among 0–24 year olds 
Hospitalisations of 0–24 year olds with eczema and dermatitis per 100,000 population 
Data sources 
Prevalence of eczema 
New Zealand Health Survey (2006/07–2014/15), see Appendix 3 
Rates of eczema and dermatitis among 0–24 year olds 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
Prevalence of eczema 
The NZ Health Survey utilised adjusted rate ratios to account for the potential influence of other demographic factors when 
undertaking demographic comparisons. Gender comparisons are adjusted for age, ethnic comparisons are adjusted for age 
and gender, and deprivation comparisons are adjusted for age, sex and ethnicity.7 
Rates of eczema and dermatitis among 0–24 year olds 
This section presents analyses where the condition was the primary diagnosis or was documented within any of the first 15 
diagnoses (all cases). The rationale for presenting all cases is to highlight the full spectrum of health issues experienced by 
those with this condition, and their consequent requirement for acute health services. Analyses are per hospital discharge 
event therefore events are only included if the condition is documented within either the primary diagnosis or within any of 
the first 15 diagnoses. Codes used for identifying cases are documented in Appendix 5. 
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National trends and distribution 
From 2009 to 2013 there were less than five deaths of 0–24 year olds with a skin condition as an underlying 
cause, as documented within the National Mortality Collection.  
Children aged 0–4 had the greatest prevalence of eczema that required medication with male children having a 
higher prevalence than females. Female children aged 5–9 and 10–14 had a higher incidence of eczema than 
male children of the same age (Figure 57). The prevalence of children aged 0–14 with eczema reduced with 
age. Children of Pacific ethnicity had the highest prevalence of eczema, followed by children of Māori, Asian or 
European/Other ethnicities. There was not a marked difference between the NZDep index deciles, however 
children living in the most deprived areas did have the highest incidence of eczema (Figure 58; Figure 59). 
There has been some year to year variation amongst the sexes (Figure 60). 
Figure 57. Eczema (medicated) in 0–14 year olds, by age group and sex, NZ Health Survey 2014/15 
  
Source: NZ Health Survey 
Figure 58. Eczema (medicated) in 0–14 year olds, by demographic factor, NZ Health Survey 2014/15 
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Figure 59. Comparisons for 0–14 year olds diagnosed with eczema, by demographic factor, NZ Health Survey 
2014/15 
 
Source: NZ Health Survey  
Figure 60. Eczema (medicated) in 0–14 year olds, by sex and survey year, NZ Health Surveys 2006/07–2014/15 
 
Source: NZ Health Survey  
The number of 0–24 year olds hospitalised between 2011 and 2015 with any diagnosis of eczema and dermatitis 
is presented by age group in Table 45, together with the total number of hospitalisations with eczema and 
dermatitis as a primary or any diagnosis. These diagnoses were characterised by high All:Primary ratios in 0–14 
and 15–24 year olds which means that hospitalisations occurred more often when the primary diagnosis was a 
condition other than eczema and dermatitis. Surveillance using primary diagnoses only for these conditions 
would lead to a large undercount of hospitalisations.  
Only about a quarter of hospitalisations of 0–24 year olds with eczema and dermatitis had these conditions as 
the primary diagnosis and the specific types of dermatitis are listed in Table 46. Other common primary 
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Table 45. Individuals hospitalised with eczema and dermatitis by age group, 0–24 year olds New Zealand 
2011– 2015  
Age group Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Eczema and dermatitis* 
0–24 years 15,331 5,022 18,950 3.77 
0–14 years 11,949 4,153 15,065 3.63 
15–24 years 3,412 869 3,885 4.47 
Source: National Minimum Dataset. All cases’ corresponds to hospitalisations with eczema or dermatitis included in any of the 
first 15 diagnoses; The sum of the age groups may total to more than the 0–24 year old total 










95% CI % 
Eczema and dermatitis* in 0–24 year olds 
New Zealand  
Dermatitis due to substances taken internally 480 96 6.25 5.71–6.83 2.5 
Atopic dermatitis 279 56 3.63 3.23–4.08 1.5 
Diaper [napkin] dermatitis 144 29 1.87 1.59–2.21 0.8 
Allergic contact dermatitis 143 29 1.86 1.58–2.19 0.8 
Seborrhoeic dermatitis 118 24 1.54 1.28–1.84 0.6 
Herpesviral infections† 389 78 5.06 4.59–5.59 2.1 
Other dermatitis‡ 3,469 694 45.16 43.69–46.69 18.3 
Eczema and dermatitis total 5,022 1,004 65.38 63.60–67.22 26.5 
Other skin and subcutaneous tissue diseases 1,126 225 14.66 13.83–15.54 5.9 
Infectious and parasitic diseases§ 1,441 288 18.76 17.82–19.75 7.6 
Diseases of the respiratory system 3,623 725 47.17 45.66–48.73 19.1 
Certain conditions originating in the perinatal period 1,467 293 19.10 18.15–20.10 7.7 
Injury and/or poisoning 1,148 230 14.95 14.11–15.84 6.1 
Symptoms and/or abnormal clinical findings NEC 1,082 216 14.09 13.27–14.95 5.7 
Other diagnoses 4,041 808 52.61 51.01–54.26 21.3 
Total 18,950 3,790 246.72 243.23–250.25 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Eczema or dermatitis in 
any of the first 15 diagnoses; † Herpes viral infections encompasses: Eczema herpeticum, Herpesviral vesicular dermatitis; ‡Other 
dermatitis includes: Irritant contact dermatitis, Unspecified contact dermatitis, Exfoliative dermatitis, Lichen simplex chronicus 
and prurigo, Pruritus; § Infectious and parasitic diseases excludes herpesviral infections; NEC = not elsewhere classified 
Since 2000 hospitalisation rates for eczema and dermatitis have risen markedly for 0–4 year olds and slightly for 
5–14 and 15–24 year olds. The highest hospitalisation rates were for 0–4 years olds when all cases were 
included (Figure 61). Similar increases in hospitalisation rates over time were seen in all ethnic groups. 
Hospitalisation rates for 0–24 year olds were consistently higher for Pacific and Māori 0–24 year olds compared 
with their European and Asian/Indian peers. This ethnic disparity was most marked when all cases were 
included in the analysis (Table 47).  
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Figure 61. Hospitalisations for eczema and dermatitis in 0–24 year olds, by age group, New Zealand 2000–2015 
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with eczema or dermatitis in any of the first 15 diagnoses 
Table 47 presents the demographic distribution of individuals hospitalised with eczema and dermatitis in New 
Zealand between 2011 and 2015. There was a strong social gradient among these individuals, with statistically 
significant increases in prevalence in each NZDep 2013 quintile (NZDep2013 deciles 3–4 to 9–10) compared 
with those living in areas with the lowest NZDep2013 deprivation scores (deciles 1–2). Prevalence rates were 
significantly higher for Māori, Pacific, Asian/Indian and MELAA 0–24 year olds than for European/Other. The 
majority of 0–24 year olds hospitalised with eczema and dermatitis were 0–4 year olds.  




Rate per 100,000 
population 
Rate ratio 95% CI 
Eczema and dermatitis* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 1,606 113.17 1.00   
Deciles 3–4 1,876 140.30 1.24 1.16–1.33 
Deciles 5–6 2,343 162.54 1.44 1.35–1.53 
Deciles 7–8 3,617 222.65 1.97 1.86–2.09 
Deciles 9–10 6,234 335.51 2.96 2.81–3.13 
Prioritised ethnicity 
Māori 5,197 288.12 2.07 2.00–2.15 
Pacific 2,800 395.12 2.84 2.72–2.97 
Asian/Indian 1,421 148.24 1.07 1.01–1.13 
MELAA 199 197.32 1.42 1.23–1.63 
European/Other 5,714 139.07 1.00   
Gender 
Female 7,643 203.57 1.00   
Male 7,687 195.78 0.96 0.93–0.99 
Age group (years) 
0–4 9,501 609.16 5.60 5.39–5.82 
5–14 2,531 84.81 0.78 0.74–0.82 
15–24 3,412 108.76 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population; * Eczema or dermatitis in 
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Regional distribution 
Table 48 presents the number of individuals resident in each district health board area that had one or more 
hospitalisations with a diagnosis of eczema and dermatitis between 2011 and 2015. The All:Primary diagnosis 
ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic conditions occur when this 
condition is not the primary diagnosis. A high ratio may be associated with more thorough documentation and 
result in less undercounting than would occur if only the primary diagnosis is included in discharge data. For 
eczema and dermatitis the All:Primary diagnosis ratio was higher than two in all DHBs, and particularly high in 
West Coast, Waikato, Canterbury, Otago and Lakes DHBs. The All:Primary diagnosis ratio was considerably 
lower than the national ratio in Hawke's Bay, Whanganui, MidCentral and South Canterbury DHBs and similar 
to the national ratio in the remaining district health boards. 
Table 48. Hospitalisations for eczema and dermatitis in 0–24 year olds, by district health board, New Zealand 
2011–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Eczema and dermatitis in 0–24 year olds  
Northland 782 239 977 4.09 
Waitemata 1,567 505 1,909 3.78 
Auckland 1,613 493 1,926 3.91 
Counties Manukau 2,443 747 2,937 3.93 
Waikato 1,342 316 1,606 5.08 
Bay of Plenty 845 309 1,035 3.35 
Lakes 616 177 798 4.51 
Tairawhiti 270 120 382 3.18 
Taranaki 201 87 266 3.06 
Hawke's Bay 351 198 450 2.27 
MidCentral 477 200 575 2.88 
Whanganui 212 105 272 2.59 
Hutt Valley 610 263 789 3.00 
Capital & Coast 1,049 409 1,287 3.15 
Wairarapa 129 51 161 3.16 
Nelson Marlborough 253 81 311 3.84 
South Canterbury 115 49 146 2.98 
Canterbury 1,598 393 1,865 4.75 
West Coast 80 6 92 15.33 
Southern 903 264 1,100 4.17 
New Zealand 15,331 5,022 18,950 3.77 
Source: National Minimum Dataset; ‘All cases’ corresponds to hospitalisations with eczema or dermatitis listed in any of the first 
15 diagnoses; Sum of DHBs may equal more than NZ total due to some individuals changing DHB of domicile during the period 
Evidence for good practice 
Possibilities for prevention 
No primary prevention strategy has been established for eczema and there is no clear evidence for effectiveness 
of measures such as maternal dietary antigen avoidance during pregnancy and breastfeeding, long-term 
breastfeeding, hydrolysed protein formulas, soy formulas, omega-3 or omega-6 fatty acid supplementation or 
delayed introduction of solid foods.5 There is some emerging but weak evidence about possible preventive 
effects of probiotics administered in pregnancy where there is a high risk of eczema in the fetus.8,9 Prevention 
approaches aiming to enhance skin barrier function, such as daily full-body emollient therapy from birth may 
reduce the cumulative incidence of eczema in infants.5 Secondary prevention through prevention and control of 
flares is a key goal of evidence-based management of eczema.3 
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Evidence-based health care for children and young people with eczema 
Topical corticosteroids are the mainstay of the management of active eczema in combination with the regular 
use of emollients, the management of triggers and the treatment of concurrent infection. It is important for all 
healthcare professionals to be aware of the robust safety profile of topical corticosteroids so as to facilitate 
optimal treatment and counteract prevalent misinformation which raises unwarranted concerns about adverse 
effects.4 Treatment for eczema should be tailored to the individual child, with treatments stepped up and down 
according to the recorded severity of symptoms.2,3  
Eczema can usually be managed in primary care.10 Specialist referral is recommended if: symptoms are severe 
and persist despite optimum topical treatment, flares are occurring frequently or eczema is associated with 
repeated infections, there are serious social or psychological problems for the child or caregiver or if a child has 
severe food allergy or fails to grow at the expected growth trajectory.2,3 Engagement with a multidisciplinary 
team and nurse-led clinics may improve outcomes for children with eczema and their families.11 
New Zealand guidelines 
• New Zealand Child and Youth Clinical Networks. 2014. Guidelines for the diagnosis and assessment of 
childhood eczema. https://www.starship.org.nz/for-health-professionals/new-zealand-child-and-youth-
clinical-networks/child-and-youth-eczema-clinical-network/diagnosis-and-assessment-of-eczema/  
• New Zealand Child and Youth Clinical Networks. 2014. Guidelines for the outpatient/primary care 
management of childhood eczema. https://www.starship.org.nz/for-health-professionals/new-zealand-child-
and-youth-clinical-networks/child-and-youth-eczema-clinical-network/guidelines-for-the-outpatient-
primary-care-managment-of-childhood-eczema/  
• Purvis D & Stewart D. 2016. Starship clinical guidelines: Eczema. https://www.starship.org.nz/for-health-
professionals/starship-clinical-guidelines/e/eczema/  
International guidelines 
• National Institute for Health and Care Excellence. 2016. Eczema pathway. 
https://pathways.nice.org.uk/pathways/eczema  
• Galli E, et al. 2016. Consensus conference on clinical management of pediatric atopic dermatitis. Italian 
Journal of Pediatrics, 42, 26 http://dx.doi.org/10.1186/s13052-016-0229-8  
• Eichenfield LF, et al. 2015. Translating atopic dermatitis management guidelines into practice for primary 
care providers. Pediatrics, 136(3), 554-65. http://dx.doi.org/10.1542/peds.2014-3678  
• Ring J, et al. 2012. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the 
European Academy of Dermatology and Venereology, 26(8), 1045–60. http://dx.doi.org/10.1111/j.1468-
3083.2012.04635.x  
• Ring J, et al. 2012. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. Journal of the 
European Academy of Dermatology and Venereology, 26(9), 1176-93. http://dx.doi.org/10.1111/j.1468-
3083.2012.04636.x  
Evidence-based medicine reviews 
• Cuello-Garcia CA, et al. 2015. Probiotics for the prevention of allergy: A systematic review and meta-
analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology, 136(4), 952-61. 
http://dx.doi.org/10.1016/j.jaci.2015.04.031  
• Ersser SJ, et al. 2014. Psychological and educational interventions for atopic eczema in children. Cochrane 
Database of Systematic Reviews, 1. http://dx.doi.org/10.1002/14651858.CD004054.pub3 
• Tam H, et al. 2016. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane 
Database of Systematic Reviews, 2. http://dx.doi.org/10.1002/14651858.CD008774.pub2  
• Zuccotti G, et al. 2015. Probiotics for prevention of atopic diseases in infants: Systematic review and meta-
analysis. Allergy, 70(11), 1356-71. http://dx.doi.org/10.1111/all.12700  
Other relevant publications 
• Lodge CJ, et al. 2015. Breastfeeding and asthma and allergies: A systematic review and meta-analysis. Acta 
Paediatrica, 104, 38-53. http://dx.doi.org/10.1111/apa.13132  
• Mooney E, et al. 2015. Adverse effects of topical corticosteroids in paediatric eczema: Australasian 
consensus statement. Australasian Journal of Dermatology, 56(4), 241-51. 
http://dx.doi.org/10.1111/ajd.12313  
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• Weidinger S & Novak N. 2016. Atopic dermatitis. Lancet, 387(10023), 1109-22. 
http://dx.doi.org/10.1016/s0140-6736(15)00149-x  
Websites 
• New Zealand Child and Youth Clinical Networks. 2014. https://www.starship.org.nz/for-health-
professionals/new-zealand-child-and-youth-clinical-networks/child-and-youth-eczema-clinical-network/ 
• Ministry of Health. 2014. http://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-
illnesses/eczema  
• Kidshealth. 2016. http://www.kidshealth.org.nz/eczema  
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Musculoskeletal disorders are common in children and often debilitating.1 This section includes juvenile 
idiopathic arthritis, juvenile osteochondroses and scoliosis.  
Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatologic disease.2 The term JIA describes 
all forms of arthritis that have an onset before age 16 years with joint inflammation that lasts more than 6 weeks 
and exclusion of other known conditions.2-4 Children with specific subtypes of JIA can have additional 
symptoms or conditions including: fever, tiredness, rash, loss of appetite and weight loss. The arthritis that 
occurs as a manifestation of the skin condition psoriasis is also included as a subtype of JIA.4 JIA has significant 
morbidity and can be painful, disable a child, limit quality of life, add to the financial stress of families, and 
have a substantial societal cost.1,5 Children with arthritis that involves five or more joints have a particularly 
refractory disease course and are at higher risk of poorer functional outcomes compared to those with 
involvement of fewer joints.2,6 Inadequately controlled disease may lead to abnormalities of growth such as 
short stature, localised bone overgrowth or premature fusion, and alteration of limb length.3 Patients with JIA 
are less likely than healthy peers to engage in physical activity.7 Important differential diagnoses include 
rheumatic fever, systemic lupus erythematosus, and orthopaedic problems. Some children with inflammatory 
bowel disease (IBD) may have a peripheral arthritis before or after the bowel problems become obvious.1 
Fatigue and uveitis are common comorbidities; other comorbidities include allergic rhinitis, migraine and atopic 
dermatitis and heart problems such as pericarditis.8-10 
The term juvenile osteochondrosis describes a group of disorders that affect patients with an immature skeleton. 
The usual presentation is pain and limited mobility of the affected joint.5 Joints commonly affected are the hip, 
knee, elbow and back. Osteochondrosis occurs as a result of abnormal growth, injury, or overuse of the 
developing bone growth plate.5 Symptoms may be intermittent, and may be associated with athletic activity.11 
The association of symptoms with athletic activity means that osteochondrosis is sometimes classified as sports-
related overuse injury.12 Osteochondrosis at different body sites has traditionally been considered as separate 
diseases, often with eponymous titles (e.g. osteochondrosis of the knee is known as Osgood-Schlatter disease) 
although the disease process is similar wherever it occurs in the body.5,11,12 
Scoliosis is a lateral deviation of the spine and is one of the most common paediatric spinal deformities. Most 
cases, especially if diagnosed after infancy, are ‘idiopathic’ or not associated with any known cause. Congenital 
scoliosis has a high association with other congenital anomalies arising at the same period of fetal 
development.13 Juvenile scoliosis also occurs in the setting of neuromuscular disorders such as cerebral palsy 
and muscular dystrophy, or as part of genetic syndromes and conditions such as Marfan syndrome and 
neurofibromatosis.13-15 
Data sources and methods 
Indicators  
 Rates of chronic musculoskeletal diseases among 0–24 year olds 
Definition  
Hospitalisations of 0–24 year olds with a chronic musculoskeletal disease per 100,000 population  
Data sources 
Numerator: National Minimum Dataset 
Denominator:  
Statistics New Zealand Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Additional information 
A chronic musculoskeletal disease was the primary diagnosis or was documented as one of the first 15 diagnoses. Chronic 
musculoskeletal diseases comprises juvenile arthritis, juvenile osteochondrosis, and scoliosis. 




National trends and distribution 
There were less than five deaths of 0–24 year olds where a chronic musculoskeletal disease was the underlying 
cause of death in New Zealand between 2009 and 2013, as documented within the National Mortality 
Collection. 
The number of 0–24 year olds hospitalised with chronic musculoskeletal diseases during 2011 to 2015 is 
presented in Table 49. It also presents the number of hospital discharges in which chronic musculoskeletal 
diseases were documented as the primary diagnosis or as any diagnosis.  
The rate of hospitalisations where a chronic musculoskeletal disease was the primary diagnosis has increased 
since 2000 (Figure 62). 
Table 49. Individuals aged 0–24 years hospitalised with chronic musculoskeletal diseases using primary diagnosis 
compared to all cases, New Zealand 2011–2015 
  Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Chronic musculoskeletal diseases 
Hospitalisation 
0–24 years 1,506 2,431 3,016 1.24 
0–14 years 962 1,595 1,968 1.23 
15–24 years 578 836 1,048 1.25 
Chronic musculoskeletal diseases in 0–24 year olds 
Juvenile arthritis 377 1,269 1,494 1.18 
Juvenile osteochondrosis 415 444 541 1.22 
Scoliosis 720 718 982 1.37 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with chronic musculoskeletal diseases listed in 
any of the first 15 diagnoses; The sum of the age groups may total to more than the 0–24 year old total 






























































































s Chronic musculoskeletal diseases 0–24 years
 
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with chronic musculoskeletal diseases listed in any of the first 15 diagnoses 
Demographic distribution 
Table 50 presents the demographic distribution of individuals with chronic musculoskeletal diseases in New 
Zealand between 2011 and 2015. Chronic musculoskeletal diseases were significantly lower among males, and 
among 0–4 year olds compared to 15–24 year olds, and significantly higher among 5–14 year olds. There was 
no significant difference by deprivation score. The majority of individuals with chronic musculoskeletal 
diseases were of European/Other ethnicities.  
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Table 50. Individuals aged 0–24 years hospitalised with chronic musculoskeletal diseases, by demographic factor, 




Rate per 100,000 
population 
Rate ratio 95% CI 
Chronic musculoskeletal diseases* in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 308 21.70 1.00   
Deciles 3–4 286 21.39 0.99 0.84–1.16 
Deciles 5–6 287 19.91 0.92 0.78–1.08 
Deciles 7–8 315 19.39 0.89 0.76–1.05 
Deciles 9–10 371 19.97 0.92 0.79–1.07 
Prioritised ethnicity 
Māori 248 13.75 0.54 0.47–0.62 
Pacific 95 13.41 0.53 0.43–0.65 
Asian/Indian 89 9.28 0.36 0.29–0.45 
MELAA 19 18.84 0.74 0.47–1.16 
European/Other 1,049 25.53 1.00   
Gender 
Female 875 23.31 1.00   
Male 631 16.07 0.69 0.62–0.76 
Age group (years) 
0–4 137 8.78 0.48 0.40–0.57 
5–14 860 28.82 1.56 1.41–1.74 
15–24 578 18.42 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. * Chronic musculoskeletal 
diseases in any of the first 15 diagnoses; Rate per 100,000 age-specific population; Rate ratios are unadjusted; Ethnicity is Level 
1 prioritised; Decile is NZDep2013; Summation of components may equal more than the 0–24 year old unique total 
Hospitalisations for chronic musculoskeletal diseases had increased for the three age groups since 2000, and 
most notably for the 0–4 year olds (Figure 63). Over the same period, the hospitalisation rate had gradually 
increased for each ethnic group, although European/Other had a consistently higher hospitalisation rate than the 
other ethnic groups (Figure 64). 
Figure 63. Hospitalisations involving chronic musculoskeletal diseases in 0–24 year olds, by age group, 


































































































Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with chronic musculoskeletal diseases listed in any of the first 15 diagnoses 
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Figure 64. Hospitalisations involving chronic musculoskeletal diseases in 0–24 year olds, by ethnicity, 




































































































Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population. ‘All cases’ corresponds to 
hospitalisations with chronic musculoskeletal diseases listed in any of the first 15 diagnoses 
Regional distribution 
Table 51 presents the number of individuals resident in each district health board that had a chronic 
musculoskeletal disease diagnosis during 2011 to 2015. It also presents the number of hospital discharges in 
which a chronic musculoskeletal disease was documented as the primary diagnosis or any diagnosis.  
The All:Primary diagnosis ratio reflects the extent to which hospitalisations of 0–24 year olds with chronic 
conditions occur when this condition is not the primary diagnosis. A high ratio may be associated with more 
thorough documentation and avoid undercounting that would occur if only primary diagnoses are included in 
discharge data. For chronic musculoskeletal diseases the All:Primary diagnosis ratio was higher than the 
national ratio in Waikato, Bay of Plenty, Lakes, Hawke's Bay, MidCentral, Whanganui, Hutt Valley, 
Nelson Marlborough, and Southern DHBs. Ratios were lower than the national ratio in the remaining district 
health boards (Table 51). 
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Table 51. Hospitalisations for chronic musculoskeletal diseases in 0–24 year olds, by district health board, 
New Zealand 2011–2015 
DHB Unique individuals (n) 
Hospitalisations (n) 
Ratio All:Primary 
Primary diagnosis All cases 
Chronic musculoskeletal diseases in 0–24 year olds 
Northland 55 109 133 1.22 
Waitemata 209 275 336 1.22 
Auckland 137 279 342 1.23 
Counties Manukau 184 354 429 1.21 
Waikato 97 157 209 1.33 
Bay of Plenty 97 181 227 1.25 
Lakes 43 61 90 1.48 
Tairawhiti 15 49 52 1.06 
Taranaki 38 54 63 1.17 
Hawke's Bay 63 82 116 1.41 
MidCentral 54 77 99 1.29 
Whanganui 33 32 43 1.34 
Hutt Valley 52 67 87 1.30 
Capital & Coast 98 150 166 1.11 
Wairarapa 18 21 25 1.19 
Nelson Marlborough 39 79 101 1.28 
South Canterbury 16 19 19 1.00 
Canterbury 155 246 294 1.20 
West Coast 6 6 7 1.17 
Southern 113 123 167 1.36 
New Zealand 1,506 2,431 3,016 1.24 
Source: National Minimum Dataset. ‘All cases’ corresponds to hospitalisations with chronic musculoskeletal diseases listed in 
any of the first 15 diagnoses; Rate per 100,000 0–24 year olds; Sum of DHBs may equal more than NZ total due to some 
indiviudal's changing DHB of domicile during the period 
Evidence for good practice 
Possibilities for prevention 
The causes of juvenile idiopathic arthritis (JIA) are unknown but include complex interactions between genetic 
makeup and environmental exposures.16 The causes of osteochondrosis are also complex and involve vascular, 
traumatic, microtraumatic factors.12 Most cases (80%) of scoliosis are also idiopathic.13 For all of these 
conditions the focus is on prompt diagnosis and treatment that is consistent with best practice. There is a lack of 
evidence for or against population screening for scoliosis, although school programmes exist in many US 
States.13 Every clinician involved in the care of children and young people ought to competent in the 
examination of the musculoskeletal system, and musculoskeletal examination results should be documented in 
all paediatric hospitalisation records.1 
Evidence-based health care for children and young people with juvenile 
idiopathic arthritis 
The goal of therapy is to target the underlying inflammation and prevent complications associated with the 
condition. Early accurate diagnosis is important to allow early aggressive treatment of juvenile idiopathic 
arthritis (JIA) and optimal prognosis.1,6 Uveitis is a common and often asymptomatic comorbidity of JIA which 
can lead to blindness if untreated.4 Initial screening for uveitis is recommended within a month of JIA 
diagnosis.17 Commonly used therapies for JIA include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-
modifying antirheumatic drugs (DMARDs), and biologic agents such as the tumour necrosis factor (TNF-α) 
inhibitors.3 Flares affecting one or more joints are common after the disease becomes inactive. Clinical decision-
making needs to balance the risk of flare if treatment is discontinued with the risks and inconveniences of 
continuing treatment.18 Markers of early atherosclerosis are present more often in patients with JIA patients than 
in their healthy peers, and, in relation to later overt cardiovascular disease, this is likely to be part of a slowly-
developing, multifaceted process which may be amenable to preventive measures. A broader management 
approach to JIA will include promotion of a healthy lifestyle so that patients gain full benefit of effective anti-
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inflammatory treatment and secure a healthy life in adulthood.19 Physical activity can both increase and decrease 
inflammatory effects for patients with JIA depending on duration and intensity of exercise and personal 
training.20 
Juvenile osteochondrosis usually comes to attention only when it is symptomatic.11 Symptoms are usually self-
limiting and respond well to activity modification and anti-inflammatory drug treatment. Surgery may be 
required for older children and young people with mature skeletons who continue to have disabling symptoms.5  
Surgery for adolescent idiopathic scoliosis can prevent curve progression and lessen deformity, with statistically 
and clinically significant improvement in self-image.21 Surgery is also associated with positive outcomes for 
children with neuromuscular or genetic conditions.14,15 A plethora of non-surgical interventions is used for 
scoliosis including bracing, scoliosis-specific exercises, manual therapy and electrical stimulation. The 
methodological quality of systematic reviews for such interventions is generally low, and findings from higher 
quality reviews have not found sufficient evidence to make an informed judgment about the effectiveness of 
non-surgical interventions in adolescents with idiopathic scoliosis.22 
International guidelines 
• National Institute for Health and Care Excellence. 2016. Musculoskeletal conditions pathway. 
https://pathways.nice.org.uk/pathways/musculoskeletal-conditions  
• Ringold S, Weiss PF, Beukelman T, et al. 2013. 2013 update of the 2011 American College of 
Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the 
medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among 
children receiving biologic medications. Arthritis & Rheumatism, 65(10) 2499-512. 
http://dx.doi.org/10.1002/art.38092  
• Cincinnati Children's Hospital Medical Center. 2012. Best evidence statement (BESt). Screening for uveitis 
in children with juvenile idiopathic arthritis (JIA). Cincinnati: Cincinnati Children's Hospital Medical 
Center. http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/best.htm  
• Valovich McLeod TC, Decoster LC, Loud KJ, et al. 2011. National athletic trainers' association position 
statement: Prevention of pediatric overuse injuries. Journal of Athletic Training, 46(2) 206-20. 
http://dx.doi.org/10.4085/1062-6050–46.2.206  
Evidence-based medicine reviews 
• Płaszewski M & Bettany-Saltikov J. 2014. Non-surgical interventions for adolescents with idiopathic 
scoliosis: An overview of systematic reviews. PLoS ONE, 9(10). 
http://dx.doi.org/10.1371/journal.pone.0110254  
Other relevant publications 
• Launay F. 2015. Sports-related overuse injuries in children. Orthopaedics and traumatology: Surgery and 
Research, 101(1) S139-S47. http://dx.doi.org/10.1016/j.otsr.2014.06.030  
Websites 
• Kids with arthritis New Zealand http://www.kidswitharthritis.org.nz/  
• Arthritis New Zealand http://www.arthritis.org.nz/information/children-with-arthritis/  
References 
1. Spencer CH, Patwardhan A. 2015. Pediatric rheumatology for the primary care clinicians-recognizing 
patterns of disease. Current Problems in Pediatric and Adolescent Health Care, 45(7) 185-206. 
http://dx.doi.org/10.1016/j.cppeds.2015.04.002  
2. Ringold S, Weiss PF, Beukelman T, et al. 2013. 2013 update of the 2011 American College of 
Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations 
for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis 
screening among children receiving biologic medications. Arthritis & Rheumatology, 65(10) 2499-512. 
http://dx.doi.org/10.1002/art.38092  
3. Canadian Agency for Drugs and Technologies in Health. 2014. Common drug review: Clinical review 
report for tocilizumab (Actemra, intravenous) for the treatment of signs and symptoms of active 




4. National Institute for Health and Care Excellence. 2015. Abatacept, adalimumab, etanercept and 
tocilizumab for treating juvenile idiopathic arthritis.  https://www.nice.org.uk/guidance/ta373 accessed 
September, 2016. 
5. Atanda A, Shah SA, O'Brien K. 2011. Osteochondrosis: Common causes of pain in growing bones. 
American Family Physician, 83(3) 285-91. http://www.aafp.org/afp/2011/0201/p285.html 
6. van Dijkhuizen EHP, Wulffraat NM. 2015. Early predictors of prognosis in juvenile idiopathic 
arthritis: a systematic literature review. Annals of the Rheumatic Diseases, 74(11) 1996-2005. 
http://dx.doi.org/10.1136/annrheumdis-2014-205265  
7. Cavallo S, April KT, Grandpierre V, et al. 2014. Leisure in children and adolescents with juvenile 
idiopathic arthritis: A systematic review. PLoS ONE, 9(10) e104642. 
http://dx.doi.org/10.1371/journal.pone.0104642  
8. Armbrust W, Siers NE, Lelieveld OTHM, et al. 2016. Fatigue in patients with juvenile idiopathic 
arthritis: A systematic review of the literature. Seminars in Arthritis and Rheumatism, 45(5) 587-95. 
http://dx.doi.org/10.1016/j.semarthrit.2015.10.008  
9. Raab A, Sengler C, Niewerth M, et al. 2013. Comorbidity profiles among adult patients with juvenile 
idiopathic arthritis: results of a biologic register. Clinical and Experimental Rheumatology, 31(5) 796-
802.  
10. Koca B, Sahin S, Adrovic A, et al. 2016. Cardiac involvement in juvenile idiopathic arthritis. 
Rheumatology International, 37(1) 137-42. http://dx.doi.org/10.1007/s00296-016-3534-z  
11. McCoy AM, Toth F, Dolvik NI, et al. 2013. Articular osteochondrosis: A comparison of naturally-
occurring human and animal disease. Osteoarthritis and Cartilage, 21(11) 1638-47. 
http://dx.doi.org/10.1016/j.joca.2013.08.011  
12. Launay F. 2015. Sports-related overuse injuries in children. Orthopaedics and Traumatology: Surgery 
and Research, 101(1) S139-S47. http://dx.doi.org/10.1016/j.otsr.2014.06.030  
13. Horan MP, Milbrandt TA. 2009. Scoliosis in pediatric patients: Comorbid disorders and screening. 
Pediatric Health, 3(5) 451-56. http://dx.doi.org/10.2217/phe.09.48  
14. Harvey A, Baker L, Williams K. 2014. Non-surgical prevention and management of scoliosis for 
children with Duchenne muscular dystrophy: what is the evidence? (Provisional abstract). Journal of 
Paediatrics and Child Health, 50(10) E3-e9. http://dx.doi.org/10.1111/jpc.12177  
15. Legg J, Davies E, Raich AL, et al. 2014. Surgical correction of scoliosis in children with spastic 
quadriplegia: Benefits, adverse effects, and patient selection. Evidence-Based Spine-Care Journal, 5(1) 
38-51. http://dx.doi.org/10.1055/s-0034-1370898  
16. Moncrieffe H, Prahalad S, Thompson SD. 2014. Genetics of juvenile idiopathic arthritis: new tools 
bring new approaches. Current Opinion in Rheumatology, 26(5) 579-84. 
http://dx.doi.org/10.1097/bor.0000000000000094  
17. Cincinnati Children's Hospital Medical Center. 2012. Best evidence statement (BESt). Screening for 
uveitis in children with juvenile idiopathic arthritis (JIA). Cincinnati: Cincinnati Children's Hospital 
Medical Center. http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/best.htm 
18. Guzman J, Oen K, Huber AM, et al. 2016. The risk and nature of flares in juvenile idiopathic arthritis: 
Results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 75(6) 1092-98. 
http://dx.doi.org/10.1136/annrheumdis-2014-207164  
19. Bohr A-H, Fuhlbrigge RC, Pedersen FK, et al. 2016. Premature subclinical atherosclerosis in children 
and young adults with juvenile idiopathic arthritis. A review considering preventive measures. 
Pediatric Rheumatology Online Journal, 14(1) 3. http://dx.doi.org/10.1186/s12969-015-0061-5  
20. Rochette E, Duché P, Merlin E. 2015. Juvenile idiopathic arthritis and physical activity: Possible 
inflammatory and immune modulation and tracks for interventions in young populations. Autoimmunity 
Reviews, 14(8) 726-34. http://dx.doi.org/10.1016/j.autrev.2015.04.007  
21. Rushton PR, Grevitt MP. 2013. What is the effect of surgery on the quality of life of the adolescent 
with adolescent idiopathic scoliosis? A review and statistical analysis of the literature. Spine, 38(9) 
786-94. http://dx.doi.org/10.1097/BRS.0b013e3182837c95  
22. Płaszewski M, Bettany-Saltikov J. 2014. Non-surgical interventions for adolescents with idiopathic 








Cancer is the name given to a group of related diseases all characterised by having abnormal (cancer) cells 
which grow and divide in an uncontrolled fashion and can invade and damage nearby tissues and spread to other 
parts of the body.1 The types of cancer that commonly affect children are different from those that commonly 
affect adults.2 
In New Zealand around 130 children (aged 0–14 years) and 160 young people (aged 15–24 years) are diagnosed 
with cancer each year3,4 and around 50 children and young people die from cancer.5 Cancer is the third most 
common cause of death in New Zealand children and young people (aged 28 days to 24 years), after transport-
related injuries and suicide.5 
The most common types of cancer diagnosed in New Zealand children during 2000–2009 were leukaemias and 
central nervous system tumours.3 In young people, the most common types were melanomas, carcinomas, 
lymphomas, germ cell and trophoblastic neoplasms, and leukaemias.4 
Over the last half century there have been great improvements in the treatment of childhood cancer. Overall 
child cancer five-year survival rates in New Zealand are now around 80%, comparable to those in other 
developed countries.2 Five-year cancer survival rates for New Zealand 15−24 year olds (81%) and 15−19 year 
olds (75%) are somewhat lower than those in other developed countries.4 
Data sources and methods 
Indicators  
 Incidence of cancer as notified to the New Zealand Cancer Registry (NZCR) 
Data sources 
Numerator: New Zealand Cancer Registry (NZCR), unless indicated otherwise 
Denominator:  NZ Statistics NZ Estimated Resident Population 
Additional information 
The NZCR records cancers diagnosed in New Zealand. NZCR registers each cancer once, in the year of first known diagnosis. 
Registrations cover new cases of primary cancer, or secondary cancers where the primary cancer is unknown. In the few 
instances where an individual had multiple registrations for the same cancer, only one registration for the same cancer has 
been kept. 
Year is registration year. Age is age at date of diagnosis. Rates are age-standardised, unless stated otherwise. 
Included cancers are as defined by the Ministry of Health, and the codes utilised to identify cases are available in Appendix 5. 
Unless otherwise stated, cancer notifications exclude in-situ neoplasms. 
National trends and distribution 
From 2000 to 2014 a total of 12,309 individual 0–24 year olds were diagnosed with cancer, an average of 880 
individuals per year. Most of these individuals had one cancer diagnosis. As shown in Figure 65 there has been 
a small but statistically significant decline in cancer registration rates for 0–14 and 15–24 year olds over this 15-
year time period. In 15–24 year olds the decline is due to a fall in incidence of in-situ neoplasm registrations and 
cancer registration rates were stable over time (Figure 66). 
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Figure 65. Notifications to NZ Cancer Registry for 0–24 year olds, by age group and year, New Zealand 2000–2014 
 
Numerator: National Cancer Registry, Denominator: Statistics NZ Estimated Resident Population; ASR = Age standardised rate 
(standardised to 2013 NZ Census population) 
Figure 66. Notifications to NZ Cancer Registry for 15–24 year olds, by type and year, New Zealand 2000–2014 
 
Numerator: National Cancer Registry, Denominator: Statistics NZ Estimated Resident Population; ASR = Age standardised rate 
(standardised to 2013 NZ Census population)  
Table 52 presents the rate of cancer diagnosis, deaths and hospitalisations by age group and sex during the most 
recent five-year period that had data available for each measure. The highest rates of new cancer diagnoses and 
cancer deaths were among 20–24 year olds, followed by 0–4 year olds. The highest hospitalisation rate was for 
0–4 year olds. With the exception of 20–24 year olds, cancer incidence was higher in males than females. The 
death rate was higher for 0–4 and 15–19-year-old males compared to females, with little difference by gender in 
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Table 52. Cancer in 0–24 year olds, by age group and sex, New Zealand  
Age (years) 
Incidence per 100,000 
population (2010–2014)  
Mortality per 100,000 
population (2009–2013)  





0–4 23.16 3.61 188.37 
5–9 10.71 1.48 117.71 
10–14 12.19 2.06 112.41 
15–19 19.77 4.16 113.67 
20–24 32.87 4.80 103.14 
Males 
0–4 24.66 4.23 215.03 
5–9 12.29 1.18 133.09 
10–14 13.70 2.07 126.03 
15–19 20.37 5.00 130.87 
20–24 31.28 4.76 109.43 
Females 
0–4 21.59 2.97 160.23 
5–9 9.04 1.79 101.58 
10–14 10.59 2.05 98.08 
15–19 19.14 3.27 95.58 
20–24 34.49 4.84 96.71 
Numerator(s): Incidence: National Cancer Registry; Mortality: National Mortality Collection; Hospitalisations: National Minimum 
Dataset; Denominator: Statistics NZ Estimated Resident Population. Rates are age-specific rates; Cancer includes all malignant 
tumours and other neoplasms of uncertain/unknown behaviour; Incidence by new registrations, Mortality by underlying cause 
of death; Hospitalisation by primary diagnosis 
Diagnosis  
The most common types of cancer in 0–14 year olds between 2010 and 2014 were tumours of the lymphoid, 
haematopoietic and related tissue, in particular leukaemia, followed by tumours of the central nervous system 
(including brain and eye) (Table 53). Tumours of the lymphoid, haematopoietic and related tissue were also the 




Table 53. Cancer notifications for 0–14 year olds, by cancer group, New Zealand, 2010–2014 
2010–2014 Notifications (n) ASR per 100,000 population 95% CI 
New Zealand 
0–14 year olds 
Cancer notifications 
All cancers 699 15.47 14.34–16.66 
Lymphoid, haematopoietic and related tissue 325 7.19 6.43–8.02 
Leukaemia 246 5.45 4.79–6.17 
Leukaemia: Lymphoid leukaemia 194 4.30 3.72–4.95 
Leukaemia: Acute myeloid leukaemia 20 0.44 0.27–0.68 
Hodgkin lymphoma 30 0.66 0.44–0.94 
Non-Hodgkin lymphoma (except Burkitt lymphoma) 26 0.57 0.38–0.84 
Burkitt lymphoma 12 0.27 0.14–0.46 
Eye, Brain and other parts of the central nervous system 138 3.06 2.57–3.61 
Mesothelial and soft tissue 62 1.38 1.05–1.76 
Bones, joints and articular cartilage 47 1.03 0.76–1.37 
Thyroid and other endocrine glands 35 0.78 0.54–1.08 
Urinary tract 35 0.78 0.54–1.08 
Digestive organs 26 0.57 0.38–0.84 
Respiratory system and intrathoracic organs <10 s s 
Lip, oral cavity and pharynx <10 s s 
Skin <10 s s 
Female genital organs <10 s s 
Male genital organs <10 s s 
Ill-defined, secondary or unspecified sites <10 s s 
Numerator: National Cancer Registry, Denominator: Statistics NZ Estimated Resident Population. Cancer includes all malignant 
tumours and other neoplasms of uncertain/unknown behaviour; ASR = Age standardised rate (standardised to 2013 NZ Census 
population) 
Table 54. Cancer notifications and incidence for 15–24 year olds, by cancer group, New Zealand, 2010–2014 
2010–2014 Notifications (n) ASR per 100,000 population 95% CI 
New Zealand 
15–24 year olds 
Cancer notifications 
All cancers 821 26.34 24.57–28.21 
Lymphoid, haematopoietic and related tissue 233 7.47 6.54–8.49 
Leukaemia 87 2.79 2.23–3.44 
Leukaemia: Lymphoid leukaemia 34 1.09 0.75–1.52 
Leukaemia: Acute myeloid leukaemia 23 0.74 0.47–1.10 
Hodgkin lymphoma 99 3.17 2.58–3.86 
Non-Hodgkin lymphoma 38 1.22 0.86–1.67 
Skin 115 3.70 3.05–4.44 
Male genital organs* 109 6.89 5.66–8.31 
Thyroid and other endocrine glands 67 2.15 1.67–2.73 
Digestive organs 57 1.83 1.39–2.37 
Eye, Brain and other parts of the central nervous system 51 1.64 1.22–2.15 
Bones, joints and articular cartilage 46 1.47 1.08–1.96 
Female genital organs* 55 3.60 2.71–4.68 
Mesothelial and soft tissue 36 1.15 0.81–1.60 
Lip, oral cavity and pharynx 16 0.51 0.29–0.83 
Respiratory system and intrathoracic organs 14 0.45 0.25–0.75 
Breast* 14 0.92 0.50–1.54 
Urinary tract <10 s s 
Numerator: National Cancer Registry, Denominator: Statistics NZ Estimated Resident Population. Cancer includes all malignant 
tumours and other neoplasms of uncertain/unknown behaviour; ASR = Age standardised rate (standardised to 2013 NZ Census 




Table 55 and Table 56 present the number of cancer notifications age-standardised incidence rate (ASR) in 
each district health board (DHB) between 2010 and 2014 for 0–14 year olds (Table 55) and 15–24 year olds 
(Table 56). Five DHBs had fewer than ten notifications; notifications in all remaining DHBs did not differ 
significantly from the national notification rate. 
Table 55. Cancer notifications and incidence for 0–14 year olds, by district health board, New Zealand 2010–2014 
2010–2014 Notifications (n) ASR per 100,000 population Rate ratio 95% CI 
0–14 year olds 
Cancer notifications 
Northland 27 14.94 0.97 0.41–2.27 
Waitemata 72 12.88 0.83 0.49–1.43 
Auckland DHB 68 16.51 1.07 0.61–1.86 
Counties Manukau 90 15.18 0.98 0.60–1.60 
Waikato 65 15.99 1.03 0.59–1.82 
Bay of Plenty 32 14.13 0.91 0.41–2.01 
Lakes DHB 22 18.78 1.21 0.47–3.14 
Tairawhiti <10 s s s 
Taranaki 20 16.83 1.09 0.41–2.92 
Hawke's Bay 29 16.76 1.08 0.47–2.48 
MidCentral 20 11.64 0.75 0.28–2.04 
Whanganui <10 s s s 
Hutt Valley 32 21.19 1.37 0.62–3.03 
Capital & Coast 53 19.38 1.25 0.67–2.34 
Wairarapa <10 s s s 
Nelson Marlborough 17 12.69 0.82 0.28–2.40 
South Canterbury <10 s s s 
Canterbury 81 17.13 1.11 0.66–1.85 
West Coast <10 s s s 
Southern DHB 41 14.67 0.95 0.47–1.91 
New Zealand 699 15.47 1.00   
Numerator: National Cancer Registry, Denominator: Statistics NZ Estimated Resident Population. Cancer includes all malignant 
tumours (ICD-10-AM codes C00–C97) and other neoplasms of uncertain/unknown behaviour (D45–D47); ASR = Age 
standardised rate (standardised to 2013 NZ Census population) 
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Table 56. Cancer notifications and incidence for 15–24 year olds, by district health board, New Zealand 2011–2015 
2010–2014 Notifications (n) ASR per 100,000 population Rate ratio 95% CI 
15–24 year olds 
Cancer notifications 
Northland 30 31.16 1.18 0.53–2.66 
Waitemata 83 21.71 0.82 0.50–1.36 
Auckland DHB 99 26.70 1.01 0.64–1.61 
Counties Manukau 91 24.13 0.92 0.57–1.48 
Waikato 65 24.11 0.92 0.52–1.61 
Bay of Plenty 40 32.01 1.22 0.60–2.46 
Lakes DHB 25 37.72 1.43 0.59–3.47 
Tairawhiti <10 s s s 
Taranaki 19 27.81 1.06 0.38–2.91 
Hawke's Bay 37 37.94 1.44 0.69–3.00 
MidCentral 44 34.89 1.32 0.67–2.61 
Whanganui 12 30.76 1.17 0.33–4.19 
Hutt Valley 26 27.52 1.04 0.44–2.50 
Capital & Coast 62 26.86 1.02 0.57–1.81 
Wairarapa 10 42.42 1.61 0.40–6.41 
Nelson Marlborough 20 26.59 1.01 0.37–2.72 
South Canterbury <10 s s s 
Canterbury 85 23.99 0.91 0.55–1.50 
West Coast <10 s s s 
Southern DHB 47 19.89 0.75 0.39–1.46 
New Zealand 821 26.34 1.00   
Numerator: National Cancer Registry, Denominator: Statistics NZ Estimated Resident Population. Cancer includes all malignant 
tumours (ICD-10-AM codes C00–C97) and other neoplasms of uncertain/unknown behaviour (D45–D47); ASR = Age 
standardised rate (standardised to 2013 NZ Census population) 
Evidence for good practice 
Possibilities for prevention 
Unlike adult cancers, very few childhood cancers have known preventable causes.6 One of the few preventable 
causes is exposure to ionising radiation in utero from diagnostic radiography.6 Since this association was 
recognised in the 1950s, health services have been careful to minimise women’s radiation exposure during 
pregnancy.6 
While childhood cancers are largely not preventable, there are important preventive measures that children and 
young people can take to reduce their risks of getting cancer later in life. Getting sunburnt in childhood is 
associated with an increased risk of developing melanoma skin cancer in adulthood.7 There has been little 
research on sun protection specifically for children but evidence from  studies in adults suggests that the 
following measures are effective: avoiding sun exposure when sun is at its highest; avoiding the use of artificial 
UV sources such as sun beds; wearing sun-protective clothing, wide-brimmed hats and sunglasses; and liberal 
use of sunscreen products on all exposed skin.8 
Infection with human papilloma virus is the main cause of cervical cancer and it is also a significant cause of 
vaginal, vulvar, penile, anal and oropharyngeal cancers.9 Vaccination against HPV (for both girls and boys) 
offers protection against HPV-related cancers.9 Vaccination against hepatitis B reduces the incidence of 
hepatocellular carcinoma (a type of liver cancer), which is associated with chronic hepatitis B infection.10 
Smoking is a cause of many types of cancer in adults: lung, larynx, oral cavity, pharynx, oesophagus, pancreas, 
bladder, kidney, cervix, and stomach, and acute myeloid leukaemia.11 Since most adult smokers started smoking 
as teenagers or young adults, discouraging young people from taking up smoking is a very effective way to 
prevent cancers caused by smoking.12 
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Evidence-based health care for children and young people with cancer 
Treatment for child cancer is complex, involving multiple types of treatment (chemotherapy, radiotherapy, 
surgery) that are delivered over several years by multidisciplinary teams.13 There is evidence that better 
treatment outcomes for child cancer are achieved by high (vs. low) volume hospitals, high (vs. low) volume 
providers, and specialised (vs. non-specialised) hospitals, although the differences are relatively small.14 
Suggested explanations for this include ‘practice makes perfect’ and ‘selective referral’ (hospitals or physicians 
with good reputations receive more referrals).15 These factors have not been explored in relation to child cancer 
treatment specifically and it is likely that both play a part.14 
New Zealand’s small population makes it challenging to provide high quality child cancer services nationwide. 
New Zealand currently has two specialist child cancer services, located in Auckland and Christchurch. These 
have shared care arrangements with the other DHBs so that a specialist paediatric oncology service is 
responsible for advising on and coordinating the initial diagnostic work-up, the provision of intensive therapy, 
and overall management of a child’s care but once the child is stabilised, some components of treatment can be 
provided closer to the child’s home.13 
In developed countries, including New Zealand, children with cancer are generally treated according to 
protocols developed through international collaborative research studies.16 Since the early 2000s, the rate of 
decrease in child cancer mortality has slowed considerably and it is probable that optimisation of currently 
available anti-cancer treatments has been achieved.16 New therapies are being developed which target the 
molecular biomarkers associated with particular sub-types of cancer17 but so far targeted drugs have been of 
benefit to only a very small proportion of child cancer patients.18 (Biomarkers are substances, mostly proteins, 
that are produced by cancer cells or by other body cells in response to cancer, and that can be detected and 
measured in tissues or body fluids.19) 
Treatment for child cancer has both short term and long term adverse effects. Commonly experienced short term 
effects include fatigue, lack of energy, pain, anaemia, infection, lack of appetite, hair loss, bruising, nausea, 
vomiting, diarrhoea, and mucositis (painful mouth ulcers due to inflammation and ulceration of the lining of the 
digestive tract).20 In the long term child cancer survivors are at lifelong risk of developing a subsequent primary 
cancer and of having multiple physical and psychosocial health problems including cardiovascular disease, 
cardiomyopathy, pulmonary fibrosis, renal dysfunction, obesity, mental health problems, and endocrinopathies 
(e.g. premature gonadal failure, thyroid disease, and osteoporosis).21 Most of the serious health problems do not 
become apparent until decades after cancer treatment has ended.22 Lifelong follow-up of survivors is therefore 
regarded as best practise.23,24 
These national and international guidelines, systematic reviews, other publications and websites relevant to the 
prevention and management of cancer are suggested for further reading. 
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APPENDIX 1. EVIDENCE FOR GOOD PRACTICE 
For most indicators in this report there is a section devoted to evidence for good practice. These sections 
comprise evidence summaries, references and links. They aim to provide readers with a starting point from 
which to consider the most effective interventions that are available to address particular child and youth health 
issues. Included are New Zealand policy documents such as Ministry of Health Strategies and Toolkits, New 
Zealand and international guidelines, and evidence-based reviews that are relevant to the prevention and 
management of child and youth health issues. The approach taken in these sections is intended to assist health 
professionals use the principles of evidence-based medicine (EBM), that is, to solve problems by using the best 
available research evidence and combining this with clinical expertise and patient values.1 Evidence-based 
reviews, the best known of which are those produced by the Cochrane Collaboration, collate all the available 
evidence (published and unpublished trials, observational studies etc.) relevant to a particular health 
intervention, evaluate it in a rigorous manner, and publish the resulting synthesis of the evidence in a format that 
allows readers to quickly evaluate the effectiveness of the intervention. 
When preparing the Evidence for Good Practice section for each indicator, the authors searched a number of 
EBM journals and databases (e.g. the Cochrane Library) as well as Ovid MEDLINE and PubMed for systematic 
reviews of population level interventions in child and youth health (see Text Box below). They also conducted 
smart searches in Google Scholar for journal articles and Google for government documents.  
Methodology used in preparing policy/evidence of good practice sections 
New Zealand (health) policy documents  
Each review section provides a list of Ministry of Health (or where appropriate, other Government Agency) policy documents 
and strategies relevant to the area. Using Google.com a smart search was conducted of Ministry of Health and other 
government departments.  
Example smart searches used: 
("fetal alcohol syndrome" OR “fetal alcohol spectrum disorder” OR FAS OR FASD) site:.health.govt.nz 
("fetal alcohol syndrome" OR “fetal alcohol spectrum disorder” OR FAS OR FASD) site:.govt.nz 
Evidence of good practice 
The databases listed below were searched for reviews assessing the effectiveness of population level interventions to prevent 
and/or manage each of the issues included in this report. These databases were chosen because of the high calibre of the 
institutions maintaining them. The search strategy concentrated on publications that attempted to synthesise all of the available 
evidence, thereby providing the broadest possible coverage of the relevant literature. In general, only literature from the last 
three years was searched, although earlier publications were included if there was a lack of more recent information. Individual 
trials and protocols were not specifically sought but if there was no other relevant information available, an attempt was made 
to locate individual research reports or recommendations. It is hoped that that, although the lists of references provided are not 
completely comprehensive, they will nevertheless provide a useful starting point for DHBs wishing to explore strategies to 
address particular child and youth health issues. 
Evidence-Based Medicine Reviews  
This database allows seven EBM resources to be searched at once including The Database of Reviews of Effects (DARE), Health 
Technology Assessments (HTA) and the NHS Economic Evaluation Database (NHSEED) all produced by National Health Services’ 
Centre for Reviews and Dissemination at the University of York, U.K., The Cochrane Database of Systematic Reviews, and the 
ACP Journal Club. 
National Guideline Clearinghouse http://www.guideline.gov  
This is a searchable database of evidence-based clinical practice guidelines maintained by the Agency for Healthcare Research 
and Quality in the United States. 
Centre for Reviews and Dissemination (CRD) http://www.york.ac.uk/inst/crd 
This is a department of the University of York and is part of the National Centre for Health Research (NCHR). While CRD 
produces the database of Review Effects (DARE), captured in the Evidence-Based Medicine Review Database, searching the CRD 
site identifies other reviews not captured by DARE. This database is available through most local library services. Due to 
cessation of funding, no new records have been added to the database since March 2015. 
National Institute for Health and Clinical Excellence (NICE) http://www.nice.org.uk  
This is an independent organisation based in the United Kingdom which provides national guidance on the promotion of good 
health and the prevention and treatment of ill health. 
Guide to Community Preventive Services: Systematic Reviews and Evidence Based Recommendations 
This guide was developed by the non-federal Task Force on Community Preventive Services whose members are appointed by 
the Director of the Centres for Disease Control and Prevention (CDC). The Community Guide summarises what is known about 




In addition to these databases the websites of the World Health Organization, and government health departments in Australia, 
the UK, the US, and Canada, often yielded relevant guidance, as did the sites of international clinical collaborations such as the 
European Cystic Fibrosis Society and the International Society for Pediatric and Adolescent Diabetes. 
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APPENDIX 2. STATISTICAL METHODS  
Inferential statistics are used when a researcher wishes to use a sample to draw conclusions about a larger 
population as a whole; for example, weighing a class of 10-year-old boys, in order to estimate the average 
weight of all 10-year-old boys in New Zealand. The findings obtained from the sample provide an estimate for 
the population, but will always differ from it to some degree, simply due to chance. Similarly, samples are used 
when a researcher questions whether the risk of developing a particular condition is different between two 
groups, and the fit of the estimate obtained from the samples to the actual population needs to be carefully 
considered. An example of this would be a study examining whether lung cancer is more common in smokers or 
non-smokers: researchers using sample groups would have to consider the possibility that some of the 
differences observed arose from chance variations in the populations sampled.  
Over time, statisticians have developed a range of measures to quantify the uncertainty associated with random 
sampling error. These measures can assign a level of confidence to estimates and conclusions drawn from 
samples, allowing researchers to assess, for example, whether the average weight of boys in the sample reflects 
the true weight of all 10-year-old boys, or the rates of lung cancer in smokers are really different to those in non-
smokers. Two of the most frequently used statistical significance tests are: 
P values: The p value from a statistical test measures the probability of finding a difference at least as large as 
the one observed between groups, if there were no real differences between the groups studied. For example, if 
statistical testing of the difference in lung cancer rates between smokers and non-smokers resulted in a p value 
of 0.01, this tells us that the probability of such a difference occurring if the two groups were identical is 0.01 or 
1%. Traditionally, results are considered to be statistically significant if the p<0.05; that is, when the probability 
of the observed differences occurring by chance is less than 5%.1 
Confidence Intervals: When sampling from a population a confidence interval is a range of values that 
contains the measure of interest. While a confidence interval for the average height of 10-year-old boys could be 
20cm to 200cm, for example, the smaller range of 130cm to 150cm is a more informative statistic. A 95% 
confidence interval suggests that if you were to repeat the sampling process 100 times, 95 times out of 100 the 
confidence interval would include the true value.1 Where the observed counts are small and the denominator is 
large, then a Poisson distribution has been utilised for both rate and confidence interval calculations,2 in 
particular for the congenital anomaly and cancer indicators. 
Crude rates: Measures the number of people with the condition of interest in relation to the number of people 
in the population. It is calculated by dividing the number of people with the condition of interest in a specific 
time period by the total number of people in the population in the same time period. 
Age-specific rates: Measures the occurrence of an event within a defined age group in relation to the number of 
people in that group. Age-specific rate is calculated by dividing the number of people with the condition of 
interest in a specific age group and time period by the total number of people in the population in the same age 
group and time period.  
Age-standardised rates (ASR): Age-standardised rates (ASR): A statistical technique that makes it possible to 
make meaningful comparisons between populations with different age structures. Age-standardisation adjusts 
rates for differences in the age distribution of the population over time or differences in age distribution between 
population groups. The direct standardisation method has been used to calculate ASR in this report. 3 The 
population used as the standard population was the New Zealand 2013 Census Estimated Resident population 
(Table 57), which is different from the standard population used by the Ministry of Health. The cancer indicator 
presents age-standardised rates, as indicated in information accompanying the relevant tables and graphs. The 
indicators in this report are mainly presented using crude (unadjusted) rates or age group (age-specific) rates, 
with the exception of cancer which uses age-standardised rates. 
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Table 57. Individuals aged 0–24 years by age group, and sex, New Zealand 2013 census data 
Age group (year) Male Female Total 
NZ population 
weightings 
New Zealand 2013 Census population 
0–4 160,160 151,780 311,940 0.343 
5–9 153,580 146,490 300,070 0.330 
10–14 152,180 144,580 296,760 0.327 
Total 0–14 465,920 442,850 908,770   
15–19 160,160 152,330 312,490 0.498 
20–24 159,190 155,730 314,920 0.502 
Total 15–24 319,350 308,060 627,410   
Source: Statistics NZ Estimated Resident Population 2013 Census  
Statistical significance testing in this report 
When tests of statistical significance have been applied in a particular section, the statistical significance of the 
associations presented has been signalled in the text with the words significant, or not significant. Where the 
words significant or not significant do not appear in the text, then the associations described do not imply 
statistical significance or non-significance.  
Several data sources are used in this report. In general they belong to one of two groups: 1) population surveys 
or 2) routine administrative datasets. The relevant statistical testing for each of these data sources are as follows: 
Population surveys: Some of the indicators reported on here are derived from data from national surveys where 
information from a sample has been used to make inferences about the population as a whole. In this context, 
statistical significance testing is appropriate and, where such information is available in published reports, it has 
been included in the text accompanying graphs and tables. In a small number of cases, information on statistical 
significance was not available, and any associations described do not imply statistical significance. 
Numbers derived from routine administrative data: A large number of the indicators included in this report 
are based on data from New Zealand’s administrative datasets, for example the National Mortality Collection, 
which capture information on all of the events occurring in a particular category.  
Rate ratios derived from routine administrative data: To facilitate comparisons between different time 
periods, and for examining the data from New Zealand in a wider context, whenever measures of association 
(rate ratios) are presented in this report, 95% confidence intervals have been provided.4 
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APPENDIX 3. DATA SOURCES 
This report contains information derived from several national administrative datasets and population surveys. 
These are described briefly below, and limitations to be aware of when interpreting results drawn from these 
sources are outlined. 
National Mortality Collection 
The National Mortality Collection is a dataset managed by the Ministry of Health that contains information on 
the underlying cause, or causes, of death along with basic demographic data for all deaths registered in New 
Zealand since 1988. Fetal and infant death data are a subset of the Mortality Collection, with cases in this subset 
having additional information on factors such as birth weight and gestational age.1 Each of the approximately 
28,000 deaths occurring in New Zealand each year is coded manually by Ministry of Health staff. For most 
deaths the Medical Certificate of Cause of Death provides the information required, although coders also have 
access to information from other sources such as Coronial Services, Police, NZ Transport Agency, the New 
Zealand Cancer Registry (NZCR), the Institute of Environmental Science and Research, and Water Safety NZ.2 
National Minimum Dataset 
The National Minimum Dataset (NMDS) is a national hospital discharge dataset and is maintained by the 
Ministry of Health. It is used for policy formation, performance monitoring, and research purposes, providing 
key information about the delivery of hospital inpatient and day patient health services both nationally and on a 
provider basis. It is also used for funding purposes.3 
Information in the NMDS includes principal and additional diagnoses, procedures, external causes of injury, 
length of stay and sub-specialty codes; and demographic information such as age, ethnicity and usual area of 
residence. Data have been submitted by public hospitals electronically since the original NMDS was 
implemented in 1993, with additional data dating back to 1988 also included. The private hospital discharge 
information for publicly funded events has been collected since 1997. The current NMDS was introduced in 
1999.3 
Birth Registration Dataset 
Since 1995 all New Zealand hospitals and delivering midwives have been required to notify the Department of 
Internal Affairs within five working days of the birth of a live or stillborn baby. This applies to stillborn babies 
born at or more than 20 weeks gestation, or weighing 400g or more: prior to 1995, only stillborn babies reaching 
more than 28 weeks of gestation required birth notification. Information on the hospital’s notification form 
includes maternal age, ethnicity, multiple birth status, and the baby’s sex, birth weight and gestational age. In 
addition, parents must jointly complete a birth registration form as soon as reasonable practicable after the birth, 
and within two years of delivery, which duplicates the above information with the exception of birth weight and 
gestational age. Once both forms are received by Internal Affairs the information is merged into a single entry. 
This two-stage process it is thought to capture 99.9% of births occurring in New Zealand and cross-checking at 
the receipting stage allows for the verification of birth details.4 
National Cancer Register 
The New Zealand Cancer Registry (NZCR) is national population-based cancer/tumour registry maintained by 
the Ministry of Health. The role of the NZCR is:  
1. to provide information on the incidence of, and mortality from, cancer 
2. to provide a basis for cancer survival studies and research programmes 
The NZCR holds information on individuals diagnosed in New Zealand with a new malignant tumour (invasive 
and in-situ; excluding squamous and basal cell skin cancers), including pathological information. Information in 
the NZCR includes tumour information (such as morphology, site, diagnostic test, multiplicity), staging 
information, and demographic information such as age, ethnicity and usual area of residence. The quality of the 
data has improved since 1998. Data have been collated from pathology reports submitted electronically by 




New Zealand Health Survey 
The Ministry of Health’s New Zealand Health Survey (NZHS) became an annual survey in 2011. The survey is 
conducted by interviewing a sample of adults and children’s parents or caregivers in New Zealand, and utilises a 
core set of questions that cover a range of health-specific indicator areas, including health behaviours, 
conditions and use of health services.8 Table 58 presents the number of participants selected for each NZ Health 
Survey conducted and the corresponding coverage rate. The coverage rate is a measure related to survey 
response and is defined as the ratio of the sum of the selection weights for the survey respondents to the known 
external population size.8 
The NZ Health Survey utilised adjusted rate ratios to account for the potential influence of other demographic 
factors when undertaking demographic comparisons. Gender comparisons are adjusted for age, ethnic 
comparisons are adjusted for age and gender, and deprivation comparisons are adjusted for age, sex and 
ethnicity.8 
Table 58. Number of survey participants and coverage, New Zealand Health Survey 
Survey year (1 July–30 June) 
Adults (15 years and over) Children (2–14 year olds) 
n Coverage (%) n Coverage (%) 
New Zealand Health Survey 
2006/2007 12,488 59 4,921 67 
2011/2012 12,370 54 4,478 68 
2012/2013 13,009 59 4,485 69 
2013/2014 13,309 54 4,699 63 
2014/2015 13,497 59 4,754 69 
Source: New Zealand Health Survey Methodology reports 2006/07–2014/15 
Estimated prevalence 
The NZ Health Survey presents the demographic factors for each surveyed condition using unadjusted and 
adjusted prevalence rates, and the total estimated prevalence as calculated by the Ministry of Health have been 
presented in this report. The Ministry of Health has weighted the survey data used for calculating prevalence to 
ensure that each group is represented appropriately, i.e. not under or over represented, in the survey estimates. 
This is achieved by a weight being devised for each respondent based on their chance of selection, such that a 
lower change of selection results in a higher weight and vice versa, or survey response rate (e.g. lower response 
rate means a higher weighting).8 
The prevalence of a condition, or the proportion of the population with the condition e.g. diabetes, was 
estimated by calculating the sum of the weights for the survey respondents with the condition divided by the 
sum of the weights of all survey respondents. For example, the sum of the weights for survey respondents with 
diabetes is divided by sum of the weights for all survey respondents.8 
Further information on the prevalence estimates, methodology and interpretation of the NZ Health Survey are 
available on the NZ Health Survey pages of Ministry of Health website http://www.health.govt.nz/nz-health-
statistics/national-collections-and-surveys/surveys/current-recent-surveys/new-zealand-health-survey  
Data limitations 
There are limitations when using any of these datasets. The following are of particular relevance to this report. 
Clinical coding accuracy and coding changes over time 
The quality of data submitted to the administrative national datasets may vary. While the data for the National 
Mortality Collection and the Birth Registration Dataset are coded by single agencies, the clinical information 
held in the NMDS is entered by health providers before being collated by the Ministry of Health. In a 2001 
review of the quality of coding in the data submitted to the NMDS, 2,708 events were audited over ten sites 
during a three-month period. Overall the audit found that 22% of events required a change in coding, although 
this included changes at a detailed level. Changes to the primary diagnosis involved 11% of events, to additional 
diagnoses 23%, and to procedure coding, 11%. There were 1,625 external causes of injury codes, of which 15% 
were re-coded differently.9 These findings were similar to an audit undertaken a year previously. While the 
potential for such coding errors must be taken into consideration when interpreting the findings of this report, 
the average 16% error rate indicated by the 2001 review may be an overestimate as, in the majority of the 




Changes in the coding systems used over time may result in irregularities in time series analyses.2 New Zealand 
hospitals use the clinical coding classification developed by the World Health Organization and modified by the 
National Centre for Classification in Health, Australia. The current classification is called The International 
Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification 
(ICD-10-AM), the Australian Classification of Health Interventions (ACHI) and Australian Coding Standards 
(ACS). The introduction of ICD-10-AM represented the most significant change in classification in over 50 
years, expanding the number of codes from ~5,000 to ~8,000, to provide for recently recognised conditions and 
allow greater specificity about common diseases. 
From 1988 until 1999, clinical information in the NMDS was coded using versions of the ICD-9 classification 
system. From July 1999 onwards, the ICD-10-AM classification system has been used. Back and forward 
mapping between the two systems is possible using predefined algorithms,9 and for most conditions there is a 
good correspondence between ICD-9 and ICD-10-AM codes. Care should still be taken when interpreting time 
series analyses which include data from both time periods as some conditions may not be directly comparable 
between the two coding systems.  
Variation in reporting hospitalisations to the NMDS  
Historically, there have been differences in the way New Zealand’s 20 district health boards (DHBs) have 
reported their emergency department (ED) hospitalisations to the NMDS, which can affect the interpretation of 
hospitalisation data. Inconsistent recording of ED cases has resulted from differing definitions of the time spent 
in the ED, and at what point this time constitutes an admission. This is important in paediatrics where 
hospitalisations for acute onset infectious and respiratory diseases in young children especially are mainly of 
short duration. In addition, there are regional differences in treatment processes for paediatric emergency cases.  
This report includes all ED day cases in its analyses of hospitalisations for medical conditions. This approach 
differs from that commonly used by the Ministry of Health when analysing NMDS hospital discharge data, 
which the Ministry of Health uses to minimise the impact of the inconsistent reporting of ED cases. Short stay 
ED events are often excluded from the Ministry’s analyses to improve comparability between regions. However, 
as noted above, the treatment of children in acute cases differs from that of adults, and the inclusion of ED day 
cases is justified when considering hospitalisations for medical conditions, despite inconsistencies in the dataset. 
The Ministry of Health’s practice of filtering out ED day cases for hospitalisations for injuries is followed in this 
report as it is considered that the processes for injury assessments are relatively consistent around the country.  
Further information on the details of the inconsistencies can be seen in earlier reports by the NZCYES 
www.otago.ac.nz/ncyes  
Changes in the way ethnicity information has been recorded over time 
Due to inconsistencies in the way ethnicity information was recorded in the health sector, and in census data 
before 1996, all ethnic group specific analyses in this report are for the year 1996 onwards. See Appendix 4 for 
a brief review of the changes in the recording of ethnicity information over the past 35 years in New Zealand. 
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APPENDIX 4. DEMOGRAPHIC FACTORS 
Ethnicity data 
Because of inconsistencies in the manner in which ethnicity information in New Zealand was collected prior to 
1996, all ethnic group specific analyses presented in this report are for the 1996 year onwards, and reflect self-
identified concepts of ethnicity. Details of the changes made in the census question on ethnicity, and why they 
were made, can be found on the Statistics New Zealand website www.stats.govt.nz. 
Unless otherwise specified, prioritised ethnic group has been used to ensure that each health event is only 
counted once. Despite significant improvements in the quality of ethnicity data in New Zealand’s national health 
collections since 1996, care must still be taken when interpreting the ethnic-specific rates as the potential still 
remains for Māori and Pacific children and young people to be undercounted in our national data collections.  
The authors of Hauora IV developed a set of adjusters which could be used to minimise the bias such 
undercounting introduced when calculating population rates and rate ratios. These, or similar, adjusters were not 
utilised in this report because previous research has shown that ethnicity misclassification can change over time 
and ethnic misclassification may vary significantly by district health board.1,2 Adjusters developed using 
national level data (as in Hauora IV) may not be applicable to district health board level analyses, with separate 
adjusters needing to be developed for each. 
In addition, the development of adjusters requires the linkage of the dataset under review with another dataset 
for which more reliable ethnicity information is available, and this process is resource-intensive and not without 
error, particularly if the methodology requires probabilistic linkage of de-identified data. The development of a 
customised set of period and age specific adjusters was seen as being beyond the scope of the current project. 
The data presented in this report may undercount Māori and Pacific children to a variable extent depending on 
the dataset used, and in the case of the hospital admission dataset for Māori, this undercount may be as high as 
5–6%. 
NZ Deprivation Index 
The NZ index of deprivation (NZDep) was first created using information from the 1991 census, and has been 
updated following each census. It is a small area index of deprivation, and is used as a proxy for socioeconomic 
status. The main concept underpinning small area indices of deprivation is that the socioeconomic environment 
in which a person lives can confer risks or benefits which may be independent of their own social position 
within a community.3 They are aggregate measures, providing information about the wider socioeconomic 
environment in which a person lives, rather than information about their individual socioeconomic status.  
The latest index, NZDep2013, combines nine variables from the 2013 census to reflect eight dimensions of 
material and social deprivation (Table 59). Each variable represents a standardised proportion of people living in 
an area who lack a defined material or social resource. These are combined to give a score representing the 
average degree of deprivation experienced by people in that area. Individual area scores are ranked and placed 
on an ordinal scale from 1 to 10, with decile 1 reflecting the least deprived 10% of small areas and decile 10 
reflecting the most deprived 10% of small areas.4 
The advantage of the NZDep2013 is its ability to assign measures of socioeconomic status to the older 
population, the unemployed and to children, to whom income and occupational measures often don’t apply, as 
well as to provide proxy measures of socioeconomic status for large datasets when other demographic 
information is lacking. Small area indices have limitations, however, as not all individuals in a particular area 
are accurately represented by their area’s aggregate score. While this may be less of a problem for very affluent 
or very deprived neighbourhoods, in average areas, aggregate measures may be much less predictive of 
individual socioeconomic status.3 Despite these limitations, the NZDep2013 has been shown to be predictive of 




Table 59. Variables used in the NZDep2013 
Dimension Variable in order of decreasing weight in the index 
Communication People aged < 65 with no access to the Internet at home  
Income People aged 18–64 receiving a means tested benefit 
Income People living in equivalised* households with income below an income threshold  
Employment People aged 18–64 unemployed  
Qualifications People aged 18–64 without any qualifications  
Owned home People not living in own home  
Support People aged <65 living in a single parent family  
Living space People living in equivalised* households below a bedroom occupancy threshold  
Transport People with no access to a car  
*The setting of the household equivalised income threshold was based on two principles: 1) the proportion of the population 
identified as being socioeconomically deprived by the threshold should be broadly consistent with the other variables in the 
index, and 2) the threshold should be broadly consistent with other measures of income poverty.4 
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APPENDIX 5. CLINICAL CODES 
The following are the codes associated with the conditions presented in this report. 
 ICD-10-AM ICD-9-CM 
Cancer C00–C96, D45–D47 140–208, 235–238 
Cystic fibrosis E84  277.0  
Eczema or dermatitis L20–L30, B00.0, B00.1, H01.1 690–698, 0540, 3733 
Diabetes   
Type 1 diabetes E10 250.x1, 250.x3  
Type 2 diabetes E11  250.x0, 250.x2  
Diabetes - other E09, E12, E13, E14  
Chronic lower respiratory diseases J40–J47 490–494, 496 
CLRD: Bronchitis J40–J42 490–491 
CLRD: Emphysema J43  492 
CLRD: Asthma (incl Status asthmaticus & Wheeze) J45–J46, R06.2 493 
CLRD: Bronchiectasis J47 494 
CLRD: Other J40–J47 490–494, 496 
Digestive   
Constipation K59.0 564.0 
Crohn disease K50  555 
Ulcerative colitis  K51 556 
Mental and behavioural   
Autism or other pervasive developmental disorders F84 299 
Intellectual disability and developmental delay F70–F79, R62 317–319, 7834 
Musculoskeletal   
Juvenile arthritis M08–M09 714.3 
Juvenile osteochondrosis M91–M92, M42.0, M93.2 732.0–732.1, 732.3–732.7 
Scoliosis M41  737.43 
Nervous system   
Cerebral palsy G80 343 
Epilepsy or status epilepticus G40–G41  345  
Nutritional and eating disorders   
Eating disorders F50 307.1, 307.5 
Obesity E66 278.0 
Congenital anomalies 
 ICD–10–AM ICD–9–CM/A 
All anomalies Q codes, P350, P351, P371 740–759 
Non-chromosomal anomalies (NCA) Q0–Q8 740–757, 759 
Nervous system anomalies Q00–Q07 740–742 
Neural tube defects Q00, Q01, Q05 740, 741, 742.0 
Anencephalus and similar Q00 740 
Encephalocele Q01 742.0 
Spina bifida Q05 741 
Hydrocephalus Q03 742.3 
Microcephaly Q02 742.1 
Arhinencephaly/holoprosencephaly Q04.1, Q04.2 742.2 
Eye anomalies Q10–Q15 743 
Anophthalmos/microphthalmos Q11.0, Q11.1, Q11.2 743.0, 743.1 
Congenital cataract & lens anomalies Q12.0 743.3 
Congenital glaucoma Q15.0 743.20 
Ear, face and neck anomalies Q16, Q18, Q17.8 744.0, 744.21, 744.24, 744.29, 
744.4–744.9 




 ICD–10–AM ICD–9–CM/A 
Congenital Heart Defects (CHD) Q20–Q26 745–746, 747.0–747.4 
Severe CHD 
Q20.0, Q20.3, Q20.4, Q21.2, 
Q21.3, Q22.0, Q22.4, Q22.5, 
Q22.6, Q23.0, Q23.4, Q25.1, 
Q26.2 
745.00, 745.10, 745.2, 745.3, 
745.6, 746.1, 746.2, 746.00, 
746.3, 746.7, 747.1, 747.42 
Common arterial truncus Q20.0  745.00 
Transposition of great vessels Q20.3 745.10 
Single ventricle Q20.4  745.3 
VSD Q21.0  745.4 
ASD Q21.1  '745.5 
AVSD Q21.2 745.6 
Tetralogy of Fallot Q21.3  '745.2 
Tricuspid atresia and stenosis Q22.4 746.1 
Ebstein's anomaly Q225  746.2 
Pulmonary valve stenosis Q221  746.01 
Pulmonary valve atresia Q22.0  746.00 
Aortic valve atresia/stenosis Q23.0  746.3 
Hypoplastic left heart Q23.4  746.7 
Hypoplastic right heart Q22.6 no code 
Coarctation of aorta Q25.1  747.1 
Total anomalous pulmonary venous return (TAPVR) Q26.2  747.42 
Term PDA  Q25.0 747.0 
Respiratory anomalies Q30–Q34 748 
Choanal atresia Q30.0  748.0 
Cystic adenomatous malformation of lung Q33.80 no code 
Oro-facial clefts Q35–Q37,  749.0–749.2 
Cleft lip with or without cleft palate Q36, Q37 749.1, 749.2 
Cleft palate with cleft lip Q37 749.2 
Cleft lip only Q36 749.1 
Cleft palate Q35 749.0 
Digestive system Q38–Q45, Q79.0 and not Q38.1, 
Q38.2 
750–751, 756.6 and not 750.0, 
750.15 
Oesophageal atresia (OA) with or without tracheo-
oesophageal fistula (TOF) 
Q39.0, Q39.1 750.30, 750.31 
Duodenal atresia or stenosis Q41.0 751.10 
Atresia or stenosis of other parts of small intestine Q41.1–Q41.8 751.11–751.12 
Ano-rectal atresia and stenosis Q42.0–Q42.3 751.21–751.24 
Hirschsprung's disease Q43.1 751.30–751.33 
Atresia of bile ducts Q44.2 751.65 
Annular pancreas Q45.1 751.72 
Diaphragmatic hernia Q79.0 756.61 
Abdominal wall defects Q79.2, Q79.3, Q79.5  756.7 and not 756.72 
Omphalocele / Gastroschisis Q79.2, Q79.3 756.7 and not 756.72 
Gastroschisis Q79.3  
Omphalocele Q79.2  
Urinary Q60–Q64, Q79.4 753, 756.72, 752.62 
Bilateral renal agenesis (including Potter syndrome) Q60.1, Q60.6 753.00 
Renal dysplasia Q61.4 753.16 
Congenital hydronephrosis Q62.0 753.20 
Bladder exstrophy and/or epispadias Q64.0, Q64.1 753.5, 752.62 
Posterior urethral valve and/or prune belly Q64.20, Q79.4  753.60 
Genital Q50–Q52, Q54–Q56 and not 
Q53 
752.0–752.4, 752.6, 752.7–752.9 
and not 752.5 
Female genital anomalies Q50–Q52 752.0–752.4 
Hypospadias Q54 752.6 




 ICD–10–AM ICD–9–CM/A 
Indeterminate sex Q56 752.7 
Limb anomalies Q65–Q74 754.3–754.8, 755 
Limb reduction Q71–Q73 754.3–754.8, 755.6 
Upper limb reduction Q71 755.2 
Lower limb reduction Q72 755.3 
Complete absence of a limb Q71.0, Q72.0, Q73.0 755.20, 755.30, 755.40 
Club foot Q66.0 754.50 
Hip dislocation and/or dysplasia Q65.0–Q65.2, Q65.80, Q65.81 754.30, 754.31, 754.35 
Polydactyly Q69 755.0 
Syndactyly Q70 755.1 
Other anomalies / syndromes   
Skeletal dysplasias 
Q78.2–Q78.8, Q74.02, Q77, 
Q78.00, Q87.16 
no code 
Craniosynostosis Q75.0 756.00 
Congenital constriction bands/amniotic band Q79.80 751.42, 762.80 
Situs inversus Q89.3 759.3 
Conjoined twins Q89.4  759.4 
Congenital skin disorders 
Q80–Q81, Q82 and not Q82.5, 
Q82.8 
757.1 and not 757.32, 757.39 
Teratogenic syndromes with malformations Q86, P35.0, P35.1, P37.1 760.71, 771.0, 771.1, 771.21 
Fetal alcohol syndrome Q86.0,  760.71 
Valproate syndrome Q86.80 no code 
Maternal infections resulting in malformations P35.0, P35.1, P37.1 771.0, 771.1, 771.21 
Genetic syndromes + microdeletions  
Q44.71, Q61.90, Q74.84, Q75.1, 
Q75.4, Q75.81, Q87, Q93.6 
759.8 
Sequences 
Q60.6, Q64.10, Q79.4, Q79.80, 
Q87.03, Q87.08, Q87.24, Q89.80 
no code 
Chromosomal defects Q90–Q93, Q96–Q99, Q95.2–
Q95.9 
758.0–758.3, 758.5–758.9  
Down syndrome Q90 758.0 
Patau syndrome (trisomy 13) Q91.4–Q91.7 758.1 
Edwards syndrome (trisomy 18) Q91.0–Q91.3 758.2 
Turner syndrome Q96 758.6 
Klinefelter syndrome Q98.0–Q98.4 758.7 
 
